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1.1 Anatomy of the eye
When light enters the front of the eye through the cornea, the light waves are refracted 
by several tissues in the eye and ultimately focus on the central retina at the back of the 
eye (Figure 1.1). The axial length of the adult human eyeball is 21-26 mm. Short eyes (axial 
length <20 mm) have their focal point behind the retina and are called hyperopic, whereas 
long eyes (axial length >26 mm) have their focal point in front of the retina and are called 
myopic. 
In eyes that have a short axial length, the anterior chamber angle (the angle formed 
between the cornea and the iris) is also narrow and can close, resulting in acute angle-
closure glaucoma, like in some patients with dominant cystoid macular dystrophy (DCMD). 
Figure 1.1 Anatomy and visual pathway of the human eye. (Figure derived from http://www.lasik.
md/ learnaboutlasik/refractiveerrors.php)
1.1.1 The retina
The retina is subdivided into the overlying neurosensory retina and the underlying retinal 
pigment epithelium (RPE) (layer 1). The neurosensory retina consists of several layers of 
neurons that are interconnected by synapses and supporting cells, which are arranged in 
a highly organized manner and form eight distinct layers (Figure 1.2). The photoreceptor 
layer (layer 2) contains the outer and inner segments of the rod and cone cells. The outer 
nuclear layer (layer 3) contains the nuclei of the photoreceptor cells. The inner segments of 
the photoreceptor cells are connected to interneurons via synapses in the outer plexiform 
layer (layer 4). The inner nuclear layer (layer 5) is composed of the nuclei of the supporting 
Müller cells and the interneurons (amacrine cells, bipolar cells, and horizontal cells). These 
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cells are connected via synapses in the inner plexiform layer (layer 6) to the ganglion cells 
(layer 7). The axons of the ganglion cells in the nerve fiber layer (layer 8) are oriented towards 
the optic disc. The Müller cells have long processes spanning from the outer nuclear layer 
to the internal limiting membrane (layer 9) and serve as supporting cells, helping to protect 
and repair retinal neurons.1
Figure 1.2 Schematic representation of the cellular organization and layers of the human central 
retina (left), with a corresponding transverse image of the central macula by optical coherence 
tomography (right). The following layers of the retina can be seen in the image. 1: retinal pigment 
epithelium (RPE); 2: inner segment (IS) and outer segment (OS) of the photoreceptors; 3: outer nuclear 
layer (ONL); 4: outer plexiform layer (OPL); 5: inner nuclear layer (INL); 6: inner plexiform layer; 7: 
ganglion cell layer (GCL); 8: nerve fiber layer (NFL); 9: internal limiting membrane (ILM). (Adapted 
from http://webvision.med.utah.edu/imageswv/schem.jpeg)
The visual function of the retina is based upon the anatomical location in the central 
macula and the peripheral retina. The macula, which is the central part of the retina, is 
located inside the temporal vascular arcades and is typically 5-6 mm in diameter. The 
macula contains cones and rods and is responsible for high visual acuity, color vision, 
and contrast sensitivity; the macula subserves the central 15-20° of the visual field. Thus, 
impaired function in the macula results in a loss of sharp vision, altered color vision, 
and the development of a central scotoma. The center of the macula contains a 1.5 mm 
wide circular depression called the fovea, which contains primarily cone cells. Although 
the fovea accounts for only 0.5% of the retina’s surface, approximately 50% of the nerve 
fibers in the optic nerve carry information from the fovea, due to the high density of cone 
photoreceptors. 
In contrast, the peripheral retina contains predominantly rod cells, thus providing vision 
in dim lighting. The peripheral retina also supports the peripheral visual field. Consequently, 
retinal diseases affecting the peripheral retina cause impaired night vision (nyctalopia) and 
constricted peripheral visual field.
The RPE is the deepest layer in the retina and is attached—albeit tenuously—to the 
sensory retina by interdigitation of the apical processes of the RPE cells.2 RPE cells have 
many physical, optical, metabolic, and molecular transport functions, which together play 
an essential role in the visual process. Melanin absorbs scattered light and is expressed 
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in RPE cells, with the highest density in the foveal region. RPE cells actively transport 
nutrients and growth factors to the photoreceptor cells, and they regulate the transport 
of waste products, water, and ions between choroidal vessels and the subretinal space. 
In addition, the RPE layer plays a key role in the regeneration of visual pigments and the 
phagocytosis of outer segments shed by cone and rod photoreceptors. Finally, the RPE 
secretes several factors, including vascular endothelial growth factor (VEGF), tissue inhibitor 
of metalloproteinases-3 (TIMP-3), and complement-associated factors. Overexpression 
of VEGF promotes the formation of choroidal neovascularization in several conditions, 
including age-related macular degeneration (AMD). 
1.1.2 Blood-retina barrier
The retina is provided with oxygen by the choriocapillaris and the retinal vessels. The 
choroidal capillaries are 40-60 µm in diameter, providing the highest rate of blood flow 
in the body compared to other tissues; 3, 4 these capillaries have thin, fenestrated walls 
that enable the diffusion of molecules to nourish the outer part of the retina (i.e., the RPE 
and photoreceptors). To regulate the movement of solutes and nutrients from the choroid 
to the subretinal space, RPE cells are tightly interconnected via tight cellular junctions, 
thus forming the outer blood-retina barrier. A breach in this barrier can cause a serous 
exudative detachment. The non-fenestrated blood vessels of the central retinal artery lie 
in the nerve fiber layer, close to the internal limiting membrane of the retina; these vessels 
connect with the retinal veins via an extensive capillary network that extends outward to 
the external border of the inner nuclear layer. This network supplies blood to the internal 
layers of the retina. The endothelial cells in the retinal vessels are also tightly connected to 
one another by tight cellular junctions, forming the inner blood-retina barrier. This barrier 
mediates the highly selective diffusion of molecules between the blood and the retina and 
is essential for maintaining retinal homeostasis. Specifically, retinal homeostasis is based 
on a balance between osmotic force, hydrostatic force, capillary permeability, and tissue 
compliance, yielding a capillary filtration rate that is balanced by the rate of fluid removal 
from extracellular retinal tissue (for example, by glia and RPE cells). Perturbations in the 
outer and inner blood-retina barriers can increase the level of extracellular fluid in the 
retina, leading to cystoid spaces in the retina. These cystoid fluid collections are located 
primarily within the inner nuclear layer and the outer plexiform layer, as the anatomical 
avascular zone has relatively few retinal vessels that provide a pathway for extracellular 
fluid to return to the intravascular compartment.5 Müller cells may also play a role in the 
development of cystoid macular edema (CME), as the outer cell processes of Müller cells 
contain tight junctions, providing a partial barrier against the passage of subretinal exudates 
into the retina.2 Thus, CME may be associated with a deterioration in the cellular integrity 
—and subsequent swelling— of Müller cells.6 
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1.1.3 The aging retina
The retina is particularly susceptible to the effects of aging due to several intrinsic 
factors. First, because most cell types in the retina are non-dividing, damaging effects 
are cumulative. Second, photoreceptors and RPE cells are metabolically highly active; 
indeed, these cells are among the highest energy-consuming cells in the body. Third, 
the retina is highly oxygenated and directly exposed to light; together, these two factors 
increase the organ’s susceptibility to oxidative damage. With age, reactive oxygen species 
are formed in RPE cells, thereby causing damage to the retina. In addition, RPE cells lose 
the light-absorbing pigment melanin, reducing their antioxidant capacity. As a result of 
phagocytosis of photoreceptor outer segments and oxidative stress, with age, lipofuscin—
and its toxic constituent N-retinylidene-N-retinyl-ethanolamine (A2E)—accumulates in the 
RPE.7, 8 Lipofuscins are a heterogeneous group of lipids, proteins, and various fluorescent 
compounds that are formed primarily from incompletely digested retinoids in the visual 
cycle.9-11
In the RPE, the highest concentration of lipofuscin occurs at the parafoveal zone, where 
the density of rod cells is highest. In this zone, the rods are particularly vulnerable to age-
related changes,12 leading to a decline in the density of rod cells. Thus, the parafoveal zone 
has been suggested as the area in which atrophic AMD typically originates.8, 13
The choriocapillaris is closely related to the RPE. RPE-derived VEGF can influence 
the choriocapillaris, and with increasing age both the density and diameter of the 
choriocapillaris decrease in the macula, resulting in reduced blood flow. With RPE thinning, 
the choriocapillaris can become atrophic and become less fenestrated, thereby reducing its 
molecular transport capacity.14, 15
Bruch’s membrane separates the RPE from the underlying choriocapillaris. With 
aging, this membrane becomes thicker due to the deposition of collagen lipids and other 
substances such as complement components.16-18 This accumulation of substances reduces 
the transepithelial transport of fluid and nutrients. In addition, Bruch’s membrane —which 
is thinnest in the macula— becomes more fragile with increasing age, making it more 
susceptible to neovascular ingrowth.19 Extracellular deposits such as drusen preferentially 
develop between Bruch’s membrane and the basement membrane of the RPE. Drusen are 
subretinal deposits that are mainly situated in the macula, and they contain a mixture of 
lipids, cellular debris, and/or inflammatory components. Taken together, the combination 
of its extremely high metabolism, oxidative stress caused by the local phagocytosis of 
photoreceptor outer segments by the RPE, and the accumulation of waste products 
predisposes the macula to develop drusen.
1.2 Clinical evaluation of retinal anatomy and function
An ophthalmological examination often begins with a measure of visual acuity in order 
to determine visual function. The aspect of the retina on ophthalmoscopy (Figure 1.3A) 
provides important clues regarding the nature of the disease. However, a complete 
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evaluation of the retina’s anatomy and function can often provide important information 
useful for making a differential diagnosis and can shed light on the severity of the disease. 
Such an examination can include conventional diagnostic techniques as well as recently 
developed specialized (multimodal) imaging techniques. 
1.2.1 Retinal imaging
1.2.1.1 Fluorescein angiography
Fluorescein angiography (FA) is an imaging technique that enables the practitioner to image 
the choroidal and retinal vasculature following an intravenous injection or oral dose of 
sodium fluorescein (Figure 1.3B). The fluorescein dye diffuses from the large fenestrated 
capillaries of the choriocapillaris, but normally cannot pass either the outer blood-retina 
barrier of the RPE or the inner barrier of the retinal vessels. 
1.2.1.2 Optical coherence tomography
Optical coherence tomography (OCT) provides a cross-sectional high-resolution image of 
the retina (Figure 1.3C). This non-invasive imaging technique measures differences in light 
reflectivity between different tissue components and can reveal the anatomical location of 
structural abnormalities.
1.2.1.3 Fundus autofluorescence
Another non-invasive imaging technique is fundus autofluorescence (FAF), which provides 
a topographical map of lipofuscin distribution within the RPE. FAF uses short-wavelength 
(i.e., blue) light to excite lipofuscin, which autofluoresces (Figure 1.3D). FAF can reveal 
metabolic changes at the level of the RPE and can therefore provide functional information 
that cannot be obtained using conventional imaging techniques such as FA and OCT.
Figure 1.3 Examples of techniques used to image the fundus. The examples show a healthy fundus 
imaged using color fundus photography (A), fluorescein angiography (B), spectral domain optical 
coherence tomography (SD-OCT) (C), and fundus autofluorescence imaging (D).
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1.2.2 Retinal function tests
1.2.2.1 Electro-oculography
Electro-oculography (EOG) measures the function of the entire RPE-photoreceptor complex. 
EOG displays the positive electrical potential generated in the eye during repeated eye 
movements; this potential is photosensitive, decreasing in the dark and recharging during 
light adaptation. The difference in electrical potential between dark and light is called the 
Arden ratio. The conditions for performing electrophysiological tests in the eye have been 
standardized by the International Society for Clinical Electrophysiology of Vision (ISCEV).
1.2.2.2 Electroretinography
Full-field electroretinography (ERG) records the total electrical activity generated by the 
retina in response to a flash of light. A flash stimulus is followed by an initial negative 
‘a-wave’, which arises from the photoreceptors, and then by a ‘b-wave’, which arises from 
the bipolar and Müller cells. Under scotopic (dark-adapted) conditions, a weak flash is used 
to stimulate the rods, and this is followed by a very strong flash, which stimulates both the 
rods and cones. After exposing the eye to light-adapted conditions, a strong flash is then 
used to measure the photopic potential arising from the cones, and the cone-derived flicker 
response is obtained using a 30-Hz white light flicker stimulus.
1.2.2.3 Dark adaptation
Dark adaptation measurement is used to evaluate the absolute thresholds of cone and 
rod sensitivity in complete darkness. The sensitivity of cones recovers more rapidly than 
rods; however, the sensitivity of rods eventually exceeds the sensitivity of cones and can 
therefore be used as an indicator of rod photoreceptor dysfunction.
1.2.2.4 Color vision
Our ability to perceive colors is based on the retina’s ability to discriminate light of different 
wavelengths. This is achieved by the presence of three types of cones (red, green, and blue 
cones), which are located primarily in the macula.
1.2.2.5 Visual field testing
Visual field testing measures decreased (or absent) sensitivity to light stimuli in both the 
central and peripheral visual fields. A region with decreased light sensitivity surrounded 
by a zone of relatively normal sensitivity is called a scotoma. Dynamic perimetry (e.g., 
Goldmann perimetry) can be used to define the peripheral visual field (and its borders) by 
confrontation of a moving light stimulus into the visual field; this technique can also be used 
to roughly locate a relative or absolute central scotoma. Static perimetry (e.g., Humphrey 
visual field testing) measures the sensitivity of the retina within the central visual field by 
applying several non-moving spots of light of varying brightness.
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1.3 Molecular genetics
1.3.1 DNA structure and function
Deoxyribonucleic acid (DNA) is comprised of a double-helical sequence containing four 
different nucleotides (adenine, A; thymine, T; guanine, G; and cytosine, C). This sequence is 
organized in 23 pairs of chromosomes, with each pair containing one maternal chromosome 
and one paternal chromosome. Because we inherit our chromosomes from our parents, we 
also inherit many of our traits—and therefore diseases—from our parents.
The human genome encodes approximately 20.000 to 25.000 genes, which are specific 
DNA sequences that encode instructions for the formation of proteins. The transcription 
of genes into messenger ribonucleic acid (mRNA) is controlled by regulatory sequences 
such as promoters and enhancers. Prior to protein translation, the non-coding parts of 
a gene (i.e., the introns) are excised from the nascent RNA by an event called splicing, 
leading to the concatenation of the coding parts of the gene (exons). Combinations of three 
adjacent nucleotides (i.e., codons) in the mRNA code for specific amino acids to adhere to 
the peptide chain during translation. Finally, the formation of a protein is terminated by the 
presence of a ‘stop’ codon, a specific sequence of three nucleotides (TAG, TAA, or TGA) that 
does not encode an amino acid, but forms the code to stop the translation of a protein.
1.3.2 Genetic variants
DNA is subject to various forms of heritable alterations. These variations can affect an entire 
chromosome or chromosomal region (for example, in trisomy 21, which is more commonly 
known as Down syndrome) or only an individual gene. Changes that affect an individual 
gene can be roughly categorized into two types: single-nucleotide polymorphisms (SNPs) 
and mutations.
1.3.2.1 Single-nucleotide polymorphisms
SNPs are natural variations in the DNA sequence, which affect only one single nucleotide, 
and occur in at least 1% of the population. When a SNP occurs within an exon of a gene or 
in a regulatory region near a gene, it can affect the gene’s function or expression. Although 
individual SNPs do not usually cause disease, individuals carrying several SNPs can have an 
increased risk of developing certain diseases, for example AMD (see Chapter 3).
1.3.2.2 Mutations
A pathogenic mutation is a relatively rare alteration of the DNA sequence that gives rise 
to disease, for example by impairing protein function. Heterozygous individuals have one 
mutant allele and one unaffected (i.e., ‘wild-type’) allele, whereas homozygous individuals 
have two mutant alleles (i.e., both copies of the gene contain the mutation). Based on the 
effect they have on the resulting amino acid sequence, DNA variations in exons can be 
either synonymous or non-synonymous. A synonymous variant does not change the amino 
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acid sequence of the protein, whereas a non-synonymous variant changes the protein 
sequence. Several types of non-synonymous mutations can occur. A missense mutation 
replaces the wild-type amino acid with a different amino acid, and this can change the 
protein’s structure and/or function. A frameshift mutation arises from the insertion or 
deletion of one or more (but not a multiple of 3) nucleotides in an exon. This shifts the 
mRNA’s reading frame, giving rise to a change in the resulting amino acid sequence in the 
protein. This can cause a significant change in the protein’s structure and often results in 
a non-functional protein product. If the replacement of a single nucleotide creates a stop 
codon, this mutation is called a nonsense mutation, which causes a prematurely terminated 
protein and can have severe phenotypic consequences. Unlike mutations in exons, variants 
that occur in the introns do not usually affect the protein’s function, unless they occur in 
DNA sequences involved in gene regulation. Mutations in regulatory elements can affect 
the level of gene expression, and mutations in or near a splice site can cause altered splicing 
between introns and exons and can result in exonic sequences being removed from—or 
intronic sequences being added to—the mRNA. 
1.3.2.3 Pathogenicity
It is often difficult to determine whether a specific genetic variant is the cause of a particular 
disease. In order to establish a causal relationship, the sequence variant in question should 
segregate with the disease in the family as expected for dominant or recessive mutations. 
The effect of a genetic variant on the structure and/or function of the resulting protein 
can often be predicted using various bioinformatics programs such as PhyloP, Grantham, 
Sorting Intolerant From Tolerant (SIFT), and Polymorphism Phenotyping (PolyPhen). The 
effect of variants in or near splice sites can be predicted with splice site prediction software. 
Other arguments to suggest pathogenicity of a genetic variant may arise when a specific 
genetic variant is conserved in many species throughout evolution (suggesting that the 
variant is disadvantageous) and by the absence of the variant in control subjects who do 
not have the disease. 
1.3.2.4 Mode of inheritance
Diseases may be inherited in several ways. In autosomal dominant inheritance, a variant or 
mutation in one of the two gene copies is sufficient to inherit a specific trait or disorder. A 
carrier of an autosomal dominant mutation has a 50% likelihood of passing the mutation 
to his/her offspring and therefore, theoretically 50% of the children would inherit the 
disease. This is only the case if the mutation is fully penetrant and thus results in a disease 
in all carriers of the mutation, like in DCMD. Reduced penetrance results in some carriers 
who have the mutation but not the corresponding phenotype; this can occur due to the 
presence of additional modifying genetic factors and/or interactions with environmental 
factors. Thus, reduced penetrance can mask the dominant mode of inheritance.
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In autosomal recessive inheritance, the mutation must be present on both gene copies 
(allele) in order to cause the disease. When an affected patient carries an identical mutation 
on both alleles, the mutation is homozygous; a carrier of different mutations on each allele 
is referred to as compound heterozygous. If both parents are heterozygous carriers of a 
mutation, each child has a 25% chance of inheriting both mutant copies (50% chance of 
inheriting the paternal mutant allele and 50% chance of inheriting the maternal mutant 
allele) and developing the disease phenotype. If the mutation occurs on an X chromosome, 
female heterozygous carriers are usually unaffected, as they also have a second, wild-type 
X chromosome. Male offspring have a 50% probability of inheriting the mutation from their 
carrier mother and will develop disease as they carry only one (affected) X chromosome. 
Finally, mutations can be located in the mitochondrial DNA, which is maternally inherited, 
and can affect both male and female offspring if the mother is affected.
1.3.3 Mutation detection
1.3.3.1 Monogenic diseases
The identification of the underlying mutation in a monogenic disease can confirm or establish 
a clinical diagnosis, which will help to provide the patient with adequate information 
regarding the prognosis of the disease, and it can facilitate genetic counseling in the family 
members of the patient. To date, knowing the precise genetic cause of a disease rarely 
has therapeutic consequences, as gene therapy is still being developed. Nevertheless, this 
information can help clinicians understand the pathogenesis of the disease.
The identification of the underlying disease-causing genetic defect in a monogenic 
disease of unknown cause can be started with linkage analysis in order to determine the 
chromosomal location of the defect; for example, this approach was used to determine 
that the DCMD locus is located on chromosome 7 (7p15.3).20 The genetic defect and 
surrounding polymorphisms tend to inherit together during meiosis, and these so-called 
‘polymorphic markers’ can be used to link the phenotype to a specific chromosomal locus. 
To identify a disease locus with genome-wide significance, a relatively large family with 
multiple affected individuals is required. To find the disease-causing mutation within 
the identified locus, candidate genes with a function related to the disease process can 
be screened for mutations by performing DNA sequence analysis. Traditionally, Sanger 
sequencing has been used for this approach, which is labor-intensive and expensive if 
a large number of candidate genes must be analyzed. Therefore, new ‘next-generation’ 
sequencing technologies can now be used to sequence all of the genes located in the 
chromosomal interval (targeted sequencing) or even all of the genes in the entire genome 
(exome sequencing). If a mutation is found, segregation of this mutation with the disease 
must be confirmed in the affected family. 
In patients with a retinal phenotype in which the genetic defect cannot be mapped 
to a specific locus (for example, due to small family size), currently identified mutations 
and/or other gene variants can be screened using a microarray (‘gene chip’), providing a 
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rapid, cost-effective method for testing hundreds of known mutations in multiple genes. 
If no mutations are found, exome sequencing can be applied to attempt to detect novel 
mutations in known retinal disease-related genes, or even to identify new disease-related 
genes. 
1.3.3.2 Complex diseases
In complex diseases such as AMD, identifying the underlying genetic variants can provide 
information regarding the pathways involved in the development of the disease and can 
therefore provide a possible therapeutic target. Additionally, factors playing a role in the 
development of the disease can be incorporated into prediction models to estimate more 
precisely someone’s risk of developing the disease.
In complex or multifactorial diseases, genetic variants in multiple genes can increase 
the risk of developing the disease, in addition to environmental factors. Family and twin 
studies may be used to estimate the inherited component of the disease. Previously, twin 
studies clearly suggested the importance of genetic factors in the pathogenesis of AMD, 
as monozygotic twins showed a higher concordance of disease features in intermediate 
and late-stage AMD compared to dizygotic twins.21,22 Detecting genetic variants in complex 
disease such as AMD can be difficult due to the relatively small contribution of individual 
genetic factors and phenotypic variability. Some clinical features have a more significant 
genetic component than others, like small peripheral drusen and cuticular drusen.23-25 
Genome-wide association studies in large cohorts have already identified several AMD-
associated SNPs.26 Simulation studies showed a significantly lower mean genotypic load of 
common AMD risk alleles in densely affected families than expected, suggesting that these 
families may carry rare, highly penetrant genetic variants.27 However, the question remains, 
How can we identify these genetic variants?
To analyze a complex disease, linkage studies are often problematic, as they require 
large, multi-generation families, which is challenging when studying an age-related disease 
such as AMD. In addition, the inheritance pattern is often not clear, genetic variants may 
not be fully penetrant, and phenocopies may occur due to the contribution of other genetic 
(and environmental) factors. Exome sequencing may be used to identify new genetic causes 
by sequencing all 180.000 exons of the human genome.28 For each individual subject, 
exome sequencing generally provides approximately 40.000 variants that differ from the 
reference sequence; therefore, after several filtering steps have been applied, several 
affected and non-affected family members must be analyzed in order to identify variants 
that segregate in the family.28 For example, filtering can be performed by inclusion of only 
coding variants of high and moderate impact on protein sequence (missense, nonsense, 
frameshift, and splice variants), exclusion of variants with a minor allele frequency >0.1% 
in the ‘1000 Genomes Project’ or the Exome Sequencing Project (ESP), and inclusion of 
missense variants that are annotated as ‘probably damaging’ by PolyPhen or ‘deleterious’ 
by SIFT. 
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Screening all exons in the genome provides a small chance (<4%) that potentially 
pathogenic gene variants associated with an increased risk of other unrelated diseases (for 
example, cancer or a neurological disorder) will be identified by chance.29 This could have 
important consequences for patients and their family members. Therefore, patients must 
be counseled thoroughly by their clinician on the chance of such incidental findings, and 
patients must provide written consent before exome sequencing is performed.
1.4 Age-related macular degeneration
AMD affects 30-50 million people worldwide and is the most common cause of visual 
impairment and blindness in the Western world.30-33 As the name suggests, AMD primarily 
affects the macula, leading to a progressive loss of the central visual field and a decline 
in visual acuity and color vision. AMD can have a profound impact on quality of life, as 
affected patients can no longer read, recognize faces, or discriminate colors.34, 35
1.4.1 Stages of AMD
Pathologically, AMD is characterized initially by changes in the RPE, followed by a loss 
of RPE and photoreceptor cells and/or secondary angiogenesis. Based on the anatomic 
abnormalities that develop in the fundus, AMD can be divided into early AMD and advanced 
AMD.
1.4.1.1 Early AMD
In early AMD, a spectrum of changes is observed in the aging macula despite relatively 
preserved visual acuity. The presence of drusen is the most characteristic early fundoscopic 
finding in AMD. Drusen usually present after the age of 50 years and appear on fundoscopy 
as focal white/yellow subretinal deposits. Histologically, drusen are focal extracellular 
deposits between the inner collagenous zone of Bruch’s membrane and the basal lamina of 
the RPE, consisting of cellular remnants and debris derived from degenerated RPE cells.36-39 
The molecular composition of drusen indicates that they may be the result of a chronic 
inflammatory stimulus that exacerbates the effect of primary pathogenic stimuli.39
Based on their characteristics and appearance, drusen can be distinguished as ‘hard’, 
‘soft’, ‘crystalline’, ‘reticular’, or ‘cuticular’. Hard drusen are defined as small (<63 µm), 
sharply defined structures, whereas soft drusen are larger (>63 µm) and irregularly shaped 
with poorly demarcated borders. The progression of early AMD to intermediate AMD is 
characterized by an increase in the number and/or size of drusen, which also increases 
the risk of progressing to advanced AMD.40 Both hard drusen and soft drusen can undergo 
calcification (crystalline drusen). On the other hand, reticular pseudodrusen (RPD) and 
cuticular drusen (CD) are defined based on the drusen patterns. RPD are defined as 
multiple ‘drusen-like structures’ that form poorly defined networks of broad interlacing 
ribbons.41 RPD can be identified easily using blue-channel examination, OCT, near-infrared 
imaging, red-free photography, or FAF imaging. OCT imaging shows clearly that RPD 
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are located above the RPE and that subretinal drusenoid deposits can cross the inner/
outer segment of the retina.42 The presence of RPD is strongly associated with the risk of 
developing advanced AMD.43-45 On fundoscopy, CD appear as innumerable small, yellow 
lesions that are scattered throughout the fundus; these lesions have a typical ‘stars in the 
sky’ appearance on fluorescein angiography. Anatomically, CD are located between the RPE 
and Bruch’s membrane. 
1.4.1.2 Advanced AMD
Early AMD can progress to advanced AMD, which can be classified as geographic atrophy 
(GA) or neovascular AMD. GA is characterized by the development of one or more 
sharply delineated regions of atrophy of the RPE and photoreceptors in the macula. GA 
accounts for the majority of advanced AMD cases. Neovascular AMD is due to choroidal 
neovascularization (CNV), which is the formation of new blood vessels that arise primarily 
from the choroidal vessels; these vessels grow through defects in Bruch’s membrane and 
infiltrate the retinal and/or subretinal space. These newly developed fenestrated vessels 
are friable and can cause serous RPE detachment, hemorrhage, and secondary fibrous 
scarring in the macula, resulting in rapid and severe loss of vision.
1.4.2 Risk factors
AMD is a complex, multifactorial disease and has been associated with several demographic, 
environmental, and genetic risk factors. Advanced age is the major risk factor associated 
with AMD.31 The prevalence of AMD increases with age and is more prevalent among 
females than males.31, 46, 47 The aging population will result in an increasing prevalence 
of AMD, leading to a higher social and healthcare burden. Therefore, new advances in 
preventive and therapeutic options—and the ability to predict high-risk individuals before 
disease onset—are urgently needed.
1.4.2.1 Environmental risk factors
Current cigarette smoking is the most important modifiable risk factor that has consistently 
been associated with a 2-3-fold increased risk in the development and progression of 
AMD.48-50 Although the precise mechanism is still unknown, oxidative damage, vascular 
inflammation, changes in choroidal blood flow, hypoxia, and antioxidant depletion have all 
been implicated in the retinal change that occurs in AMD patients secondary to smoking 
cigarettes.50-52 Quitting can reduce the risk of AMD, but even after 20 years the risk still 
remains higher than among individuals who never smoked.53 Several other modifiable risk 
factors have also been associated with AMD and include obesity,54, 55 low physical activity, 
sunlight exposure,56 cardiovascular disease,48 and certain dietary factors.50 With respect to 
diet, the consumption of omega 3, carotenoids (e.g., lutein and zeaxanthin), vitamin A, 
vitamin E, and antioxidants such as zinc may protect against the development of AMD.57
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1.4.2.2 Family history
Approximately one-third of all patients with AMD have a positive family history for the 
disease.58-61 Familial and twin-based studies initially revealed that genetic factors are strongly 
associated with developing AMD.21, 62-64 The heritability of AMD is estimated between 45% 
and 70%; the heritability of advanced cases is 67-71%.22 Since then, AMD-associated SNPs 
have been identified at 19 distinct loci; together, these SNPs can explain up to 65% of the 
heritability.26, 65 Part of the missing heritability may be explained by rare, more penetrant 
genetic variants.66-69 Genetic testing of AMD families seems to be the ideal approach for 
identifying these rare variants, as the aggregation of AMD in families cannot be attributed 
entirely to the clustering of known genetic and/or environmental risk factors.70 In patients 
with familial AMD, genetic factors seem to play a more important role.71 To date, rare 
variants have been identified in a small number of families with AMD.28, 67, 72, 73 Thus, the 
genetic variants that explain familial occurrence still need to be identified in the majority of 
families with AMD families. 
1.4.2.3 Genetic risk factors
Genome-wide association studies have identified several common genetic variants that 
are associated with AMD; these variants have relatively small effect sizes and are found in 
or near several genes that play a role in AMD-associated pathways (Table 1.1).26 The two 
major AMD-associated SNPs are the Ala69Ser variant in ARMS2 (which encodes age-related 
maculopathy susceptibility protein 2) and the Tyr402His variant in CFH (which encodes 
complement factor H); each of these variants causes a nearly three-fold increase in the risk 
of developing AMD.26 The function of the ARMS2 protein is not currently know, although 
mitochondrial dysfunction in photoreceptors and a defect in the extracellular matrix have 
been suggested;74, 75 this protein may also be associated with increased complement 
activation.76 The CFH gene encodes the principal regulator of the alternative complement 
pathway.77-79 Other complement system genes have been associated with AMD and 
include complement component 2 (C2),80 complement component 3 (C3),81, 82 complement 
component 9 (C9),82 complement factor B (CFB),80 and complement factor I (CFI).26, 82, 83 
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Table 1.1 Loci that are significantly associated with age-related macular degeneration
Chromosome Gene SNP Risk allele EAF OR [95% CI]
10 ARMS2/HTRA1 rs10490924 T 0.30 2.76 [2.72–2.80]
1 CFH rs10737680 A 0.64 2.43 [2.39–2.47]
6 C2/CFB rs429608 G 0.86 1.74 [1.68–1.79]
19 C3 rs2230199 C 0.20 1.42 [1.37–1.47]
22 TIMP3 rs5749482 G 0.74 1.31 [1.26–1.36]
19 APOE rs4420638 A 0.83 1.30 [1.24–1.36]
3 COL8A1/FILIP1L rs13081855 T 0.10 1.23 [1.17–1.29]
16 CETP rs1864163 G 0.76 1.22 [1.17–1.27]
6 IER3/DDR1 rs3130783 A 0.79 1.16 [1.11–1.20]
8 TNFRSF10A rs13278062 T 0.48 1.15 [1.12–1.19]
6 VEGFA rs943080 T 0.51 1.15 [1.12–1.18]
22 SLC16A8 rs8135665 T 0.21 1.15 [1.11–1.19]
4 CFI rs4698775 G 0.31 1.14 [1.10–1.17]
9 TGFBR1 rs334353 T 0.73 1.13 [1.10–1.17]
15 LIPC rs920915 C 0.48 1.13 [1.09–1.17]
14 RAD51B rs8017304 A 0.61 1.11 [1.08–1.14]
6 COL10A1 rs3812111 T 0.64 1.10 [1.07–1.14]
3 ADAMTS9/MIR548A2 rs6795735 T 0.46 1.10 [1.07–1.14]
13 B3GALTL rs9542236 C 0.44 1.10 [1.07–1.14]
SNP = single-nucleotide polymorphism; EAF = allele frequency of the risk-increasing allele; OR = odds 
ratio; CI = confidence interval.(Table derived from Fritsche et al.26)
Other genes that harbor AMD-associated SNPs are located in the high-density lipoprotein 
cholesterol pathway (APOE,84, 85 ABCA1,86 CETP,86 FADS1_3,87 LIPC,87 and LPL86), the 
extracellular collagen matrix pathway (COL8A1,87 COL10A1,88 and TIMP386), and vascular 
endothelial growth factors (VEGFA and TGFBR1). In addition, rare, highly penetrant variants 
with a strong association with AMD were recently identified by performing sequence 
analysis of complement genes and exome sequencing in patients with sporadic or familial 
AMD (Figure 1.4).28, 67, 69, 82, 89
1.4.3 Pathogenesis
The pathogenesis of AMD is complex and incompletely understood. Genetic association 
studies have implicated several biological pathways in which the immune system and 
inflammation play a central causative role in the pathogenesis of AMD. A growing body 
of evidence suggests that the complement system plays a key role in the pathogenesis of 
AMD.91 Histopathology studies indicate that chronic inflammation in response to cellular 
debris derived from degenerated RPE cells leads to the formation of drusen.39 This notion 
is supported by the finding of genetic associations between AMD and several common and 
rare variants in genes that encode complement components.74, 77-81, 83
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Figure 1.4 Genetic architecture of age-related macular degeneration. The effect size (odds ratio) of 
common and rare AMD-associated variants is plotted against minor allele frequency (MAF). Common 
variants with a relatively small effect size are shown in green.26 Rare variants with low population 
allele frequencies and large effect sizes are shown in red: CFI Gly119Arg (MAF: 0.001, OR: 22.0);89 CFH 
Arg1210Cys (MAF: 0.0002, OR: 18.8);69 C3 Lys155Gln (MAF: 0.004, OR: 3.7);66 and C9 Pro167Ser (MAF: 
0.008, OR: 2.2).82 MAF was calculated from the NHLBI Exome Sequencing Project based on alleles in 
populations of European ancestry. (figure derived from den Hollander et al.90)
1.4.3.1 The complement system
The complement system is part of the innate immune system (Figure 1.5) and can be 
activated via three distinct pathways (the classical, the alternative and the lectin pathway). 
Activation of the complement system leads to the removal of potentially harmful materials 
such as cellular debris and generates the production of inflammatory chemotactic proteins 
that trigger inflammation (e.g., complement components C3a and C5a) and opsonized 
proteins that attract other immune cells (e.g., C3b). The complement system is tightly 
regulated by several proteins such as complement factor H (CFH) and CFI. Dysregulated 
complement activation can cause substantial damage to self-tissues, leading to a variety 
of diseases, including AMD.92 Increased levels of complement components (e.g., CFB) and 
complement activation products (e.g., C3d and C3a) have been found in the plasma of AMD 
patients.93-95 In addition, chronic continuous activation of the complement system occurs 
in the eyes of elderly individuals. Activation of the complement system may lead to the 
formation of drusen and to degeneration of the RPE and photoreceptor cells.18 Consistent 
with this hypothesis, several components of the complement system have been detected in 
drusen.96, 97 Drusen and RPE degeneration can in turn activate the complement system, and 
this vicious cycle causes further damage to RPE cells and the retina.
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The complement system can also affect other mechanisms associated with the 
pathophysiology of AMD. For example, the chemotaxis of macrophages causes a release 
of reactive oxygen species, thus causing oxidative damage, which plays an important role 
in the development of AMD. In addition, the membrane attack complex (MAC), a final 
component in the complement cascade that results in cell lysis, can disrupt the delicate 
balance between anti-angiogenic and pro-angiogenic factors in the choroid and retina, thus 
causing CNV.98
Figure 1.5 Schematic representation of the complement system. The complement system can be 
activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation 
of the system initiates the formation of component 3 (C3) convertase (Initiation). This enzyme cleaves 
C3 into C3a and C3b (C3 convertase). C3b generates C3bBb, which amplifies the C3 convertase. If 
activation of the system progresses, C5 convertase, which cleaves C5 into C5a and C5b, is generated. 
C5b can initiate the terminal pathway, which recruits components C6, C7, C8, and C9 and forms the 
membrane attack complex. Overall, complement activation results in three effector responses: 1) the 
anaphylactic peptides C3a and C5a cause inflammation; 2) C3b causes opsonization of the foreign 
surface, leading to phagocytosis; and 3) the membrane attack complex is inserted into the membrane, 
resulting in cell lysis. (Figure modified according to Kandhadia et al.99)
1.4.4 Prevention and therapy
With the identification of several AMD susceptibility genes and the revealed inflammatory 
pathways playing a critical role in the pathophysiology of AMD, genetic studies of AMD may 
contribute to our ability to prevent the progressive loss of central vision and may facilitate 
the development of new treatments. This is very important as the prevalence of AMD will 
increase over time by aging of the population, and visual impairment reduces quality of life. 
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Drugs that target the complement system are currently being tested for their efficacy 
in AMD,100, 101 and future work on rare variants and non-coding DNA in the pathogenesis 
of AMD will likely reveal additional biochemical pathways with AMD-associated genetic 
variants. Pharmacologic targets in these pathways may lead to rational, effective therapeutic 
approaches for preventing and treating this sight-threatening disease.102
The only therapeutic approach currently available for reducing the risk of progressing to 
advanced AMD is the consumption of certain dietary supplements (e.g., vitamin C, vitamin 
E, zinc, beta-carotene, and/or lutein/zeaxanthin), which can reduce the risk of progression 
by up to 25%.103 Although neovascular AMD can be treated successfully with anti-VEGF 
drugs, some patients with neovascular AMD do not benefit from anti-VEGF therapy. 
Clinical factors such as age, baseline visual acuity, and baseline CNV lesion size appear to 
be important predictors of whether a patient with neovascular AMD will respond to anti-
VEGF treatment;104 in addition, response to treatment may also depend on the genotype of 
several AMD-associated genes, including CFH,104-106 VEGFA,104, 107, 108 and ARMS2.109 However, 
the pharmacogenetic relationship was not consistently replicated for all AMD-associated 
genes.106, 110 Currently, no therapeutic option is available for geographic atrophy.
1.5 Dominant cystoid macular dystrophy
DCMD is an extremely rare retinal dystrophy with an autosomal dominant inheritance 
pattern. However, in the Netherlands, one large family with DCMD exists in which the 
disease can be traced back to a single common ancestor in the early 18th century. In 
the 1970s, Pinckers and Deutman collected clinical and electrophysiological data from 
this family, and to date a large body of clinical data has been collected from 97 affected 
members and 52 unaffected family members.
DCMD typically presents within the first or second decade of life, with intraretinal cystoid 
fluid collections (CFCs) as the most remarkable finding (Figure 1.6); in addition, patients can 
present with a (highly) hypermetropic refraction error. The degree of CFCs can vary widely, 
corresponding with a variable visual acuity over time. During disease progression, CFCs 
diminish and are replaced by chorioretinal atrophy, eventually resulting in a visual acuity at 
the level of legal blindness. Corresponding with the progression of structural abnormalities 
in the retina, the retinal function becomes impaired, expressed by an abnormal EOG and 
full-field ERG. DCMD can be classified into three stages, as discussed in Chapter 4.
Linkage analysis showed a shared DCMD haplotype (i.e., a combination of alleles at 
a certain chromosomal locus) located on the short arm of chromosome 7 (7p15-p21).20 
DCMD is a monogenic, autosomal dominant disease; however, the causative genetic defect 
has not yet been identified. Advanced next-generation sequencing techniques are currently 
being used in an attempt to identify the genetic cause of this devastating disease. 
Chapter 1
34
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
Figure 1.6 Optical coherence tomography image of cystoid fluid collections in the macula of a 23–
year–old patient with dominant cystoid macular dystrophy. 
1.6 Butterfly-shaped pigment dystrophy
Butterfly-shaped pigment dystrophy (BSPD) was first described in 1970 by Deutman 
et al.111 BSPD is one of the autosomal dominant pattern dystrophies,112 which have 
been subdivided into five groups based on the pattern of pigment distribution. Pattern 
dystrophies are clinically heterogeneous diseases, as the shape of the central yellow lesions 
can vary considerably. Thus, members of a single family with a given genetic mutation can 
have several different patterns, and an individual patient can have different patterns in 
the left and right eyes or can even progress from one pattern to another pattern.113-115 
BSPD is characterized by the deposition of pigment at the level of the RPE; these deposits 
are arranged symmetrically in a triradiate pattern confined to the center of the macula, 
resembling the shape of a butterfly.111 BSPD has also been called butterfly-shaped macular 
dystrophy. The pigment figure is generally surrounded by a zone of depigmentation, which 
corresponds to hyperfluorescence in the early phases of fluorescein angiography, thus 
outlining the hypofluorescent pigment shape in the macula (Figure 1.7).112 Usually BSPD 
causes a mild loss of central vision in midlife, and it has a relatively good prognosis. Patients 
often present with an abnormal EOG, but the ERG remains normal. In addition to phenotypic 
heterogeneity, BSPD also shows marked genetic heterogeneity. BSPD is inherited as an 
autosomal dominant disease and can be partly explained by mutations in the peripherin-2 
(PRPH2) gene.116-119 The PRPH2 gene is located on chromosome 6 (6p21.2) and encodes an 
integral membrane protein that plays an important role in the morphogenesis of rod outer 
segment discs and cone lamellae.120 
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Figure 1.7 Fluorescein angiograph of a 36-year-old patient with butterfly-shaped pigment dystrophy. 
1.7 Aims and outline of this thesis
The aim of this thesis is to increase our understanding of the clinical and genetic 
characteristics of AMD and other macular diseases. Specifically, we studied the importance 
of a positive family history of AMD with respect to clinical, phenotypic, and genetic aspects, 
and our results will likely facilitate the development of reliable models for predicting 
AMD. This may provide more accurate information regarding the individual risk for AMD, 
particularly for individuals in which AMD has a strong familial component. In addition, the 
identification of genetic variants in familial AMD and BSPD will facilitate risk assessment 
and genetic counseling of family members and will aid to elucidate the pathophysiology of 
these diseases.
Chapter 1 provides the reader with information on the basic aspects of the retina, 
as well as the clinical and genetic methods that may be applied in the analysis of retinal 
disease. In addition, the general characteristics of AMD, DCMD and BSPD are described 
with emphasis on the importance of the familial occurrence in macular disease.
Chapter 2 discusses the characteristics of AMD and macular dystrophies that may 
mimic AMD and provides a practical differential diagnostic guideline based on overlapping 
and distinguishing clinical and genetic characteristics.
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Chapter 3 concerns the clinical and genetic analysis of AMD with respect to the presence 
or absence of a family history of AMD. 
Chapter 3.1 starts with an evaluation of the differences and similarities between familial 
and sporadic AMD with respect to risk factors, clinical characteristics, and phenotypes. 
Chapter 3.2 provides an analysis of the family history of AMD and the importance of family 
history in AMD prediction models that are based on the density of a positive family history 
and family size. The non-significant additive value of common SNPs in an AMD prediction 
model for familial patients may be explained by the contribution of additional rare genetic 
factors that segregate within these families.
Chapter 3.3 presents the differences in the contribution of common genetic variants and 
complement activation levels between familial and sporadic AMD. A better understanding 
of the factors that interact with family history will aid in reliable prediction for AMD. 
Chapter 3.4 describes the clinical differences between affected carriers of a rare variant in 
the CFI, C9, or C3 complement gene compared to non-carriers with AMD. In addition, the 
presence of a rare variant has been analyzed with respect to a positive family history.
Chapter 3.5 reveals the identification of novel rare variants in the CFH gene in patients 
with cuticular drusen, a subtype of AMD, and describes the clinical features of individuals 
carrying these genetic variants.
Chapter 4 provides a system for classifying DCMD into three distinct stages based on 
the clinical characteristics and long-term follow-up data obtained from a large Dutch family 
with DCMD. Additionally, we discuss our evaluation of the efficacy of therapeutic options and 
the penetrance of the genetic locus in this family.
Chapter 5 presents the identification of rare mutations in the CTNNA1 gene as a novel 
cause of BSPD, followed by functional studies to investigate the impact of these mutations 
on protein function. In addition, mouse models are used to evaluate the impact of this 
mutated gene on retinal architecture and function.
In Chapter 6 the studies described in this thesis are further discussed and placed in a 
broader perspective. Finally, a summary of the findings is provided in Chapter 7.
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Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in 
the elderly population in the Western world. AMD is a clinically heterogeneous disease 
presenting with drusen, pigmentary changes, geographic atrophy and /or choroidal 
neovascularization. Due to its heterogeneous presentation, it can be challenging to 
distinguish AMD from several macular diseases that can mimic the features of AMD. 
This clinical overlap may potentially lead to misdiagnosis. In this review, we discuss the 
characteristics of AMD and the macular dystrophies that can mimic AMD. The appropriate 
use of clinical and genetic analysis can aid the clinician to establish the correct diagnosis, 
and to provide the patient with the appropriate prognostic information. An overview is 
presented of overlapping and distinguishing clinical features. 
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1. INTRODUCTION
1.1 AMD 
Age-related macular degeneration (AMD) is a progressive chronic disease of the central 
retina and the leading cause of irreversible blindness in the elderly population in 
industrialized countries.1 Based on a meta-analysis of studies in white people aged 40 years 
and older, the prevalence of early AMD is estimated to be 6.8% and the late stages to be 
1.5%.2 The prevalence of AMD increases exponentially with age.3 In the Beaver Dam Eye 
Study that includes predominantly white participants, individuals of age 75 years and older, 
the fifteen year cumulative incidence of early AMD was 24.4% and of late AMD was 7.6%.4 
The prevalence of AMD, however, differs in ethnic groups. The Baltimore Eye Study has 
shown that late stage AMD was nine to ten times more prevalent in the white as compared 
to the black participants.5 In the Asian population, the prevalence of late stage AMD appears 
to be largely similar to that in white people.6
Different cell layers are involved in the disease process: the photoreceptors, the retinal 
pigment epithelium (RPE), Bruch’s membrane and the choriocapillaris. Different stages 
and phenotypic manifestations of AMD have been categorized 7: The early stages (early 
and intermediate AMD) are characterized by pigmentary alterations and/or the formation 
of so called ‘drusen’, extracellular material located between the RPE and the Bruch’s 
membrane. Patients with early AMD are usually asymptomatic. AMD may progress to 
exudative (neovascular) AMD and non-exudative (atrophic) AMD, both resulting in vision 
loss. Typically, patients with neovascular AMD describe sudden worsening of central vision 
with distortion of straight lines or a dark patch in their central vision. In atrophic AMD 
progressive loss of vision develops over many years. Neovascular AMD and atrophic AMD 
may also occur in combination. The most severe decline of visual acuity from AMD is 
caused by these advanced forms of the disease. In addition, psychophysical studies have 
demonstrated that several parameters of visual function, in particular contrast sensitivity, 
visual adaptation, central visual field, and color discrimination, deteriorate already in the 
early stages of AMD.8 Since the disturbance in psychophysical function in AMD is not limited 
to the macular region, but extends well into the retinal periphery, it appears that there is a 
global impairment of retinal function.9, 10 
The pathogenesis of AMD is incompletely understood. As a complex, multifactorial 
disease, it is thought to involve variations in a number of genetic, systemic and 
environmental factors. Aging itself appears to be the major risk factor that renders the 
retina more susceptible to environmental effects.11
Biochemical, histological and genetic studies have indicated several pathways in 
AMD pathogenesis, including excessive accumulation of lipofuscin, oxidative damage, 
malfunctioning of the complement system, and chronic low-grade inflammation and 
possible sequences of events have been proposed.
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Lipofuscin accumulates in postmitotic RPE cells with age apparently due to incomplete 
lysosomal degradation of photoreceptor outer segments (reviewed by Boulton).12 Lipofuscin 
consists of a multitude of molecules including the dominant fluorophore N-retinyl-N-
retinylidene ethanolamine (A2E), a by-product of the visual cycle.13, 14 Exposure of lipofuscin 
containing RPE cells to blue light (390-520nm) results in a lipofuscin-dependent lipid 
peroxidation, protein oxidation, loss of lysosomal integrity, mitochondrial DNA damage, 
and RPE cell death (reviewed by Boulton).12 It has further been suggested that products of 
the photooxidation of A2E in RPE cells could serve as a trigger for complement activation.15 
An aberrant complement regulation - that is implicated by the association of the risk for 
AMD with DNA sequence variants in genes encoding for complement factors (see below) 
- appears to contribute to chronic inflammation. Herein, drusen are thought to form as a 
product of those local inflammatory processes.16, 17
In recent years, major progress was made in elucidating the genetic basis of AMD 
through the identification of two common variants on chromosome 1 and 10, together likely 
accounting for approximately 50% of cases. On chromosome 1, a strong association was 
identified with variants in the complement factor H (CFH) gene, suggesting an involvement 
of the complement cascade in AMD pathogenesis.18-21 Subsequently, AMD risk variants 
in other genes involved in the complement cascade were identified, for example in the 
complement component 2 /factor B,22 component 3 (C3),23 and complement factor I genes.23 
The second major AMD risk locus was identified on chromosome 10. Disease associated 
variants support a region harbouring two genes in strong linkage disequilibrium, named 
the age-related maculopathy susceptibility 2 gene and the high temperature requirement 
factor A1 gene.24, 25 However, the functional implications of the chromosome 10 locus on 
AMD pathology are still unclear. A genomic wide association study recently performed by 
the AMD Gene Consortium found in total 19 loci associated with AMD, including seven new 
loci.26 Recently, rare, highly penetrant mutations in the CFH and Complement Factor I genes 
have been identified besides the common genetic variants, conferring a high risk of AMD.27-
30 Rare variants may play an important role in the pathogenesis of AMD particularly in case 
of densely affected families.
Recently, a predictive model for late stage AMD based on data from population-based 
studies (the Rotterdam Study, the Beaver Dam Eye Study, and the Blue Mountains Eye 
Study) has been reported. It has been shown that best prediction for late AMD was based 
on age, sex, 26 genetic variants, 2 environmental variables, and early AMD phenotype. 31, 32
1.2 Differentiating macular dystrophies from AMD: difficulties and relevance
There are no pathognomonic clinical characteristics for AMD, despite the fact that drusen 
are a hallmark feature. Different clinical manifestations may be present, leading to a broad 
phenotypic spectrum of AMD. Due to this clinical variability of AMD, there is a considerable 
overlap with a number of macular dystrophies that are often monogenic with specific 
inheritance patterns. Also, AMD and the macular dystrophies show a considerable variation 
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in their clinical presentation and severity. Flecks that may resemble drusen can be present in 
several hereditary macular conditions. Many macular dystrophies may show chorioretinal 
atrophy comparable to geographic atrophy (GA) in AMD. Choroidal neovascularization 
(CNV) can also occur in macular dystrophies, although it is rare and appears to have a 
relatively favourable prognosis as compared to CNV in AMD. 33 
A differentiation between AMD and other macular disorders is important as the exact 
diagnosis can have implications for the prognosis and genetic counselling as well as for 
preventive and therapeutic strategies. 
This review aims to give an overview of macular dystrophies that may mimic AMD. 
For every disease we describe the symptoms, multimodal imaging and psychophysical 
and electrophysiological testing. In addition, we also summarize the genetic background 
and the pathophysiology of each disease. Based on these specific clinical and genetic 
characteristics, we provide a practical differential diagnostic guideline. 
2. FUNDOSCOPIC FINDINGS IN AMD AND MACULAR DYSTROPHIES
2.1 Drusen and ‘drusen-like lesions’
Drusen are considered as the phenotypic hallmark of AMD, but they are not pathognomonic 
of AMD.34 Drusen are focal deposits of extracellular debris located between the basal lamina 
of the RPE and the inner collagenous layer of Bruch’s membrane.35, 36 Drusen are known to 
contain carbohydrates, zinc, and at least 129 different proteins, including apolipoproteins 
and excluding extracellular matrix. 37-43 
Fundoscopically, drusen are yellowish nodular lesions located at the posterior pole. 
Previous classifications of AMD have included the following qualities of drusen: drusen size 
(e.g., large vs. small), character (e.g., soft vs. hard), location, number, and area. 44-46 The 
recently reported AMD classification by Ferris et al. again stresses the importance of drusen 
size in AMD patients, particularly with regards to the prognostic relevance for late-stage 
disease development. Hereby, small drusen (≤63 µm) are considered to represent normal 
aging changes and should be differentiated from early AMD. 7 Medium sized drusen (>63 
µm and ≤ 125 µm) without associated pigment abnormalities represent early while large 
drusen (< 125 µm) and/or any AMD-related pigmentary abnormality (i.e. any definite hyper- 
or hypopigmentary abnormalities associated with medium or large drusen) represent 
intermediate AMD (Figure 2.1A).7 Drusen may present as clusters and become confluent 
(‘confluent drusen’). Large confluent drusen may form clinically evident pigment epithelial 
detachments without underlying CNV (‘drusenoid pigment epithelium detachment’).47 
On fluorescein angiography (FA), small drusen may show a focal hyperfluorescence in the 
late-stage, whereas larger drusen usually show a hypofluorescence due to the blockage of 
choroidal background fluorescence. Fundus autofluorescence (FAF) does not allow clear 
distinction of most AMD-related drusen because drusen exhibit a similar signal compared 
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to the background (Figure 2.1B). One exception is large, confluent drusen that show a 
mildly increased signal. Compared to fundus photography, the area involved by soft drusen 
appears to be better detectable by FAF imaging. On spectral-domain optical coherence 
tomography (SD-OCT) imaging, drusen typically present as ‘dome-shaped’ elevations of 
variable size of the outer retinal layers and the RPE (Figure 2.1D). SD-OCT herein enables to 
reveal differential reflectivity of the drusen material by itself 48. This may point to differences 
in the biochemical composition of drusen. 
Cuticular drusen, formerly known as ‘basal laminar drusen’ that have been firstly 
described by Gass in 1977.49 It has been estimated that the cuticular drusen phenotype 
comprises approximately 10% of the AMD spectrum.28 Cuticular drusen are usually 25 - 75 
µm in size and are discretely round, slightly raised, yellow, subretinal pigment epithelium 
nodules that initially may be randomly scattered in the macular area in young adults, but 
later often become more numerous and in some patients are grouped in clusters of 15 - 20 
drusen (Figure 2.1E).49 These clusters, in turn, may be closely arranged in a knit pattern 
giving the entire macula and the paramacula an orange-peel appearance.49 FA is particularly 
helpful for the visualization of cuticular drusen. They fluoresce discretely during the early 
arterio-venous phase and in many patients they give the fundus a ‘stars-in-the-sky’ picture 
(Figure 2.1G).49 FAF shows cuticular drusen as areas of ill-defined autofluorescence centered 
by punctate hypo-autofluorescent lesions (Figure 2.1F).50-52 Besides correlating with ‘dome-
shaped’ elevations, cuticular drusen have been reported to further appear as irregular 
slight thickening of RPE/Bruch’s membrane complex or as a ‘sawtooth’ RPE elevation on 
SD-OCT scans (Figure 2.1H).50
A higher allele frequency of the CFH Y402H risk allele in patients with cuticular drusen 
suggests that activation of the alternative pathway of the complement system may play a 
larger role in the pathogenesis of the cuticular drusen phenotype than in the remainder 
of the AMD phenotypes. 53-55 This is supported by previous studies that identified rare 
pathogenic CFH mutations in a subset of families with cuticular drusen. 28, 30
In addition, reticular (pseudo-)drusen have been described. Initially reported by Mimoun 
et al. as ‘pseudodrusen visible en lumière bleu’ [‘the pseudo-drusen visible in blue light’].56 
It has been described by others using different terms, including ‘reticular drusen’.57 There is 
still an ongoing debate whether reticular drusen are located anterior or posterior to the RPE. 
Reticular drusen are subtle, fundoscopically hardly detectable individual lesions showing 
an interlacing network of round or oval shaped multiple, yellowish irregularities with an 
approximately size between 50 and 250 µm (Figure 2.1I). Several studies, for instance the 
Beaver Dam Eye study, identified reticular drusen as a risk factor for the development of 
late-stage AMD.58, 59 On FA reticular drusen may show a discrete hypofluorescence towards 
the later phases. The reticular pattern is typical for reticular drusen by FAF imaging showing 
multiple spots with decreased intensity surrounded by mildly increased intensity (Figure 
2.1J). The reticular drusen pattern in cSLO (confocal scanning laser ophthalmoscopy) 
images correlates with marked changes at a level anterior to the RPE/Bruch’s membrane 
Age-related macular degeneration and macular dystrophies mimicking AMD
51
2
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
complex.60-62 By scanning precisely through a row of reticular lesions by SD-OCT, 
accumulation of material between the ellipsoid zone of the photoreceptors and the RPE/
Bruch’s membrane complex is visible (Figure 2.1K) 60-62 (anatomical correlations of SD-OCT 
bands are according to the nomenclature proposed by the ‘International Nomenclature for 
Optical Coherence Tomography Panel’).
Large colloid drusen are large (200 to 300 µm) lesions associated with an early age 
at onset and a relatively good vision.63 The lesions show increased autofluorescence 
on FAF and are mildly hyperfluorescent in the early phases of FA, with a progressive 
staining in late phases.63 On indocyanine green angiography (ICGA), large colloid drusen 
are hypofluorescent in the early phase, and in later phases the hypofluorescent centre is 
surrounded by a hyperfluorescent halo bordered by a thin hypofluorescent ring.63 
Irregular flecks: Fundus flavimaculatus is characterized by the presence of irregular 
yellowish flecks in the deeper retinal layers of the posterior pole. The flecks are variable 
in size, shape and distribution. In the midperipheral retina, these yellowish flecks can be 
interconnected to form a reticular pattern.64 
Vitelliform lesions: The term ‘vitelliform’ is aspecific, referring to a round, yellowish 
lesion that looks like an egg yolk. Vitelliform lesions show intense hyperautofluorescence 
on FAF and hypofluorescence on FA, due to the accumulation of hyperreflective material 
between the neuroretina and RPE, which is visible on SD-OCT. 65, 66 Vitelliform lesions can be 
seen in a broad range of macular conditions, such as adult-onset foveomacular vitelliform 
dystrophy (AFVD), Best vitelliform macular dystrophy (BVMD), drusenoid vitelliform RPE 
detachments, mitochondrial retinal dystrophy associated with the m.3243A>G mutation, 
vitreofoveal traction, acute vitelliform polymorphous exudative maculopathy, and 
paraneoplastic vitelliform retinopathy. 67, 68
2.2 Pigmentary changes
Pigmentary changes appear on clinical examination either as hypopigmentary changes, 
which are seen as depigmented areas of the RPE or hyperpigmentary changes, which 
are deposits of grey or black pigment within the retina or at the level of the RPE.46, 69 
Hyperpigmentation in AMD is presumed to result from RPE displacement, migration, or 
degeneration.46, 69 Any hyper- or hypopigmentary abnormality associated with medium or 
large drusen is a defining feature of intermediate AMD. 7 
On FA, hyperpigmentations usually appear hypofluorescent due to blocked background 
fluorescence, while on FAF, there is frequently a correlating increased signal (Figure 2.1B). 
On SD-OCT, hyperpigmentary alterations usually correlate with hyperreflective foci (Figure 
2.1C). These foci may be located at the level of the RPE or in more inner retinal layers.60, 70 
Serial examinations in vivo by high-resolution OCT imaging have shown migration of these 
hyperreflective foci into more inner retinal layers with time. 71, 72
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2.3 Geographic atrophy
Fundoscopically, GA appears as a sharply demarcated area with depigmentation and 
typically enhanced visualisation of deep choroidal vessels (Figure 2.1L). GA may occur as 
uni-focal or multi-focal lesion. The configuration of atrophy may vary from round or oval 
to lobular. Histologically, areas of GA in AMD are characterized by loss of the RPE, of outer 
layers of the neurosensory retina and the choriocapillaris. 73, 74
On FA, GA typically presents with late well-defined hyperfluorescence. Due to the loss of 
the RPE, the hyperfluorescent signal derives from the staining of the exposed deep choroid 
and sclera (‘window defect’).
Due to RPE atrophy and thus loss of intrinsic fluorophores, GA in AMD presents as 
well-demarcated lesion with decreased FAF signal (Figure 2.1M). FAF imaging allows for 
more precise delineation of the atrophy process as compared to fundus photography. 
Furthermore, in the area surrounding the GA, different patterns of abnormal FAF may be 
differentiated. 75, 76 This allows for phenotypic sub-classification of GA. Herein, the ‘banded’ 
and the ‘diffuse’ GA sub-types have been shown to be associated with a significantly faster 
progression of the GA lesions as compared to the ‘none’ and ‘focal’ sub-types.75 
On SD-OCT imaging, GA is characterized by loss of the outer retinal layers, including 
the outer nuclear layer, the external limiting membrane, ellipsoid zone, myoid zone, and 
interdigitation zone, respectively, and by loss of the inner part of the RPE/Bruch’s membrane 
complex (assumed RPE-layer) (Figure 2.1N).60 The GA border in AMD usually shows marked 
alterations of the outer retinal SD-OCT layers. In the area surrounding GA, SD-OCT imaging 
may reveal various microstructural alterations that may also be found in eyes with only 
drusen and hyperpigmentation. 60
2.4 Choroidal neovascularization
CNV is the in-growth of pathologic new blood vessels through Bruch’s membrane into 
the sub-RPE and/or the subretinal space originating from the choriocapillaris. Leakage of 
plasma or blood into the surrounding tissue is characteristic of CNV lesion. The natural 
course of CNV is evolution to fibrovascular scar formation. Retinal Angiomatous Proliferation 
(RAP) has recently been recognized as a variant of neovascular AMD that is characterized 
by the formation of pathologic new vessels within the retina that may secondarily invade 
into the subretinal space or into the choroid.77 Polypoidal choroidal vasculopathy (PCV) 
is characterized by branching vascular networks terminating in polypoidal dilations that 
appear as reddish-orange structures beneath the RPE. 78 It is still debated if PCV is a sub-
form of AMD or if it is a separate clinical entity. CNV may present fundoscopically as greyish 
subretinal lesion (Figure 2.1O). Other fundoscopic changes that suggest CNV include 
macular edema, subretinal fluid, hard exudates, haemorrhage, and RPE detachment.
It has been shown that CNV may be associated with normal, increased, or decreased 
focal RPE autofluorescence. 79-83 Abnormal FAF intensities visible in eyes with CNV often 
extend beyond the edge of a lesion defined by FA, which indicates a more widespread 
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disease process, over and above that witnessed on conventional angiograms (Figure 2.1P). 
It has been speculated that this observation may reflect the proliferation of RPE cells 
around the CNV. 84 
Fluorescence angiography is the gold standard for visualization of CNV and differentiation 
of CNV variants. According to its appearance during FA, CNV can be classified into classic or 
occult lesion types. The classic type shows well-defined margins and homogeneous leakage 
of dye within the entire lesion, whereas occult lesions demonstrate irregular margins with 
heterogeneous leakage of fluorescein within the lesion (Figure 2.1Q).85 Originally, the 
differences in leakage pattern were assumed to be explained by the anatomic location – 
subretinal or sub-RPE - of the CNV. However, clinico-pathological correlations indicated 
a lack of strong correlation between fluorescein angiography pattern and anatomic 
localization of the CNV. 86
For the diagnosis and visualization of PCV and RAP, indocyanine green (ICG) angiography 
is superior to other imaging modalities.
High-resolution OCT imaging allows for precise visualization of subretinal and intraretinal 
fluid and other CNV-associated characteristics (Figure 2.1R). Furthermore, detection of 
changes in retinal thickness by OCT imaging has become an important indicator in the 
monitoring of therapeutic effects in CNV.
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Figure 2.1 (A-D) Drusen and hyperpigmentation in a 67-year-old patient with intermediate Age 
related macular degeneration (AMD). The color fundus image (A) shows medium and large sized 
drusen associated with hyperpigmentation. Fundus autofluorescence (FAF) imaging (B) shows an 
increased signal that is mainly associated with the hyperpigmentary changes. Drusen are associated 
with increased, decreased or normal FAF. Note the ‘reticular drusen’ FAF pattern pronounced superior-
temporally. Optical coherence tomography (OCT) imaging reveals hyperreflective foci that correspond 
to the hyperpigmentary changes (C) or shows the characteristic dome-shaped appearance of drusen 
(D). The images (E-H) show cuticular drusen in a 38-year-old patient. (E) Color fundus photograph 
showing small yellow cuticular drusen in the macula and peripheral retina. (F) FAF image showing 
increased autofluorescence of the deposits in the posterior pole (black arrows). (G) Fluorescein 
angiography (FA) image showing the hyperfluorescent deposits as a typical ‘stars-in-the-sky’ 
picture in the early phase. (H) Horizontal OCT scan showing the cuticular drusen corresponding to 
hyperreflective elevations of the retinal pigment epithelium (RPE). The images (I-K) show reticular 
drusen in an 80-year-old patient associated with intermediate AMD. The color fundus image (I) shows 
the superior central area with drusen and hyperpigmentation in an interlacing network of round and 
oval shaped yellowish irregularities. FAF imaging (J) shows multiple spots with decreased intensity 
surrounded by mildly increased intensity. SD-OCT imaging (K) reveals a wavy pattern of the ellipsoid 
zone (black arrow) with accumulation of highly reflective material between the ellipsoid zone and 
the RPE/Bruch’s membrane complex (white arrow) corresponding to the reticular pattern in the IR 
image. The images (L-N) show a multifocal geographic atrophy (GA) secondary to AMD, in a 77-year-
old patient. Fundoscopically (L), the GA appears as a sharply demarcated area with depigmentation 
and typically enhanced visualisation of deep choroidal vessels. On FAF imaging (M) there is a well-
demarcated area with decreased FAF corresponding to the GA lesion. On SD-OCT imaging (N), GA is 
characterized by loss of the outer retinal layers and a signal enhancement within the choroid. (O-R) 
Choroidal neovascularization (CNV) in a 68-year-old patient with occult CNV secondary to AMD. In the 
fundus image (O), there is a PED and drusen. In the FAF image (P), the lesion extends beyond the edge 
of the lesion defined by FA (Q). On SD-OCT imaging (R), there is a PED visible with subretinal fluid in 
the inferior part of the lesion.
3. DIFFERENTIAL DIAGNOSTIC TOOLS
The most important differential diagnostic findings and genetic associations of each 
macular dystrophy are summarized in Table 2.1. With the advancements in multimodal 
retinal imaging and genetic testing, a spectrum of diagnostic tools is currently available to 
establish the correct diagnosis. An overview of important differentiating findings with the 
available differential diagnostic tools is given below.
3.1 Symptoms and fundoscopy
Patients with early AMD usually present with normal central visual acuity. Impaired dark 
adaptation upon moving from brightly lit to dim environments, however, is commonly 
reported by patients with early AMD, although central visual acuity remains normal. 
87 Furthermore, distinct drusen may cause metamorphopsia. Progression of the disease 
generally results in vision loss, increased metamorphopsia and/or a dark patch in central 
vision. The course of visual symptoms and the age of onset may help to discriminate AMD 
from macular dystrophies. 
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North Carolina macular dystrophy (NCMD) patient for instance, typically present with 
visual complaints during their childhood and complaints and fundoscopic features have 
a stable course. The visual acuity is relatively good and stable, like in patients with late-
onset Stargardt and pseudo-Stargardt pattern dystrophy. Patients with late-onset retinal 
degeneration (LORD), Sorsby fundus dystrophy (SFD) and pseudo-Stargardt pattern 
dystrophy may also present with night vision problems or loss of peripheral vision. Some 
macular diseases discussed in this review are multisystemic disorders presenting with 
additional multisystemic symptoms. Patients with maculopathy in myotonic dystrophy 
often present with muscle weakness and myotonia and patients with pseudoxanthoma 
elasticum (PXE) may suffer from cardiovascular disease, gastro-intestinal bleeding and skin 
papules. Hearing loss and diabetes in maternally inherited diabetes and deafness (MIDD) 
patients and renal disease in membranoproliferative glomerulonephritis type II (MPGN II) 
patients are also systemic symptoms, which may help to come to the correct diagnosis.
In AMD, fundoscopic features are present mainly in the macular area. In contrast, 
deposits in SFD patients are present in the entire posterior pole, extending to the equator. 
The presence of comet tail lesions, angioid streaks and peau d’orange point to PXE-related 
dystrophy. In addition, the aspect of the optic disc and the peripapillary region may provide 
distinguishing information like drusen of the optic disc in PXE dystrophies, and juxtapapillary 
drusenoid lesions in Malattia Leventinese (ML). 
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3.2 Fundus autofluorescence
Besides fundoscopy, FAF is probably the most valuable differentiating tool to distinguish 
the different macular dystrophies from each other and from AMD. Abnormalities on FAF 
are often more extensive than the abnormalities seen on fundoscopy or FA. FAF gives an 
indirect reflection of metabolic changes and lipofuscin accumulation at the level of the 
RPE and allows topographical mapping of lipofuscin distribution in the RPE. Lesions with 
increased FAF often corresponds to fundoscopically visible yellow lesions that contain 
lipofuscin, either due to accumulation of abnormally increased amounts of lipofuscin in the 
RPE (such as the flecks seen in Stargardt disease), and/or accumulation of autofluorescent 
material between the neuroretina and RPE that contains lipofuscin precursors (such as in 
BVMD).66, 88 Decreased FAF is observed for instance in areas of RPE atrophy (Figure 2.1M, 
2.2I and 2.5F). Lesions in AMD show increased, decreased or normal autofluorescence, but 
generally to a more modest degree than in macular dystrophy (Figure 2.1M, 2.1F, 2.5B and 
2.5F). In contrast, macular dystrophies often have very marked FAF abnormalities because 
of the higher and earlier-onset overload of autofluorescent lipofuscin due to the underlying 
effects of the genetic defect. As will be discussed below in the disease-specific sections, 
FAF imaging is able to identify fairly disease-specific distributions of FAF that strongly point 
to specific macular dystrophies. In a way, FAF can show a certain ‘genetic fingerprint’. For 
instance, markedly autofluorescent irregular flecks in the posterior pole are very suggestive 
of either autosomal-recessive Stargardt macular dystrophy or autosomal-dominant pseudo-
Stargardt pattern dystrophy. 89
3.3 Fluorescein angiography
Fluorescein angiography (FA) permits the study of the retinal and choroidal circulation by 
administration of fluorescein dye. Although FA is used less frequently in the era of FAF 
and OCT, it can sometimes still be useful in the diagnosis and follow-up of specific macular 
dystrophies. Although CNV is rare present in most macular dystrophies, it is a prominent 
and early-onset feature for instance in SFD. 90 
FA can also show a typical pattern of flecks, such as a ‘stars in the sky’ appearance 
in cuticular drusen and MPGN II, and a ‘dot-and-halo’ or ‘solar eclipse’ lesion in AFVD. 
Moreover, FA can show other hallmark features such as an absence of choroidal background 
fluorescence (‘dark choroid’) in Stargardt disease and delayed choroidal filling in SFD. 88, 91
 
3.4 Optical coherence tomography
Spectral-domain optical coherence tomography (SD-OCT) allows a high-resolution analysis 
of the anatomical location of deposits and/or flecks in or under the retina/RPE. Deposits 
located under the RPE, like drusen in AMD, can be found in several macular dystrophies 
such as, LORD, ML and cuticular drusen.92 Deposits in ML and cuticular drusen appear as 
sawtooth RPE elevations or dome-shaped elevations and may also present as thickening of 
the RPE/Bruch’s membrane complex. Thickening of the RPE may also be found on SD-OCT 
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in patients with SFD, NCMD, and MIDD. In contrast to AMD drusen, the subretinal deposits 
in pattern dystrophy, AFVD, BVMD and reticular pseudodrusen are located anterior to the 
RPE. 65, 93 In addition to the localizing value of OCT in the analysis of deposits, SD-OCT will 
also show the location of atrophic lesions. Finally, SD-OCT is able to visualize evidence of 
intraretinal and subretinal fluid accumulation, such as in CNV.
 
3.5 Psychophysical and electrophysiological testing
Despite the fact that most of the discussed dystrophies predominantly affect the macula, 
the full-field electroretinography (ERG) - which reflects panretinal cone and rod function - 
can become progressively abnormal in some diseases, such as in pseudo-Stargardt pattern 
dystrophy. Multifocal ERG and pattern ERG can become abnormal early in the course of 
the disease, although these examinations are of limited differential diagnostic value. The 
electro-oculography (EOG), which reflects panretinal function of the RPE, can be performed 
to distinguish between BVMD and AFVD, as the EOG response is markedly abnormal in 
BVMD in contrast to AFVD. 67, 94 These examples illustrate that the so-called ‘macular’ 
dystrophies can actually affect photoreceptor and/or RPE function of the entire retina in 
selected entities.
3.6 Genetics
AMD is a multifactorial disease in which several genetic as well as environmental factors 
play a role. Although the majority of AMD cases are sporadic, the disease may also run 
in the family. 95 Some families are very densely affected, and it has been suggested that 
such families may carry rare genetic variants that confer a large risk on developing AMD. 96 
Most disease discussed in this review are monogenic diseases caused by a known genetic 
mutation or locus, which may help in the diagnostic procedure. 
A thorough family history and drawing of a pedigree can be pivotal in the identification of 
an inheritance pattern in a specific macular disorder. Patients with an autosomal-dominant 
macular dystrophies, like Central areolar choroidal dystrophy, ML, NCMD, LORD, AFVD 
and butterfly-shaped pattern dystrophy, frequently have family members with a history of 
macular disease. However, incomplete penetrance and variable expression can complicate 
the recognition of inheritance patterns 
Some genes and their defects are associated with a certain degree of genotype-
phenotype correlation, such as the ABCA4 gene and its associated phenotypes,97 although 
the spectrum of clinically defined ABCA4 disease is notably broad. 98, 99 Mutations in 
other genes, such as the PRPH2 and BEST1 gene, are associated with marked phenotypic 
heterogeneity and show relatively limited genotype-phenotype correlation. 67, 100
Genetic testing may play an important role in the diagnostic procedure, as the 
identification of the causative gene in many cases can be the definitive confirmation of 
a specific macular dystrophy. This is especially helpful in patients with early and end-
stage disease, with less specific, ophthalmoscopic abnormalities, as it may be difficult to 
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discern macular diseases. Genetic confirmation of a clinically suspected diagnosis can aid in 
providing a clinical prognosis for the patient, and the identification of a causative gene will 
facilitate genetic counselling. Table 2.2 provides an overview of identified genes and loci 
and the associated macular dystrophies that are discussed in this review.
Table 2.2 Summary of macular dystrophies associated with identified genes and loci
Gene or locus Associated diseases
5q21.2-q33.2 Pattern dystrophy
ABCA4 Late-onset Stargardt
ABCC6 Angioid streaks related dystrophy
BEST1 Adult-onset foveomacular vitelliform dystrophy
Best-vitelliform macular dystrophy
C1QTNF5 Late-onset retinal degeneration
C3 Cuticular drusen
Membranoproliferative glomerulonephritis type II
CFH Cuticular drusen
Membranoproliferative glomerulonephritis type II
CNBP Maculopathy in Myotonic dystrophy
DMPK Maculopathy in Myotonic dystrophy
EFEMP1 Malattia leventinese
m.3243A>G MIDD/MELAS associated macular dystrophy
MCDR1 locus North Carolina macular dystrophy
PRPH2/RDS Central areolar choroidal dystrophy
Pseudo-Stargardt pattern dystrophy
Pattern dystrophy
Adult-onset foveomacular vitelliform dystrophy
TIMP3 Sorsby fundus dystrophy
Abbreviations: MIDD, Maternally Inherited Diabetes and Deafness; MELAS, Mitochondrial 
Encephalopathy, Lactic Acidosis and Stroke-like episodes.
4. MACULAR DYSTROPHIES MIMICKING AMD
4.1 Drusen and ‘drusen-like deposits’
4.1.1 Malattia leventinese 
4.1.1.1 Introduction
Malattia leventinese (ML), also known as Doyne honeycomb retinal dystrophy, is an 
autosomal-dominantly inherited macular dystrophy. Some authors refer to this entity as 
‘dominant drusen’, although this term is not specific as there are more forms of dominantly 
inherited drusen, such as cuticular drusen.28, 101-103 
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4.1.1.2 Clinical characteristics
The onset of ML is generally in the third to fourth decade of life, but shows a wide variation.63, 
92, 102, 104 Most patients are asymptomatic until the age of 30 to 40 years, when they may start 
to experience a variety of early visual symptoms, including central vision loss, paracentral 
scotomata, photophobia, color vision problems, and metamorphopsia.105, 106 A more rapid, 
progressive central vision loss generally starts around the mid-40s as a result of extensive 
pigmentary changes, GA, and/or CNV. 102 The evolution of the disease and its impact on 
visual function are highly variable between families and between individuals of the same 
family. 102, 106, 107
4.1.1.3 Ophthalmoscopic features
The first ophthalmoscopic signs of ML appear by the age of 20 years, through the appearance 
of typical small, radially oriented drusen in the macular area (Figure 2.2A).102, 103, 108 In this 
early stage, visual acuity is relatively preserved. With time, large round drusen appear in 
the macula, extending in the nasal area and around the optic disc. Centrally in the macula 
the drusen usually become a confluent yellow-white subretinal plaque with pigmentary 
changes. ML may progress to central chorioretinal atrophy in 26-69% of patients older than 
45 years and may be complicated by CNV in 6-24% of these patients. 102, 106, 108
4.1.1.4 Fundus autofluorescence
FAF reveals an intense autofluorescence of large round drusen located around the macular 
area and optic disc area, whereas smaller radial drusen are faintly visible (Figure 2.2B).63, 92, 
104 The association of increased autofluorescence with large drusen may be stronger in ML 
patients than in AMD patients. 92, 109, 110
4.1.1.5 Fluorescein and indocyanine green angiography (ICGA)
In the early phase of FA, the large central drusen are indistinct and hypofluorescent, whereas 
the small radial drusen are well demarcated and highly hyperfluorescent (Figure 2.2C).63, 92, 
104 In the late phase of FA, the large round central drusen are intensely hyperfluorescent 
due to staining and the fluorescence of small drusen decrease.63, 92, 104 The fluorescence 
pattern on ICGA is comparable to that in FA, but the hyperfluorescent large drusen are 
surrounded by a hypofluorescent halo in the late phase of ICGA.63, 92, 104 Possible CNV on 
ophthalmoscopy and SD-OCT may be confirmed on FA and ICGA.
4.1.1.6 Optical coherence tomography
The small radial drusen on SD-OCT correspond to irregular slight thickening of the RPE/
Bruch’s membrane complex and/or ‘sawtooth RPE elevation’ (Figure 2.2D).92 The large round 
drusen correspond to focal dome-shaped or more diffuse deposition of hyperreflective 
material between the RPE and Bruch’s membrane within the macular and peripapillary 
area (Figure 2.2E).92 SD-OCT also shows confluence of large focal drusen over time.92 Large 
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drusen may be associated with a relative preservation of the overlying neurosensory retina 
and may be compatible with relatively spared visual acuity. 111
4.1.1.7 Psychophysical and electrophysiological testing
The EOG is normal in ML, suggesting that the disease does not lead to a diffusely 
dysfunctional RPE. 102, 107 Multifocal ERG abnormalities localized to the macular region may 
be recorded only in patients with advanced disease. 102, 107, 112 The full-field ERG is generally 
normal, but the 30-Hz flicker responses may be reduced. 102, 105, 107 Visual fields are normal 
or show loss of sensitivity of the central visual field. 102, 106, 112
4.1.1.8 Genetic association
ML and Doyne honeycomb retinal dystrophy were considered separate entities until a 
single autosomal-dominantly inherited mutation (p.Arg345Trp) in the EFEMP1 gene, also 
known as fibulin-3, was identified in both conditions. 101, 102, 113
4.1.1.9 Pathophysiology
Histopathological studies of ML demonstrate drusenoid deposits between the RPE and 
Bruch’s membrane with thickening of Bruch’s membrane, atrophy of the RPE and structural 
damage to rod and cone photoreceptors. 114, 115 The EFEMP1 gene encodes fibulin-3, an 
extracellular matrix protein.108, 116 Efemp1 Arg345Trp mutation knock-in mice studies have 
shown aberrant EFEMP1/fibulin-3 and Tissue Inhibitor of Metalloproteinase 3 (TIMP3) 
protein accumulation within RPE cells and between the RPE and Bruch’s membrane. 
117, 118 In this mouse model of ML, sub-RPE drusen-like deposits, RPE abnormalities, and 
complement activation in the RPE and Bruch’s membrane are seen. 118, 119 These findings 
in ML show that there is not only a clinical overlap, but also a pathophysiological overlap 
with AMD.
 
4.1.1.10 Differential diagnosis with age-related macular degeneration
ML may be confused with AMD because of:
- the presence of drusen and possible evolution to GA and CNV. 102, 108 
Features that help to distinguish ML from AMD:
- an earlier age at onset
- a positive family history with an autosomal-dominant inheritance pattern
- the presence of drusen localized nasal of the disc and the presence of typical 
radially oriented macular drusen, which can evolve to large densely packed and 
confluent drusen in later stages, often with nodular juxtapapillary drusenoid 
lesions
- genetic analysis revealing a mutation in the EFEMP1gene
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4.1.2 Sorsby fundus dystrophy
4.1.2.1 Introduction
Sorsby fundus dystrophy (SFD) is an autosomal-dominantly inherited retinal dystrophy, 
leading to bilateral loss of central vision secondary to CNV, pigment epithelial atrophy, 
or both at the macula. 120-123 Also, the peripheral vision may be severely affected. 123 SFD 
is exceptional among the inherited retinal dystrophies mimicking AMD in that subretinal 
neovascularization is characteristic of the disease, whereas CNV only occurs rarely in other 
macular dystrophies. 90 
4.1.2.2 Clinical characteristics
The majority of SFD cases present during the fourth to fifth decades of life, but with a broad 
range of age at onset up to the eight decade.121, 124, 125 A large clinical variability is possible 
both within and between affected families, with regard to age at onset, disease progression 
and fundus appearance.120, 121, 126 In their early 40s, more than half of the patients have 
difficulties with dark adaptation as an early symptom without other visual symptoms.91, 
127 Nyctalopia is the result of peripheral retinal dysfunction,120, 121, 128 which can eventually 
lead to progressive loss of peripheral vision.129 Some patients remain asymptomatic until 
the onset of central vision loss, often in the 4th-6th decade of life, because of CNV or GA of 
the macula.91, 121, 124 In approximately 60% of patients, a CNV with rapid vision loss develops 
in at least one eye in the fifth decade of life, and 50% of the patients develop CNV in the 
second eye within a few years after the onset of CNV in the first eye.121 SFD usually leads to 
legal blindness in the 5th-7th decade because of marked central and peripheral vision loss.90, 
122, 124, 128
4.1.2.3 Ophthalmoscopic features
The first ophthalmoscopic findings are subretinal, fine, yellow drusen-like deposits, located 
in the entire posterior pole with extension to the equator (Figure 2.2F).121, 124 These deposits 
often appear after the age of twenty, with preservation of visual acuity.121, 124 Within a few 
years after the first symptoms, pigmentary changes, chorioretinal atrophy, and CNV can 
appear in the macula (Figure 2.2F), resulting in a more rapid loss of central vision.91, 124, 128, 
129 Patients can also develop extensive and extrafoveal CNV in the macula.121 After the age 
of 60, extensive and peripheral chorioretinal atrophy can develop, together with a central 
disciform scar and atrophy that is indistinguishable from AMD.49, 121, 123, 124, 128
4.1.2.4 Fundus autofluorescence
The yellow deposits on ophthalmoscopy correspond to reduced FAF, unlike drusen in 
AMD and yellowish deposits in most other macular dystrophies. 109, 120, 130 Areas of stippled 
increased and decreased autofluorescence extend toward and sometimes beyond the 
vascular arcades corresponding to the areas of subretinal fluid.120 In the late stage, FAF 
shows bilateral areas of central confluent decreased autofluorescence corresponding to 
Chapter 2
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the areas of RPE atrophy, with hyperautofluorescent borders surrounding these atrophic 
areas. 120
4.1.2.5 Fluorescein and indocyanine green angiography
The earliest phenotypic marker of SFD is a delayed filling of the choriocapillaris on FA. 
91, 124 This patchy hypofluorescence may be a typical finding before the onset of CNV 
and becomes more profound and extend centrifugally with time.121, 124 The deposits in 
SFD are not markedly hyperfluorescent in contrast to AMD and cuticular drusen. In SFD, 
hyperfluorescent CNV can develop multifocally with multiple recurrences, and classic CNV is 
more frequent than in AMD.121, 129 ICGA can show early mottling and late hyperfluorescence 
in the peripheral retina.131
4.1.2.6 Optical coherence tomography
SD-OCT images demonstrate focal hyperreflectivity of the ellipsoid zone to the choroid layer 
which may represent the thickened Bruch’s membrane.120 In early stages, SD-OCT can show 
evidence of retinal atrophy, specifically loss of the outer nuclear layer in the perifoveal 
region.120 This finding may represent early morphological changes related to the symptoms 
of night blindness.120 In cases with CNV, SD-OCT can show subretinal and/or intraretinal 
fluid before clinical or angiographic evidence of CNV.91, 120, 121
4.1.2.7 Psychophysical and electrophysiological testing
Even early in the course of the disease, EOG results show an abnormally low light rise in 
most SFD cases,128, 132 indicating a generalized RPE dysfunction. Full-field ERG results remain 
normal until extensive and peripheral chorioretinal atrophy become apparent.90, 128, 131, 132 
In the early stage of SFD, a tritananomaly may be present 126, 128, 131 with prolonged dark 
adaptation times in patients with nyctalopia.128 Visual field testing may show (para)central 
scotoma and moderate peripheral constriction. 90, 128, 131
4.1.2.8 Genetic association
SFD is an autosomal-dominantly inherited fundus dystrophy with full penetrance and 
variable expression. 120, 133 Several mutations in the TIMP3 gene are associated with SFD, 
of which p.Ser181Cys is the most common mutation.134, 135 The onset and severity of SFD 
appears to depend roughly on the specific TIMP3 mutation.134 
4.1.2.9 Pathophysiology
TIMP3 protein is secreted by the RPE and deposited into Bruch’s membrane.136 TIMP3 
has various functions: it regulates extracellular matrix remodelling by modulating matrix 
metalloproteinase activity, it inhibits angiogenesis by blocking vascular endothelial growth 
factor (VEGF) receptors, and it regulates inflammation. 136, 137 SFD is thought to be caused 
by an accumulation of abnormal TIMP3 protein, leading to a thickened and dysfunctional 
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Bruch’s membrane.138, 139 This TIMP3 accumulation inhibits transport across Bruch’s 
membrane, either by inhibiting normal turnover of the extracellular matrix or by creating a 
direct physical barrier.134, 139 Such a barrier would impair retinal nutrition, leading to atrophy 
of the RPE and photoreceptor death. Neovascularization may be a secondary response 
to retinal malnutrition, hypoxia, and VEGF upregulation.129, 137, 139 The clinically observed 
yellowish deposits in SFD are localized between the basement membrane of the RPE and 
the inner collagenous layer of Bruch’s membrane 127, 140 and are strongly positive for TIMP3 
protein.140 
4.1.2.10 Differential diagnosis with age-related macular degeneration
SFD may be confused with AMD because of:
- the overlap in age at onset
- the presence of drusen-like deposits, pigmentary changes, GA and CNV
Features that help to distinguish SFD from AMD:
- a positive family history with an autosomal-dominant inheritance pattern
- the earlier age at the onset of complaints and fundoscopic findings
- delayed choroidal filling on FA
- extramacular chorioretinal atrophy and CNV 
- genetic analysis revealing a mutation in the TIMP3 gene
4.1.3 North Carolina macular dystrophy
4.1.3.1 Introduction
North Carolina macular dystrophy (NCMD) is an autosomal-dominantly inherited macular 
dystrophy which was initially described in 1971 in a large family in North Carolina, USA. 141 
4.1.3.2 Clinical characteristics
The onset of NCMD is in early childhood and it has a stable course.142, 143 In most cases, there 
are only minor changes in clinical appearance or visual acuity over time.144-146 The visual 
acuity is often better than expected from the clinical examination and does not correlate 
significantly to the grade of the disease or to the age of the patient.143, 147, 148 Patients may 
be largely asymptomatic unless they develop CNV 49, which is rare. Atrophic lesions can 
result in vision loss, but even in those cases the visual acuity may be relatively preserved as 
a result of eccentric fixation.146, 149
4.1.3.3 Ophthalmoscopic features
The phenotype is highly variable and can be subdivided in 3 grades.142, 145 In grade 1, fine 
small yellow drusen-like lesions and pigmentary changes may be observed in the central 
macula with relatively preserved visual acuity.49 The yellow lesions that seem to be located 
at the level of the RPE, can have a radial pattern, and can also be present in the peripheral 
retina.49, 142, 145, 146 In grade 2, patients show larger, confluent macular lesions with or without 
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RPE atrophy, which can be associated with some visual impairment. Grade 3 NCMD is 
characterized by larger areas of profound chorioretinal atrophy in the macula that may 
even resemble a coloboma or staphyloma, with hyperpigmentation and drusen-like lesions 
surrounding this atrophic lesion (Figure 2.2H). Occasionally, NCMD is complicated by CNV 
resulting in a markedly central vision loss.142, 146 
4.1.3.4 Fundus autofluorescence
The small drusen-like yellowish lesions in NCMD patients are hyperautofluorescent.147 
Markedly atrophic areas on ophthalmoscopy correspond to absent autofluorescence with 
a hyperautofluorescent surrounding border of the lesion (Figure 2.2I). 146
4.1.3.5 Fluorescein angiography
In grade 1 and 2 NCMD, FA shows transmission defects with hyperfluorescence of the 
drusen-like lesions both in the early and late phases of FA.49 In grade 3 disease, the FA 
highlights the remaining choroidal vessels in the atrophic area due to the RPE window 
defect. 
4.1.3.6 Optical coherence tomography
On SD-OCT, a thickening of the ellipsoid zone to the RPE layer can be present,147 but no 
clear accumulation of material between the RPE and Bruch’s membrane is present, in 
contrast to drusen in AMD.147, 150 In grade 3 disease, SD-OCT shows a marked thinning and 
atrophy of the neurosensory retina, RPE, and choroid, but intact photoreceptors adjacent 
to the lesion (Figure 2.2J).144, 146, 150 
4.1.3.7 Psychophysical and electrophysiological testing
The EOG and full-field ERG are normal in all stages, indicating that there is both no 
generalised retinal or RPE dysfunction.149 The multifocal ERG can show decreased amplitudes 
within fundoscopically visible lesions in the macular area.144 Color vision is relatively well-
preserved. 147, 149 
4.1.3.8 Genetic association
NCMD is an autosomal-dominantly inherited disorder,141 linked to the MCDR1 locus on 
chromosome 6q16,151, 152 but the exact gene and its function are currently unknown. An 
early-onset autosomal-dominant macular dystrophy (MCDR3) resembling NCMD has been 
mapped to chromosome 5. 147, 153
4.1.3.9 Pathophysiology
The pathogenesis of NCMD is unknown. Histopathological studies in eyes with markedly 
atrophic NCMD lesions have shown a complete loss of photoreceptors and RPE, attenuation 
of Bruch’s membrane, and choroidal atrophy.154, 155 Adjacent to the central lesion, lipofuscin 
accumulation has been identified in the RPE. 154, 155
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4.1.3.10 Differential diagnosis with age-related macular degeneration
NCMD can be confused with AMD because of:
- the association with yellow drusen-like lesions, GA and CNV 
Features that help to distinguish NCMD from AMD include:
- an early age at the onset (in childhood or possibly congenital) 
- a positive family history with an autosomal-dominant inheritance pattern, and Irish- 
American ancestry 
- a relatively stationary course, except in rare cases of CNV 
- no sub-RPE deposits visible on SD-OCT
4.1.4 Late-onset retinal degeneration
4.1.4.1 Introduction
Late-onset retinal degeneration (LORD) is an autosomal-dominantly inherited macular 
dystrophy, first described in patients with Scottish ancestry. 156, 157 
4.1.4.2 Symptoms
Patients with LORD usually present with night blindness in the fifth to sixth decade of life,156, 
158, 159 followed by progressive central and peripheral vision loss in the following decades.156, 
158, 159 
4.1.4.3 Clinical features
Patients with LORD typically have long anteriorly inserted lens zonules and peripupillary 
iris atrophy (Figure 2.2K and L). 156, 160 Fundoscopic changes become visible from the fifth 
decade onwards, together with the onset of night blindness, with drusenoid deposits in the 
mid-peripheral retina often being the first visible retinal manifestations (Figure 2.2M).156, 
160 In the following decades, scalloped areas of chorioretinal atrophy in the posterior pole 
and beyond the vascular arcades develop.158, 159 When this atrophy affects the fovea, this 
results in marked central vision loss. In the late stages of the disease, peripheral bone-
spicule hyperpigmentation as well as central or peripheral CNV may develop. 156, 158, 159
4.1.4.4 Fundus autofluorescence
The early drusenoid yellow dots in the retina may show increased FAF.156 FAF highlights 
marked autofluorescence changes in macular atrophy by decreased autofluorescence with 
scalloped borders. 159, 160
4.1.4.5 Fluorescein angiography
The fine structure and staining characteristics of the sub-RPE deposits in early LORD may 
resemble those in AMD, and in advanced disease FA shows RPE window defects of the 
scalloped atrophic lesions. 49, 158
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Figure 2.2 (A-E) Malattia Leventinese in a 51-year-old patient who carried an EFEMP1 mutation. (A) 
Color fundus photograph showing small radiating drusen (white arrow) and larger confluent drusen 
in the macular area (black arrow) and around the optic disc. Centrally located large drusen confluence 
to a yellow-white plaque. (B) Fundus autofluorescence (FAF) image showing that large drusen located 
in the macula (black arrow) and drusenoid lesions nasally in the optic disc correspond to increased 
FAF, whereas the small radial drusen (white arrow) are faintly visible. (C) Fluorescein angiography (FA) 
image showing blockage of background fluorescence caused by the central large drusen and small 
hyperfluorescent radially oriented drusen. (D) Horizontal optical coherence tomography (OCT) scan 
showing the sawtooth elevations of the retinal pigment epithelium (RPE) corresponding to the small 
radial drusen. (E) Horizontal OCT scan (scan in the plane indicated by black arrowhead in A), showing 
diffuse deposition of hyperreflective material between the RPE and Bruch’s membrane, corresponding 
to large round drusen. (F-G) Sorsby fundus dystrophy (Courtesy of SM Downes). (F) Color fundus 
photograph showing typical drusen along the arcade with a central choroidal neovascular complex. 
(G) Color fundus photograph showing poor response to previous photodynamic therapy. (H-J) North 
Carolina macular dystrophy stage 3 in a 19-year-old patient (Courtesy of Alessandro Iannaccone, 
MD, MS, Retinal Degeneration & Ophthalmic Genetics Service, Hamilton Eye Institute, University of 
Tennessee Health Science Center, Memphis, TN, USA). (H) Color fundus photograph showing a large 
circumscribed area of chorioretinal atrophy in the macula, with surrounding drusen-like lesions. (I) 
FAF image showing decreased autofluorescent in the atrophic lesion with a hyperautofluorescent 
surrounding edge of the lesion. (J) OCT scan (scan in the plane indicated by black arrowhead in H) 
showing atrophy of the neurosensory retina, RPE, and choroid, but intact photoreceptors adjacent to 
the lesion. (K-M) Late onset retinal dystrophy in an 82-year-old patient who carried the p.Ser163Arg 
mutation in the C1QTNF5 gene (Courtesy of Moorfields Eye Hospital). (K) Slit lamp examination 
showing long anteriorly inserted lens zonules and peripupillary atrophy. (L) An enlarged view of slit 
lamp examination image K clearly showing long anteriorly inserted lens zonules. (M) Color fundus 
photograph showing small drusenoid deposits in the posterior pole with some pigmentary changes.
4.1.4.6 Optical coherence tomography
Midreflective deposits located between the RPE and Bruch’s membrane may be seen on 
SD-OCT. 158-160 In advanced cases, SD-OCT shows chorioretinal atrophy with also outer 
retinal abnormalities. 156, 159, 160
4.1.4.7 Psychophysical and electrophysiological testing
Abnormal dark adaptation is the first manifestation of LORD, preceding subjective night 
blindness and fundus changes. 156, 158 The full-field ERG may become abnormal in advanced 
disease, 158, 160 revealing a generalized rod-cone dysfunction.157, 159 In advanced LORD, the 
peripheral visual field also becomes constricted. 49, 156, 158 
4.1.4.8 Genetic association
LORD is a genetically heterogeneous disease with an autosomal-dominant inheritance 
pattern 157, 161 caused by a heterozygous p.Ser163Arg founder mutation in the C1QTNF5 
gene on chromosome 11. 161 This mutation presumably originates from a single ancestor 
from south-east Scotland. 156
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4.1.4.9 Pathophysiology
Histopathological studies reveal loss of photoreceptors and extensive sub-RPE deposits, 
resembling AMD drusen in structure and lipid composition. 157, 158 Although a C1qtnf5 knock-
in mouse model closely mimics the phenotypic features of LORD,162 the exact function of 
the C1QTNF5 gene is unknown. The C1QTNF5 is highly expressed in the RPE, lens and ciliary 
body epithelium.161 Deposits may be caused by misfolded C1QTNF5 protein accumulating in 
the endoplasmic reticulum of the RPE, compromising the function of the RPE and resulting 
in sub-RPE deposits as well as impaired RPE adhesion to Bruch’s membrane. 161, 163 
4.1.4.10 Differential diagnosis with age-related macular degeneration
LORD may be confused with AMD because of:
- the presence of drusenoid deposits, chorioretinal atrophy and sometimes CNV 
Features that help to distinguish LORD from AMD include:
- an autosomal-dominant inheritance pattern 
- onset of night vision problems before the age of 60 
- extensive ‘scalloped’ areas of chorioretinal atrophy 
- long anteriorly inserted lens zonules and peripupillary iris transillumination 
- evidence of widespread retinal disease on dark adaptation and full-field ERG in 
advanced LORD 
- mutation in the C1QTNF5 gene 
4.2 Irregular yellowish flecks
4.2.1 Late-onset Stargardt disease
4.2.1.1 Introduction
Autosomal-recessive Stargardt disease is a hereditary retinal dystrophy, usually diagnosed 
within the first two decades of life.164 A later age at onset (≥50 years) has been reported in 
a small number of patients. Late-onset Stargardt disease belongs to the spectrum of retinal 
dystrophies caused by mutations in the ABCA4 gene. 88 The estimated carrier frequency 
of mild ABCA4 mutations in population studies is 1/25 individuals.165, 166 Over 600 disease-
causing mutations in the ABCA4 gene have been identified and some ABCA4 mutations 
have been associated with STGD1, cone-rod dystrophy, retinitis pigmentosa and AMD. 99
4.2.1.2 Clinical characteristics
Usually at the age of 55 patients present with progressive central vision loss and may be 
accompanied by metamorphopsia or oscillopsia. 88 The fundus abnormalities, however, 
may be coincidentally found in asymptomatic patients at ophthalmologic screening for 
glaucoma, diabetes or thyroid eye disease.
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4.2.1.3 Ophthalmoscopic features
Fundus examination shows irregular, pisciform, flavimaculatus flecks scattered throughout 
the posterior pole or spread to the midperipheral retina (Figure 2.3A). Yellowish flecks or 
dots may be limited to the centre of the macula, whereas sometimes no flecks, but small 
yellowish spots are present in the macula. Extensive chorioretinal atrophy may be present 
and it is rarely complicated by CNV. 167-169
4.2.1.4 Fundus autofluorescence
The yellowish flecks correspond to intense autofluorescence on FAF imaging (Figure 2.3B).88 
Some flecks may be surrounded by a halo of reduced autofluorescence. In up to 50% of the 
cases, a relatively preserved autofluorescence signal of the fovea is seen, indicating foveal 
spare. This difference in autofluorescence signal and degree of foveal sparing corresponded 
with structural findings on SD-OCT. 
4.2.1.5 Fluorescein angiography
A decreased choroidal background fluorescence (‘dark choroid’) on FA is present in about 
80% of the patients (Figure 2.3C).88 In rare cases, CNV is visible by focal staining and leakage 
of dye in respectively the early and late phase. 169
4.2.1.6 Optical coherence tomography
SD-OCT shows hyperreflective thickening of the RPE layer in Stargardt disease, which is 
distinguishing from sub-RPE drusen in AMD (Figure 2.3D). The accumulation in Stargardt 
disease is usually associated with photoreceptor thinning. 88 In cases of foveal sparing, a 
near normal photoreceptor layer in the fovea may be observed explaining the late onset of 
visual complaints.
4.2.1.7 Psychophysical and electrophysiological testing
Photopic and scotopic full-field ERG recordings are normal in the majority of cases.88 In 
contrast, multifocal ERG is in the majority of cases outside normal limits. Patients with 
foveal sparing have normal multifocal ERG amplitudes in the foveal area. Central visual 
field examinations show paracentral scotomata and central scotoma of varying extensions.
4.2.1.8 Genetic association
Homozygous or compound heterozygous mutations in the ABCA4 gene encoding the 
photoreceptor-specific, ATP-binding cassette transporter A4 are responsible for STGD.170 
In half of the late-onset Stargardt disease patients, only one heterozygous mutation in the 
ABCA4 gene may be found. 88, 171 It is possible that the latter patients carry a second mild 
mutation in one of the introns or they may carry variants in modifier genes or a variant in a 
promoter or enhancer region near the ABCA4 gene, which causes lower expression of the 
intact ABCA4 allele. 
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4.2.1.9 Pathophysiology
ABCA4 defects lead to the intracellular accumulation of N-retinylidene-N-retinylethanolamine 
(A2E) in RPE cells.172, 173 A2E is cytotoxic to the RPE in high concentrations 174 and may be 
visualized in living eyes using FAF. In heterozygous abca4 (+/-) mice, a light-dependent 
fourfold increase in lipofuscin compounds has been observed.175 These findings in animal 
studies may indicate that heterozygous ABCA4 mutations in humans eventually also lead to 
increased lipofuscin accumulation and possibly even retinal pathology. A study in the Abca4 
knockout mouse model for Stargardt disease has identified oxidative stress, complement 
activation, and down-regulation of protective complement regulatory proteins as potential 
mechanism of retinal dystrophy.176 These animal data and the association of ABCA4 variants 
with AMD could indicate that there is a pathophysiologic overlap between late-onset 
Stargardt disease and AMD. 
4.2.1.10 Differential diagnosis with age-related macular degeneration
It is important to distinguish late-onset Stargardt disease from AMD because some AMD 
patients use nutritional supplements, containing the vitamin A-derivative beta-carotene, to 
prevent progression to advanced disease.177 However, studies in Abca4 knockout mice, an 
animal model for Stargardt disease, have shown that vitamin A supplementation can cause 
an increase of lipofuscin accumulation in the RPE.178 Therefore, beta-carotene or vitamin A 
supplementation should be discouraged in Stargardt disease patients as it may accelerate 
lipofuscin accumulation and retinal degeneration. 
Late-onset Stargardt disease may be confused with AMD because of:
- the late age at onset (>50 years) 
- the presence of yellowish flecks, chorioretinal atrophy and rarely CNV 
Features that help to distinguish late-onset Stargardt disease from AMD include:
- ‘flavimaculatus’ flecks are more irregularly shaped than drusen 
- intense autofluorescence of flecks on FAF imaging with a surrounding halo of 
decreased FAF. 
- ‘dark choroid’ on FA 
- mutations in the ABCA4 gene 
4.2.2 Pattern dystrophies
4.2.2.1 Introduction
The heterogeneous group of ‘pattern dystrophies’ encompass a broad spectrum of inherited 
diseases that are characterized by various patterns of pigment distribution at the posterior 
pole. These include butterfly-shaped pigment dystrophy, adult-onset foveomacular 
vitelliform dystrophy (AFVD) (see Chapter 4.3.1.), reticular dystrophy of the RPE, fundus 
pulverulentus and pseudo-Stargardt pattern dystrophy. However, the value of this clinical 
classification is subject of debate,179 because different types of pattern dystrophy are 
known to occur in different members of the same family carrying an identical mutation. 
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Furthermore, one form of pattern dystrophy can evolve into another within a single patient, 
and the type of pattern dystrophy can even be different between the two eyes of a patient. 
49, 89, 100, 180, 181
4.2.2.2 Clinical characteristics
Pattern dystrophies present in midlife with mild central visual disturbances in one or both 
eyes. In advanced cases, patients can develop CNV and/or GA. However, many patients will 
retain driving vision in at least one eye well into their seventh decade of life. 182
4.2.2.3 Ophthalmoscopic features
Butterfly-shaped pigment dystrophy has first been described by Deutman and co-workers 
in a family with autosomal-dominant inherited pigmentation in a pattern that showed 
resemblance to the wings of a butterfly. 183 The pigmentation can be yellow-white or dark. 
The central lesion can be surrounded by depigmentation. 
Reticular dystrophy of the RPE was first reported in 1950 by Sjögren as a clearly defined 
network of pigmented lines that resemble a fishnet with knots.184 
Fundus pulverulentus is characterized by coarse, punctiform mottling of the RPE in 
the macular area.185 This rare entity is seen mostly in patients with macular dystrophy 
associated with PXE (for pseudoxanthoma elasticum see Chapter 4.5.2). 186
Patients with pseudo-Stargardt pattern dystrophy show irregular yellowish flecks in the 
posterior pole and around the retinal vascular arcades, resembling the flecks seen in 
fundus flavimaculatus phenotype of Stargardt disease (Figure 2.3E). The yellowish flecks 
are preceded by typical macular pattern dystrophy or by non-specific pigmentary changes 
in the fovea. 89, 187 
4.2.2.4 Fundus autofluorescence
Like in most macular dystrophies, the pattern dystrophies have variable patterns of markedly 
abnormal autofluorescence. In pseudo-Stargardt pattern dystrophy the flecks show highly 
increased autofluorescence (Figure 2.3F). With time, the flecks tend to evolve toward a 
confluent atrophic area which shows larger zones of decreased FAF signal.
4.2.2.5 Fluorescein angiography
The pigmented areas in the pattern dystrophies usually show early hypofluorescence on 
FA, surrounded by hyperfluorescence, with some degree of late staining.100, 188 In pseudo-
Stargardt pattern dystrophy the flecks are hyperfluorescent, sometimes with a central 
hypofluorescent spot (Figure 2.3G).89, 187 A dark choroid, as seen in Stargardt disease, is 
typically absent.
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4.2.2.6 Optical coherence tomography
SD-OCT imaging reveals relatively consistent features among the different subtypes of 
pattern dystrophies:189 hyperreflectivity between the RPE/Bruch’s membrane complex 
and more inner retinal layers (Figure 2.3H).; further, disruptions of the ellipsoid zone are 
common findings. 189 
4.2.2.7 Psychophysical and electrophysiological testing
Full-field ERG shows normal cone and rod amplitudes and implicit times in most patients 
with pattern dystrophies, except in pseudo-Stargardt pattern dystrophy. Herein, the full-field 
photopic and scotopic ERG results can vary from normal in mild cases to non-recordable in 
advanced disease, and the EOG is abnormal in half of the patients. 89 
The EOG in pattern dystrophies is usually normal or only moderately reduced. 190 
4.2.2.8 Genetic association
Mutations in the PRPH2 gene are the most common cause of the different pattern 
dystrophies. Recently, an association of AFVD and butterfly-shaped pigment dystrophy 
phenotypes has been suggested with a high temperature requirement factor A1 risk SNP in 
individuals who did not carry PRPH2 gene mutations. 191 
4.2.2.9 Pathophysiology
The PRPH2 gene encodes a photoreceptor-specific glycoprotein that plays a role in the 
development and maintenance of photoreceptor outer segment discs. 100, 192-194 Mutation 
in PRPH2 could mediate pattern dystrophy disease pathogenesis by interfering with the 
integrity of the photoreceptor membrane. 195
Further, secondary atrophic changes where observed.196 In a patient with butterfly-
shaped pigment dystrophy due to mutation in the PRPH2 gene, there was an abrupt 
transition between healthy and degenerated retina and RPE with massively lipofuscin-laden 
RPE cells at the transition.195 Surgical specimens from a patient with a PRPH2 mutation 
exhibited ultra-structural alterations in outer-segment disc structure. 197 Based on these 
genetic and histopathologic findings, the primary defect in pattern dystrophies may be 
assumed to be localized in the photoreceptors with subsequent changes in the RPE and 
choriocapillaris.
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Figure 2.3 (A-D) Late-onset Stargardt in a 58-year-old patient. (A) Color fundus photograph showing 
irregular, pisciform, flavimaculatus flecks in the posterior pole and central irregularities of the retinal 
pigment epithelium. (B) Fundus autofluorescence (FAF) image showing increased autofluorescence 
of the flecks. (C) Fluorescein angiography (FA) image showing decreased choroidal background 
fluorescence causing a ‘dark choroid’ aspect and hyperfluorescent flecks. (D) Horizontal optical 
coherence tomography (OCT) scan (scan in the plane indicated by black arrowhead in A) showing 
hyperreflective thickening of the retinal pigment epithelium (RPE) corresponding to the flecks. The 
RPE thickening is associated with thinning of the photoreceptor layer. (E-H) Pseudo-Stargardt pattern 
dystrophy in a 57-year-old patient. (E) Color fundus photograph showing irregular yellowish flecks in 
the posterior pole and around the vascular arcades. (F) FAF image showing increased autofluorescence 
of the flecks with an adjacent hypofluorescent zone, showing the ‘dot and halo’ feature with 
enlargement of the macular hypoautofluorescent zone. (G) FA image showing hyperfluorescent flecks. 
(H) Horizontal OCT scan showing some hyperreflective focal thickening of the photoreceptor-RPE 
complex, but without sub-RPE deposits. (I-K) Pattern dystrophy in a 63-year-old patient who carried a 
mutation in the PRPH2 gene (Courtesy of J.R.M. Cruysberg, UMC St. Radboud). (I) FAF image showing 
increased autofluorescence of the hyperpigmentation. (J) FA image showing hyperfluorescence that 
outlines the hypofluorescent figures. (K) Horizontal OCT scan (scan in the plane indicated by black 
arrowhead in I) showing hyperreflective material between the RPE and Bruch’s membrane.
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4.2.2.10 Differential diagnosis with age-related macular degeneration
Patients with pattern dystrophies may be misdiagnosed as having AMD because:
- clinically visible signs commonly present in midlife and visual complains may 
manifest later in life
- secondary changes such as CNV or GA may be present
Features that help to distinguish pattern dystrophies from AMD include:
- a relatively early age at onset
- positive family history
- absence of typical sub-RPE drusen
- more pronounced autofluorescence changes than in AMD (pseudo-Stargardt 
pattern dystrophy)
- specific patterns on fluorescein angiography and fundus autofluorescence 
- peripheral retinal abnormalities with corresponding abnormal full-field ERG 
(pseudo-Stargardt pattern dystrophy)
- genetic analysis revealing a mutation in the PRPH2 gene
4.3 Vitelliform lesions
4.3.1 Adult-onset foveomacular vitelliform dystrophy
4.3.1.1 Introduction
Adult-onset foveomacular vitelliform dystrophy (AFVD) was first described by Gass in 1974. 
According to the classification of Gass, AFVD is considered one of the pattern dystrophies. 49 
4.3.1.2 Clinical characteristics
Patients experience mild loss of visual acuity and/or metamorphopsia in one or both eyes, 
usually after the age of 35, but may also remain asymptomatic. 
4.3.1.3 Ophthalmoscopic features
In typical AFVD, bilateral small round yellow-white lesions of less than 1/3 disc diameter are 
seen in the fovea, without surrounding drusen (Figure 2.4A).94 The central part of the lesion 
can be mildly pigmented. Lesions in AFVD can go through stages that are similar to BVMD 
(Chapter 4.3.2),198 and can be multifocal.199 Some cases can be complicated by CNV, which 
can respond to anti-VEGF treatment. 200
4.3.1.4 Fundus autofluorescence
Lesions in AFVD are hyperautofluorescent, especially when the lesions have a yellowish 
fundoscopic aspect without significant RPE atrophy (Figure 2.4B).94, 130
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4.3.1.5 Fluorescein angiography
FA typically shows a hypofluorescent centre of the lesion, surrounded by a small 
hyperfluorescent ring (‘dot-and-halo’ or ‘solar eclipse’ aspect). Some larger, less pigmented 
lesions may show a central, patchy hyperfluorescence with late staining (Figure 2.4C).
4.3.1.6 Optical coherence tomography
On SD-OCT, lesions are located between the neuroretina and RPE, with a variable amount 
of hyperreflective material accumulated in the space between these layers (Figure 2.4D).93 
This material corresponds to the yellowish material seen on fundoscopy. Based on their 
high-definition OCT findings in patients with different stages of AFVD, Querques and 
co-workers hypothesized that early changes involve the layer between the RPE and the 
ellipsoid zone, first with accumulation of material beneath the sensory retina. In advanced 
disease, the photoreceptors and RPE layer eventually become disrupted and attenuated. 201
4.3.1.7 Psychophysical and electrophysiological testing
A characteristic differential diagnostic feature to distinguish AFVD from BVMD is the 
presence of a normal or only slightly subnormal light rise on the EOG,94 whereas this light 
rise on EOG is often virtually absent in Best disease. The full-field ERG is normal.
4.3.1.8 Genetic association
A genetic cause may be identified in a minority of cases. 202 Autosomal-dominant inheritance 
has been described, and mutations in the PRPH2 gene account for 2-18% of the cases, 
whereas mutations in the BEST1 gene cause up to 25% of cases. 203-205 
4.3.1.9 Pathophysiology
Histopathologic evaluation of patients with AFVD revealed an accumulation of vitelliform 
material between the neuroretina and RPE beneath the fovea, consisting of photoreceptor 
outer segment-derived material and lipofuscin loaded pigmented cells, accounting for the 
vitelliform appearance.67, 206, 207 Lipofuscin accumulation was also seen in the RPE, with focal 
atrophy of the RPE bordered by hypertrophic RPE. 208
4.3.1.10 Differential diagnosis with age-related macular degeneration
AFVD can be confused with AMD because of:
- the presence of small, round yellow-white macular lesions that may be complicated 
by CNV 
Features that help to distinguish AFVD from AMD include:
- central vitelliform lesion without surrounding drusen
- marked autofluorescence changes within AFVD lesions
- lesion corresponding to hyperreflective accumulation above the RPE on SD-OCT
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4.3.2 Best vitelliform macular dystrophy
4.3.2.1 Introduction
Best vitelliform macular dystrophy (BVMD) was first described by Friedrich Best in 1905, 
and is an autosomal-dominantly inherited macular dystrophy with incomplete penetrance 
and variable expression.67 
4.3.2.2 Clinical characteristics
The age at the onset of central vision loss is highly variable, ranging from the first to the sixth 
decade. 65, 199, 209-211 Most patients become symptomatic before the age of 40. A commonly 
associated finding is mild to moderate hyperopia. 67
4.3.2.3 Ophthalmoscopic features
In most classifications of BVMD, the first stage is the asymptomatic carrier (‘previtelliform’) 
stage. 67, 209, 212 In this stage, no or very mild RPE abnormalities are visible in the fundus, 
although the EOG is already markedly abnormal. This stage may evolve into a typical 
yellowish, slightly elevated, round-to-oval vitelliform lesion in the fovea, usually with a size 
of at least a disc diameter (as mentioned in Chapter 2 in drusenoid vitelliform lesions). When 
the vitelliform material gradually shows inhomogeneous clumping, this is referred to as the 
vitelliruptive or ‘scrambled-egg’ stage (Figure 2.4E and 2.4I). The vitelliform material may 
also gravitate to the inferior part of the lesion, which corresponds to the pseudohypopyon 
stage. With time, a variable degree of chorioretinal atrophy and subretinal scarring may 
develop, to form the atrophic and cicatricial stage, respectively. Many patients show a 
different stage in each eye, characteristics of different stages within a single lesion, and 
sometimes even multifocal vitelliform lesions.65, 199, 209 CNV occurs in 2-9% of patients with 
BVMD, which tends to show a relatively benign and self-limiting course,209, 210, 213 although 
CNV in these cases also responds to intravitreal anti-VEGF treatment. 214
4.3.2.4 Fundus autofluorescence
BVMD lesions show variably-sized areas of intense hyperautofluorescence, corresponding 
to the vitelliform material (Figure 2.4F and J) 65-67 (as mentioned in Chapter 2 in drusenoid 
vitelliform lesions). Areas of scarring and/or RPE atrophy within a lesion show decreased 
autofluorescence.
4.3.2.5 Fluorescein angiography
On FA, the early phases show blocking of background fluorescence in lesions with large 
amounts of vitelliform material (Figure 2.4K), but in other cases the BVMD lesions show 
mild hyperfluorescence due to an RPE window defect and/or staining (Figure 2.4G).65, 66
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4.3.2.6 Optical coherence tomography
Like in AFVD, early lesions in BVMD are located between the neuroretina and RPE on SD-
OCT, with a variable amount of hyperreflective material accumulated in the space between 
these layers (Figure 2.4L).65, 66 In more advanced lesions, hyperreflective subretinal scars 
and intraretinal edema may be seen (Figure 2.4H).
4.3.2.7 Psychophysical and electrophysiological testing
A virtually pathognomonic feature for BVMD and other BEST1-gene related diseases is the 
absence of a normal light rise on the EOG, reflected in a markedly diminished Arden ratio.67 
This abnormal EOG also allows to detect asymptomatic carriers of a BEST1 mutation.215 The 
full-field ERG is normal.
4.3.2.8 Genetic association
BVMD, a member of the group of ‘bestrophinopathies’, is caused by autosomal-dominantly 
inherited mutations in the BEST1 gene.67, 216 The BEST1 gene encodes the bestrophin-1 
protein, a calcium-activated chloride channel that also influences voltage-gated calcium 
channels within the RPE.67 Patients with autosomal-recessive bestrophinopathy have more 
extensive retinal abnormalities and carry a BEST1 mutation on both alleles.217
4.3.2.9 Pathophysiology
The accumulation of subretinal fluid and vitelliform material - which supposedly originates 
from outer photoreceptor debris - has been postulated to be the result of RPE dysfunction 
due to abnormal RPE ionic transport.67 The prolonged neuroretinal detachment and 
lipofuscin overload of the RPE may eventually lead to photoreceptor and RPE dysfunction.
4.3.2.10 Differential diagnosis with age-related macular degeneration
BVMD may be confused with AMD because of:
- the presence of yellowish lesion(s) with chorioretinal atrophy and CNV
Features that help to distinguish BVMD from AMD include:
- an age at the onset before the age of 50
- a positive family history with an autosomal-dominant inheritance pattern
- central vitelliform lesions without surrounding drusen
- marked autofluorescence changes within BVMD lesion
- lesions corresponding to hyperreflective accumulation above the RPE on SD-OCT
- a markedly abnormal EOG
- identification of a mutation in the BEST1 gene
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Figure 2.4 (A-D) Adult onset foveomacular vitelliform dystrophy in a 49-year-old patient who did 
not carry a mutation in the PRPH2 or BEST1 gene. (A) Color fundus photograph showing a round 
yellow lesion in the fovea with some small yellow lesions temporally in the fovea. (B) Fundus 
autofluorescence (FAF) image showing increased autofluorescence of the foveal round lesion and 
hyperautofluorescence of the smaller lesions temporally in the fovea. (C) Fluorescein angiography 
(FA) image showing late staining of the central lesion, as well as hyperfluorescence of some temporal 
small spots. (D) Horizontal optical coherence tomography (OCT) scan showing the foveal yellow 
lesion corresponding to accumulation of material between the neuroretina and the retinal pigment 
epithelium (RPE). (E-L) Best vitelliform macular dystrophy in a 15-year-old (E-H) and 13-year-old 
patient (I-L). (E) Color fundus photograph showing a scrambled-egg appearance with a fibrotic scar. 
(F) FAF image showing irregularly hyperautofluorescence of the yellow lesion in the macula. (G) FA 
image showing hyperfluorescence due to RPE window defects, as well as hypofluorescence caused by 
blocking of background fluorescence. (H) Horizontal OCT scan (scan in the plane indicated by black 
arrowhead in E) showing subretinal fibrous scar tissue associated with subretinal fluid. (I) Color fundus 
photograph showing a vitelliform/ vitelliruptive lesion in the macular area. (J) FAF image showing 
intense hyperfluorescence of the subretinal material. (K) Two years later, the vitelliform/vitelliruptive 
stage has been evolved into the pseudohypopyon stage. FA image clearly shows hyperfluorescent 
material of the partly scrambled vitelliform lesion. (L) Vertical OCT scan showing hyperreflective 
material between the neuroretina and the RPE. 
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4.4 Miscellaneous
4.4.1 Central areolar choroidal dystrophy 
4.4.1.1 Introduction
Central areolar choroidal dystrophy (CACD) is an autosomal-dominantly inherited macular 
dystrophy that belongs to the wide spectrum of retinal dystrophies caused by mutations in 
the PRPH2 gene.100 Other PRPH2-associated retinal dystrophies include multifocal pattern 
dystrophy simulating Stargardt disease/fundus flavimaculatus (‘pseudo-Stargardt pattern 
dystrophy’),89 pattern dystrophies such as butterfly-shaped pigment dystrophy and AFVD, 
as well as autosomal-dominant retinitis pigmentosa. 100 
4.4.1.2 Clinical characteristics
The visual acuity in CACD generally deteriorates in the fourth to fifth decade of life, 218-220 
which is earlier than in patients with AMD. 221 However, a later onset (after the age of 55) or 
even an absence of visual symptoms may be seen in up to a third of CACD patients, depending 
on the type of PRPH2 mutation.100, 218 Therefore, late-onset CACD may be confused with 
atrophic AMD.218, 222 Visual disturbances are mainly associated with the development of 
GA, and marked central vision loss will eventually develop when the chorioretinal atrophy 
affects the fovea.218 Besides loss of visual acuity and metamorphopsia, some CACD patients 
may experience mild photophobia.100, 218, 223 Nyctalopia is reported only rarely in CACD and 
seems to be associated with pigmentary changes of the peripheral retina.218, 223 A positive 
family history of vision loss is more common in CACD than in AMD. 218, 221 
4.4.1.3 Ophthalmoscopic features
Four clinical stages of CACD have been described.100, 219, 220 In stage 1, fine parafoveal 
pigmentary RPE changes may be observed, usually under the age of 50 (Figure 2.5A).218, 224 
In stage 2, an oval-to-round, mildly atrophic, hypopigmented area may be observed. Stage 
3 is characterized by one or more patches of well-circumscribed RPE atrophy outside the 
fovea (Figure 2.5E). The areas of GA tend to enlarge concentrically and become confluent. 
220, 225, 226 In stage 4, the area of profound chorioretinal atrophy affects the fovea, resulting 
in a markedly decreased visual acuity. Patients with CACD usually do not have any flecks 
or drusen, but in some cases it is associated with drusen-like deposits, 219, 225, 227 making the 
differential diagnosis with AMD more difficult. 
4.4.1.4 Fundus autofluorescence
Like in most other macular dystrophies, marked FAF changes are a hallmark feature of 
CACD that distinguishes this disease entity from the more moderate FAF abnormalities in 
most cases of early AMD and GA in AMD. 109, 218, 221 FAF abnormalities are more sharply 
demarcated, regularly oval-shaped and are confined to the central macular region, in 
contrast to AMD FAF abnormalities, which frequently covers the entire posterior fundus. In 
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early CACD, a speckled pattern of increased and decreased FAF signal predominates (Figure 
2.5B).100, 221, 222 Areas of markedly decreased to absent FAF appear in stages 3 and 4 (Figure 
2.5F).100, 218, 221, 222 
4.4.1.5 Fluorescein angiography
FA is helpful in detecting the earliest stage 1 abnormalities, showing pigmentary changes 
and small parafoveal window defects (Figure 2.5C).218, 220 In stage 2-4, hyperfluorescent 
window defects become more prominent. 218, 219 
4.4.1.6 Optical coherence tomography
SD-OCT reveals reduced retinal thickness in CACD with a disruption of the ellipsoid zone of 
the photoreceptors, proportional to the degree of chorioretinal atrophy (Figure 2.5D).218, 
221, 222 In contrast to AMD, sub-RPE deposits (drusen) are generally absent and rosette-
like structures are more often present. 221 In eyes with atrophic lesions due to CACD, the 
remaining retinal layers have a relatively homogeneous aspect (Figure 2.5G), whereas eyes 
with GA due to AMD frequently have an irregular structure of the remaining retinal layers 
within the atrophic lesion on SD-OCT. 221
4.4.1.7 Psychophysical and electrophysiological testing
Tests of the macular function, such as the pattern ERG and multifocal ERG, as well as results 
from color vision testing usually become abnormal early in the course of CACD.220, 222, 223 The 
full-field ERG is generally normal, but may display generalized cone or cone-rod dysfunction 
in advanced CACD, depending on the associated PRPH2 mutation 100, 220, 223, 224. The EOG 
is normal or slightly subnormal. 218-220 Early in the course visual fields are normal, but 
with disease progression a relative and eventually absolute paracentral scotoma may be 
demonstrated, corresponding to the area of advanced atrophy. 219, 220, 222, 228 The peripheral 
visual field is normal. 219, 224, 228
4.4.1.8 Genetic association
In most cases, CACD has an autosomal-dominant inheritance pattern, caused by mutations 
in the PRPH2 gene, although autosomal-recessive and sporadic cases have also been 
reported. 100, 218
4.4.1.9 Pathophysiology
Several histopathological studies on non-genotyped CACD patients have shown an 
absence of photoreceptors, RPE, and choriocapillaris in the area of atrophy.226, 229 Boon 
and co-workers have suggested that the abnormal peripherin/rds protein structure results 
in a dysmorphic cone and possibly rod outer segment structure. 218 These structural 
abnormalities hinder normal photoreceptor function and lead to alterations in the normal 
photoreceptor outer segment-RPE interaction. These changes may raise the level of 
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lipofuscin and toxic byproducts in the RPE cells, resulting in RPE and photoreceptor cell 
death through apoptosis. Atrophy of the RPE and choriocapillaris eventually lead to the 
typical ‘punched-out’ CACD lesions.218 The term ‘central areolar choroidal dystrophy’ may, 
therefore, be a misnomer, as it suggests that the primary dystrophic focus is the choroid 
instead of the retina.
4.4.1.10 Differential diagnosis with age-related macular degeneration
CACD may be confused with atrophic AMD because of:
- the overlap in age at the onset (in late-onset CACD) 
- the decreased penetrance and variable expression, that complicates recognition 
of the mode of inheritance 223 
- the association with drusen-like lesions, RPE changes, chorioretinal atrophy 
Features that help to distinguish CACD from AMD:
- a relatively early onset 
- a positive family history with an autosomal-dominant inheritance pattern 
- absence of genuine drusen on ophthalmoscopy and SD-OCT 
- more pronounced autofluorescence changes than in atrophic AMD 
- genetic analysis revealing a mutation in the PRPH2 gene 
4.4.2 Late-onset cone dystrophy
4.4.2.1 Introduction
Clinical signs of cone dystrophies may develop progressively during all decades of life.230 Late 
onset, in the fourth 231, 232 or even after the sixth decade,230, 231 however, is rare. Therefore, 
the diagnosis of cone dystrophy is not often considered in older patients. 233 In addition, 
age-related morphological changes, such as pigment irregularities and drusen, may mask 
the correct diagnosis. 233
4.4.2.2 Clinical characteristics
In cone dystrophy, patients suffer from progressive visual loss, central visual field defects, 
color vision impairment and photophobia. 230 In cases with cone dystrophy with late 
onset, symptoms and signs may be mild to moderate and often non-specific, leading to 
misdiagnosis. 234 Patients with late onset cone dystrophy develop slowly progressive loss 
of central or paracentral vision usually in the absence of any fundoscopic abnormalities. 49
4.4.2.3 Ophthalmoscopic features
Ophthalmoscopic findings in late-onset cone dystrophy range from normal or unspecific 
retinal pigment irregularities to bull’s eye maculopathy and atrophy (Figure 2.5H). 
Furthermore, pallor of the optic disc has been described.230, 233
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4.4.2.4 Fundus autofluorescence (cone dystrophy in general)
Fundus and near-infrared autofluorescence allow detection of retinal structural 
abnormalities even when findings from ophthalmoscopy are normal.235 However, in about 
8.5% of patients, FAF and near-infrared autofluorescence also do not show pathological 
findings.235 Similar to the variability in the fundoscopic appearance of cone dystrophy, FAF 
and near-infrared autofluorescence may show a high heterogeneity ranging from normal 
signals to widespread RPE atrophy (Figure 2.5I).
4.4.2.5 Fluorescein angiography (cone dystrophy in general)
FA may show a dark choroid in patients with ABCA4 associated cone dystrophy. Otherwise, 
FA imaging in patients with cone dystrophy does not add significant information. 235
4.4.2.6 Optical coherence tomography (cone dystrophy in general)
High-resolution OCT imaging frequently reveals thinning of the retina (Figure 2.5J).235 In the 
outer retinal layers and at the RPE-level, unspecific alterations may be visible even when 
findings from ophthalmoscopy are normal.235
4.4.2.7 Psychophysical and electrophysiological testing
Initially, full-field ERG findings may be normal. In advanced stages, full-field ERG reveals 
decreased or absent photopic responses implying severe cone function impairment with 
normal to slightly depressed rod responses. 234
4.4.2.8 Genetic association
There are only a few reports of patients with late-onset cone dystrophy. Possible familial 
inheritance has been reported in some of these patients. 231, 233 
4.4.2.9 Pathophysiology
The exact pathogenesis of late-onset cone dystrophy remains unclear. The cones appear to 
be primarily affected with subsequent photoreceptor loss in the cone-rich central retina. 
The pathological changes in the underlying RPE appear to be secondary. 
4.4.2.10 Differential diagnosis with age-related macular degeneration
Late-onset cone dystrophy may be confused with atrophic AMD because of:
- the age at onset (>50y)
- presence of pigmentary abnormalities
Features that help to distinguish late-onset cone dystrophy from AMD are:
- absence of drusen
- temporal optic disc pallor 
- full-field and/or multifocal ERG findings typical for cone dystrophy
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4.4.3 Central serous chorioretinopathy
4.4.3.1 Introduction
Central serous chorioretinopathy (CSC) is a relatively common cause of maculopathy 
characterized by serous fluid leakage under the neuroretina. CSC is usually sporadic, 
although familial cases have been described. Acute CSC often resolves spontaneously 
but sometimes recurs or becomes chronic. 236 Risk factors for developing CSC include 
corticosteroid use, male sex, and type A personality. 237 
4.4.3.2 Symptoms
Although the chronic form of CSC may be preceded by acute CSC episodes, it is most often 
observed as a primary lesion. 238, 239 Generally, chronic CSC becomes manifest before the 
sixth decade and may cause bilateral vision loss. 49, 237-239 In bilateral chronic cases of CSC in 
which the serous subretinal fluid has eventually resorbed, the remaining central atrophic 
lesions may mimic AMD and atrophic macular dystrophies. Chronic CSC is more often 
bilateral and may be complicated by CNV, further complicating the differential diagnosis 
with AMD. 240
4.4.3.3 Clinical features
In chronic CSC, persistent serous detachment or recurrent multifocal detachments of the 
retina and/or RPE may lead to atrophy of the RPE and the outer retina (Figure 2.5K).49, 241 
Some patients develop yellowish subretinal deposits, intraretinal cystoid edema, fibrinous 
grey-white subretinal material, and/or CNV. 49, 237 
4.4.3.4 Fundus autofluorescence
Areas of RPE atrophy in chronic CSC correspond to hypoautofluorescence and most long-
standing CSC lesions also have speckled areas of increased FAF (Figure 2.5L).49, 242 These 
hyperautofluorescent areas may be explained by the accumulation of lipofuscin in the RPE, 
and/or from autofluorescent A2E-precursors in the subretinal space, derived from the shed 
outer segments of photoreceptors. 242
4.4.3.5 Fluorescein angiography
On FA, chronic CSC typically shows granular areas of hyperfluorescence, often with one or 
more ‘hot spots’ of active subretinal fluid leakage (Figure 2.5M).237 With more extensive 
disease, larger hyperfluorescent RPE window defects may be seen due to RPE atrophy, 
sometimes with characteristic descending atrophic tracts (Figure 2.5M).49, 238 ICGA in active 
disease shows multiple areas of choroidal hyperfluorescence due to choroidal vascular 
dilation and hyperpermeability. 243
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4.4.3.6 Optical coherence tomography
A shallow subretinal detachment, often combined with one or more small pigment 
epithelial detachments may be seen on SD-OCT in chronic CSC patients (Figure 2.5N),242, 
244 but – in contrast to AMD – there are no drusen. 245 In severe cases, atrophy of the outer 
retinal layers and RPE remains after the serous fluid has disappeared. 241, 242, 244 Enhanced 
depth imaging OCT may demonstrate a thickened choroid. 237 
 
4.4.3.7 Psychophysical and electrophysiological testing
EOG is generally normal, but mfERG reveals abnormalities even in patients with a mild 
course.237 Visual field testing and microperimetry may show loss of sensitivity with 
progression to (paracentral) scotoma,246, 247 and color vision testing is often abnormal.49
 
4.4.3.8 Genetic association
Familial occurrence of CSC has been described, indicating that genetic factors may play a 
role in the pathogenesis of this disease.238, 248 So far, no genetic variants involved in CSC have 
yet been reported.
4.4.3.9 Pathophysiology
The pathophysiology of CSC remains poorly understood. There is strong evidence for 
a choroidal vasculopathy and hyperpermeability in CSC, leading to secondary RPE 
dysfunction and subretinal fluid leakage.237, 243 The underlying mechanism of the choroidal 
dysfunction remains to be determined, but it may be related to inappropriate activation of 
the mineralocorticoid receptor.249
 
4.4.3.10 Differential diagnosis with age-related macular degeneration
CSC may be confused with AMD because of:
- late central atrophic lesions and it may be accompanied by yellowish subretinal 
deposits and complicated by CNV 
Features that help to distinguish CSC from AMD include:
- a relatively early age at onset 
- (history of) serous neuroretinal detachment without drusen on ophthalmoscopy 
and SD-OCT 
- gravitational tracks on FA and FAF 
4.4.4 Macular telangiectasia
4.4.4.1 Introduction
The spectrum of idiopathic juxtafoveal retinal telangiectasia has been classified by Gass and 
Blodi in 1993.250 Type 2a, also called macular telangiectasia type 2 or ‘MacTel’, is the most 
common type and may show several morphological similarities to AMD. In recent years, 
there has been tremendous research into MacTel.251 While the underlying cause is still not 
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clear, clinical features, the natural history and the correlation to retinal dysfunction have 
been extensively studied. 
4.4.4.2 Clinical characteristics
MacTel is a bilateral disease in persons 40 years and older causing progressive visual loss. 
It usually presents with a slow decrease in vision, metamorphopsia, positive scotoma and 
reading difficulties. Symptoms may occur prior to fundoscopically visible changes.
4.4.4.3 Ophthalmoscopic features
Based on fundus photographs and FA findings, Gass and Blodi divided MacTel into five 
clinical stages according to the disease development.250 In stage 1, no abnormalities on 
biomicroscopy may be appreciated. FA may show minimal capillary dilatation and mild 
staining in the late-phase in the area temporal to the foveola.
Biomicroscopy shows in stage 2 slight greying and loss of transparency of the perifoveolar 
retina and no or minimal telangiectatic vessel with similar FA findings as in stage 1. The 
occurrence of blunted, right-angle venules that extend into the depth of the parafoveolar 
retina, typically in the temporal fovea, characterize stage 3. Stage 4 manifests with one or 
several foci of black hyperplastic RPE within the retina, often beneath the blunted tips of 
the right angle venules and extending in some cases into the inner retina (Figure 2.5O). The 
development of subretinal neovascularization is defined as stage 5. 
4.4.4.4 Fundus autofluorescence
In early disease stage, a key finding is the depletion of macular pigment in MacTel that may 
even occur before visible capillary dilatation in FA. 252, 253 This finding has been confirmed 
by FAF imaging. In later stages, localized fundoscopically visible hyperpigmentations 
show a well-defined area of severely decreased FAF intensity (Figure 2.5P). This has been 
explained by RPE atrophy with loss of intrinsic fluorophores. Hyporeflective cavities in the 
neurosensory retina may show an increased signal, particularly following bleaching of the 
retina with blue light. 254
Blue confocal reflectance imaging is usually largely neglected in the clinical setting 
although it is available by standard cSLO. In MacTel, blue confocal reflectance is particularly 
helpful as it shows a distinctive parafoveal hyperreflectivity, already in the early stages of 
the disease.255 This characteristic signal may be caused by alterations in macular pigment 
and/or Müller cell loss. 256
4.4.4.5 Fluorescein angiography
FA has traditionally been the gold-standard for the diagnosis of MacTel as it clearly 
demonstrates the capillary dilatations in the early phase with diffuse hyperfluorescence in 
the late stages (Figure 2.5Q). These telangiectatic vessels predominantly occur temporally 
to the fovea. Using stereoscopic images, these vascular alterations appear to be located in 
Chapter 2
90
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
the deeper capillary plexus. 257 Further typical findings with FA are the hypofluorescence 
at the site of hyperpigmentations due to blockage (Figure 2.5Q) and the occurrence of 
leakage by retinal neovascularization in stage 5.
4.4.4.6 Optical coherence tomography
SD-OCT imaging shows intraretinal cystoid spaces or cavities without foveal thickening 
(Figure 2.5R).251 Furthermore, disruption of the ellipsoid zone, increased reflectivity 
of the inner neurosensory layers, outer neurosensory atrophy, foveal detachment and 
laminar or full thickness macular holes may be visualized. These alterations are limited 
to the parafoveal macula and most prominent to the foveal centre. Gillies and co-workers 
have reported that the earliest subtle changes on SD-OCT imaging may be a temporal 
enlargement of the foveal pit that results in an asymmetry of the foveal contour with its 
thinnest sector temporally.258 
4.4.4.7 Psychophysical and electrophysiological testing
Paracentral scotomata at the site of pigment hypertrophy and outer retinal cavities may 
be clearly confirmed by microperimetry.252, 259 Retinal cavities limited to the inner retina 
typically show preserved function. Visible disruption of the inner segment-outer segment 
borders as shown by SD-OCT imaging is spatially confined to reduced retinal sensitivity. 
Fine matrix mapping findings suggest that rod function may be more severely affected 
as compared to cone function and occurs earlier in the disease. By contrast, routine 
examinations with visual acuity testing might not be sufficient to estimate the abilities of 
the patient to cope with daily visual tasks particularly reading.
Standard visual field testing or ERG is usually normal or subnormal in MacTel. It would be 
well conceivable that the affected retinal area in MacTel is relatively small compared to the 
sensitivity of these modalities.
4.4.4.8 Genetic association
No causal mutation has been identified, but a genetic association of the ATM gene and a 
locus have been reported.260, 261 MacTel may occur in monozygotic twin, other siblings and 
also in families with vertical transmission, suggestive of a dominant inheritance mode.258
4.4.4.9 Pathophysiology
The cause of MacTel is unknown. While the name ‘macular telangiectasia’ suggest a 
disease of the retinal vasculature, recent findings have provided increasing evidence that 
MacTel is not limited to the retinal vasculature and that early neuronal involvement may be 
implicated in the pathogenesis of disease. Furthermore, affection of Müller cells has been 
discussed recently. 256, 262-266 
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4.4.4.10 Differential diagnosis with age-related macular degeneration
MacTel may be confused with AMD because of:
- similar symptoms; bilateral slow progressive loss of central vision, metamorphopsia, 
positive scotoma and reading difficulties
- presence of pigmentary changes and CNV may develop
Features that help to distinguish MacTel from AMD are:
- an earlier age at onset
- no drusen
- affection of abnormalities limited to the parafovea and predominantly temporal to 
the foveal centre
- parafoveal hyperreflectivity in confocal blue reflectance
- presence of telangiectatic vessels
- depletion of macular pigment by fundus autofluorescence
- retinal thinning (usual no thickening) and cavities by SD-OCT imaging
4.5 Dystrophies associated with a syndrome or systemic disease
4.5.1 Mitochondrial retinal dystrophy associated with the m.3243A>G mutation (maternally 
inherited diabetes and deafness and MELAS syndrome)
4.5.1.1 Introduction
The m.3243A>G mutation was first described in association with mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS).267, 268 Up to 86% of patients 
with the m.3243A>G mutation have evidence of retinal dystrophy. 269, 270 Over time, more 
phenotypic variations of the m.3243A>G mutation have been reported, the most frequent 
being maternally inherited diabetes and deafness (MIDD).271, 272 Other systemic associations 
include cardiac, renal, and gastro-intestinal involvement. 267, 268, 271, 273-275
4.5.1.2 Clinical characteristics
Most patients have a relatively preserved central visual function because of the frequent 
occurrence of structural and functional sparing of the fovea. 270 Up to 80% of patients 
maintain a visual acuity of 20/25 or better in at least one eye 269, 270. However, even if the 
fovea is spared, considerable visual impairment may be present as a result of paracentral 
scotomata in cases of progressive atrophy around the fovea. 270
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Figure 2.5 (A-G) Central areolar choroidal dystrophy stage 2 in a 48-year-old patient (A-D) and 
stage 3 in a 54-year-old patient (E-G), both carrying a PRPH2 mutation. (A) Color fundus photograph 
showing parafoveal pigmentary changes. (B) Fundus autofluorescence (FAF) image showing 
hyperautofluorescent parafoveal changes corresponding to the pigmentary changes in A. (C) 
Fluorescein angiography (FA) image showing hyperfluorescence corresponding with hypopigmentation 
and hypofluorescence corresponding with hyperpigmentations on A. (D) Horizontal optical coherence 
tomography (OCT) scan (scan in the plane indicated by black arrowhead in A) showing a disruption of 
the photoreceptors corresponding to hypopigmentary changes and hyperreflective elevations of the 
retinal pigment epithelium (RPE) corresponding to hyperpigmentation in A. (E) Color fundus photograph 
showing hypopigmentation of the macula with two parafoveal, oval-to-round, atrophic areas. (F) 
Chorioretinal atrophy corresponding with severely decreased to absent FAF, bordered by speckled 
changes of increased and decreased FAF. (G) Horizontal OCT scan (scan in the plane indicated by black 
arrowhead in E) showing well-circumscribed chorioretinal atrophy. (H-J) Late onset cone dystrophy in 
a 49-year-old patient. (H) Color fundus photograph showing central pigmentary changes and pallor 
of the optic disc. (I) FAF image showing hyperautofluorescent foveal changes corresponding to the 
pigmentary changes in H. (J) Horizontal OCT scan (scan in the plane indicated by black arrowhead in 
H) showing thinning of the outer retinal layers in the fovea. (K-N) Central serous chorioretinopathy in 
a 49-year-old patient. (K) Color fundus photograph showing serous detachment of the retina and RPE 
changes. (L) FAF image showing speckled FAF signals of increased and decreased autofluorescence. 
(M) FA image showing a characteristic descending atrophic tract and several ‘hotspots’ of active 
subretinal leakage. (N) Horizontal OCT scan (scan in the plane indicated by black arrowhead in K) 
showing a shallow subretinal detachment combined with pigment epithelial detachment. (O-R) 
Macular telangiectasia in a 70-year-old patient. (O) Color fundus photograph showing greying of the 
perifoveolar retina. Right-angle venules extend into the depth of the temporal fovea with a lesion of 
black hyperplastic RPE beneath the venules. (P) FAF image showing decreased FAF corresponding 
with hyperpigmentation in O. (Q) FA image showing hyperfluorescenc of the capillary dilatations, 
predominantly temporal to the fovea located. Hyperpigmentations are hypofluorescent due to 
blockage. (R) Horizontal OCT scan (scan in the plane indicated by black arrowhead in O) showing 
intraretinal cysotid spaces without foveal thickening and disruption of the photoreceptor layers in the 
parafoveal macula.
4.5.1.3 Ophthalmoscopic features
The spectrum of retinal abnormalities ranges from barely discernible pigmentary 
abnormalities in the outer retinal layers of the macula to profound chorioretinal atrophy in 
the macula.270 Patients with the m.3243A>G mutation have retinal lesions that are localized 
at the posterior pole but tend to spare the fovea and often include the retina surrounding 
the optic disc (Figure 2.6A). Recently, Boon has proposed a classification system into 
4 grades based on findings on ophthalmoscopy, FAF, and SD-OCT. 270 This classification 
correlates both with age and visual acuity.
4.5.1.4 Fundus autofluorescence
The retinal abnormalities in m.3243A>G mutation associated macular dystrophy are clearly 
visible on FAF imaging.270, 276, 277 Mild hypofluorescent mottling correlates with the mild 
pigmentary abnormalities in the central fundus in grade 1 mitochondrial retinal dystrophy. 
In grade 2, fundoscopically visible yellow-white spots/flecks correspond to mostly increased 
FAF, while a decreased FAF signal is present in mildly atrophic areas (Figure 2.6B). In grade 3, 
there are one or more areas of well delineated areas of chorioretinal atrophy that present 
with a well-defined area of decreased FAF. Unlike grade 4 disease, these atrophic zones 
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may encircle the fovea but do not involve the central fovea. A diffuse speckled FAF pattern 
may be present that is significantly larger than would be expected from the fundoscopic 
appearance. 130, 276, 277
4.5.1.5 Fluorescein angiography
The FA signal may vary from small hyper and hypofluorescent spots to extensive RPE 
window defect with visibility of the underlying larger choroidal vasculature and atrophy of 
the choriocapillaris depending of the disease grade (Figure 2.6C).270
4.5.1.6 Optical coherence tomography
Irregular thickening or attenuation of the line corresponding to the ellipsoid zone and of the 
underlying RPE layer may be visualized in affected retinal area (Figure 2.6D). The atrophic 
areas correspond to a loss of the outer retinal layers on OCT imaging. 270
4.5.1.7 Psychophysical and electrophysiological testing
The full-field ERG and EOG are normal. 270 Multifocal ERG in mitochondrial retinal dystrophy 
can show reduced peak amplitudes with normal implicit times in the mfERG suggesting 
localized loss of function and indicating damage to the cone photoreceptor outer segments 
or cone photoreceptor loss in MIDD. 278
4.5.1.8 Genetic association and pathophysiology
The m.3243A>G mutation is by far the most common cause of mitochondrial retinal 
dystrophy in adults 270. The percentage of cells with the affected mitochondrial DNA in a 
specific tissue is referred to as ‘heteroplasmy’, and within a single individual, the degree 
of heteroplasmy may vary widely between tissues.270, 279 Therefore, mitochondrial disease 
may present at any age, with virtually any symptom or sign, and by any apparent mode of 
inheritance.280 This marked intra-individual and inter-individual variation in mitochondrial 
heteroplasmy explains the wide spectrum of clinical symptoms and disease severity 
observed between family members who share a given mitochondrial mutation. 280 There 
is no clear correlation of the grade of mitochondrial retinal dystrophy with systemic 
heteroplasmy levels or overall systemic disease involvement. 270
4.5.1.9 Differential diagnosis with age-related macular degeneration
m.3243A>G associated macular dystrophy may be confused with AMD because of:
- the pigmentary abnormalities and chorioretinal atrophy that can mimic drusen 
and GA in AMD 
- the maternal inheritance pattern may be masked and the systemic disease 
associations may be variable or even absent 
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Features that help to distinguish m.3243A>G associated macular dystrophy from AMD 
include:
- a typical speckled FAF pattern that may spread along the temporal retinal vascular 
arcades and surround the optic disc 130, 276 
- systemic associations such as hearing loss and early-onset diabetes 
- maternal inheritance of disease (no male-to-male transmission) 
- genetic analysis revealing the m.3243A>G mutation 
4.5.2 Dystrophies with angioid streaks
4.5.2.1 Introduction
Angioid streaks are irregular and radiating lines extending from the disc to the peripheral 
retina caused by breaks in the Bruch’s membrane. 281 Angioid streaks frequently occur 
in patients with systemic diseases, including pseudoxanthoma elasticum (PXE), osteitis 
deformans, sickle cell anaemia, acromegalie, Marfan syndrome, fibrodysplasia hyperelastica, 
thalassemia, and spherocytosis. 282 
PXE is the most commonly associated systemic disorder: 59-87% of cases with angioid 
streaks are due to PXE. 283 It is associated with accumulation of mineralized and fragmented 
elastic fibers in the skin, vascular walls, and Bruch’s membrane in the eye, 284 manifested 
in soft, ivory-colored papules in a reticular pattern that predominantly affect the neck and 
large flexor surfaces, peripheral and coronary arterial occlusive disease and gastrointestinal 
bleedings. 284
4.5.2.2 Clinical characteristics
Patients with angioid streaks usually remain asymptomatic. However, complications such 
as atrophy of outer retinal layers, choroidal rupture, or CNV, with or without haemorrhage 
and subretinal fibrosis may be associated with severe visual impairment when affecting the 
macula.285, 286 This has been reported in 73-86% of PXE cases,83, 287, 288 frequently leading to 
severe reduction of visual acuity as early as age 14. 287 By the age of 50, the majority of PXE 
patients have bilaterally impaired visual acuity of 20/200 or less. 284, 288
4.5.2.3 Ophthalmoscopic features
Typically, there is a peripapillary ring from which irregularly radiating linear streaks extend 
in all directions (Figure 2.6E). Fibrovascular ingrowth into the angioid streaks may result 
in serous and/or hemorrhagic detachment of the overlying retina. In advanced stages, 
detachment and atrophy of the RPE and may also occur. 285
In PXE, first visible changes on fundoscopy are pigmentary regularities called peau 
d’orange, which are most prominently visible temporal to the fovea. 289, 290 These pigment 
irregularities have a fine, yellow, drusen-like appearance and are assumed to be localized 
at the level of the RPE. 49, 287 Peau d‘orange typically precedes angioid streaks on average 
by 1 to 8 years.287 Additional ocular findings in PXE are multiple small chorioretinal atrophic 
lesions, so called comet tail lesions, as well as drusen of the optic disc. 291 
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4.5.2.4 Fundus autofluorescence
On FAF, angioid streaks may show areas of increased as well as decreased FAF (Figure 2.6G).292, 
293 Focal spots of increased FAF alongside angioid streaks, consisting of pigmentations on 
fundoscopy, constitute a parastreak phenomenon. 
Macular FAF patterns in PXE patients are often similar to those observed in pattern 
dystrophies.293 Comet tail lesions in the midperiphery typically show an increased FAF 
signal and appear hyperfluorescent on FA. FAF depicts RPE atrophies, which are often more 
extensive than fundoscopy or FA would suggest. 284 
4.5.2.5 Fluorescein angiography
Angioid streaks may show increased fluorescence if there is thinning of the RPE overlying 
an intact choriocapillaris. In this situation, there would be gradual fading of an early 
choroidal blush in the later phases of the angiogram. 285 If there is actual separation of 
the choriocapillaris at the time of the separation of Bruch’s membrane, one may see only 
hyperfluorescence along the margin of the streak with the central portion of the streak 
showing very little or no fluorescence. 285 CNVs usually originate from the rim of angioid 
streaks and show similar angiographic pattern to that described in AMD (Figure 2.6H). 294-296 
4.5.2.6 Optical coherence tomography
On SD-OCT scans the pathology of angioid streaks is localized to the Bruch’s membrane-RPE 
complex.297 The RPE overlying breaks in Bruch’s membrane may seem unaffected, but often 
appears altered, focally detached, or absent. In many advanced cases, fibrovascular tissue 
extends from the choroidal into the subneurosensory space (Figure 2.6I) through the gaps 
in Bruch’s membrane (Figure 2.6J). Simultaneous SD-OCT and cSLO imaging reveals the 
most reliable detection of angioid streaks in the near-infrared mode (Figure 2.6F). 297 
4.5.2.7 Psychophysical and electrophysiological testing
Full-field ERG may reveal mild to significant amplitude reduction of cone and rod responses. 
298, 299
4.5.2.8 Genetic association
PXE is an autosomal-recessive disorder and in the majority of cases, homozygosity or 
compound heterozygosity is found for mutations in the ABCC6 gene, a member of the large 
ATP-dependent transmembrane transporter family. Since the ABCC6 gene is expressed 
primarily, if not exclusively, in the liver and kidneys, it has been suggested that PXE is a 
primary metabolic disorder with secondary involvement of elastic fibres.300, 301 
4.5.2.9 Pathophysiology
Angioid streaks represent breaks of the calcified and thickened Bruch’s membrane, which 
are not associated with morphological changes in the overlying layers of the retina and the 
underlying choriocapillaris in early stages. 302 
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4.5.2.10 Differential diagnosis with age-related macular degeneration
Angioid streaks related dystrophies may be confused with AMD because of:
- atrophy and/or CNV may occur secondary to the angioid streaks 
Features that help to distinguish between angioid streaks related diseases and AMD include:
- visualization of angioid streaks by angiography, near-infrared-, AF-, and SD-OCT-
imaging
- an earlier age at onset
- accompanied ocular findings such as peau d’ orange and comet tail lesions in PXE
- accompanied systemic symptoms
- genetic analysis (mutations in ABCC6)
- skin biopsy in patients with PXE
4.5.3 Cuticular drusen in membranoproliferative glomerulonephritis II
4.5.3.1 Introduction
Membranoproliferative glomerulonephritis type II (MPGN II), also termed ‘dense deposit 
disease’, is a rare condition characterized by the deposition of abnormal electron-dense 
material within the glomerular basement membrane of the kidney and often within Bruch’s 
membrane in the eye. 303 
4.5.3.2 Clinical characteristics
The diagnosis is made in most patients between the ages of 5 and 15 years of life. Within 
10 years after diagnosis, approximately half of patients progress to end-stage renal disease, 
occasionally with the late co-morbidity of visual impairment. 303 
4.5.3.3 Ophthalmoscopic features
The majority of patients with MPGN II develop deposits at the posterior pole with the 
clinical appearance of cuticular drusen (Figure 2.6L).304 Visual acuity tends to be preserved 
until GA or CNV complicate the disease. 182, 305-307
4.5.3.4 Fundus autofluorescence
To the best of our knowledge, no descriptions of FAF imaging in patients with cuticular 
drusen and MPGN II have been published thus far. Cuticular drusen in general correspond 
with focal hypoautofluorescent lesions on FAF image, even when the lesions are not 
advanced enough to show the classic stars-in-the-sky appearance on FA. 51
4.5.3.5 Fluorescein angiography
Drusen in MPGNII are identified most readily by FA. Typically, the small drusen show 
hyperfluorescence in the early phase of the angiogram (Figure 2.6M).
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4.5.3.6 Psychophysical and electrophysiological testing
In long-standing cases, EOG may become abnormal due to widespread RPE atrophy.308, 309 In 
these advanced stages, color vision, dark adaption, as well as dark adapted ERG may also 
become mildly abnormal. 308
4.5.3.7 Genetic association
The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic 
activation of the alternative pathway of the complement cascade. In most patients, loss of 
complement regulation is caused by C3 nephritic factor, an autoantibody directed against 
the C3 convertase of the alternative pathway, but in some patients, mutations in the CFH 
gene have been identified. 303, 310
4.5.3.8 Pathophysiology
The pathophysiologic basis for MPGN II seems to be the uncontrolled systemic activation 
of the alternative pathway of the complement cascade. 311, 312 In most patients, loss of 
complement regulation is caused by the C3 nephritic factor, an immunoglobulin (Ig)G 
autoantibody that binds and prevents the inactivation of C3 convertase of the alternative 
pathway, thereby resulting in the perpetual breakdown of C3. 313 The characteristic finding 
in MPGN II is an intense deposition of C3 cleavage products along the glomerula capillary 
walls together with electro-dense deposits in the central part of the glomerula basal 
membrane. 303 Histopathological studies on drusen in MPGN II showed both linear and focal 
depositions throughout the extent of the inner collagenous layer of Bruch’s membrane.314, 
315 This draws attention to the fact that the choriocapillaris-Bruch’s membrane-RPE 
complex shows a remarkable resemblance to the capillary tuft-glomerula basal membrane-
glomerular epithelial interface. 303, 315
4.5.3.9 Differential diagnosis with age-related macular degeneration: 
MPGNII may be confused with AMD because:
- patients may develop cuticular drusen, GA and CNV 
Features that help to distinguish MPGNII from AMD include:
- renal dysfunction 
- retinal changes present at an early age and are often detectable in the first or 
second decade of life. Therefore, in patients with early onset or extensive cuticular 
drusen screening for renal dysfunction is reasonable. 28 
4.5.4 Maculopathy in myotonic dystrophy
4.5.4.1 Introduction
Steinert (1909) 316 and Batten and Gibb (1909) 317 identified myotonic dystrophy as a 
multisystemic disorder that is now recognized as one of the most common forms of 
muscular dystrophy in adults.318 This inherited disorder is accompanied by progressive 
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weakness of the distal muscles and myotonia. Cases of myotonic dystrophy are generally 
classified as one of two types based on the genetic background. 319
4.5.4.2 Clinical characteristics
In addition to muscular dystrophy and myotonia, which also may cause ptosis and weakness 
of the ocular muscles, myotonic dystrophy causes a consistent constellation of seemingly 
unrelated and rare clinical features, including cardiac conduction defects, a peculiar and 
specific set of endocrine changes, and posterior subcapsular iridescent cataracts.320 Further 
ophthalmic features include low intraocular pressure and in at least 20% to 25% of patients 
with myotonic dystrophy there is some evidence of retinal degeneration.49, 321 Most of the 
patients have minimal loss of visual acuity. 49 
4.5.4.3 Ophthalmoscopic features
A variety of fundoscopic pictures has been described. Besides peripheral pigmentary 
changes, dark and yellow spots in the macular that are configured in stellae, butterfly, and 
reticular shape resembling pattern dystrophies may occur (Figure 2.6N).49, 321 Long-term 
follow-up of patients with myotonic dystrophy suggested that these pigmentary retinal 
changes progress slowly over time. 322 
4.5.4.4 Fundus autofluorescence
To the best of our knowledge, there are no descriptions published so far.
4.5.4.5 Fluorescein angiography
FA shows window defects and blocked fluorescence by focal pigment clumps (Figure 
2.6O).323
4.5.4.6 Psychophysical and electrophysiological testing
Decreased b-wave and subnormal a-wave amplitudes in the ERG and delayed dark adaption 
have been reported in patients with myotonic dystrophy. 321 The EOG remains normal in 
patients with myotonic dystrophy. 322
4.5.4.7 Genetic association
Myotonic dystrophy type 1 is caused by the expansion of an unstable CTG trinucleotide 
repeat in the 3′ untranslated region of the myotonic dystrophy protein kinase (DMPK) 
gene.320, 324 The myotonic dystrophy type 2 mutation consists in the expansion of an 
unstable CCTG tetranucleotide within the first intron of the CCHC-type zinc finger, nucleic 
acid-binding protein (CNBP) gene (previously named myotonia). 325
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4.5.4.8 Pathophysiology
Experimental evidence supports an RNA gain-of-function mechanism of expanded 
transcripts in myotonic dystrophy type 1 and 2.318, 326-329 These ‘toxic’ RNA transcripts 
accumulate in nuclear inclusions, interfering with the activity, localization and/or steady-
state levels of RNA-interacting proteins. The exact mechanisms leading to the fundoscopic 
features of the disease are still unknown.
4.5.4.9 Differential diagnosis with age-related macular degeneration
Maculopathy in myotonic dystrophy may be confused with AMD because of:
- the pattern dystrophy-like features may resemble drusen and AMD-related 
hyperpigmentary changes 
Features that help to distinguish between myotonic dystrophy associated macular dystrophy 
and AMD include:
- posterior subcapsular cataracts that are present in almost all patients with 
myotonic dystrophy
- other associated ocular symptoms such as ptosis, ophthalmoplegia, and low 
intraocular pressure
- absence of typical sub-RPE or reticular drusen on SD-OCT
- generalized muscle weakness and myotonia and a positive family history 
- genetic testing (DMPK and CNBP)
Figure 2.6 (A-D) m.3243A>G Macular dystrophy associated with MIDD in a 26-year-old patient 
with diabetes mellitus who carried a m.3243 A>G mutation. (A) Color fundus photograph showing 
hyperpigmented irregular spots in the macula and an oval area of mottled hypopigmentation 
that involved the macula and surrounded the optic disc. (B) Fundus autofluorescence (FAF) image 
showing that the hyperpigmented spots in the macula correspond to mainly increased FAF, 
whereas the hypopigmented spots and zones mainly correspond to a decreased FAF signal. (C) 
Fluorescein angiography (FA) image showing blockage of background fluorescence in the area 
of hyperpigmentation and hyperfluorescence due to a retinal pigment epithelium (RPE) window 
defect in the retinal areas that were hypopigmented and mildly atrophic on the fundus image A. (D) 
Horizontal optical coherence tomography (OCT) scan (scan in the plane indicated by black arrowhead 
in A) showing the hyperpigmented spot corresponding to a hyperreflective dome-shaped lesion that 
seemed to originate from the RPE. (E-K) Choroidal neovascularization (CNV) associated with angioid 
streaks in a 45-year-old patient with pseudoxanthoma elasticum. On fundoscopy (E) the identification 
of angioid streaks is challenging. Infra-red (F) or FAF (G) imaging might be more reliable to detect 
angioid streaks. FA (H) shows a classic CNV originating from an angioid streak. On SD-OCT image 
(I) fibrovascular invasion with subretinal fluid is visible. The OCT image (J) reveals a break in Bruch‘s 
membrane associated with an angioid streak. (K) Magnification of image J highlighting the break in 
Bruch’s membrane (white arrow). (L-M) Membranoproliferative glomerulonephritis II in a 58-year-
old patient who carried compound heterozygous mutations in the Complement Factor H gene. (L) 
Color fundus photograph showing widespread drusenoid lesions with irregular RPE alterations. (M) 
FA image showing stars-in-the-sky appearance with small, hyperfluorescent drusen scattered in the 
posterior pole. (N-O) Maculopathy in a 53-year-old patient with myotonic dystrophy (Courtesy of J.R.M. 
Cruysberg, Radboud University Nijmegen Medical Centre). (N) Color fundus photograph showing 
pigmentary changes in the macula. (O) FA image showing window defects and hypofluorescence 
corresponding with the pigmentary changes due to blockage of background fluorescence.
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5. CONCLUSIONS AND FUTURE DIRECTIONS
A broad range of dystrophic macular disorders share clinical characteristics with AMD, 
which can make a differential diagnosis challenging. Although macular dystrophies and 
AMD show broad genetic and phenotypic heterogeneity, with overlapping features that may 
complicate a comprehensive clinical classification, there are often characteristic phenotypic 
features that can help in the differential diagnosis in a practical clinical setting. We propose 
a diagnostic flow chart in Figure 2.7. This flow chart inevitably is an oversimplification, and 
many classifications have been proposed, some based on ophthalmoscopic features, others 
are based on electrophysiologic findings or underlying molecular genetic defect(s).
It is clinically relevant to distinguish AMD from macular dystrophies, not only because of 
the prognostic implications and genetic counselling, but also because of its consequences 
for present and future preventive and therapeutic strategies. 
A correct diagnosis can have significant implications for the prognosis. Atrophy in 
macular dystrophies, for example, may show a different rate of progression from that 
in atrophic AMD 218, 330, 331 and CNV in macular dystrophies appears to have a relatively 
favourable prognosis as compared to CNV in AMD.33 
With regard to genetic counselling, it is very important to provide the patient with the 
correct information on the risk of affected offspring, for instance in late-onset Stargardt 
disease versus pseudo-Stargardt pattern dystrophy. Although these retinal dystrophies can 
be clinically very similar, Stargardt disease is inherited in an autosomal-recessive fashion, 
on contrast to autosomal-dominantly inherited pseudo-Stargardt. 
An early recognition of syndrome-associated macular dystrophies paves the way to a 
multidisciplinary approach, a timely diagnosis, prevention and/or treatment of associated 
systemic disease(s). For example, it is important to recognise macular dystrophy in the 
constellation of pseudoxanthoma elasticum because this has implications for the prevention 
and treatment of cardiovascular disease. Mitochondrial retinal dystrophy associated can be 
the first manifestation in carriers of the m.3243A>G mutation.270 These patients have a very 
high risk of other systemic abnormalities, such as hearing loss and diabetes, for which they 
should be screened in a specialized centre for mitochondrial disease. 
Nutritional supplements are widely used by AMD patients. However, Stargardt patients 
might be advised to refrain from taking vitamin A supplements, as it may accelerate 
the disease course. A misdiagnosis may therefore lead to recommendations which are 
potentially harmful.178 Misdiagnosis can lead to erroneous treatment of patients.217 Unlike 
in AMD, argon laser and photodynamic therapy may not be effective in the treatment 
of CNV in SFD patients (Figure 2.2G).121 On the other hand, anti-VEGF therapy may be a 
successful therapy,121, 332 as in neovascular AMD. 
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The development of gene therapy and stem cell based approaches for patients with 
retinal dystrophies patients is advancing at an accelerating pace, possibly leading to future 
therapeutic options in patients with retinal dystrophies in whom the affected gene has been 
identified. Therefore, a thorough differential diagnostic approach is essential to establish 
the right clinical and genetic diagnosis.
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Chapter 3
Age-related macular degeneration
3.1
Clinical characteristics of familial and 
sporadic age-related macular degeneration:
differences and similarities
N.T.M. Saksens, E. Kersten, J.M. Groenewoud, M.J. van Grinsven, J.P.H. van de Ven, 
C.I. S´anchez, T. Schick, S. Fauser, A.I. den Hollander, C.B. Hoyng, C.J.F. Boon
Published in: Investigative Ophthalmology & Visual Science 2014;55:7085-7092 
PURPOSE. We describe the differences and similarities in clinical characteristics and 
phenotype of familial and sporadic patients with age-related macular degeneration (AMD).
METHODS. We evaluated data of 1828 AMD patients and 1715 controls enrolled in the 
European Genetic Database. All subjects underwent ophthalmologic examination, including 
visual acuity testing and fundus photography. Images were graded and fundus photographs 
were used for automatic drusen quantification by a machine learning algorithm. Data on 
disease characteristics, family history, medical history and lifestyle habits were obtained by 
a questionnaire. 
RESULTS. The age at first symptoms was significantly lower in AMD patients with a positive 
family history (68.5 years) than in AMD patients with no family history (71.6 years; P = 
1.9x10-5). Risk factors identified in sporadic and familial subjects were increasing age (OR 
1.08 per year; P = 3.0x10-51 and OR 1.15; P = 5.3x10-36, respectively) and smoking (OR 1.01 
per pack year; P = 1.1x10-6 and OR 1.02; P = 0.005). Physical activity and daily red meat 
consumption were significantly associated with AMD in sporadic subjects only (OR 0.49; 
P = 3.7x10-10 and OR 1.81; P = 0.001). With regard to the phenotype, geographic atrophy 
and cuticular drusen were significantly more prevalent in familial AMD (17.5% and 21.7%, 
respectively) as compared to sporadic AMD (9.8% and 12.1%).
CONCLUSIONS. Familial AMD patients become symptomatic at a younger age. The higher 
prevalence of geographic atrophy and cuticular drusen in the familial AMD cases may be 
explained by the contribution of additional genetic factors segregating within families.
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INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial retinal disease leading to 
severe vision loss among the elderly. Advanced age, female sex, smoking, and obesity 
(body mass index (BMI) >30) are most commonly reported as important demographic and 
environmental risk factors for the development of AMD.1-6 In addition, several important 
genetic variants have been found to be associated with AMD, either as a risk factor or as a 
protective factor. The strongest associations have been reported for the single-nucleotide 
polymorphisms (SNPs) in the complement factor H gene (CFH Y402H; rs1061170), and 
in the age-related maculopathy susceptibility 2 gene (ARMS2 A69S; rs10490924), which 
strongly increase the risk of developing AMD.7-11
Previous studies have demonstrated aggregation of AMD in families.12, 13 A family 
history of AMD has been reported as a significant risk factor for AMD.14 Individuals are at a 
higher risk of developing AMD when a first-degree relative is affected. Moreover, having an 
affected parent is associated with a higher risk than having an affected sibling.13, 14 Shahid 
et al. showed an odds ratio (OR) for AMD of 27.8 in people with an affected parent and an 
OR of 12.0 for people with an affected sibling. Likewise, Luo et al. reported a relative risk 
for the development of AMD of 5.66 for people with an affected parent, and a relative risk 
of 2.95 for people with an affected sibling. 
A lower age at onset has been reported in familial AMD patients and heritability of AMD 
subtypes has been suggested.14, 15 Even though environmental and genetic risk factors can 
cluster in families, the number of affected family members in large densely affected families 
cannot be fully explained by clustering of known risk factors.12 Several recent studies 
have shown th at rare, highly penetrant genetic variants can strongly increase the risk of 
developing AMD in families with AMD, as well as in the AMD population in general.16-20 
Little is known about clinical differences and similarities between patients with and 
without a family history of AMD. The purpose of this study is to gain more insight into 
the clinical and phenotypic characteristics of familial and sporadic AMD patients, and to 
analyze if there are distinct clinical differences between these subgroups.
 
METHODS
Study population 
The European Genetic Database (EUGENDA, www.eugenda.org) is a multicenter database 
for clinical and molecular analysis of AMD founded by the Radboud University Medical 
Center (Nijmegen, the Netherlands) and the Department of Ophthalmology of the University 
Hospital of Cologne (Cologne, Germany). This database contains data of AMD patients and 
control individuals, including family history, environmental risk factors and ophthalmologic 
examination. For this retrospective study we evaluated data of 1828 Caucasian patients 
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with AMD and 1715 Caucasian controls enrolled in EUGENDA of whom family history of 
AMD, smoking status, BMI, age and sex data were available. 
This study was performed in accordance with the tenets of the Declaration of Helsinki 
and was approved by the local ethical committees at the Radboud University Medical 
Center (Nijmegen) and the University of Cologne. Written informed consent was obtained 
from all participants before enrolling in EUGENDA.
 
Questionnaire, clinical evaluation and grading
Before enrollment in the EUGENDA database, all subjects were interviewed with a detailed 
questionnaire about disease characteristics (e.g. age at first symptoms), family history, 
medical history and lifestyle habits, such as smoking status, diet and physical activity. 
For each subject, BMI was calculated using body height and body weight as reported 
in the questionnaire. Based on years of smoking and number of cigarettes smoked per 
day we calculated the number of pack years. Each subject underwent an ophthalmologic 
examination, including Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity 
testing, dilated fundus examination and color fundus photography. The best corrected visual 
acuity (BCVA) was converted to Logarithm of the Minimal Angle of Resolution (logMAR) 
visual acuity for the purpose of statistical analysis. Two independent certified reading center 
graders evaluated color fundus photographs of both eyes of all subjects according to the 
standard protocol of the Cologne Image Reading Center and Laboratory (CIRCL).21 Digital 
non-stereoscopic 30° color fundus photographs centered on the fovea were performed 
with a Topcon TRC 50IX camera (Topcon Corporation, Tokyo, Japan). The diagnosis and 
grading of AMD was based on a classification and grading scheme as described previously.22 
For all analyses in this study we used the grading of the worst affected eye, and subjects 
with only one gradable color fundus photograph were excluded. Additionally, in 1184 AMD 
subjects spectral-domain optical coherence tomography (SD-OCT) (SPECTRALIS, Heidelberg 
Engineering, Heidelberg, Germany) was available and evaluated for the presence of 
reticular pseudodrusen. In 677 subjects the presence of cuticular drusen was evaluated 
based on available fluorescein angiography, performed using the Spectralis HRA system 
(Heidelberg Engineering, Heidelberg, Germany).23 The SD-OCT volume scans consisting of 
19 or 37 parallel OCT B-scans were used for analysis, covering 6 x 4 mm of the macula. 
For each OCT B-scan, 20 images were averaged using the automated real-time function.21 
Evaluation of the presence of reticular pseudodrusen on SD-OCT and cuticular drusen on 
fluorescein angiography were done by one senior grader.
Based on diagnosis and family history, the participants in this study were divided 
into four groups: sporadic AMD, sporadic control, familial AMD and familial control. We 
classified subjects as familial in case of confirmed or possible AMD in at least one close 
relative, defined as a parent, sibling or child. Sporadic subjects were defined as individuals 
who did not have a close relative with AMD.
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Automatic drusen quantification
In addition to the human grading of AMD based on photographs, a machine learning 
algorithm for computer-aided diagnosis of AMD was used for detection and quantification 
of drusen number and area (measured in pixels). This was previously described as accurate 
in detecting and quantifying drusen number and area on color fundus photographs of 
patients with non-advanced AMD and control subjects,24. Patients with advanced AMD in 
the worst affected eye have been excluded for this specific analysis, because the automatic 
system was not designed to deal with images containing signs of advanced stage AMD. A 
quality score ranging from 0 to 1 was calculated with 0 being the worst quality and 1 best 
quality. Only color fundus photographs were selected with a quality score of 0.3 or more, 
which corresponds to sufficient quality for human grading. 
 
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics software, version 20.0 (IBM 
Corp. Released 2011, Armonk, NY). Each potential risk factor for the development of AMD 
obtained from the questionnaire was included separately in a logistic regression analysis 
adjusted for age, sex, smoking and BMI. The ORs were calculated for familial subjects 
(familial AMD versus familial controls) and sporadic subjects (sporadic AMD versus sporadic 
controls). Significant differences between ORs for sporadic and familial subjects were 
identified by interaction analysis using binary logistic regressions. All continuous variables 
were analyzed using an independent sample t-test or 1-way ANOVA. An univariate general 
linear model was used when continuous variables were analyzed with correction for other 
variables. Categorical variables were analyzed using a Chi squared test. Differences with a 
P-values less than 0.05 were considered statistically significant. Because multiple possible 
risk factors were analyzed and many tests of significance were performed in our study, 
Bonferroni correction was performed for the risk and interaction analysis of environmental 
factors.
RESULTS
Demographic characteristics of the cohort are shown in Table 3.1.1. All four groups were 
comparable for sex, smoking and BMI. The mean age of the familial subjects was slightly 
lower than in sporadic subjects (69.6 and 73.0 years, respectively; P = 4.7x10-16), mainly due 
to younger familial control individuals. In 309 subjects who reported in the questionnaire 
to have a close relative with (possible) AMD, the ophthalmologically examined AMD status 
of close relatives was available. To determine the degree of misclassification of subjects 
into familial or sporadic based on the questionnaire, we compared the family history with 
these examined data. Only in 3 out of 309 cases (1.0%) who reported in the questionnaire 
to have at least one close relative with AMD, no family members seemed to be affected 
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upon ophthalmological examination. Therefore, these cases were incorrectly classified as 
familial. No ophthalmological information was available of relatives of sporadic subjects 
included in this study.
 
Table 3.1.1 Demographic characteristics
 Sporadic Familial
 AMD Control Total AMD Control Total
Cases, n 1330 1405 2735 498 310 808
Sex, n(%)
Male 536 (40.3) 587 (41.8) 1123 (41.1) 181 (36.3) 132 (42.6) 313 (38.7)
Female 794 (59.7) 818 (58.2) 1612 (58.9) 317 (63.7) 178 (57.4) 495 (61.3)
Age, mean±SD * 75.6±9.1 70.5±7.3 73.0±8.6 74.0±8.4 62.6±10.2 69.6±10.7
Smoking, mean±SD † 14.6±20.1 11.6±16.6 13.1±18.4 14.5±17.9 12.2±15.9 13.6±17.2
BMI, n(%)
< 25 600 (45.1) 638 (45.4) 1238 (45.2) 233 (46.8) 139 (44.8) 372 (46.0)
25-30 558 (42.0) 599 (42.6) 1157 (42.3) 208 (41.8) 124 (40.0) 332 (41.1)
> 30
 
Examined family history, 
Familial
Sporadic
172 (12.9)
n(%)
168 (12.0) 340 (12.4) 57 (11.4)
165 (100)
164 (99.4)
1 (0.6)
47 (15.2)
144 (100)
142 (98.6)
2 (1.4)
104 (12.9)
309 (100)
306 (99.0)
3 (1.0)
The study included 498 familial AMD patients deriving from 393 families (393 probands and 105 family 
members) and 310 controls deriving from 216 families (216 probands and 94 family members). In 309 
familial cases information about ophthalmologic examination in their close relatives (parents, sibling, 
and/or children) was available and was compared to family history based on the questionnaire to 
determine the degree of misclassification. Familial = positive family history of AMD (confirmed or 
possible AMD in at least one close relative [parent, sibling or child]); Sporadic = no positive family 
history.
* Age of participation in years.
† Smoking in pack years.
Familial and sporadic AMD: clinical differences and similarities
Information about the age at first symptoms was available in 703 AMD patients (469 sporadic 
subjects, 234 familial subjects, Table 3.1.2). The age at first symptoms was significantly 
lower (P = 1.9x10-5) in familial AMD patients (mean 68.5 years; SD 9.8) than in sporadic 
AMD patients (mean 71.6 years; SD 8.7) with a mean difference of 3.1 years (95% CI 1.7-
4.5). When subdividing AMD in the presence or absence of the reticular pseudodrusen 
subtype, the age at first symptoms was also lower in familial AMD patients. In addition, 
AMD patients with reticular pseudodrusen have a significantly higher age at first symptoms 
than patients without reticular pseudodrusen, in both sporadic and familial patients (P = 
4.4x10-10 and P = 0.002, respectively). In contrast, in AMD patients with the cuticular drusen 
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subtype, the age at first symptoms was lower than in patients without cuticular drusen, in 
both sporadic and familial patients (P = 1.26x10-6 and P = 0.074, respectively). However, no 
significant difference in age at first symptoms was observed between familial and sporadic 
patients with the cuticular drusen subtype (P = 0.740). 
Despite a younger age at first symptoms, BCVA of both eyes did not differ significantly 
between familial and sporadic AMD patients when subdivided in three age categories (data 
shown in Table 3.1.2). Also, if young patients (< 60 years) were analyzed separately, no 
difference in BCVA was observed between familial and sporadic patients (data not shown). 
After distinguishing between advanced and non-advanced AMD subjects, BCVA also was 
comparable between sporadic and familial patients.
Table 3.1.2 Clinical features and staging of sporadic and familial AMD patients
Sporadic AMD
Mean±SD
Familial AMD
Mean±SD
P-value
Age at first symptoms, years
AMD (Total*) 71.6±8.7 68.5±9.8 1.9x10-5
AMD (Reticular pseudodrusen†) 76.2±7.2 72.5±7.3 0.008
AMD (Cuticular drusen‡) 65.8±9.2 64.5±17.7 0.740
Visual acuity per age category§
< 70 0.12±0.27 0.09±0.25 0.293
70-80 0.19±0.29 0.26±0.36 0.107
> 80 0.40±0.40 0.38±0.46 0.814
Visual acuity per stage§
Non-advanced 0.05±0.14 0.03±0.13 0.367
Advanced 0.33±0.37 0.37±0.42 0.314
Grading, n (%)
Early
Intermediate
Advanced
301 (22.6)
250 (18.8)
779 (58.6)
94 (18.9)
90 (18.1)
314 (63.1)
0.158
GA 76 (9.8) 55 (17.5) 3.0x10-4
CNV 660 (84.7) 234 (74.5)
Mixed 43 (5.5) 25 (8.0)
* Data on age of first symptoms were available in 469 sporadic and 234 familial AMD patients
† Data on age of first symptoms were available in 75 sporadic and 45 familial AMD patients with 
reticular pseudodrusen
‡ Data on age of first symptoms were available in 32 sporadic and 19 familial AMD patients with 
cuticular drusen
§ Visual acuity defined as best-corrected logMAR visual acuity
AMD = Age-related macular degeneration, SD = standard deviation, GA = Geographic atrophy, CNV = 
Choroidal neovascularization
P-values < 0.05 indicate significant associations
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To identify risk factors in our cohort, we analyzed several demographic and environmental 
factors (Table 3.1.3). Risk factors identified in both sporadic and familial AMD patients were 
increasing age (P = 3.0x10-51 and P = 5.3x10-36) and smoking (P = 1.1x10-6 and P = 0.005). 
Interaction analysis showed a significant difference between sporadic and familial subjects 
for increasing age (P = 9.4x10-7). 
In terms of comorbidity (Table 3.1.3), allergy was significantly associated with a 
decreased risk of AMD for both sporadic and familial subjects (P = 0.002 and P = 0.024, 
respectively). Diabetes mellitus was a risk factor for the development of AMD in sporadic 
patients (OR 1.34; 95% CI 1.02-1.75; P = 0.035), but not in familial cases (P = 0.704). 
No significant interaction between family history and allergy or diabetes was present. 
Cardiovascular disease, renal disease and auto-immune disease were no significant risk 
factors for AMD in our cohort. 
With regard to dietary factors, we observed that eating red meat a few times per week 
or daily is a significant risk factor in sporadic AMD patients (OR 1.24; 95% CI 1.05-1.48; P = 
0.013 and OR 1.81; 95% CI 1.30-2.54; P = 0.001, respectively), but not in familial subjects. 
A protective factor for AMD in sporadic patients was eating fruit a few times per week 
(OR 0.60; 95% CI 0.40-0.90; P = 0.013). Intake of fruit every day did not seem to further 
decrease the risk of AMD (OR 0.74; 95% CI 0.52-1.04; P = 0.085). However, consumption 
of fruit was not significantly associated with a decreased risk of AMD in familial subjects. 
Regular physical activity, 1 or 2 times a week, was significantly associated with a 
decreased risk for AMD in the sporadic AMD subgroup (OR 0.67; 95% CI 0.56-0.81; P = 
2.6x10-6) and the familial AMD subgroup (OR 0.62; 95% CI 0.42-0.94; P = 0.022). 
After Bonferroni correction of the demographic and environmental risk factors for AMD, 
the association of increasing age with AMD in familial and sporadic subjects remained 
significant, as well as the association of female sex, smoking, allergy, daily red meat 
consumption and physical activity in sporadic patients only.
 
Familial and sporadic AMD: phenotypic differences and similarities
The prevalence of early, intermediate and advanced stage AMD was similar in the familial 
and sporadic AMD patient group (Table 3.1.2). After differentiation of advanced AMD into 
geographic atrophy (GA), choroidal neovascularization (CNV) and mixed (both GA and CNV 
in one patient), we found that GA was more prevalent in familial AMD patients (17.5%) than 
in sporadic AMD patients (9.8%; P = 3.0x10-4), despite a comparable SNP load of CFH Y402H 
and ARMS2 A69S between familial (n=51) and sporadic patients (n=58) with GA (data not 
shown). In 829 sporadic subjects and 355 familial subjects data on reticular pseudodrusen 
were available and data on cuticular drusen were available in 520 sporadic subjects and 
157 familial subjects. The prevalence of reticular pseudodrusen was comparable between 
familial (18.0%) and sporadic subjects (18.8%; P = 0.749), whereas the prevalence of 
cuticular drusen was significantly higher in familial AMD (21.7%) compared to sporadic 
AMD (12.1%; P = 0.003). 
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Data on the number of drusen and area of drusen within the macular area were available 
for 689 sporadic subjects and 203 familial subjects (Table 3.1.4). Familial subjects showed 
a trend towards a higher number of drusen and a larger area of drusen in the macula as 
compared to sporadic patients, although this was only significant for the area of drusen in 
subjects with intermediate AMD (P = 0.043). After correction for age, sex, BMI and smoking, 
the mean area of drusen in sporadic subjects with intermediate AMD was 1114.49 and 
1415.63 in familial subjects, which were no longer significantly different (P = 0.160).
Table 3.1.4 Number and area of drusen in sporadic and familial control individuals and non-
advanced AMD patients
Sporadic Familial
n Mean±SD n Mean±SD P-value
Control Number of drusen 159 2.25±6.0 24 2.85±3.4 0.633
Area of drusen* 159 81.65±149.6 24 128.86±129.5 0.145
Early Number of drusen 291 8.69±20.0 93 11.69±27.37 0.254
Area of drusen* 291 219.17±353.4 93 249.67±416.6 0.489
Intermediate Number of drusen 239 40.25±62.4 86 46.37±48.9 0.411
Area of drusen* 239 1167.90±1735.4 86 1598.70±1555.4 0.043
* Area of drusen in pixels
SD = standard deviation
P-values < 0.05 indicate significant associations
DISCUSSION
Familial and sporadic AMD: clinical differences and similarities
Familial AMD patients have a lower age at first symptoms as compared to sporadic AMD 
patients. The phenomenon of a lower age at onset in patients with familial occurrence 
has been shown in other complex diseases with a significant genetic component, such as 
schizophrenia and Alzheimer’s disease.25, 26 A lower age at onset in familial AMD patients 
has previously been reported by Shahid et al. (70.4 years in familial patients and 73.2 
years in sporadic patients),14 and is in accordance with the mean difference of 3.1 years in 
our study. A significant difference in age of onset between familial and sporadic subjects 
was also observed in AMD patients with reticular pseudodrusen, but not in patients with 
cuticular drusen. However, as a result of a positive family history, familial subjects may have 
an increased awareness of visual symptoms which can lead to an earlier visit at a physician 
for evaluation. Therefore, it should be noted that the lower age at first symptoms in familial 
AMD patients may be partially attributed to an ascertainment bias.
In our study, BCVA per age category did not differ between familial and sporadic AMD 
patients, suggesting that visual acuity does not decrease earlier or at a faster rate in familial 
Chapter 3.1
136
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
patients, despite the lower age at first symptoms in familial AMD patients. Heightened 
awareness in familial patients may explain why no actual difference in BCVA was observed. 
Similar to other studies,1-3, 6 smoking and advanced age were associated with the 
development of AMD in the current study, in both sporadic and familial subjects. 
Furthermore, age was a more important risk factor for AMD in familial subjects as age 
shows a significant interaction with family history, resulting in a younger age at onset in 
familial subjects.
Ristau et al.22 have recently reported that allergy is associated with a reduced risk 
of AMD. We did not find a significant difference for the association of allergy with AMD 
between familial and sporadic subjects, so the protective effect of allergy does not seem to 
be influenced by family history. 
The pathogenesis of AMD as well as cardiovascular disease and diabetes have been linked 
to oxidative stress, inflammation and a vascular origin. Moreover, diabetes, cardiovascular 
disease, and its risk factors have been associated with the development of AMD, although 
this was not consistent among studies.1, 27-30 In the current study we observed that sporadic 
subjects with diabetes have an increased risk for AMD. However, diabetes was no risk 
factor for familial AMD, which may be explained by the larger genetic component in the 
pathophysiology of familial AMD, while sporadic AMD may be associated with a larger 
contribution of environmental or lifestyle factors such as diabetes (and associated factors). 
Several studies reported an increased risk of AMD for patients with chronic renal 
disease.31, 32 It has been shown that AMD and renal diseases, such as membranoproliferative 
glomerulonephritis type 2 and atypical hemolytic uremic syndrome, are related to the same 
genetic variants of the complement pathway, including the complement factor H gene.33-35 
Therefore, we evaluated whether renal disease might be correlated with AMD in familial 
subjects. However, we did not find a clear association between familial AMD and renal 
disease in our study population, possibly due to the low number of patients with renal 
disease. 
We also compared dietary factors between familial and sporadic subjects. It is interesting 
to investigate these dietary factors since these are modifiable. The consumption of red 
meat at least a few times a week increased the risk of AMD in our sporadic patient cohort. 
This is supported by findings of Chong et al.,36 demonstrating that higher red meat intake 
was associated with the development of AMD. In our study consumption of fruit a few 
times a week was associated with a decreased risk for the development of AMD, but we did 
not observe such an association with frequent consumption of vegetables. In agreement 
with this finding, Cho et al. and Zerbib et al. described a protective effect of frequent 
consumption of fruits for exudative AMD, but no association with the consumption of 
vegetables.37, 38 A study by Seddon et al.39 showed that intake of foods rich in carotenoids, 
in particular green leafy vegetables, decreased the risk of exudative AMD. Our study might 
be limited because we did not discriminate between different kinds of vegetables and no 
risk calculation was performed for the progression to advanced AMD. This may explain why 
Clinical characteristics of familial and sporadic age-related macular degeneration
137
3.1
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
we did not observe a protective effect for the consumption of vegetables. Also, it must be 
considered that fruit consumption can be related to a more healthy lifestyle in general, and 
therefore, these results may be confounded by other factors, other than smoking and BMI, 
related to a healthy lifestyle.
In cuticular drusen, a clinical subtype of AMD which tends to cluster in families, 
differences in environmental and genetic risk factors have been reported as compared to 
the AMD group as a whole.23, 40 We previously reported that the association with smoking 
was significantly lower in patients with cuticular drusen compared to AMD patients without 
cuticular drusen.23 In this study we observed no significant difference in environmental risk 
factors, such as smoking, between familial and sporadic AMD. However, several factors 
such as the consumption of red meat and frequent physical activity, tended to play a 
less important role in familial AMD than in sporadic AMD, supporting a stronger genetic 
component in the pathophysiology of AMD in families.
 
Familial and sporadic AMD: phenotypic differences and similarities
In our study population, GA was more prevalent in familial AMD patients than in sporadic 
patients. This cannot be explained by selection bias of familial patients, because if only 
the probands of the familial group (n = 262) were included in the analysis, GA was still 
significantly more prevalent in the familial AMD group than in the sporadic group (17.6% 
and 9.8%, respectively, P = 0.001). This finding may be explained by the stronger influence 
of genetic factors in the pathogenesis of familial AMD in certain phenotypic subtypes 
such as GA. Previously Shahid et al.14 suggested heritability of AMD subtypes, but these 
authors were not able to confirm this hypothesis due to low numbers of subjects. Sobrin 
et al.15 showed that siblings are more likely to develop the same advanced subtype as their 
proband. This may suggest the contribution of genetic variants in these familial patients,16, 
35, 41 which may increase the risk for developing GA rather than CNV. Affected members 
of densely affected families have been reported to bear a lower SNP load than expected 
based on five common known AMD risk variants; CFH (rs1061170 and rs1410996), ARMS2 
(rs10490924), C2-CFB (rs641153 and rs9332739).10 This supports the hypothesis that rare 
genetic variants in these families may explain the high prevalence of AMD.
In this study, we reported a higher prevalence of cuticular drusen in familial AMD 
compared to sporadic AMD, which is in agreement with previous reports.40, 42, 43 However, 
in our cohort the prevalence of cuticular drusen was higher and 32% of the patients with 
cuticular drusen had a positive family history of AMD compared to 44% of the patients 
in a study of Grassi et all.40 Previously, our group demonstrated that heterozygous loss-
of-function mutations in the CFH gene are found among family members with cuticular 
drusen.35, 41 In addition, rare, highly penetrant variants in the CFI gene have been identified 
in patients with cuticular drusen.16, 44 Therefore, the higher prevalence of cuticular drusen 
in families may be explained by segregation of rare, highly penetrant variants within these 
families. 
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In addition to a possible ascertainment bias, caused by an increased awareness of 
disease-associated visual symptoms in familial subjects, another limitation of this study 
is the classification of subjects into familial or sporadic based on the family history in the 
questionnaire, which may lead to misclassification. However, in a subset of the familial 
cases ophthalmologic examination data of their close relatives were available and 
compared with our classification based on the family history of the questionnaire. The 
degree of misclassification of the family history was very low in the familial subjects, as in 
only 3 cases (1.0%) no close relative with AMD was found by ophthalmologic examination. 
Unfortunately, no clinical data of family members of sporadic cases were available. The rate 
of misclassification may be higher in sporadic individuals, as these subjects may not have 
been informed of the eye disease of close relatives or the relatives were asymptomatic and 
therefore, not yet diagnosed with AMD.
In conclusion, this study demonstrates that familial AMD patients have a lower age at first 
symptoms compared to sporadic patients. Our findings also indicate that familial AMD 
patients differ from sporadic patients in terms of risk factors and clinical features. The 
higher prevalence of GA and cuticular drusen in familial AMD patients may be explained by 
the contribution of additional genetic factors segregating within these families.
Clinical characteristics of familial and sporadic age-related macular degeneration
139
3.1
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
REFERENCES
1. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular 
degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010;10:31.
2. Age-Related Eye Disease Study Research G. Risk factors associated with age-related macular 
degeneration. A case-control study in the age-related eye disease study: Age-Related Eye 
Disease Study Report Number 3. Ophthalmology 2000;107:2224-2232.
3. Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227-
253.
4. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL, 3rd, Age-Related Eye Disease Study 
Research G. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in 
the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005;112:533-
539.
5. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: 
association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 
2003;121:785-792.
6. Erke MG, Bertelsen G, Peto T, Sjolie AK, Lindekleiv H, Njolstad I. Cardiovascular risk factors 
associated with age-related macular degeneration: the Tromso Study. Acta ophthalmologica 
2014;92:662-669.
7. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H 
polymorphism and age-related macular degeneration. Science 2005;308:421-424.
8. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular 
degeneration. Science 2005;308:385-389.
9. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility 
gene for age-related macular degeneration, contributing independently of complement factor 
H to disease risk. Hum Mol Genet 2005;14:3227-3236.
10. Sobrin L, Maller JB, Neale BM, et al. Genetic profile for five common variants associated with 
age-related macular degeneration in densely affected families: a novel analytic approach. Eur J 
Hum Genet 2010;18:496-501.
11. Shastry BS. Assessment of the contribution of the LOC387715 gene polymorphism in a family 
with exudative age-related macular degeneration and heterozygous CFH variant (Y402H). J Hum 
Genet 2007;52:384-387.
12. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related 
maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-
1651.
13. Luo L, Harmon J, Yang X, et al. Familial aggregation of age-related macular degeneration in the 
Utah population. Vision Res 2008;48:494-500.
14. Shahid H, Khan JC, Cipriani V, et al. Age-related macular degeneration: the importance of family 
history as a risk factor. Br J Ophthalmol 2012;96:427-431.
15. Sobrin L, Ripke S, Yu Y, et al. Heritability and genome-wide association study to assess genetic 
differences between advanced age-related macular degeneration subtypes. Ophthalmology 
2012;119:1874-1885.
16. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of 
age-related macular degeneration. Nat Genet 2013;45:813-817.
17. Helgason H, Sulem P, Duvvari MR, et al. A rare nonsynonymous sequence variant in C3 is 
associated with high risk of age-related macular degeneration. Nat Genet 2013;45:1371-1374.
18. Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of 
age-related macular degeneration. Nat Genet 2011;43:1232-1236.
Chapter 3.1
140
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
19. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of 
advanced age-related macular degeneration. Nat Genet 2013;45:1366-1370.
20. Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in complement 3 
associated with age-related macular degeneration. Nat Genet 2013;45:1375-1379.
21. Mokwa NF, Ristau T, Keane PA, Kirchhof B, Sadda SR, Liakopoulos S. Grading of Age-Related Macular 
Degeneration: Comparison between Color Fundus Photography, Fluorescein Angiography, and 
Spectral Domain Optical Coherence Tomography. J Ophthalmol 2013;2013:385915.
22. Ristau T, Ersoy L, Lechanteur Y, et al. Allergy is a protective factor against age-related macular 
degeneration. Invest Ophthalmol Vis Sci 2014;55:210-214.
23. van de Ven JP, Smailhodzic D, Boon CJ, et al. Association analysis of genetic and environmental 
risk factors in the cuticular drusen subtype of age-related macular degeneration. Mol Vis 
2012;18:2271-2278.
24. van Grinsven MJ, Lechanteur YT, van de Ven JP, et al. Automatic drusen quantification and risk 
assessment of age-related macular degeneration on color fundus images. Invest Ophthalmol 
Vis Sci 2013;54:3019-3027.
25. Suvisaari JM, Haukka J, Tanskanen A, Lonnqvist JK. Age at onset and outcome in schizophrenia 
are related to the degree of familial loading. Br J Psychiatry 1998;173:494-500.
26. Duara R, Lopez-Alberola RF, Barker WW, et al. A comparison of familial and sporadic Alzheimer’s 
disease. Neurology 1993;43:1377-1384.
27. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence 
of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 
2007;114:1143-1150.
28. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the 
long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 
2003;110:636-643.
29. Mitchell P, Wang JJ. Diabetes, fasting blood glucose and age-related maculopathy: The Blue 
Mountains Eye Study. Aust N Z J Ophthalmol 1999;27:197-199.
30. Klein R, Klein BE, Moss SE. Diabetes, hyperglycemia, and age-related maculopathy. The Beaver 
Dam Eye Study. Ophthalmology 1992;99:1527-1534.
31. Liew G, Mitchell P, Wong TY, Iyengar SK, Wang JJ. CKD increases the risk of age-related macular 
degeneration. J Am Soc Nephrol 2008;19:806-811.
32. Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and 
incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 
2009;127:193-199.
33. Nitsch D, Douglas I, Smeeth L, Fletcher A. Age-related macular degeneration and complement 
activation-related diseases: a population-based case-control study. Ophthalmology 
2008;115:1904-1910.
34. Boon CJ, van de Kar NC, Klevering BJ, et al. The spectrum of phenotypes caused by variants in 
the CFH gene. Mol Immunol 2009;46:1573-1594.
35. van de Ven JP, Boon CJ, Fauser S, et al. Clinical evaluation of 3 families with basal laminar drusen 
caused by novel mutations in the complement factor H gene. Arch Ophthalmol 2012;130:1038-
1047.
36. Chong EW, Simpson JA, Robman LD, et al. Red meat and chicken consumption and its association 
with age-related macular degeneration. Am J Epidemiol 2009;169:867-876.
37. Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective study of intake of fruits, 
vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 
2004;122:883-892.
Clinical characteristics of familial and sporadic age-related macular degeneration
141
3.1
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
38. Zerbib J, Delcourt C, Puche N, et al. Risk factors for exudative age-related macular degeneration 
in a large French case-control study. Graefes Arch Clin Exp Ophthalmol 2013.
39. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and 
advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 
1994;272:1413-1420.
40. Grassi MA, Folk JC, Scheetz TE, Taylor CM, Sheffield VC, Stone EM. Complement factor H 
polymorphism p.Tyr402His and cuticular Drusen. Arch Ophthal 2007;125:93-97.
41. Boon CJ, Klevering BJ, Hoyng CB, et al. Basal laminar drusen caused by compound heterozygous 
variants in the CFH gene. Am J Hum Genet 2008;82:516-523.
42. Lerche W. Pigment epithelium changes in drusen of the macular region. Ber Zusammenkunft 
Dtsch Ophthalmol Ges 1975;439-446.
43. Barbazetto IA, Yannuzzi NA, Klais CM, et al. Pseudo-vitelliform macular detachment and 
cuticular drusen: exclusion of 6 candidate genes. Ophthalmic Genet 2007;28:192-197.
44. Boon CJ, van de Ven JP, Hoyng CB, den Hollander AI, Klevering BJ. Cuticular drusen: stars in the 
sky. Prog Retin Eye Res 2013;37:90-113.

3.2
Predictive value of family history 
versus genetic risk variants in 
age-related macular degeneration
N.T.M. Saksens, S.K. Verbakel, C.J.F. Boon, J.M.M. Groenewoud, 
T. Schick, S. Fauser, A.I. den Hollander, C.C.W. Klaver, C.B. Hoyng
Manuscript in preparation
PURPOSE. To compare the predictive value of family history and genetic risk variants for 
age-related macular degeneration (AMD)
METHODS. Retrospective case-control study including 1915 AMD patients and 1555 non-
affected controls aged 50+ years from ophthalmologic clinical centers in the Netherlands 
and Germany. All study participants underwent an extensive ophthalmic examination and 
a blood draw for DNA analysis. Information regarding family size and number of affected 
first degree family members was obtained by means of a questionnaire. Genotyping was 
performed for 23 single nucleotide polymorphisms (SNPs) known to be associated with 
AMD. The risk of AMD for number of affected parents and siblings was analysed by logistic 
regression, corrected for age and sex. Prediction models were generated using receiver-
operating-characteristics (ROC) curve.
RESULTS. The risk of AMD increased significantly with increasing number of affected parents 
(1 parent OR 2.038, (95%CI: 0.1361-2.59); two parents OR 8.174; (95%CI: 1.79-37.37) and 
with increasing number of affected siblings. In large families consisting of at least 5 siblings 
the OR of at least 3 affected siblings was 3.12 ((95%CI: 1.19-8.17)). The predictive value 
of developing AMD was 0.724 (95%CI: 0.693-0.756) for family history, and 0.810 (95%CI: 
0.784-0.837) for common genetic variants. For probands with at least 2 affected siblings the 
predictive value was 0.784 (95%CI: 0.639-0.928) in small families and 0.809 (95%CI: 0.677-
0.940) in large families; for probands with 2 affected parents the predictive value was 1.000 
((95%CI: 1.000-1.000).
CONCLUSIONS. Common AMD SNPs perform better than family history in the prediction 
of AMD. However, when a large number of first degree relatives is affected, the prediction 
of family history exceeds the prediction of SNPs. Our results imply that determination of 
genetic AMD variants has particular merit in small families with many non-affecteds. 
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INTRODUCTION
 
Age-related macular degeneration (AMD) is the leading cause of blindness among the 
elderly in developed countries1 and a growing health problem.2 The etiology of AMD is 
complex, and multiple genetic risk variants, smoking, BMI, and various nutrients appear to 
play a role.3-8 The importance of AMD risk prediction is increasing, since high-risk groups 
may benefit from lifestyle advice and nutritional supplements. Moreover, these groups may 
be particularly suitable for future therapeutic agents like complement inhibitors. 
For years it has been known that a positive family history is a risk factor for AMD. 
Siblings of patients with late AMD have a 4-5 times increased risk of developing AMD, 1, 9 and 
children of affected parents appear to have an even higher risk.10 Remarkably, family history 
has rarely been used as a variable in prediction models. In contrast, the recently identified 
genetic variants for AMD have frequently been incorporated in prediction models, and their 
ability to predict AMD is high.11-13 Nevertheless, current genetic testing is mostly performed 
for risk analyses in research settings, and is not yet available in most clinics. Family history 
is easily obtained in the clinic, and may be a good alternative.
The purpose of this study is to compare family history and genetic risk variants in their 
ability to predict AMD. We investigated family history in a crude as well as in a detailed 
manner, and compared them to the predictive value of a large set of currently known risk 
variants.
METHODS
Study population
In this study, we evaluated subjects aged 50+ years from the European Genetic Database 
(EUGENDA) from whom complete ophthalmic and family history data were available. 
Details of this study are described elsewhere.14 In brief, all persons underwent digital 
colour fundus photography (Topcon TRC 50IX camera, Tokyo, Japan) after pharmacologic 
mydriasis, and spectral-domain optical coherence tomography (SD-OCT, SPECTRALIS, 
Heidelberg Engineering, Heidelberg, Germany). Features of AMD were determined by 
grading of all retinal images by two independent certified reading center graders according 
to the standard protocol of the Cologne Image Reading Center (CIRCL).14 Early AMD was 
classified by the presence of pigmentary changes with at least 10 small drusen (<63µm) or 
the presence of intermediate (63-124 µm) or large drusen (≥125 µm diameter) in the Early 
Treatment Diabetic Retinopathy Study (ETDRS) grid. Advanced AMD was defined as either 
GA and/or CNV in the macula of at least one eye. Persons with early or advanced AMD were 
diagnosed as cases; persons with no retinal abnormalities or only small drusen or isolated 
pigmentary abnormalities were diagnosed as controls.
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Data on presence of AMD in parents were collected by questionnaire from the start of 
Eugenda, and were available in 3470 individuals (1915 cases and 1555 controls). Questions 
on presence of AMD in siblings were added to the questionnaire at a later phase (2011); 
therefore, data on AMD in siblings were only available in a subset of 944 cases and 512 
controls. With respect to families incorporated in Eugenda, the first family member who 
attended the examination center was included in the current analysis as the proband. 
EUGENDA was approved by the local ethics committee on Research Involving Human 
Subjects from RadboudUMC, met the criteria of the Declaration of Helsinki, and all subjects 
provided written informed consent. 
 
Family history
Information on family history was obtained by detailed, interviewer-administered 
questionnaire which included questions such as ‘Is AMD present in your family? If so, 
are your parents affected? Are your siblings affected, how many are affected and how 
many siblings are in your family?’ Family history was regarded positive when the proband 
reported the presence of AMD in either parents or siblings; persons with negative family 
history were considered sporadic. We identified two subgroups in persons with data on 
siblings: probands with 1-5 siblings, and probands with > 5 siblings, based on inclusion of 
the upper quartile of individuals in the latter group. Missing data of the number of (affected) 
siblings were due to being an only child, no contact with siblings or as a consequence of an 
incomplete questionnaire.
Genotyping
Venous blood was obtained for genetic analysis of 23 single nucleotide polymorphisms 
(SNPs) known to be associated with AMD in the three continent AMD consortium 11, 15; 
ADAMTS9 (rs6795735), APOE (rs4420638), ARMS2 (rs10490924), C3 (rs433594 and 
rs2230199), CETP (rs3764261), CFB (rs4151667 and rs641153), CFH (rs1061170, rs800292, 
and rs12144939), and CFI (rs10033900), COL10A1 (rs3812111), COL8A1 (rs13081855), 
HSPH1 (rs9542236), IER3DDR (rs3130783), MYRIP (rs2679798), RAD51B (rs8017304), SKIV2L 
(rs429608), SLC16A8 (rs8135665), TGFBR1 (rs334353), VEGFA (rs943080), TNFRSF10A 
(rs13278062). Genomic DNA was extracted from peripheral blood samples using standard 
procedures and genotyping of the 23 SNPs was performed with KASP™ genotyping assays 
(LGC Genomics) according to the manufacturer’s instructions. Genotype frequencies in the 
control individuals were tested for Hardy-Weinberg equilibrium. Genotypes of SNPs were 
coded as 0 for carriers of non-risk variants, 1 for carriers of only 1 risk variant, and 2 for 
carriers of 2 risk variants. 
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Covariates
The questionnaire also included questions regarding weight and height, allowing calculation 
of body mass index (BMI, subdivided in three groups: <25, 25-30 and >30). Smoking 
behavior was questioned as never, past, current smoking; educational level was ascertained 
as primary school, high school, and higher professional education or university.
 
Statistical analysis
Standard descriptive statistics were used to describe baseline and clinical characteristics. 
Primary outcome was presence of early and advanced AMD versus absence of AMD. The 
association between single risk variants and AMD were investigated univariately and 
multivariately using logistic regression analysis, and a genetic risk score was calculated 
by summation of the beta coefficients of the multivariate analysis. We investigated the 
association between parental family history and AMD with logistic regression analysis, 
adjusting for age and gender. Next, we repeated this analysis for family history in siblings. 
Finally, we constructed prediction models based on age, gender, family history, genotypes, 
and other AMD covariates. 11, 16-18 Models included increasing levels of informativeness of 
family history, and were based on a receiver-operating curve (ROC) with calculation of the 
area under the curve (AUC) as a measure of discriminative accuracy. Data were analyzed 
using SPSS Software version 20.0 (SPSS Inc., Chicago, IL); two-sides P-values less than 0.05 
were considered statistically significant.
RESULTS
 
Demographic characteristics of the probands, are depicted in Table 3.2.1. A positive family 
history for first degree relatives was reported in 22.4% of the AMD patients and in 12.0% of 
the controls, resulting in a significant risk of AMD (OR 2.56; 95% CI 2.10-3.12), adjusted for 
age and sex. An affected parent was reported by 12.7% AMD patients and 8.5% controls (P 
<0.001). In the subset of 512 controls and 944 AMD patients who had data on family history 
of siblings, at least one affected sibling was reported by 28.0% of patients versus 15.4% 
of controls (P <0.001). Additionally to a positive family history, an increasing age, current 
smoking behaviour, and no university education were significantly associated with AMD. 
We calculated a genetic risk score based on the beta coefficients from the multivariate 
regression analyses of 23 SNPs. The mean genetic risk score was significantly higher in AMD 
patients than in controls in the parental as well as the sibling cohort (both P < 0.001).
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Table 3.2.1 Demographic characteristics of the probands 
Controls AMD 
Parental cohort 
(N=1555)
Sibling cohort
(N=512)
Parental cohort 
(N=1915)
Sibling cohort 
(N=944)
Mean age, yrs (SD)
Gender, % Female  
Positive family history, N (%)
Affected parents, N (%) 
- 0 
- 1 
- 2
BMI, %
- <25 kg/m2 
- 25-30 kg/m2 
- >30 kg/m2
Smoking, % 
- Never 
- Past 
- Current
Education, % 
- University 
- No-university
Mean Genetic Risk  
Score (SD)
70.6 (7.4)
 
55.9 
 
186 (12.0)
1423 (92) 
130 (8) 
2 (0)
 
44.7 
43.2 
12.1
 
44.1 
48.9 
6.9
 
54.8 
45.2
1.5 (1.8)
69.8 (6.6) 
 
59.6 
 
163 (31.8) 
403 (78.7) 
107 (20.9) 
2 (0.4) 
 
43.5 
44.6 
11.9 
 
40.5 
52.2 
7.3 
 
65.2 
34.8 
 
1.5 (1.9)
75.6 (9.0)**
60.1* 
429 (22.4)**
1671 (87) 
230 (12)** 
14 (1)* 
 
46.2 
41.2 
12.6
 
41.3 
 48.3* 
 10.4**
 
43.8 
 56.2** 
2.3 (1.4)**
75.1 (8.1)** 
 
60.1 
 
383 (40.6)** 
746 (79.0) 
185 (19.6)* 
13 (1.4)* 
 
44.3 
41.3 
14.4 
 
38.7 
50.1 
 11.2** 
 
46.6 
 53.4** 
 
2.5 (1.0)**
N= number of patients; OR= odds ratio; CI = confidence interval; SD = standard deviation; Age = age at 
participation; BMI = body mass index; genetic risk score = sum of beta coefficients of 23 SNPs; Parental 
cohort is total with available parental family history. Sibling cohort is part of the total cohort with 
available family history data of siblings. Analyses of differences between AMD patients and controls 
in the parental and sibling cohort are adjusted for age and gender.
* P-value < 0.05; ** P-value < 0.001
The risk of AMD for a positive parental family history, adjusted for age and gender 
(Table 3.2.2) increased with the number of affected parents and was OR 8.17 (95% CI 
1.79-37.37, P = 0.007) when both parents were affected. A positive parental family history 
corresponded to a higher proportion of affected siblings: 20% and 22% for subjects with 
one or two affected parents versus only 11% for patients without affected parents (P < 
0.001 and P = 0.129, respectively) 
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Table 3.2.2 Family history: Risk of AMD as a function of number of affected parents
Number parents 
AMD
Controls  
Total N=1555
N (%)
AMD  
Total N=1915
N (%)
OR (95% CI) * P-value *
0 parents AMD 1423 (91.5) 1671 (87.3) Ref.
1 parent AMD 130 (8.4) 230 (12.0) 2.04 (1.61-2.59) <0.001
2 parents AMD 2 (0.1) 14 (0.7) 8.17 (1.79-37.37) 0.007
AMD = age-related macular degeneration; OR = Odds ratio; CI = confidence interval; Ref = reference; 
% siblings = mean percentage siblings with AMD. * Adjusted for age and gender.
P-values < 0.05 indicate significant associations.
Table 3.2.3 shows the ORs of AMD for the number of affected siblings adjusted for age 
and sex. In the families consisting of 1-5 siblings, having a positive sibling history significantly 
increased the OR for AMD (OR 2.02; 95% CI 1.40-2.91), but the OR did not increase by the 
number of affected siblings. In the large families (>5 siblings), having an affected sibling was 
a significant risk factor for AMD (OR 2.53; 95% CI 1.29-4.99), and the risk increased with the 
number of affected siblings resulting in an OR of 3.12 (95% CI 1.19-8.16) for having at least 
3 affected siblings. 
Table 3.2.3 Family history: Risk of AMD as a function of number of affected siblings in small and 
large families
Small families (≤5 siblings) Large families (>5 siblings)
Number 
affected 
siblings
N=1078 OR (95%CI)* P-value * Number 
affected 
siblings
N=378 OR (95%CI)* P-value *
0 
≥1
863 
215
Ref. 
2.02 
(1.40-2.91)
 
<0.001
0 
1-2
≥3
250 
96
32
Ref. 
2.41  
(1.38-4.23)
3.12 
(1.19-8.16)
 
0.002
0.021
N = number; OR = odds ratio; CI = confidence interval; Ref = reference;
* adjusted for age and gender
P-values < 0.05 indicate significant associations
We created prediction models for AMD using different sets of risk factors (Table 3.2.4). 
Prediction model 1 was based on 23 SNPs (Table 3.2.5), age and sex and showed an AUC of 
0.810 (95% CI 0.784-0.837). Prediction model 2 was based on age, sex and family history, by 
which family history was defined as at least one first-degree relative with AMD. The AUC of 
this model was 0.724 (95% CI 0.693-0.756), which is significantly lower than genetic model 
1 (P < 0.001).
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Table 3.2.4 Predictive value for family history
Variables in Model AUC (95% CI) SE Controls/
AMD (N)
1. 23 SNPs, age, sex 0.810 (0.784-0.837) 0.014 390/596
2. Family history (yes/no), age, sex 0.724 (0.693-0.756) 0.016 390/596
3. Parental history, age, sex 0.724 (0.692-0.755) 0.016 390/596
- 0 affected parents 0.702 (0.665-0.738) 0.019 305/481
- 1 affected parent 0.789 (0.727-0.852) 0.032 83/108
- 2 affected parents 1.000 (1.000-1.000) 0.000 2/7
4. Sibling history, age, sex 0.720 (0.688-0.752) 0.016 390/596
Small families: 0 affected sibs 0.720 (0.678-0.762) 0.021 240/340
1 affected sib 0.745 (0.636-0.853) 0.055 22/72
≥ 2 affected sibs 0.784 (0.639-0.928) 0.074 16/24
Large families: 0 affected sibs 0.683 (0.606-0.760) 0.039 88/96
1 affected sib 0.740 (0.565-0.915) 0.089 10/25
≥ 2 affected sibs 0.809 (0.677-0.940) 0.067 14/39
5. Parental and sibling history, age, sex 0.724 (0.692-0.755) 0.016 390/596
0 affected parents: 0 affected sibs 0.686 (0.645-0.727) 0.021 262/373
1 affected sib 0.754 (0.646-0.863) 0.055 21/68
≥ 2 affected sibs 0.801 (0.687-0.915) 0.058 22/40
1 affected parents: 0 affected sibs 0.790 (0.711-0.869) 0.040 64/60
1 affected sib 0.717 (0.538-0.895) 0.091 11/26
≥ 2 affected sibs 0.827 (0.679-0.974) 0.075 8/22
6. Parental and sibling history, age, sex,  
 smoking, BMI, education level
0.736 (0.703-0.769) 0.017 353/512
0 affected parents: 0 affected sibs 0.701 (0.658-0.744) 0.022 234/317
1 affected sib 0.744 (0.636-0.852) 0.055 19/62
≥ 2 affected sibs 0.854 (0.747-0.961) 0.054 21/31
1 affected parents: 0 affected sibs 0.792 (0.708-0.875) 0.043 61/52
1 affected sib 0.798 (0.627-0.969) 0.087 9/22
≥ 2 affected sibs 0.864 (0.726-1.000) 0.071 7/21
7. Parental and sibling history, age, sex,  
 smoking, BMI, education level, 23 SNPs
0.822 (0.794-0.850) 0.014 353/512
0 affected parents: 0 affected sibs 0.809 (0.773-0.845) 0.019 234/317
1 affected sib 0.849 (0.766-0.932) 0.042 19/62
≥ 2 affected sibs 0.825 (0.696-0.954) 0.066 21/31
1 affected parents: 0 affected sibs 0.839 (0.765-0.913) 0.038 61/52
1 affected sib 0.899 (0.788-1.000) 0.057 9/22
≥ 2 affected sibs 0.884 (0.758-1.000) 0.065 7/21
In addition to age and sex, model 1 includes 23 AMD associated SNPs, model 2 the family history for 
AMD, model 3 the parental history, model 4 the history of AMD in siblings, model 5 the parental and 
sibling history, model 6 parental and sibling history and the environmental factors smoking behaviour, 
BMI and education, and the full model 7 includes parental and sibling history, environmental factors 
and 23 SNPs.
23 SNPs include: ADAMTS9 (rs6795735), APOE (rs4420638), ARMS2 (rs10490924), C3 (rs433594 
and rs2230199), CETP (rs3764261), CFB (rs4151667 and rs641153), CFH (rs1061170, rs800292, 
and rs12144939), and CFI (rs10033900), COL10A1 (rs3812111), COL8A1 (rs13081855), HSPH1 
(rs9542236), IER3DDR (rs3130783), MYRIP (rs2679798), RAD51B (rs8017304), SKIV2L (rs429608), 
SLC16A8 (rs8135665), TGFBR1 (rs334353), VEGFA (rs943080), TNFRSF10A (rs13278062). Small 
families consist of 1-5 siblings. Large families consist of > 5 siblings.
AUC = area under the curve, CI = confidence interval; SE = standard error; AMD = age-related macular 
degeneration; BMI = body mass index; sibs = siblings
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Model 3 included the number of affected parents in addition to age and sex. The 
predictive value of this model increased with the number of affected parents. In case of 
2 affected parents the AUC was 1.000, although this was only based on 7 AMD patients 
and 2 controls. The family history concerning siblings is included in model 4 together with 
age and sex. The AUC increased with an increasing number of affected siblings. In case of 
at least 2 affected siblings, the AUC of model 4 is comparable to genetic model 1 in small 
families (P = 0.730) and in large families consisting of >5 siblings (P = 0.988). Both parental 
and sibling history are included in model 5 in addition to age and sex. The AUC of this model 
also increased with the number of affected siblings and parents. In case of 1 affected parent 
and at least 2 affected siblings the AUC curve even exceeded the AUC of genetic model 
number 1, although this was not significant (P = 0.824). Addition of the environmental 
factors BMI, smoking behaviour, and education level to model 5 leaded to model 6, which 
resulted in higher AUCs than model 5. Model 7 included age, sex, parental and sibling 
history, environmental factors and 23 SNPs, and this full model resulted in higher AUCs 
than model 6 without genetic factors. However, in case of at least 2 affected siblings or 2 
affected parents the AUC did not increase or only slightly increased (AUC increase of 0.020; 
P = 0.835) by the addition of 23 SNPs.
The ROC curves with the corresponding AUCs of prediction model 1 and 2 for AMD 
are displayed in Figure 1. Additionally, the curves of at least 2 affected siblings with 0 or 1 
affected parent (model 5) and the curve of 2 affected parents (model 3) are presented in 
Figure 1, demonstrating clinical settings in which the predictive value of the familial models 
are comparable to the genetic model 1. 
ROC curves prediction of AMD
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.0
0.1
0.2
0.3
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1.0
SNPs
2 Parents AMD
0 Parents + ≥ 2 sibs AMD
1 Parent + ≥ 2 sibs AMD
Reference line
Family history
1- spec
Se
ns
 Figure 3.2.1 ROC curves prediction of AMD. Prediction model 2 includes family history, age and sex 
and has an AUC of 0.724. Genetic model 1 includes 23 SNPs, age and sex and has an AUC of 0.810. 
Detailed information of the number of affected parents and siblings in combination with age and sex 
in model 5 resulted in an AUC of 0.801 when 2 or more siblings are affected and an AUC of 0.827 when 
at least 2 siblings and 1 parent are affected. In case both parents have AMD the AUC is 1.000.
Abbreviations= Sens: sensitivity; spec: specificity; SNPs, 23 single nucleotide polymorphisms; AMD: 
age-related macular degeneration.
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DISCUSSION
 
While risk effects of many demographic, environmental, and genetic risk factors are well 
established, little is known about the risk of a positive family history for developing AMD. 
Knowledge of these risks is important for ophthalmologists, because they are regularly 
confronted with questions about risk of AMD, particularly by persons with affected family 
members. Therefore, we investigated the risk of a positive family history for AMD and 
compared the performance of a positive family history to common genetic variants with 
respect to prediction of AMD.
In the total cohort, the model including family history is less predictive than the genetic 
model of 23 common genetic variants. Extensive information of the number of affected 
parents and siblings increases the predictive value in densely affected families. In case of 
2 affected parents or at least 2 affected siblings the AUC of the model including family 
history was comparable or exceeded the AUC of the genetic model. This demonstrates 
the importance of detailed questioning about familial occurrence of AMD in predicting 
this disease. The ROC curves of the full model including age, gender, parental and sibling 
history, environmental and genetic factors resulted in the highest AUC values in general. 
A positive family history of AMD is an established risk factor for AMD. 9, 10, 19-22 Earlier 
reports have demonstrated that incorporation of family size and the proportion affected 
helps to discriminate high- and low-risk families 23 Nevertheless, current AMD prediction 
models are based on positive family history as a dichotomous variable,16, 22, 24 although 
some sub-stratify for parental and sibling family history.9, 10, 25-27 Our results show that, the 
prediction of AMD risk improved with inclusion of family size. In large families, the number 
of affected appears to reflect the magnitude of the genetic risk better than currently known 
risk variants. As Sobrin et al showed that the genotypic load determined by common SNPs 
in densely affected families is significantly lower than expected from simulation, these 
families may harbour rare, more penetrant variants for AMD.28
AMD can aggregate in families,9, 27 and an affected first-degree relative increases 
someone’s risk on AMD.10 Several studies have shown that having an affected parent is 
associated with a higher risk than having an affected sibling.10, 27 Our results show a 
comparable OR between an affected parent and affected sibling. However, the risk of AMD 
for individuals with two affected parents was significantly higher than for those with many 
affected siblings. Even in large families with a high proportion of affected siblings, family 
history of 2 affected parents was more detrimental than family history of many affected 
siblings.
We found that assessment of 23 AMD associated SNPs does not add any value in the 
prediction in individuals with large, densely affected families. Therefore, analyses of the 23 
common genetic variants to predict personalized risk for developing AMD can be omitted if 
the family history suggests a densely affected large family. 
Predictive value of family history versus genetic risk variants in age-related macular
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Since the referral area of the Department of Ophthalmology in Nijmegen includes the 
Catholic South and the ‘Bible belt’, where around the 1940s having large families was not 
uncommon, our cohort has a high frequency of these large, densely affected families.9, 21, 23, 
25 In 1456 participants of which the family size was available, 26% have more than 5 siblings. 
Nowadays, families with more than 5 siblings are less common, making it more challenging 
to estimate the risk of AMD based on family history. 
There are several limitations to our study. Unfortunately, we do not have follow-up 
data of our cohort, which seems to be important phenotypic predicting information in 
literature.11, 16, 29-31 Because of this, we do not aim to create an ideal model, but we want to 
clarify the role of a positive family history and common genetic variants in predicting AMD.
The questionnaire was completed by the proband of the family, which may have led to 
inaccuracies or bias in several ways. We used self-reported information of the family history, 
BMI and smoking status. In has been reported that this may lead to underestimation.32, 
33 However, this is expected to be parallel for cases and controls, so we do not think 
this has affected our results.. We are aware that a positive family history is generally 
underestimated.34-39 AMD is a late-onset, often asymptomatic disease and therefore 
patients with non-advanced AMD are not always aware of their own diagnosis, let alone 
the diagnosis of their family members.35 Previously, we found that the self-reported family 
history following our definition was correct in 93% of 68 familial subjects of whom we had 
ophthalmologically examined the siblings and parents. (Saksens et al. submitted to PLoS 
One). This is in accordance to findings of shahid et al.10 However, the uncertainty of AMD 
diagnosis in family members still exists.9, 40 
In conclusion, common AMD SNP analysis has no additional value in a risk model containing 
detailed family history, demographic and environmental data, in predicting AMD in large, 
densely affected families. Our results can help clinicians in their decision to perform 
molecular testing for AMD. However, when prediction tests include more rare, high-risk 
alleles in the future, this may change. 
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PURPOSE. Age-related macular degeneration (AMD) is a multifactorial disease, in which 
complement-mediated inflammation plays a pivotal role. A positive family history is 
an important risk factor for developing AMD. Certain lifestyle factors are shown to be 
significantly associated with AMD in non-familial cases, but not in familial cases. This study 
aimed to investigate whether the contribution of common genetic variants and complement 
activation levels differs between familial and sporadic cases with AMD. 
METHODS. 1216 AMD patients (281 familial and 935 sporadic) and 1043 controls (143 
unaffected members with a family history of AMD and 900 unrelated controls without 
a family history of AMD) were included in this study. Ophthalmic examinations were 
performed, and lifestyle and family history were documented with a questionnaire. Nine 
single nucleotide polymorphisms (SNPs) known to be associated with AMD were genotyped, 
and serum concentrations of complement components C3 and C3d were measured. 
Associations were assessed in familial and sporadic individuals. 
RESULTS. The association with risk alleles of the age-related maculopathy susceptibility 2 
(ARMS2) gene was significantly stronger in sporadic AMD patients compared to familial 
cases (P = 0.017 for all AMD stages and P = 0.003 for advanced AMD, respectively). ARMS2 
risk alleles had the largest effect in sporadic cases but were not significantly associated 
with AMD in densely affected families. The C3d/C3 ratio was a significant risk factor for 
advanced AMD in familial cases, especially in patients with a densely affected family, and 
the association was significantly stronger than in sporadic patients (P = 0.038). 
CONCLUSIONS. This study suggests that in familial AMD patients, the common genetic 
risk variant in ARMS2 is less important compared to sporadic AMD. In contrast, factors 
leading to increased complement activation appear to play a larger role in patients with 
a positive family history compared to sporadic patients. A better understanding of the 
different contributions of risk factors in familial compared to non-familial AMD will aid the 
development of reliable prediction models for AMD, and may provide individuals with more 
accurate information regarding their individual risk for AMD. This information is especially 
important for individuals who have a positive family history for AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial disease and the leading cause 
of blindness among the elderly in developed countries.1 With an aging population, AMD 
is considered a major and growing health problem.2 The disease, in its early stages, is 
characterized by drusen deposits and pigmentary abnormalities. Vision loss mainly occurs 
when the disease progresses to late AMD, which can be subdivided into geographic atrophy 
(GA) and choroidal neovascularization (CNV).3 
Both environmental and genetic risk factors have been associated with the development 
and progression of AMD. The most consistently reported demographic and environmental 
risk factors are advanced age, high body mass index (BMI) and current cigarette smoking.4-8
Population-based analysis and twin studies have shown a strong genetic contribution 
to the development of AMD.2,9-12 Major associations were reported for genetic variants 
in the complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) 
genes.3,13-17 Several pathways have been described to be implicated in the development 
of AMD, including the alternative complement pathway.18,19 Genetic variants in several 
complement genes have been associated with AMD, including the CFH,13-15,20 complement 
factor 3 (C3),21-25 complement factor B (CFB),24,26,27 and complement factor I (CFI) genes.28 
Besides genetic variants in the complement genes, also systemic levels of complement 
components have been associated with AMD.24,29,30
Approximately 20% of AMD patients have a positive family history,9-11,31 and first-
degree relatives of AMD patients have an increased risk of developing AMD.9,10,32 It 
has been suggested that the familial component of AMD may be explained by shared 
genetic or environmental factors.10 However, the contribution of such factors in familial 
compared to non-familial AMD patients has not yet been studied comprehensively. We 
recently demonstrated that certain lifestyle factors, such as physical activity and red meat 
consumption, are significantly associated with AMD in sporadic cases but not in families.33 
A recent study showed that the mean genotypic load of common AMD risk alleles in AMD 
families did not deviate significantly from genotypic loads predicted by simulation models.34 
However, the mean genotypic load in densely affected families was significantly lower than 
expected, suggesting that such families may carry rare, highly penetrant genetic variants.34 
The purpose of this study is to investigate whether the contribution of common genetic 
variants differs between familial and non-familial AMD cases by interaction analyses. This 
will support the development of reliable prediction models for AMD, and may provide more 
accurate information regarding the individual risk for AMD, in particular for individuals who 
have family members with AMD and for whom this question is most urgent. 
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METHODS
Subjects 
In this study, we evaluated 2259 subjects, including 1216 AMD patients and 1043 control 
individuals from the Netherlands and Germany. All participants were derived from the 
European Genetic Database (EUGENDA, www.eugenda.org), an international database for 
molecular and clinical analysis of AMD. Subjects 50 years of age or older were included 
when information about gender, BMI, smoking behavior, and family history was available. 
In case subjects were related, only the first derived AMD patient and control subject of the 
family were included. Clinical data of their relatives were available in 68 families and were 
only used to determine the degree of reliability of the self-reported questionnaire. This 
study was approved by a local ethics committee on Research Involving Human Subjects and 
met the criteria of the Declaration of Helsinki. 
Before enrollment in the EUGENDA database, all subjects provided written informed 
consent and completed a detailed questionnaire on their medical history, family history 
of AMD, BMI, and lifestyle factors, such as smoking behavior. The study cohort was split in 
familial and sporadic subjects, based on the self-reported family history. A positive family 
history was defined as at least two first-degree relatives (parents and/or siblings) with AMD 
or possible AMD in a family. Participants with a positive family history were labeled as 
familial and participants without a positive family history were labeled as sporadic. Based 
on diagnosis and family history, the participants in this retrospective study were divided 
into four groups: unaffected individuals with a family history of AMD (referred to as familial 
controls) (n=143), familial AMD cases (n=281), unaffected individuals without a family 
history of AMD (referred to as sporadic controls) (n=900), and sporadic AMD cases (n=935). 
Familial cases were subdivided in patients with a mild (n=184) or dense (n=97) positive 
family history, in which the latter group meets one of next 3 criteria: (1) both parents have 
(possible) AMD, or (2) one affected parent and at least 25% of the siblings are affected, or 
(3) at least 50% of the siblings are affected. Subjects with a mild positive family history do 
not meet any of these criteria. The BMI was subdivided in three groups: <25, 25-30 and >30 
and smoking behavior was categorized into never, past and current smoking.
Each participant underwent digital color fundus photography performed after pupillary 
dilatation with topical 1.0% tropicamide and 2.5% phenylephrine. Both patients and 
controls also received spectral-domain optical coherence tomography (SD-OCT). Color 
fundus photographs and OCT scans of both eyes of all individuals were evaluated by 
two independent certified reading center graders according to the standard protocol of 
the Cologne Image Reading Center and Laboratory (CIRCL).35 The diagnosis of AMD was 
defined as described previously,36 based on the grading of the worst affected eye. AMD was 
classified by the presence of pigmentary changes together with at least 10 small drusen 
(<63µm) or the presence of intermediate (63-124 µm) or large drusen (≥125 µm diameter) 
in the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. The subgroup of advanced 
Analysis of risk alleles and complement activation levels in familial and non-familial 
163
3.3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
AMD was defined as either AMD with subfoveal GA and/or CNV in at least one eye. Controls 
were classified as no abnormalities or only small drusen or pigmentary abnormalities. 
Genotyping 
Venous blood was obtained for genetic analysis and the measurement of the complement 
components C3 and C3d. Complement component C3 and the activation fragment 
C3d were measured in serum samples as described previously.29 The C3d/C3 ratio was 
calculated as a measure of complement activation. Genomic DNA was extracted from 
peripheral blood samples using standard procedures. Genotyping of nine single nucleotide 
polymorphisms (SNPs) known to be associated with AMD, in the ARMS2 (rs10490924), CFH 
(rs1061170, rs800292, and rs12144939), C3 (rs2230199 and rs1047286), CFB (rs4151667 
and rs641153), and CFI (rs10033900) genes was performed in at least 85% of the included 
subjects with KASP™ genotyping assays (LGC Genomics) according to the manufacturer’s 
instructions. Genotype frequencies in the control individuals were tested for Hardy-
Weinberg equilibrium.
Statistical analysis 
Standard descriptive statistics were used to describe baseline and clinical characteristics. 
To study differences in age (at participation), gender, BMI, smoking status, risk allele 
frequencies for AMD-associated SNPs, and complement levels between AMD patients 
and controls, multivariable logistic regression analyses were performed adjusted for the 
covariates age, gender, BMI and smoking status, if possible.
Differences in association of AMD-associated SNPs and complement levels in familial 
compared to sporadic AMD were analyzed with a multivariable logistic regression analysis, 
with correction for the covariates age, gender, BMI and smoking status. Statistical analyses 
were also performed with subdivision into mildly and densely affected families for factors 
which were significantly associated with familial AMD, to study the effect of AMD-associated 
SNPs and complement levels on the density of AMD in affected families.Two-sided P-values 
of less than 0.05 were considered statistically significant
RESULTS
Baseline demographic data are depicted in Table 3.3.1. Increased age was a significant risk 
factor for AMD, in sporadic (Odds ratio (OR) 1.10; 95% Confidence Interval (CI) 1.09-1.11; P 
< 0.001) and familial patients (OR 1.17; 95% CI 1.13-1.21; P < 0.001). Female gender was not 
significantly associated with AMD in sporadic nor in familial cases. In sporadic patients the 
risk for AMD increased with increasing BMI (OR 1.45; 95% CI 1.05-1.99; P = 0.023), while 
BMI was not associated with AMD in familial patients. Current smoking was a significant 
risk factor for developing AMD in sporadic patients (OR 2.12; 95% CI 1.44-3.12; P <0.001) 
but was not significantly associated with AMD in familial patients. 
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In a subset of 68 families, clinical examination data of the siblings and parents were 
available. The self-reported family history of the probands was correct in 93%. Only 
in 1 out of 68 subjects (1.5%) who reported in the questionnaire to have close relatives 
with (possible) AMD, none of the examined family members seemed to be affected on 
ophthalmological examination and therefore he was incorrectly classified as familial. In 
addition, 4 out of 68 subjects (6%) were incorrectly classified as sporadic. 56 probands 
reported a positive family history. Of those, 30 reported a densely positive family history, 
which was correct in 29 probands (97%). Only in one proband who reported AMD in one 
parent and in 1 out of 4 sibs, the densely positive family history was incorrect since no 
siblings had AMD at ophthalmic examination. The number of affected family members was 
correct in 66%, and an underestimation or overestimation of the number affected family 
members was reported in 27% and 7%, respectively.
The allele frequencies of AMD-associated SNPs and the differences in association with 
AMD (all stages) between familial and sporadic subjects are shown in Table 3.3.2. The 
ARMS2 risk allele was a significant risk factor for AMD in sporadic cases (OR 2.49; 95% CI 
2.12-2.93; P < 0.001). In familial cases this effect was also observed, albeit with a weaker 
effect (OR 1.60; 95% CI 1.16-2.22; P = 0.005). This difference in association was significant (P 
= 0.017). The CFH Y402H allele was significantly associated with AMD in both sporadic and 
familial cases (OR 1.81; 95% CI 1.57-2.09; and OR 2.20; 95% CI 1.58-3.06, respectively (P < 
0.001)), and contrary to the ARMS2 SNP, this association did not significantly differ between 
familial and sporadic patients. Other genetic variants in the CFH, C3 and CFB genes were 
significantly associated with AMD in sporadic cases, but not in familial cases. However, 
the association of these SNPs did not significantly differ between familial and non-familial 
cases. A variant in the CFI gene (rs10033900) was not significantly associated with sporadic 
or familial AMD. The serum C3d/C3 ratio, as a measure of the systemic activity of the 
complement system, was a significant risk factor for AMD in familial patients (OR 1.12; 95% 
CI 1.00-1.25; P = 0.042) but not in sporadic patients. The difference in serum C3d/C3 levels 
between familial and sporadic subjects was not significant, but showed a trend towards 
association (P = 0.096).
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The allele frequencies of AMD-associated SNPs and the differences in association with 
advanced AMD between familial and sporadic subjects are shown in Table 3.3.3. The 
findings for advanced AMD were similar as for all AMD stages, although the ORs of the 
common variants were stronger than for all AMD stages. Also, the difference in association 
of the ARMS2 allele in subjects with a positive family history compared to those with a 
negative family history was even stronger for the development of advanced AMD (P = 
0.003). No other SNPs differed in association between familial and sporadic subjects with 
advanced AMD. The C3d/C3 ratio significantly differed with family history (P = 0.038), as it 
was a significant risk factor for advanced AMD in familial patients (OR 1.14; 95% CI 1.02-
1.27; P = 0.021) but not in sporadic patients. 
97 of the 281 familial AMD patients and 34 of the 143 familial controls reported a 
densely affected family history. The ARMS2 SNP was not associated with AMD in patients 
with a densely affected family, and this was significantly different from the association 
with sporadic AMD (P = 0.010 for all AMD stages and P = 0.002 for advanced AMD) (Table 
3.3.4 and Figure 3.3.1). The association of the CFH Y402H allele with familial and sporadic 
AMD again did not differ. The C3d/C3 ratio showed the largest risk effect in patients with 
a densely affected family for advanced AMD (OR 1.39; 95% CI 1.08-1.78; P = 0.010) and 
differed significantly (P = 0.033) from the association with sporadic AMD. The same was 
observed for all AMD stages, with an OR of 1.42 (95% CI 1.07-1.87; P = 0.015) in patients 
with a densely affected family, although there was only a trend of difference between the 
association of the C3d/C3 ratio for subjects with a densely affected family and sporadic 
subjects (P = 0.063). 
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Figure 3.3.1 Odds ratios for risk variants in ARMS2 and CFH and the C3d/C3 ratio for development 
of AMD split by family history. The risk variant in ARMS2 confers a strong risk for AMD in the sporadic 
group. In the group with a dense family history there is no effect of this SNP. The CFH Y402H risk 
allele is associated with AMD in all subgroups, irrespective of family history. In case of a dense family 
history, the C3d/C3 ratio is associated with AMD development. In the subgroups with no or a mild 
family history, this effect was not observed.
OR = odds ratio; AMD = age-related macular degeneration; Sporadic = negative family history of 
AMD; Familial = positive family history of AMD; Dense familial = a positive family history of AMD 
satisfying 1 out of 3 criteria: (1) both parents have (possible) AMD, or (2) one affected parent and at 
least 25% of number of the sibs are affected, or (3) at least 50% of the number of sibs is affected; Mild 
familial = a positive family history of AMD but in a lesser extent, not meeting one of the 3 criteria.
DISCUSSION
In addition to environmental and genetic risk factors, a positive family history of AMD is 
an important risk factor for the development of AMD.9,10,32 For a proper risk assessment it 
is therefore important to determine an individual’s family history of AMD. In this study we 
investigated whether the contribution of AMD-associated SNPs and C3d/C3 ratio differs 
between familial and non-familial AMD cases. 
Our results show that the association of the ARMS2 A69S genotype differed between 
familial and sporadic subjects. Within the group of cases and controls with a dense 
family history, ARMS2 was not associated with AMD, whereas it was a strong risk factor 
for sporadic individuals. Another difference was found for the C3d/C3 ratio between 
familial and sporadic subjects. In case of no or only a mild family history the ratio did not 
differ between cases and controls. However, in the subgroup with a dense family history, 
complement activation was significantly associated with the presence of all AMD stages 
and advanced AMD.
The ARMS2 A69S variant is one of the strongest genetic risk factors for AMD.37 However, 
in densely affected families this risk variant seems to have less effect, and a high ARMS2 
risk allele frequency was found in familial controls. Testing the ARMS2 SNP to estimate an 
Analysis of risk alleles and complement activation levels in familial and non-familial 
171
3.3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
individual’s AMD risk is thus more informative in patients without a positive family history. 
However, since both family history and SNPs are important factors in the development of 
AMD, and some discordance exists between risk estimates by genetic testing and by family 
history analysis,38 they should be used complementary in risk assessment. The fact that 
the family history for AMD affects the risk of the ARMS2 genotype, suggests that there are 
other, unknown factors that increase the risk for AMD in the patients with densely affected 
families. This supports the theory that densely affected families may harbor rare, more 
penetrant genetic variants for AMD.34,39,40 The difference in the association of the C3d/
C3 ratio with advanced AMD between familial and sporadic subjects, can point towards a 
more important role for systemic complement activation in families with AMD compared 
to sporadic AMD patients, especially for the development of advanced AMD. Risk alleles 
of CFH and ARMS2 are independently associated with an increased C3d/C3 ratio,29 and the 
higher complement level in familial AMD patients may (partly) be explained by the higher 
number of risk alleles of those SNPs in familial patients compared to sporadic patients. 
However, after additional adjustment for the ARMS2 and complement SNPs, we determined 
that the OR and corresponding CI for the C3d/C3 ratio does not significantly change. This 
further supports the hypothesis that rare, highly penetrant variants may contribute to the 
higher complement activation in familial AMD. Interestingly, several rare, highly penetrant 
AMD alleles have been described in several genes of the complement system,39,41-44 and in 
densely affected families, mutations in the CFH gene have been identified.40,43 
In this study no difference for the role of the CFH Y402H risk variant was observed 
between familial and sporadic subjects. Unlike ARMS2, the CFH Y402H risk SNP seems to be 
of equal importance for the development of AMD in sporadic and familial individuals. This 
finding further underlines the important role of the complement system in familial AMD, 
both through common SNPs as well as rare genetic variants.
Eight SNPs in the ARMS2, CFH, C3 and CFB genes were associated with AMD in sporadic 
cases in our study, but only the 2 major SNPs, ARMS2 rs10490924 and CFH rs1061170, 
were also significantly associated with AMD in familial cases. The lack of association with 
the remaining 6 SNPs in the familial cases is likely due to the limited number of available 
subjects, since the ORs of these 6 variants were comparable in sporadic and familial 
subjects and did not differ between familial and sporadic subjects. Stronger associations 
for advanced AMD compared to all AMD stages in sporadic cases indicate that the risk SNPs 
play a more important role in the development of advanced stages of AMD than in the 
development of small and intermediate drusen. In sporadic AMD, an increased BMI and 
current smoking status showed a significant association with AMD in our study, which is 
in agreement with previous studies.6-8,45 As these factors were not significantly associated 
with AMD in familial cases, environmental factors like smoking behavior and BMI may play 
a more important role in the development of AMD in sporadic patients than in familial 
patients. However, it should be noted that the absence of significant associations with AMD 
in familial subjects may be due to the limited number of available familial subjects.
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The relatively low number of familial cases and controls is the main limitation of our 
study. This may reduce the power of our analyses. However, after subdividing our familial 
dataset into mild and densely affected families we observed that the differences in 
association between familial and sporadic cases were more pronounced, and this further 
underlines our findings. Nonetheless, our results should be interpreted with care and 
should be replicated in additional familial AMD cohorts in order to confirm our hypothesis.
In conclusion, this study demonstrates that the association of the ARMS2 risk allele and 
complement activation levels in serum with AMD differs between familial and sporadic 
subjects. Our study suggests that ARMS2 risk alleles have less effect in familial AMD 
patients than in sporadic AMD. In contrast, increased complement activation levels seem 
to play a larger role in patients with a positive family history compared to sporadic patients, 
which cannot be explained by known, common SNPs in the complement genes. A better 
understanding of factors that differ between individuals with and without a family history 
will aid the development of reliable prediction models for AMD, and may provide individuals 
with more accurate information regarding their individual risk for AMD. This information is 
especially important for individuals who have a dense positive family history for AMD.
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3.4
Rare variants associated with age-related 
macular degeneration result in a lower age 
at onset and higher familial occurrence
N.T.M. Saksens, M.J. Geerlings, B. Bakker, T. Schick, M.R. Daha, 
S. Fauser, C.J.F. Boon, E.K. de Jong, C.B. Hoyng, A.I. den Hollander
JAMA Ophthalmology; Under review 
PURPOSE. Recently, rare variants in the complement genes CFH, CFI, C9 and C3 were found 
to be highly associated with age-related macular degeneration (AMD). The aim of the current 
study was to determine the contribution of these rare variants in the development of AMD in 
22 multiplex families. In addition, we aimed to describe clinical differences in carriers versus 
non-carriers, in these families and in a large case-control cohort.
METHODS. Retrospective case-control study including 114 affected and 60 unaffected family 
members of 22 multiplex AMD families, as well as 1589 AMD patients and 1386 control 
individuals from the European Genetic Database (EUGENDA). All individuals underwent an 
extensive ophthalmic examination and completed a questionnaire on family history for AMD 
and age at first symptoms. Venous blood was obtained for genetic analysis and measurement 
of complement activation levels. Main outcome measures are differences in age at first 
symptoms, family history for AMD, complement activation levels (C3d/C3 ratio), presence 
of reticular pseudodrusen, and AMD phenotype between carriers and non-carriers of rare 
variants.
RESULTS. Rare variants CFI Gly119Arg, C9 Pro167Ser and C3 Lys155Gln were confirmed in 
five out of 22 multiplex AMD families, but did not completely segregate with the disease. 
In our case-control cohort affected carriers of these variants had a significantly lower age at 
first symptoms (67.4 vs 71.3 years; P = 0.010), and more often had a positive family history 
for AMD (44.9% vs 30.6%; P = 0.008) compared to non-carriers. Patients with advanced 
atrophic AMD carried these rare variants more frequently than patients with neovascular 
AMD (11.8% vs 4.8%; P = 0.044).
CONCLUSIONS. Previously reported rare variants do not completely segregate within AMD 
families. However, patients carrying these rare variants differ clinically from non-carriers by 
a lower age at first symptoms, a higher prevalence of a positive family history, and by AMD 
phenotype. Genetic tests for AMD should therefore be designed to detect common and 
rare genetic variants, especially in families, since rare variants significantly contribute to the 
age at onset and progression of the disease.
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of irreversible, central 
vision loss in the elderly population in developed countries.1 A combination of genetic and 
non-genetic factors plays a role in the development and progression of this multifactorial 
disease.2,3 Genome-wide association studies have identified common genetic risk variants 
that are strongly associated with AMD, such as single nucleotide variant Tyr402His 
(rs1061170) in the CFH gene, and Ala69Ser (rs10490924) in the ARMS2 gene.2,4,5
Previous family- and twin-studies have demonstrated a strong genetic component and 
aggregation of AMD within families.6-9 Approximately 20-30% of the patients have a positive 
family history for AMD,7,10-12 which has been reported as a significant risk factor for AMD. A 
positive family history has also been associated with an earlier age at onset of disease.13-17 
Clustering of known common genetic risk factors does not fully explain the number of 
affected family members in large, densely affected families.7 Several recent studies have 
identified rare genetic variants, which strongly increase the risk of AMD, including CFH 
Arg1210Cys, CFI Gly119Arg, C9 Pro167Ser, and C3 Lys155Gln.15,18-21 These rare variants are 
located in genes of the complement system, which plays a major role in the pathogenesis 
of AMD.2,22 Due to their strong effect size, these rare, highly penetrant genetic variants 
may account for clustering of AMD in families, and might lead to a more severe disease. 
Recently, highly penetrant variants have been identified in AMD families confirming the 
hypothesis that rare variants can cluster in families.15-17
The aim of the current study was to determine the contribution of known rare genetic 
variants in the development of AMD in large, multiplex AMD families. In addition, we aimed 
to describe differences in clinical characteristics in carriers versus non-carriers of these rare 
genetic variants, in multiplex families and in a large case-control cohort.
METHODS
Subjects
In this retrospective study, we evaluated 114 affected and 60 unaffected family members 
of 22 multiplex AMD families, and 1589 AMD patients and 1386 control individuals from 
the European Genetic Database (EUGENDA). This study was approved by the local ethics 
committees on Research Involving Human Subjects and met the criteria of the Declaration 
of Helsinki.
Before enrolment in the EUGENDA database, all subjects provided written informed 
consent and completed a detailed questionnaire on their medical history, age at onset of 
first symptoms, family history of AMD, and lifestyle factors. A positive family history of 
AMD was defined as at least two first-degree relatives (parents and/or siblings) with AMD 
or possible AMD in a family.
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Each participant underwent digital color fundus photography and spectral-domain 
optical coherence tomography (SD-OCT, Spectralis; Heidelberg Engineering, Heidelberg, 
Germany) after pupillary dilatation with topical 1.0% tropicamide and 2.5% phenylephrine. 
Digital non-stereoscopic 30° color fundus photography centered on the fovea was performed 
with a Topcon TRC 50IX camera (Topcon Corporation, Tokyo, Japan). SD-OCT volume scans 
consisting of 19 or 37 parallel OCT B-scans were used for analysis, covering 6x4 mm of the 
macula. For each OCT B-scan, 20 images were averaged using the automated real-time 
function.23 Color fundus photographs and OCT scans of both eyes of all individuals were 
evaluated by two independent certified reading center graders according to the standard 
protocol of the Cologne Image Reading Center and Laboratory (CIRCL).23 AMD was classified 
by the presence of pigmentary changes together with at least 10 small drusen (<63µm) 
or the presence of intermediate (63-124 µm) or large drusen (≥125 µm diameter) in the 
Early Treatment Diabetic Retinopathy Study (ETDRS) grid. Advanced AMD was defined 
as either AMD with subfoveal geographic atrophy (GA) or choroidal neovascularization 
(CNV) in at least one eye. Age at onset of AMD was defined as the age at which first visual 
complaints occurred. Controls were classified as having no abnormalities or only small 
drusen or pigmentary abnormalities, and were 60 years of age or older. Additionally, in 303 
AMD patients infrared images and SD-OCTs were evaluated for the presence of reticular 
pseudodrusen by one senior grader. 
Genotyping 
Whole exome sequencing was used to genotype 85 affected members of 22 multiplex AMD 
families. The samples were sequenced at the Erasmus Medical Center (Rotterdam, the 
Netherlands) using DNA obtained from venous blood, extracted using standard procedures. 
The DNA was fragmented using Covaris Adaptive Focused Acoustics shearing according to 
the manufacturer’s instructions (Covaris, Inc., Woburn, MA), and Kapa Library preparation 
(Kapa Biosystems, Inc., Wilmington, MA) was performed on a Caliper Sciclone NGS 
workstation (Caliper Life Sciences, Hopkinton, MA). Exome capture was achieved using the 
Nimblegen SeqCap EZ V2 kit (Roche Nimblegen, Inc., Madison, WI), designed to capture over 
44 Mb of exonic regions. Paired-end 2 ×100 sequencing was done on an Illumina HiSeq2000 
sequencer using Illumina TruSeq V3 chemistry (Illumina, Inc., San Diego, CA). Downstream 
analyses included demultiplexing (CASAVA software, Illumina) and alignment to the hg19 
reference genome (Genome Reference Consortium Human Reference 37) by the Burrows-
Wheeler alignment tool.24 Alignments were sorted by Picard (http://broadinstitute.github.
io/picard) and subsequently processed by GATK (Indel Realignment and Base-Quality Score 
Recalibration).25 Finally, PCR duplicates were marked by Picard, Mean Depth of Coverage 
was determined using GATK, and Freemix values were estimated through verifyBAMid.26 
Samples that passed technical QC metrics were genotyped to gVCF level through GATKs 
HaplotypeCaller. Insertions and deletions (Indels) and single nucleotide variants (SNVs) 
were filtered separately using GATKs Variant-Quality Score Recalibration, and both the SNV 
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and indel sets were annotated using ANNOVAR.27 We used simple filtering steps to select 
the previously associated variants in CFH (Arg1210Cys; rs121913059), CFI (Gly119Arg; 
rs141853578), C9 (Pro167Ser; rs34882957) and C3 (Lys155Gln; rs147859257) from the 
exome files of the 85 affected family members. The annotation of the identified variants 
were confirmed manually using Alamut Visual (Interactive Biosoftware, Rouen, France) by 
uploading the BAM alignments obtained by exome sequencing into the reference genome. 
In addition, the variants were confirmed by Sanger sequencing using primers designed with 
Primer3 software. The variants were also analyzed in all collected affected and unaffected 
family members using Sanger sequencing (Table 3.4.1).
Table 3.4.1 Primer sets used to amplify and Sanger sequence the rare variants in five AMD families
Primer Primer sequence Melting 
temp (°C)
Product 
length (in 
basepairs)
CFI Gly119Arg forward CGTAAAATGATTGCTTACTATTACTTG 57.1
431
CFI Gly119Arg reverse TGATGCACATAGTTAATTTTCTTAGG 58.0
C3Lys155Gln forward AGATCCGGAAGCTGGACC 60.2
444
C3Lys155Gln reverse TTGCCTCTCCTAAGCCTGTG 60.5
C9 Pro167Ser forward ACGGTGACATGAACTGAAGC 58.7
388
C9 Pro167Ser reverse CCAAACTACATCGCCTCTTC 57.4
Genotyping of the rare genetic variants CFH Arg1210Cys, CFI Gly119Arg, C9 Pro167Ser, 
and C3 Lys155Gln was performed in all included subjects of the EUGENDA case-control 
cohort. Genotyping of CFI Gly119Arg was performed using a custom-made TaqMan assay 
(Life Technologies), as described previously.18 Genotyping of CFH Arg1210Cys, C9 Pro167Ser 
and C3 Lys155Gln were performed by competitive allele-specific PCR assays (KASP SNP 
Genotyping System, LGC). CFH as previously described28 and C9, C3, according to the 
manufacturers’ recommendations (Table 3.4.2).
Table 3.4.2 KASPAR assays used for genotyping the rare variants in EUGENDA case-control cohort
ID C9_rs34882957 C3_rs147859257
Primer_AlleleFAM CATTGTCAAAAGGTGTGCTTAGGGA GGATCTTCACCGTCAACCACC
Primer_AlleleHEX GTCAAAAGGTGTGCTTAGGGG CGGATCTTCACCGTCAACCACA
Primer_Common TTCTCAGGATCAACATTTTAGGGATGGAT ACCGTCCGGCCCACGGGTA
Complement measurements 
Complement component C3 and the activation fragment C3d were measured in serum 
samples as described previously.29 The C3d/C3 ratio was calculated as a measure of 
complement activation,30 and is a strong marker for AMD.29 For the statistical analysis the 
C3d/C3 ratio was log transformed to normalize the data.
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Statistical analysis
The odds ratio (OR) of the presence of a rare variant for AMD was calculated by binary 
logistic regression analysis. Statistical analyses were performed to study differences in age 
at first symptoms, complement activation levels, family history for AMD and AMD subtype 
between carrier and non-carrier patients of the rare variants CFI Gly119Arg, C9 Pro167Ser 
or C3 Lys155Gln. We analyzed mean values of the continuous traits, complement activation 
levels, and age at first symptoms using independent sample t-tests and compared the mean 
value using Pearson’s chi-square for the other variables. Data were analyzed using SPSS 
Software version 20.0 (SPSS Inc., Chicago, IL), and two-sided P-values of less than 0.05 were 
considered statistically significant.
RESULTS
The rare variants CFI Gly119Arg, C9 Pro167Ser and C3 Lys155Gln were observed in five of 
the 22 multiplex AMD families. Although these variants aggregated within these families, 
they did not segregate completely with the disease (Figure 3.4.1). The CFH Arg1210Cys 
variant was not observed in any of the 22 families. 
The CFI Gly119Arg variant was detected in one family (Figure 3.4.1, family A). Of the 
four affected individuals, three were carrier of the CFI Gly119Arg variant. Affected individual 
II:4, lacking the CFI Gly119Arg, carried the CFH Tyr402His risk allele homozygously. The 
youngest unaffected individual (64 years of age) carried the risk conferring CFI variant. In a 
second family (Figure 3.4.1, family B), two rare variants, C9 Pro167Ser and C3 Lys155Gln, 
were identified heterozygously. While both variants were only found in affected individuals, 
neither variant segregated fully with the disease phenotype. The C3 Lys155Gln variant was 
found to cluster in two additional families (Figure 3.4.1, families C and D). In family C, 
the C3 Lys155Gln variant was detected in two affected individuals (II:2 and II:4), who also 
carried the ARMS2 Ala69Ser and CFH Tyr402His risk alleles homozygously. Individuals II:1 
and II:3 were both affected by intermediate AMD without carrying the rare variant in C3, 
and were heterozygous for the common ARMS2 Ala69Ser and CFH Tyr402His risk alleles. In 
family D, five individuals carried the C3 Lys155Gln variant, of which four were affected by 
AMD and one was unaffected (II:8). Individuals II:6 and II:7 carried the C3 variant and were 
diagnosed with intermediate AMD. Their older siblings II:4 and II:5 who did not carry the 
rare variant did not develop AMD, although they had a higher genotypic load of the two 
common variants. Additionally to family B, the C9 Pro167Ser variant was also identified in 
family E (Figure 3.4.1). Two affected individuals carrying the variant had a more advanced 
AMD stage than the affected non-carrying family members.
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Figure 3.4.1. Pedigrees of five AMD families carrying rare variants in CFI, C9 and C3. Segregation 
analysis of the rare variants, and common variants CFH Tyr402His and ARMS2 Ala69Ser. Risk alleles 
are indicated in red. Affected individuals are numbered to represent the stage of AMD (1 early; 2 
intermediate; 3 advanced geographic atrophy; 4 advanced choroidal neovascularization). The circles 
mark the individuals analyzed by whole-exome sequencing.
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Within the five families, rare variants were detected in 16 affected individuals and 2 
unaffected individuals (Table 3.4.3). Carrying one of the variants in CFI, C9 or C3 resulted in 
an OR of 7.11 for AMD (95% CI 1.23-40.98; P = 0.028). 
The age at first symptoms was lower in affected family members who carried the rare 
variants CFI Gly119Arg, C9 Pro167Ser, or C3 Lys155Gln, as compared to affected individuals 
who did not, although this difference was not statistically significant (63.9 vs 69.4 years; P = 
0.254)(Figure 3.4.2). The complement activation level (log C3d/C3 ratio) was slightly higher 
in affected family members who carried a rare variant in a complement gene compared to 
non-carriers, although this difference was also not statistically significant (P = 0.141)(Figure 
3.4.2). Most patients graded as advanced AMD carried a rare variant. This holds true for 
the single patient affected by GA and five out of the six patients affected by CNV (P = 0.167)
(Figure 3.4.1).
Figure 3.4.2 Age at onset and complement activation in carriers versus non-carriers in the five AMD 
families and EUGENDA cohort. There is a possible trend (P = 0.254) in the families and a significant 
association (P = 0.010) in the cohort for an earlier age at onset for rare variant carriers. Complement 
activation levels (Log C3d/C3 ratio) do not differ significantly in the cohorts. Lines indicate mean 
values. 
Rare variants associated with age-related macular degeneration result in a lower age 
185
3.4
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
Ta
bl
e 
3.
4.
3.
 C
lin
ic
al
 c
ha
ra
ct
er
is
ti
cs
 o
f c
ar
ri
er
s 
an
d 
no
n-
ca
rr
ie
rs
 o
f t
he
 r
ar
e 
va
ri
an
ts
 in
 t
he
 5
 A
M
D
 fa
m
ili
es
Ca
rr
ie
r 
an
d 
di
se
as
e 
st
at
us
G
en
de
r
Fe
m
al
e 
%
A
ge
 a
t 
pa
rti
ci
pa
ti
on
 t
o 
EU
G
EN
D
A
* 
A
ge
 a
t 
fi
rs
t 
sy
m
pt
om
s*
 
Co
m
pl
em
en
t 
ac
ti
va
ti
on
M
ea
n 
Lo
g 
C3
d/
C3
 r
ati
o 
(S
D
)
Pa
ti
en
t 
gr
ad
ed
 w
it
h 
G
A
 a
nd
 C
N
V
 
N
um
be
r 
In
di
vi
du
al
s 
w
it
h 
re
ti
cu
la
r 
dr
us
en
  
N
um
be
r 
(%
)
A
ff
ec
te
d 
ca
rr
ie
rs
 (n
 =
 1
6)
87
.5
%
74
.9
63
.9
0.
63
6 
(0
.0
84
)
1 
an
d 
5 
5 
(3
1.
3%
)
A
ff
ec
te
d 
no
n-
ca
rr
ie
rs
 (n
 =
 9
)
55
.6
%
71
.4
69
.4
0.
51
8 
(0
.1
94
)
0 
an
d 
1 
0 
(0
.0
%
)
U
na
ff
ec
te
d 
ca
rr
ie
rs
 (n
 =
 2
)
10
0.
0%
66
.0
-
0.
54
7 
(0
.2
02
)
-
0 
(0
.0
%
)
U
na
ff
ec
te
d 
no
n-
ca
rr
ie
rs
 (n
 =
 8
)
50
.0
%
66
.9
-
0.
50
8 
(0
.0
97
)
-
0 
(0
.0
%
)
* 
M
ea
n 
ag
e 
in
 y
ea
rs
; S
D
 =
 s
ta
nd
ar
d 
de
vi
ati
on
; G
A
 =
 g
eo
gr
ap
hi
c 
at
ro
ph
y;
 C
N
V
 =
 c
ho
ro
id
al
 n
eo
va
sc
u-
la
ri
za
ti
on
; c
ar
ri
er
 =
 c
ar
ry
in
g 
a 
ra
re
 v
ar
ia
nt
 C
FI
 
G
ly
11
9A
rg
, C
9 
Pr
o1
67
Se
r 
or
 C
3 
Ly
s1
55
G
ln
Ta
bl
e 
3.
4.
4.
 C
lin
ic
al
 c
ha
ra
ct
er
is
ti
cs
 o
f c
ar
ri
er
s 
an
d 
no
n-
ca
rr
ie
rs
 o
f t
he
 r
ar
e 
va
ri
an
ts
 in
 t
he
 E
U
G
EN
D
A
 c
as
e-
co
nt
ro
l c
oh
or
t
Ca
rr
ie
r 
an
d 
di
se
as
e 
st
at
us
G
en
de
r
Fe
m
al
e 
%
A
ge
 a
t 
pa
rti
ci
pa
ti
on
 t
o 
EU
G
EN
D
A
* 
A
ge
 a
t 
fi
rs
t 
sy
m
pt
om
s*
Co
m
pl
em
en
t 
ac
ti
va
ti
on
M
ea
n 
Lo
g 
C3
d/
C3
 r
ati
o 
(S
D
)
Pa
ti
en
t 
gr
ad
ed
 w
it
h 
G
A
 a
nd
 C
N
V
 
N
um
be
r
In
di
vi
du
al
s 
w
it
h 
re
ti
cu
la
r 
dr
us
en
  
N
um
be
r 
(%
)
A
ff
ec
te
d 
ca
rr
ie
rs
 (n
 =
 9
1)
56
.0
%
73
.7
67
.4
0.
65
6 
(0
.1
53
)
11
 a
nd
 4
0
3 
(3
.3
%
)
A
ff
ec
te
d 
no
n-
ca
rr
ie
rs
 (n
 =
 1
49
8)
56
.1
%
75
.5
71
.3
0.
63
3 
(0
.1
49
)
82
 a
nd
 7
95
56
 (3
.7
%
)
U
na
ff
ec
te
d 
ca
rr
ie
rs
 (n
 =
 4
3)
67
.4
%
70
.2
-
0.
54
5 
(0
.1
61
)
-
0 
(0
.0
%
)
U
na
ff
ec
te
d 
no
n-
ca
rr
ie
rs
 (n
 =
 1
34
3)
56
.9
%
70
.4
-
0.
59
6 
(0
.1
57
)
-
0 
(0
.0
%
)
* 
M
ea
n 
ag
e 
in
 y
ea
rs
; S
D
 =
 s
ta
nd
ar
d 
de
vi
ati
on
; G
A
 =
 g
eo
gr
ap
hi
c 
at
ro
ph
y;
 C
N
V
 =
 c
ho
ro
id
al
 n
eo
va
sc
ul
ar
iz
ati
on
; c
ar
ri
er
 =
 c
ar
ry
in
g 
a 
ra
re
 v
ar
ia
nt
 C
FI
 
G
ly
11
9A
rg
, C
9 
Pr
o1
67
Se
r 
or
 C
3 
Ly
s1
55
G
ln
Chapter 3.4
186
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
Five of 25 affected family members showed an AMD phenotype with reticular 
pseudodrusen, and all of these patients carried the rare variant CFI Gly119Arg, C9 
Pro167Ser, or C3 Lys155Gln (Table 3.4.3). Carrying one of these variants was associated 
with developing reticular pseudodrusen (P = 0.019). The Pro167Ser variant in the C9 gene 
appeared to segregate with the reticular pseudodrusen phenotype in the family E, since 
II:2 and II:3, who carried the rare variant, showed reticular pseudodrusen while II:1 and 
II:4 did not. However, the rare variants in the CFI and C3 gene did not segregate with the 
reticular drusen phenotype. Individual II:1 of family A, and individuals II:2 and II:6 of family 
D, showed the reticular pseudodrusen phenotype, but this phenotype was not observed in 
their siblings who carried the same rare variant.
To verify the findings observed in the five families, the analyses were replicated in a 
large case-control cohort from the EUGENDA database, which was genotyped for the rare 
variants CFH Arg1210Cys, CFI Gly119Arg, C9 Pro167Ser, and C3 Lys155Gln. Out of the 1589 
patients and 1386 control individuals we identified 91 (5.7%) carriers in the AMD cohort 
and 43 (3.1%) carriers in the cohort of the controls (Table 3.4.4). The CFH Arg1210Cys 
variant was not present in our case-control cohort. The presence of a rare genetic variant 
was significantly associated with AMD and conferred an OR of 1.90 (95% CI 1.31-2.75; P = 
0.001). This was comparable with the OR for advanced AMD (OR 1.90; 95% CI 1.27-2.85; 
P = 0.002). Separate analyses for each rare variant showed large effect sizes for the CFI 
Gly119Arg variant (OR 11.38; 95% CI 1.49-87.06; P = 0.003), while the effect size of the C9 
Pro167Ser variant (OR 1.54; 95% CI 0.96-2.45 P = 0.070) and the C3 Lys155Gln variant (OR 
1.81; 95% CI 0.96-3.44; P = 0.064) were smaller (Table 3.4.5). AMD patients who carried 
rare variant CFI Gly119Arg, C9 Pro167Ser or C3 Lys155Gln reported a positive family history 
for AMD significantly more often than AMD patients without these rare variants (44.9% 
and 30.6%, respectively P = 0.008). This difference in positive family history was the largest 
for carriers of the CFI Gly119Arg variant (58.3% vs 30.6%, P = 0.038), followed by variant 
Pro167Ser in C9 (44.7% vs 30.6%, P = 0.040)(Table 3.4.6). 
Table 3.4.5. Frequencies and effect sizes of the rare variants in the EUGENDA case-control cohort
Rare variant Carrier patients Carrier controls OR 95% CI P-value
CFI Gly119Arg 13 (0.008%) 1 (<0.001%) 11.38 (1.49 - 87.06) 0.003
C9 Pro167Ser 49 (0.031%) 28 (0.020%) 1.54 (0.96 - 2.45) 0.070
C3 Lys155Gln 29 (0.018%) 14 (0.010%) 1.81 (0.96 - 3.44) 0.064
CFH Arg1210Cys 0 (0%) 0 (0%) - - -
P-value and OR printed in bold indicate a significant association.
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Table 3.4.6. Quantitative traits for each of the rare variants in the EUGENDA case-control cohort
Rare variant Mean age at 
onset in carriers 
vs non-carriers 
(years)
P-value Familial occurrence 
in affected carriers 
vs non-carriers (%)
P-value Mean log C3d/C3 
ratio in affected 
carriers vs non-
carriers
P-value
CFI Gly119Arg 58.75 vs 71.3 0.005 58.3 vs 30.6 0.038 0.705 vs 0.633 0.198
C9 Pro167Ser 69.12 vs 71.3 0.225 44.7 vs 30.6 0.040 0.645 vs 0.633 0.599
C3 Lys155Gln 66.5 vs 71.3 0.127 36.6 vs 30.6 0.556 0.663 vs 0.633 0.332
P-values printed in bold indicate significant associations.
Additionally, a lower age at first symptoms was found in AMD patients with rare variant 
CFI Gly119Arg, C9 Pro167Ser, or C3 Lys155Gln than in patients who did not carry these rare 
variants (67.4 and 71.3 years, respectively; P = 0.010)(Figure 3.4.2). In individuals carrying 
a rare variant, the mean complement activation level (log C3d/C3 ratio) was significantly 
higher in cases compared to controls (P = 0.001). In contrast, the mean log C3d/C3 ratio in 
AMD patients carrying one of the rare variants was not different from non-carriers of these 
variants (P = 0.189)(Figure 3.4.2). In advanced AMD patients, rare variants CFI Gly119Arg, 
C9 Pro167Ser, or C3 Lys155Gln were present significantly more often in patients with GA 
(11.8%) than patients with CNV (4.8%; P = 0.044)(Table 3.4.4). A reticular pseudodrusen 
phenotype was present in 59 of 202 AMD patients and none of the 183 controls (Table 
3.4.4). No association was found between the presence of reticular pseudodrusen and the 
presence of one of these rare variants in the large AMD cohort (P = 0.804).
DISCUSSION
The development of AMD in densely affected families can be influenced by rare genetic 
variants, of which four (CFH Arg1210Cys, CFI Gly119Arg, C9 Pro167Ser, and C3 Lys155Gln) 
were previously associated to AMD.15,18-21 In our EUGENDA case-control cohort, the presence 
of a variant resulted in an OR of 1.90 for AMD, which is comparable with previously reported 
effect sizes for the C9 Pro167Ser and C3 Lys155Gln variants.15,18-21 However, the effect size of 
the Gly119Arg variant in the CFI gene was much stronger, with an OR of 11.38, which is in 
line with previous reports (OR 8.5 and 22.2).18,31 The CFH Arg1210Cys variant was previously 
associated to AMD in North-American cohorts,15,20 but not in Icelandic and Han Chinese 
cohorts.19,32 The absence of this variant in our AMD case-control cohort may reflect the 
different distribution of low-frequency alleles among populations.28
Almost half of the patients who carried one of the rare genetic variants CFI Gly119Arg, C9 
Pro167Ser or C3 Lys155Gln reported a positive family history for AMD, which has important 
implications for counseling of these patients and their family members, and underlines the 
importance of including these rare variants in genetic tests for AMD. Despite their strong 
association with AMD in case-control cohorts,18-21 variants CFI Gly119Arg, C9 Pro167Ser and 
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C3 Lys155Gln do not segregate with the disease in the five families in this study. This could 
point to the contribution of other genetic risk alleles and environmental factors in such 
multiplex families. Further research is warranted to determine whether additional rare 
variants aggregate in the remaining 17 multiplex AMD families in this study. 
Patients carrying a known rare genetic variant differ clinically from patients that do 
not. We demonstrated that carriers of rare variants CFI Gly119Arg, C9 Pro167Ser or C3 
Lys155Gln have a 4-year-earlier onset of first symptoms, of which CFI Gly119Arg shows the 
strongest effect. This is comparable to the earlier onset previously described in patients 
carrying the rare Arg1210Cys variant in the CFH gene,15 and is in line with the lower age at 
first symptoms in familial AMD patients.14 
Many of the common genetic variants associated with AMD reside in genes encoding 
components of the complement cascade,2,4,34-36 some of which have been associated with 
increased systemic levels of complement activation and complement components.29,37,38 
Additionally, nearly all the recently identified rare variants are located in complement 
genes,15,17-21,33,39,40 enphasizing the important role of the complement system in the 
pathophysiology of AMD. Mean complement activation levels were slightly higher in AMD 
patients carrying rare variants in CFI, C9, or C3 compared to non-carriers, but this difference 
was not significant. This suggests that the difference in complement activation levels cannot 
be explained by the presence of the rare variants evaluated in this study. Preventive and 
therapeutic options inhibiting the complement cascade have been suggested to be effective 
in treating AMD,41 but our current results do not support the hypothesis that subjects who 
carry a rare variant in a complement gene will benefit more from such treatments than 
non-carriers. 
In this study rare variants were more frequently identified in advanced AMD patients 
with GA than in patients with CNV. This is in line with a recent study, which observed a 
higher prevalence of GA among patients carrying the CFH Arg1210Cys variant.42 We 
previously suggested that additional genetic factors may contribute to the development of 
GA in familial patients, because we found a higher prevalence of GA in familial AMD cases 
than in sporadic patients,14 and it had been shown that siblings are more likely to develop 
the same advanced AMD subtype as the proband of the family.30 The findings of the current 
study are thus consistent with our suggestion that additional genetic factors play a role in 
GA development.14
In conclusion, we observed a higher familial occurrence and a lower age at onset in 
carriers of rare variants CFI Gly119Arg, C9 Pro167Ser or C3 Lys155Gln. This emphasizes 
the importance of counseling of patients and family members to increase awareness and 
enable early detection of the disease. Genetic tests for AMD should therefore be designed 
to detect common and rare genetic variants, especially in families, since these rare variants 
significantly contribute to the age at onset and progression of the disease. 
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Analysis of rare variants in the CFH gene in 
patients with the cuticular drusen subtype 
of age-related macular degeneration
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T. Schick, W.M. Nillesen, S. Fauser, L.H. Hoefsloot, C.B. Hoyng, 
E.K. de Jong, A.I. den Hollander 
Published in: Molecular Vision 2015; 21:285-292
PURPOSE. Age-related macular degeneration (AMD) and cuticular drusen (CD), a clinical 
subtype of AMD, have both been linked to genetic variants in the complement factor H 
(CFH) gene. In this study we aimed to investigate the frequency of rare variants in the 
CFH gene in 180 cases with CD. In addition, we aimed to determine the frequency of a 
previously reported rare, highly penetrant CFH variant (p.Arg1210Cys) in a Dutch-German 
non-CD type AMD case-control cohort, and to describe the phenotype of patients carrying 
the p.Arg1210Cys variant.
METHODS. Study subjects were selected from the European Genetic Database (EUGENDA), 
a joint AMD database of the Radboud University Medical Centre and the University Hospital 
of Cologne, and graded at the Cologne Image Reading Centre and Laboratory (CIRCL). 
Additionally, two CD cases were recruited from the VU Medical Centre in Amsterdam. The 
CFH gene was analyzed in 180 CD cases by Sanger sequencing. All identified variants were 
analyzed for potential damaging effects by prediction software tools SIFT and PolyPhen. In 
addition, we genotyped the p.Arg1210Cys variant in 813 non-CD type AMD cases and 1175 
controls. 
RESULTS. Sequencing identified 11 rare, heterozygous missense variants, one frameshift 
variant, and one splice acceptor site variant in 16 CD cases. The p.Arg1210Cys variant was 
identified in two CD cases, but was not identified in our Dutch-German non-CD type AMD 
case-control cohort.
CONCLUSIONS. The present study identified the presence of rare variants in the CFH 
gene in 16 (8.8%) of 180 patients with the CD subtype of AMD. The carriers of rare CFH 
variants displayed a significantly earlier age at onset than non-carriers (P = 0.016). The rare 
missense variant p.Arg1210Cys was identified in two CD cases, but was not detected in 
813 non-CD type AMD cases nor 1175 controls of our Dutch-German cohort. The current 
study suggests that the p.Arg1210Cys variant may be restricted to a subset of AMD patients 
with CD. Detailed clinical phenotyping, including fluorescein angiography, of AMD patients 
carrying the p.Arg1210Cys variant in other cohorts is required to confirm this finding. 
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INTRODUCTION
Age-related macular degeneration (AMD, MIM 603075) is the most common cause of 
vision loss and irreversible blindness in the Western world among the elderly.1 A major 
hallmark of AMD is the appearance of drusen in the macula accompanied with loss of 
sharp and central vision with advancing disease.2 Cuticular drusen (CD, MIM 126700), also 
termed ‘basal laminar drusen’ or ‘early adult-onset, grouped drusen’, is a clinical subtype 
of AMD, characterized by the fundoscopic findings of innumerable, small (25-75µm), 
slightly raised, round drusen, scattered throughout the central and peripheral retina.3 CD 
commonly appear in early adulthood, and are readily visualized by fluorescein angiography 
(FA). In more advanced stages the large number of CD present as a typical ‘stars-in-the-
sky’ appearance in the early phases of the angiogram.4 Approximately 10% of AMD cases 
display the CD phenotype.5 
The early age of onset and the clustering of the CD phenotype in families implies a 
large genetic contribution to the development of CD.5-8 This is supported by the observation 
that heterozygous mutations in the complement factor H (CFH) gene segregate with 
the CD phenotype in multiplex families.5, 8 Common variants in and near the CFH gene 
have been associated with CD and with AMD.6, 7 In addition, a rare, highly penetrant 
variant (p.Arg1210Cys) in the CFH gene has been associated with AMD.9, 10 However, the 
p.Arg1210Cys variant was not detected in an Icelandic cohort nor in the Han Chinese 
population.11, 12 This suggests that the rare p.Arg1210Cys variant does not consistently 
associate with AMD among different populations. 
In this study we aimed to investigate the frequency of rare variants in the CFH gene in 
180 cases with CD. In addition, we aimed to determine the frequency of the rare, highly 
penetrant p.Arg1210Cys variant in a Dutch-German non-CD type AMD case-control cohort, 
and to describe the phenotype of patients carrying the p.Arg1210Cys variant.
METHODS
EUGENDA Study
The study participants were recruited from the European Genetic Database (EUGENDA), a 
multicenter database consisting of subjects from the Nijmegen area, the Netherlands and 
Cologne area, Germany (Table 3.5.1). In addition, two CD cases were recruited at the VU 
Medical Centre in Amsterdam. All subjects analyzed in this study are Dutch and German 
and are of Caucasian descent. All subjects underwent ophthalmological examinations, 
and AMD staging was performed by the Cologne Image Reading Centre and Laboratory 
(CIRCL). CD was classified as a symmetric distributed pattern in both eyes of at least 50 
scattered, uniformly-sized, small (25-75µm) and hyperfluorescent drusen on FA in each 
eye, with a minimum of 20 drusen located outside the Wisconsin age-related maculopathy 
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grading template.6, 13 AMD was classified by the presence of at least 15 intermediate 
(63-124μm) drusen or at least one large (≥125μm) druse in the Early Treatment Diabetic 
Retinopathy Study (ETDRS) grid (intermediate AMD) or geographic atrophy or choroidal 
neovascularization secondary to AMD (advanced AMD). Control subjects were ≥65 years 
of age and did not display AMD, which includes cases without drusen, with only small 
drusen (<63µm) or with pigmentary abnormalities alone or combined with less than 10 
small drusen. Early AMD cases with ≥10 small drusen and pigmentary abnormalities or 1-14 
intermediate drusen were excluded. The age at onset of subjects was noted as the age at 
which first visual complaints were experienced. 
The EUGENDA study was approved by the local research ethics committees (Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen, the Netherlands, and the Ethics 
Committee of the University Hospital Cologne, Germany). Written informed consent was 
obtained from all participants, and the study was performed in accordance with the tenets 
of the Declaration of Helsinki.
Table 3.5.1 Demographics of studied subjects of the EUGENDA cohort
Variables CD Intermediate AMD Advanced AMD Controls
Number (Total) 180 207 606 1175
Mean age (±SD) 70 ± 13.7 74 ± 6.8 77 ± 7.7 70 ± 5.9
Gender
Male 59 (32.8%) 80 (38.6%) 251 (41.4%) 504 (42.9%)
Female 121 (67.2%) 127 (61.4%) 355 (58.6%) 671 (57.1%)
CD: Cuticular drusen; AMD: Age-related macular degeneration; SD: Standard deviation
Sequencing
Sanger sequencing of the CFH (NM_000186) gene was performed in 178 CD cases from the 
EUGENDA database and two CD cases from Amsterdam. Primers were designed to amplify all 
22 exons and flanking intron-exon junctions by Primer3 software (Table 3.5.2). Polymerase 
chain reactions (PCR) were performed, and amplification products were sequenced using 
an automated sequencer (BigDye Terminator, version 3, 3730 DNA analyzer; Applied 
Biosystems). All sequencing chromatograms were compared to the reference sequence 
using ContigExpress (Vector NTI Advance, Version 11.0, Life Technologies). Each newly 
identified variant was confirmed by a second independent PCR and bidirectional Sanger 
sequencing. All identified variants were annotated based on the Human Genome Variation 
Society (HGVS) nomenclature. Variants with a minor allele frequency <1% (MAF<1%) were 
considered as rare variants. The number of carriers of rare variants discovered in the CD 
cohort (n = 180) was compared to the general population (n = 4300) using data from Exome 
Variant Server (EVS). Rare coding (missense, frameshift, and nonsense) and splice site 
variants in the CFH gene, were utilized in the analysis. 
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Table 3.5.2 List of CFH gene sequencing primers
Primers Sequence (5’- 3’) Product (bp)
Exon 1F tgtaaaacgacggccagtttgtggcttgtggttgattt 409
Exon 1R caggaaacagctatgacctcaaaagccactcaattgtca  
Exon 2F tgtaaaacgacggccagtcctgtgactgtctaggcattttt 519
Exon 2R caggaaacagctatgaccatctcaaaattgcgccactg  
Exon 3F tgtaaaacgacggccagtcttgttcccccactcctaca 462
Exon 3R caggaaacagctatgacctgttttcccactctcccataa  
Exon 4F tgtaaaacgacggccagttggacactcagaatggcatc 395
Exon 4R caggaaacagctatgaccagatcaggctgcattcgttt  
Exon 5F tgtaaaacgacggccagtcactcccatagaaaagaatcagg 586
Exon 5R caggaaacagctatgaccgaacttagctcaattacaggcaga  
Exon 6F tgtaaaacgacggccagtcctgatggaaacaacatttctg 527
Exon 6R caggaaacagctatgacctgaacttttctggccctgtt  
Exon 7F tgtaaaacgacggccagtaagggattaagagcccagga 585
Exon 7R caggaaacagctatgacctttcggcaacttcgaaaact  
Exon 8F tgtaaaacgacggccagtgcatcatgtgatccacaagacat 592
Exon 8R caggaaacagctatgacctggtcactttgcttgaacaact  
Exon 9F tgtaaaacgacggccagttctttttgtgcaaacctttgttag 505
Exon 9R caggaaacagctatgaccccattggtaaaacaaggtgaca  
Exon 10F tgtaaaacgacggccagtcagggaactcttcttgtttgg 517
Exon 10R caggaaacagctatgaccgcagtgagtaaatgccctcaa  
Exon 11F tgtaaaacgacggccagtgcttatggttatccaggttttcag 424
Exon 11R caggaaacagctatgacccagcccccacaaaaagacta  
Exon 12F tgtaaaacgacggccagtttggggcttaagcaatgaaa 591
Exon 12R caggaaacagctatgaccaaactcccttcttttcccagtt  
Exon 13F tgtaaaacgacggccagttctgatgcccctctgtatga 413
Exon 13R caggaaacagctatgacctgggagcccaaacaaaatta  
Exon 14F tgtaaaacgacggccagtccattcttgattgtttaggatgc 516
Exon 14R caggaaacagctatgacccagccatgttcaagttcagg  
Exon 15F tgtaaaacgacggccagttgtgttgatggagagtggaca 482
Exon 15R caggaaacagctatgaccttgaagactggaaatgttgagg  
Exon 16F tgtaaaacgacggccagttgatgcaatgtgatcaggaa 491
Exon 16R caggaaacagctatgacccctgccttattcagtagcatttg  
Exon 17F tgtaaaacgacggccagttctatgagaatacaagccaaaagttc 612
Exon 17R caggaaacagctatgaccagtggtgattgattaatgtgccta  
Exon 18F tgtaaaacgacggccagtggaggaatatatctttgcgagtt 458
Exon 18R caggaaacagctatgacccctcactttgataacaagagattat  
Exon 19F tgtaaaacgacggccagtttggtgacagtccgatagaca 535
Exon 19R caggaaacagctatgaccaatttcccacagcagtccag  
Exon 20F tgtaaaacgacggccagttctcaattgctacggctacca 735
Exon 20R caggaaacagctatgacctggcccacttcaatcttcat  
Exon 21F tgtaaaacgacggccagttcagtgttctagcgaaggatg 660
Exon 21R caggaaacagctatgaccccaactctcaatttggtcgaa  
Exon 22F tgtaaaacgacggccagtcagtgctgtgtttgcgttt 435
Exon 22R caggaaacagctatgacccagaaatatttggtaggcaagc  
Exon 23F tgtaaaacgacggccagtacgcagggatcctaaaatga 838
Exon 23R caggaaacagctatgaccgctttccattttctgtaaaacagtg  
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The average age at onset of CD patients were compared in carriers of rare CFH variants (n = 
16; age at onset known = 13) versus non-carriers of rare CFH variants (n = 164; age at onset 
known = 64). The predicted effects of identified missense variants were examined using 
Polymorphism Phenotyping (PolyPhen) and Sorting Intolerant from Tolerant (SIFT).14, 15 
Genotyping
The CFH p.Arg1210Cys variant was genotyped in 813 non-CD type AMD cases and 1175 
controls from the EUGENDA database using a competitive allele-specific PCR assay (KASPar 
SNP Genotyping System, KBiosciences). KASPar genotyping was performed according to 
the manufacturer’s protocol in a volume of 4µl containing 10ng of genomic DNA, 2.5µl of 
2X reaction mix, and 0.069µl of assay (Table 3.5.3). Thermal cycling conditions included a 
pre-incubation step at 94⁰C for 15min, 20 cycles of 94⁰C for 10s, 57⁰C for 5s, 72⁰C for 10s, 
followed by 23 cycles of 94⁰C for 10s, 57⁰C for 20s, 72⁰C for 40s. Plates were analyzed on a 
7900 Fast Real-Time PCR system (Applied Biosystems). 
RESULTS
Through sequencing of the exons and flanking intron-exon boundaries of the CFH gene in 
180 unrelated CD cases 13 heterozygous rare variants in 16 cases (8.8%) were identified 
(Table 3.5.4). Of these 13 variants, 11 were missense variants, one was a frameshift variant 
(p.Ala301Asnfs*25), and one was a splice acceptor site variant (c.428-2A>G). Seven variants 
(c.428-2A>G, p.Ala161Ser, p.Ala173Gly, p.Arg175Gln, p.Ser193Leu, p.Ala301Asnfs*25, 
and p.Trp379Arg) were not present in public genetic variant databases (dbSNP, ESP6500/
EVS) and therefore represent rare, unique variants. Six variants (p.Leu3Val / rs139254423, 
p.Ile216Thr / rs183474263, p.Gln400Lys / rs201671665, p.Gln950His/rs149474608, 
p.Thr956Met / rs145975787, and p.Arg1210Cys / rs121913059) had very low reported 
minor allele frequencies (MAF) in these databases (MAF<0.001). The total number of 
carriers of rare CFH variants in CD patients (16 (8.8%) of 180) is significantly higher than 
the total number of carriers of rare CFH variants in the general population (185 (4.3%) 
of 4300) (P = 0.008, Fisher’s test). The mean age at onset in carriers of rare CFH variants 
(57.2 ± 16.8 years) is significantly earlier than non-carriers of rare CFH variants (66.1 ± 10.8 
years) (P = 0.016, Student’s t-test). Using online prediction algorithms SIFT and PolyPhen, 
potential damaging effects of the missense variants were assessed. Three missense 
variants (p.Ser193Leu, p.Trp379Arg and p.Gln950His) showed a consistent deleterious and 
damaging score by both PolyPhen and SIFT, while three variants were predicted deleterious 
or damaging by one of the prediction algorithms. Five missense variants were not predicted 
to be deleterious or damaging by either algorithm, including the p.Arg1210Cys variant. 
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The p.Arg1210Cys variant was identified in two unrelated individuals with CD. To test 
for a possible association of the p.Arg1210Cys variant in our Dutch-German non-CD type 
AMD case-control cohort, we genotyped this variant in 813 cases and 1175 controls from 
the EUGENDA database (Table 3.5.1). The p.Arg1210Cys variant was not found in our 
genotyped cohort, besides the two CD patients in which the p.Arg1210Cys variant was 
identified by sequence analysis of the CFH gene.
Both individuals carrying the p.Arg1210Cys variant presented with hyperfluorescent 
drusen on FA, typical for the CD subtype of AMD (Figure 3.5.1). In case 1 drusen were first 
noted at 50 years, with both eyes displaying numerous small drusen in the posterior pole 
and peripheral retina (Figure 3.5.1A-D). Case 2 had an age of onset of visual impairment 
at 64 years and presented with numerous small drusen in the posterior pole in both eyes. 
Furthermore, case 2 displayed a large fibrotic scar in the right eye (Figure 3.5.1E and G), 
pigmentary changes and an occult choroidal neovascularization in the left eye (Figure 
3.5.1F and H).
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Figure 3.5.1 Fundus photographs and fluorescein angiographs of two cases carrying the Arg1210Cys 
variation. Case 1, displayed numerous small drusen (arrow) in the posterior pole and in peripheral 
retina in both eyes (A and B represent color fundus photographs of the posterior pole and the periphery 
of the left eye respectively, whereas C and D represent fluorescein angiographs of the posterior pole 
and the periphery of the left eye respectively). Case 2, showed small drusen of the posterior pole in 
both eyes (E and F represent color fundus photographs of right and left eye respectively, whereas 
G and H represent fluorescein angiographs of right and left eye respectively). In addition, case 2 
displayed a large fibrotic scar (G, arrow) in the right eye. In the left eye pigmentary changes (F, arrow) 
and an occult choroidal neovascularization (H, arrow) were observed.
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DISCUSSION
The present study identified the presence of rare variants (MAF<1%) in the CFH gene in 16 
(8.8%) of 180 patients diagnosed with the CD subtype of AMD. This number is significantly 
higher than the number of carriers of rare CFH variants in the general population (4.3%, P = 
0.008). This study evidenced that carriers of rare CFH variants display an earlier age at onset 
than non-carriers of rare CFH variants (P = 0.016). The rare missense variant p.Arg1210Cys 
was identified in two CD cases, but was not detected in 813 non-CD type AMD cases and 
1175 controls of our Dutch-German cohort. The p.Arg1210Cys variant was previously 
found to be highly associated with AMD in North American cohorts, with a frequency in 
AMD patients of 40/2423 (1.65%) 10 and 23/2335 (0.99%),9 respectively. However, the 
p.Arg1210Cys variant was not detected in an Icelandic cohort (consisting of 1143 AMD 
patients) nor in a Han Chinese cohort (consisting of 258 AMD patients).11, 12 
The current study suggests that the p.Arg1210Cys variant may be restricted to a 
subset of AMD patients with CD. Since the cohort of CD patients analyzed in our study 
was too small to reliably test for an association, this finding would need to be confirmed 
in additional cohorts of patients with CD, and/or by detailed clinical phenotyping of AMD 
patients carrying the p.Arg1210Cys variant using FA. An under or overrepresentation of 
AMD patients with CD-like characteristics between cohorts might explain the observed 
discrepancy of the p.Arg1210Cys association between the North American,10 Icelandic,11 
Han Chinese,12 and the Dutch-German cohorts. On the other hand it is well-known that the 
distribution of low-frequency alleles varies among populations, since they tend to be the 
result of recent mutation and are expected to geographically cluster around the location 
at which the mutation first arose.16 Indeed, the frequency of disease-causing variants can 
significantly differ among populations ,17 or can even be restricted to a geographical region.18 
The CFH protein is an important regulator of the alternative pathway of the complement 
cascade that plays a key role in clearance of pathogens and immune complexes, and 
modulates adaptive immunity.19 CFH is composed of 20 sequential complement control 
protein (CCP) domains (Figure 3.5.2). Five of the identified rare variants (p.Ala161Ser, 
p.Ala173Gly, p.Arg175Gln, p.Ser193Leu and p.Ile216Thr) are clustered within the N-terminal 
domains CCPs 1-4. This region has been demonstrated to be involved in cofactor activity 
,20 suggesting that these variants potentially have an impact on CFH cofactor activity. Two 
variants, p.Trp379Arg and p.Gln400Lys, are located within the CCP6 and CCP7 domains 
respectively, close to the common p.Tyr402His 21 AMD risk variant which is known to cause 
defective heparin binding properties.20 This raises the possibility that these variants may 
exert a similar effect. Three variants (p.Gln950His, p.Thr956Met and p.Arg1210Cys) are 
clustered in the C-terminal CCP domains 16-20. Functional studies have demonstrated that 
these four C-terminal CCP domains are necessary for host cell recognition or discrimination 
properties of CFH.22 In addition, we identified one frameshift (p.Ala301Asnfs*25) variant 
and one splice-acceptor site (428-2A>G) variant, which are both predicted to abolish CFH 
function. 
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Figure 3.5.2 Schematic representation of factor H and its functional domains. Factor H is composed 
of 20CCP domains, and the approximate locations of missense variations are indicated on top of the 
diagram. The location of binding sites for C3b in black, cofactor activity in purple, heparin in orange, 
sialic acid in green, and self-surface recognition in blue bars, are mentioned below.
Notably, not all missense variants identified in this study were predicted to be pathogenic 
by SIFT and PolyPhen. In particular this is the case for the p.Arg1210Cys variant, which 
was not predicted to be deleterious or damaging by either algorithm. However, functional 
studies demonstrate that the p.Arg1210Cys variant compromises CFH function, as the 
mutant protein exhibits defective binding to C3d, C3b, heparin, and endothelial cells, and 
forms a covalent interaction with human serum albumin.10, 23-26 Therefore it should be noted 
that although prediction software tools like SIFT and PolyPhen may assist in the assessment 
of potential damaging rare variants, functional validation of CFH mutant proteins is needed 
in order to properly assess the functional consequence of these genetic variations. 
The majority of identified variants were not present in public databases, nor have they 
previously been linked to other diseases, demonstrating that many CFH variants are novel 
and unique for individual patients. The number of carriers of rare variants is significantly 
higher in CD patients than the number of carriers in the general population (EVS) (P = 
0.008). The carriers of rare CFH variants displayed an earlier age at onset than non-carriers 
(P = 0.016). This underlines the importance of sequence analysis of the entire CFH coding 
region and splice junction of the CFH gene to identify the causative allele, in particular in 
individuals with the CD subtype of AMD. The p.Arg1210Cys variant has previously been 
demonstrated to confer a high risk of developing AMD,10 underscoring its pathogenicity. 
However, two CFH variants were recently identified in a large scale sequencing study, and 
were found not to be associated with the disease: p.Glu950His was identified in 9/3343 
AMD patients and 10/1480 controls (P = 0.98), p.Thr956Met was identified in 4/3348 
AMD patients and 6/1484 controls (P = 0.99).27 This implies that these alleles may not be 
causative for AMD. Interestingly, four of the identified variants (p.Gln400Lys, p.Gln950His, 
p.Thr956Met and p.Arg1210Cys) were previously reported in patients with atypical 
haemolytic uremic syndrome (aHUS), a devastating renal disease, supporting a previously 
proposed theory that an allelic overlap exists between two distinct pathologies, AMD and 
aHUS.28-30 CD patients carrying aHUS mutations did not have renal complaints at the time 
of recruitment (Table 3.5.5). This suggests that additional genetic variants and/or external 
triggers determine the disease outcome in individuals carrying these alleles. 
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In conclusion, the present study identified the presence of rare variants in the CFH gene 
in 16 (8.8%) of 180 patients with the CD subtype of AMD. The carriers of rare CFH variants 
displayed an earlier age at onset than non-carriers (P = 0.016). A previously reported rare 
missense variant, p.Arg1210Cys, was identified in two CD cases, but was not detected in 
813 non-CD type AMD cases and 1175 controls of our Dutch-German cohort. The current 
study suggests that the p.Arg1210Cys variant may be restricted to a subset of AMD patients 
with CD. Detailed clinical phenotyping, including fluorescein angiography, of AMD patients 
carrying the p.Arg1210Cys variant in other cohorts is required to confirm this finding. 
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Chapter 4
Dominant cystoid macular dystrophy
Dominant cystoid macular dystrophy
 
N.T.M. Saksens, R.A.C. van Huet, J.J. van Lith-Verhoeven, 
A.I. den Hollander, C.B. Hoyng, C.J.F. Boon
 
Published in: Ophthalmology 2015;122:180-191 
PURPOSE. Retrospective case series to describe the clinical characteristics and long-term 
follow-up in patients with autosomal dominant cystoid macular dystrophy (DCMD).
METHODS. Extensive ophthalmic examination, including visual acuity (VA), fundus 
photography, fluorescein angiography (FA), fundus autofluorescence (FAF) imaging, optical 
coherence tomography (OCT), color vision testing, dark adaptation testing, full-field 
electroretinography (ERG), and electro-oculography (EOG) in ninety-seven patients with 
DCMD. Blood samples were obtained for DNA extraction and subsequent haplotype analysis. 
Main outcome measures are age at onset, VA, fundus appearance, and characteristics on 
FA, FAF, OCT, ERG, and EOG.
RESULTS. Cystoid fluid collections (CFCs) were the first retinal abnormalities detectable in 
DCMD, developing during childhood. At long-term follow-up, the CFCs decreased in size 
and number, and eventually disappeared with concurrent development of progressive 
chorioretinal atrophy and hyperpigmented deposits in the posterior pole. Dominant 
cystoid macular dystrophy could be classified into 3 stages, based on characteristics on 
ophthalmoscopy, FAF, FA, and OCT, as well as on results of electrophysiologic analysis. The 
staging system correlated with age and VA. In stage 1 DCMD (20 patients; 22%), patients 
generally were younger than 20 years and had CFCs with fine folding of the internal limiting 
membrane and mild pigment changes. In stage 2 DCMD (48 patients; 52%), the CFCs tended 
to decrease in size, and moderate macular chorioretinal atrophy developed. Patients with 
stage 3 DCMD (24 patients; 26%) generally were older than 50 years and showed profound 
chorioretinal atrophy, as well as coarse hyperpigmented deposits in the posterior pole. 
Most patients were (highly) hyperopic (72 patients; 92%). All DCMD patients shared the 
disease haplotype at the DCMD locus at 7p15.3.
CONCLUSIONS. Dominant cystoid macular dystrophy is a progressive retinal dystrophy, 
characterized primarily by early-onset cystoid fluid collections in the neuroretina, which 
distinguishes this disorder from other retinal dystrophies. The phenotypic range of DCMD 
can be classified into 3 stages. The genetic locus for this retinal dystrophy has been mapped 
to 7p15.3, but the involved gene is currently unknown.
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INTRODUCTION
Dominant cystoid macular dystrophy (DCMD) is an autosomal-dominantly inherited retinal 
disorder that primarily affects the macula.1, 2 A hallmark feature and presenting symptom 
of DCMD is the appearance of cystoid intraretinal fluid collections (CFCs) in the macula 
that resemble cystoid macular edema before any other visible retinal abnormalities appear. 
The onset of these CFCs is generally in the first or second decade of life. Most patients 
with DCMD have moderate to high axial hyperopia.3-5 As the disease progresses, the CFCs 
diminish, and progressive central vision loss develops between 20 and 50 years of age as a 
result of progressive chorioretinal atrophy.1, 5
DCMD has been linked to a genetic interval on chromosome 7p15-p21,6 but the 
causative gene has not been identified to date. DCMD has also been abbreviated as CYMD 
(OMIM 153880). In the Netherlands, one large family with DCMD is known and extensive 
genealogical studies revealed a common Dutch ancestor, who supposedly lived in the 
early 18th century.4 In addition to this large Dutch family, one unrelated American family 
of Greek ancestry,7 and an American and a Spanish patient,8 have been described with 
presumed DCMD.7, 9 
Little is known about the spectrum and variability of fundus abnormalities in DCMD, 
as well as the visual outcome. We report the clinical characteristics and follow-up data 
of the large Dutch DCMD family with 97 affected family members. Based on multimodal 
imaging and electrophysiological studies, we propose a clinical classification system for 
DCMD in 3 stages. In addition, we evaluate the therapeutic options and discuss a possible 
pathophysiologic disease sequence.
METHODS
Clinical Assessment 
This study included 97 patients with DCMD, who were all examined at the Institute of 
Ophthalmology of the Radboud University Medical Center (Nijmegen, the Netherlands) 
between October 1958 and August 2013. All patients belong to one large pedigree, 
descending from one common Dutch ancestor (Figure 4.1).4 Most patients originated from 
the southeast region of the Netherlands. Patients received the diagnosis of DCMD based 
on the aspect of the lesions on ophthalmoscopy, fluorescein angiography (FA) and optical 
coherence tomography (OCT).4 In addition, genealogical research and haplotype analysis 
confirmed the diagnosis DCMD. 
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Figure 4.1 Diagram showing that all dominant cystoid macular dystrophy patients in the Netherlands 
belong to one large pedigree with a common ancestor.
The medical history, age at onset, (best-corrected) Snellen visual acuity (VA), 
fundus appearance, including slit-lamp examination, fundus examination by indirect 
ophthalmoscopy, and fundus photography, as well as results of electrophysiological testing 
were retrieved from medical records. To analyze the course of the VA over time, we recorded 
the age at which the decrease in VA exceeded 20/40, 20/60, and ≤ 20/200 for survival 
analyses. Fundus autofluorescence (FAF) imaging was performed with a confocal scanning 
laser ophthalmoscope (Spectralis; Heidelberg Engineering, Heidelberg, Germany; excitation 
light 488 nm). FAF follow-up images were available in 9 patients. Based on ophthalmoscopy, 
autofluorescence, or both, mild atrophy of the retinal pigment epithelium (RPE) was defined 
as indistinct granular hypopigmented RPE changes, and profound atrophy was defined as 
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sharply demarcated areas of chorioretinal atrophy in the macula, corresponding with a 
decrease and absence of autofluorescence. Spectral-domain OCT (Spectralis™, Heidelberg 
Engineering, Heidelberg, Germany) was performed using the ‘Macular Thickness Map’ 
protocol provided by the manufacturer (Heidelberg Eye Explorer Software, version 1.6.4.0; 
Heidelberg Engineering, Heidelberg, Germany). Follow-up OCT scans were available in 
14 patients to detect progression of retinal changes. Follow-up FA data were available in 
29 of them. In addition electro-oculography (EOG), full-field electroretinography (ERG), 
visual field analysis by means of Goldmann perimetry (stimuli V4e-III4e-I4e-I3e-I2e-I1e), 
dark adaptation, and color vision testing were performed in selected patients as described 
previously (Table 4.1).10 Altogether, follow-up data were available in 71 DCMD patients. 
Furthermore, 10 DCMD patients were invited for an additional, extensive clinical examination 
to complete the follow-up data, resulting in a better appreciation of the disease course 
and characteristics. EOG and full-field ERG recordings were performed according to the 
standards of the International Society for Clinical Electrophysiology of Vision (ISCEV).11-13 
EOG Arden ratios were registered and stratified as normal (≥1.8), mildly reduced (<1.8, 
but ≥1.5), or severely reduced (<1.5). Full-field ERG was defined as normal (equal to or 
above the lower 5% of the range for a normal population: photopic ≥78 µV, scotopic ≥263 
µV), subnormal in case of moderately reduced amplitudes of the B-wave (1-5% of normal 
range: photopic ≥69 µV and <78 µV, scotopic ≥195 µV and <263 µV) or as abnormal in case 
of severely reduced amplitudes (<1% of normal range: photopic <69 µV, scotopic <195 
µV). The study adhered to the tenets of the Declaration of Helsinki, and Ethics Committee 
approval was obtained. Informed consent was received from all examined subjects.
Haplotype Analysis
Peripheral venous blood samples were obtained from 69 patients for analysis of the 
haplotypes at the previously described DCMD locus.6 The haplotypes at the DCMD locus 
were also determined in 52 unaffected family members. The genomic DNA was isolated 
as described elsewhere.14 Haplotype analysis was performed with microsatellite markers 
(D7S493 and D7S673) surrounding the genetic locus located at 7q15-p21. 
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RESULTS
Clinical Findings
General characteristics
The study cohort included 97 patients, of which 55 were female (57%) and 42 male (43%), 
as well as 52 unaffected family members. The age at the first visit of the DCMD patients 
to our department ranged from 1 month to 72 years (median: 27 years). The mean age at 
onset of visual symptoms was 12.9 years (range: 2–45 years), and showed a remarkable 
trend of a lower age at onset in younger generations (P = 0.02). At first presentation, the 
fundus aspect ranged from no abnormalities or only an absence of the foveal reflex and 
mild pigment changes in the fovea (Figure 4.2A) to profound chorioretinal atrophy with 
extensive hyperpigmentation in the posterior pole (Figure 4.2M).
All patients experienced a certain degree of central vision loss, with a progressive 
decline, but the course of the VA loss was highly variable among patients as shown in Figure 
4.3. The age at which patients reached the level of legal blindness (VA ≤20/200) in the better 
eye, despite optimal refractive correction, varied widely from 10 to 65 years (median: 43.5 
years). Two patients (2%) became totally blind (no light perception) in 1 eye, at the age of 
58 and 73, respectively, due to serous retinal detachment that resulted in phthisis bulbi 
despite several vitreoretinal procedures. In addition to vision loss, 7 patients (7%) reported 
difficulties with night vision, and 5 patients (5%) with advanced disease experienced (para)
central scotoma. Four female patients (7%) noticed a more rapid and irreversible visual 
decline during hormonal events, like first menarche, pregnancy, and menopause. 
Hyperopia was a frequent finding in DCMD patients. Information about the refractive 
error of the eye was available in 78 patients, of which 72 had hyperopia at presentation, 
with a mean hyperopic refraction of +5.78 diopters (D, range of spherical equivalents (SE): 
+1.00 to +13.00 D), of which 30 patients (38%) were highly hyperopic (SE ≥+6.00 D). The 
axial length measurements were available in 24 eyes of 12 patients, performed with A-scan 
ultrasound measurement. In all cases, the axial length was significantly below normal 
(mean: 19.6 mm; range: 18.6–21.0 mm). 
Acute angle-closure glaucoma occurred in 6 patients (6%), at a mean age of 48 years 
(range: 42-58 years). Although normal intraocular pressure could be accomplished by either 
topical treatment, laser intervention, surgical treatment or a combination, all 6 patients 
experienced irreversible vision loss. In 1 patient with acute angle-closure glaucoma, laser 
iridotomy and iridectomy treatment had insufficient effect. Finally, this patient received a 
Baerveldt tube implant which resulted in hypotonia, causing a serous retinal detachment. 
This was treated with pars plana vitrectomy with oil tamponade and laser treatment. The 
retina eventually redetached, resulting in complete blindness with phtisis bulbi leading 
to evisceration of this eye. The other eye was treated preventively with laser iridotomy 
resulting in a prolonged normal intra-ocular pressure. One patient with a narrow anterior 
chamber angle was treated preventively with phaco-emulsification, but nevertheless acute 
glaucoma developed in 1 eye.
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Figure 4.2 Clinical classification of dominant cystoid macular dystrophy (DCMD) into 3 stages. A-F 
Stage 1 DCMD. G-L Stage 2 DCMD. M-R Stage 3 DCMD. (A) Color fundus photograph of a 15-year-
old patient with stage 1 DCMD (visual acuity 20/63; spherical equivalent (SE) +4.00 diopters (D), 
subjectively fluctuating vision for 4 years), showing cystoid fluid collections (CFCs) and fine pigment 
changes in the macula. (B) Fluorescein angiography (FA, early phase) showing mild hyperfluorescence 
of the foveal fluid collections. (C) FA (late phase) showing hyperfluorescent CFCs located in the fovea 
and more diffuse hyperfluorescence in the macula. (D) Fundus autofluorescence (FAF) showing areas 
of mildly increased autofluorescence at the cystoid areas and diffuse hyperautofluorescence within 
the vascular arcades. (E) Horizontal optical coherence tomography (OCT) scan through the fovea 
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(scanning plane indicated by black arrow head in A) showing CFCs in the inner and outer nuclear 
layer. (F) Six months before, only some small CFCs were visible on OCT at the same level as in E, 
demonstrating the fluctuating course of the CFCs without any treatment intervention. (G) Color fundus 
photograph of a 32-year-old patient with stage 2 DCMD (visual acuity 20/100, SE +1.50 D), showing 
pigment changes in the macula and mild residual CFCs. (H-I) FA showing a central hyperfluorescent 
lesion caused by an retinal pigment epithelium (RPE) window defect and residual edema in the early 
(H) and late (I) phase, surrounded by mild, indistinct hyperfluorescence. (J) FAF showing moderately 
decreased autofluorescence in the central macula, corresponding with atrophy of the RPE in the 
fovea on OCT (K) at the level of the black arrowhead in G. (L) A horizontal OCT scan through the 
scanning plane indicated by the white arrowhead in G, showing possible mild thickening of the outer 
nuclear layer but an RPE layer that seemed largely intact. (M) Color fundus photograph of a 67-year-
old patient with stage 3 DCMD (visual acuity 20/800; SE +7.00 D), showing profound chorioretinal 
atrophy in the macula with attenuated arterioles and coarse hyperpigmentations. (N-O) Early (N) 
and late (O) phase FA showing early hypofluorescence and some late staining in the deeply atrophic 
central macula, encircled by hyperfluorescence that seems to be diffuse edema, extending beyond the 
vascular arcade and optic nerve. (P) FAF showing a large area of markedly decreased autofluorescence 
as a result of RPE atrophy in and beyond the macula. (Q) Horizontal OCT scan (scanned through plane 
indicated by black arrowhead in M) showing chorioretinal atrophy in the macula, with hyperreflective 
lesions consistent with the hyperpigmentations on color fundus photograph (M). (R) Vertical OCT scan 
through the fovea of the fellow (right) eye showing marked attenuation of the outer photoreceptor 
and RPE layers, although there appears to be a certain degree of persistent thickening of the inner and 
outer nuclear layer centrally in the macula.
Figure 4.3 Kaplan-Meier survival curves of visual acuity (VA) of >20/40 (a threshold of visual disability, 
according to the United States definition reflecting the legal inability to drive a car); VA>20/60 (a 
cutoff point for low vision defined by the World Health Organization criteria associated with increasing 
difficulties in reading without visual aids); VA≥20/200 (a threshold of legal blindness according to 
World Health Organization criteria) related to the age. The median age at which the VA in our cohort 
exceeded 20/40, 20/60, and decreased to 20/200 or less were, 34, 45, and 57 years, respectively. 
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Disease Spectrum and Clinical Classification
The spectrum of retinal abnormalities in this DCMD cohort could be subdivided generally 
into 3 stages by an experienced retina specialist (C.J.F.B.) based on ophthalmoscopy and 
supported by the findings obtained from multimodal imaging (Table 4.1). These 3 stages 
were delineated by analyzing ophthalmoscopic findings in combination with FA, FAF, and 
SD-OCT, which were available in 92 DCMD patients.
Stage 1 DCMD (20 patients, 22%; Table 4.1) was characterized by wrinkling of the internal 
limiting membrane, CFCs and mild granular pigment changes in the macula (Figure 4.2A). 
The CFCs were visible as mildly hyperautofluorescent areas in the fovea and perimacular 
area on fundus autofluorescence (Figure 4.2D); on OCT the CFCs were located in the 
inner and outer nuclear layer of the retina (Figure 4.2E). FA clearly showed an aspect of 
hyperfluorescent cystoid macular edema, and in 60% evidence of mild perifoveal capillary 
dilation was seen (Figure 4.2B and C). In 14 patients (70%) the CFCs gradually increased 
in size, number, and extent during follow-up, affecting the entire posterior pole. However, 
during this progression the degree of CFCs was highly variable, corresponding with intra-
individual variability of the VA (Figure 4.2E-F and Figure 4.4A-E). 
In addition to the CFCs, in two patients with stage 1 DCMD, the OCT also showed a 
serous detachment of the neuroretina with a fluctuating course. The mean VA was 20/37 
and decreased to less than 20/125 in only 4 patients (20%). In one patient with stage 1 
DCMD and large CFCs who had a VA of 20/200, the VA recovered to 20/50 after remission 
of the cysts by treatment with acetazolamide. 
In stage 2 DCMD (48 patients, 52%; Table 4.1), the CFCs tended to become progressively 
smaller over time (Figure 4.2K). Unlike stage 1 DCMD, only 5 cases showed evidence of 
perifoveal capillary dilatation on FA. Mildly atrophic lesions appeared in the macula, with a 
corresponding decrease in VA (Figure 4.2G, J and K). 
In stage 3 DCMD (24 patients, 26%; Table 4.1), the macula was affected by profound 
chorioretinal atrophy (Figure 4.2M-R). In the macula and mid-peripheral retina, multiple 
coarse hyper-pigmentations were present in all patients, who also showed attenuated 
arterioles in varying degrees (Figure 4.2N). In this advanced disease stage, CFCs were no 
longer present on OCT (Figure 4.2Q and R). A variable degree of small whitish punctate 
deposits in the vitreous were seen in stage 2 and 3 DCMD. 
The VA decreased to the level of legal blindness in 18 patients (75%) with stage 3 DCMD. 
Most patients (88%) were above the age of 50 years. The majority (77%) of the full-field 
ERG results were abnormal without selective cone or rod impairment in stage 3 DCMD 
(Figure 4.5). The EOG and full-field ERG results in all stages are depicted in Table 4.1.
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Figure 4.4 Follow-up of 2 dominant cystoid macular dystrophy (DCMD) patients with cystoid fluid 
collections (CFCs) on time-domain (A) or spectral-domain (B-J) optical coherence tomography (OCT). 
(A-E) Patient with stage 1 DCMD and fluctuation of CFCs without treatment over 7 years. The OCT 
follow-up data of the left eye shows the fluctuating natural course of CFCs. (A) At 8 years of age, 
OCT clearly showed moderate CFCs in the inner and outer nuclear layers without visual symptoms 
(visual acuity (VA): 20/20; spherical equivalent (SE) +4.00 diopters (D)). During the ensuing years, she 
experienced vision loss with fluctuating vision. (B) At the age of 11, no fluid collections were present 
on OCT, but fundoscopy showed fine pigment changes in the fovea with some wrinkling of the internal 
limiting membrane. The patient experienced fluctuating vision for 1 year (VA in this eye 20/40). (C) 
Two months after image B was obtained, mild CFCs recurred and her visual complaints increased 
(VA decreased to 20/63). (D) Three years after image C was obtained, the CFCs and vision symptoms 
decreased, whereas the VA increased to 20/50. (E) Five months after the image D was obtained, 
extensive and large CFCs recurred, associated with vision loss (VA: 20/63). (F-J) Stage 1 DCMD patient 
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treated with octreotide-acetate (20 mg intramuscular monthly) and oral acetazolamide (250 mg 1-4 
times a day), reducing the CFCs and showing a possible dose-dependent effect of acetazolamide on 
OCT follow-up of 1 year. (F) Nineteen-year-old patient with late stage 1 DCMD with mild CFCs causing 
visual complaints before starting treatment (VA: 20/25; SE +3.25 D). (G) One year later, despite 
treatment with monthly intramuscular octreotide-acetate injections (20 mg) and oral acetazolamide 
125 mg twice daily either separately or combined, CFCs increased with loss of vision (VA: 20/50). (H) 
Increasing the dose of acetazolamide to 250 mg three times a day, in addition to octreotide-acetate 
treatment, resulted in a significant decrease of CFCs within 2 weeks, with an increase of the VA to 
20/32. (I) The CFCs increased markedly within 2 weeks after lowering the dose of acetazolamide to 
250 mg twice a day, with a corresponding vision loss (VA: 20/80). (J) Raising the dose of acetazolamide 
to 250 mg four times daily resulted in a significant resolution of the CFCs within the next 2 weeks, with 
an increase in VA to 20/50.
Figure 4.5 Representative full-field electroretinograms (ERGs) of 3 patients with dominant 
cystoid macular dystrophy (DCMD), showing normal, subnormal and abnormal results of 
the rod, rod and cone, cone, and 30-hertz flicker ERG. (Left) Normal full-field ERG results in a 
15-year-old patient with stage 1 DCMD (visual acuity (VA): 20/50; spherical equivalent (SE) 
+4.25 diopters (D)). (Middle) Subnormal cone and rod driven responses on full-field ERG in a 
67-year-old patient with stage 3 DCMD (VA: 20/800; SE +7.25 D). (Right) Abnormal photopic 
and scotopic full-field ERG in a 58-year-old patient with stage 3 DCMD (VA: 1/200; SE +4.00 D). 
Hz = hertz; ms = milliseconds; μV = microvolts.
An atypical phenotype was seen in 4 patients with stage 3 DCMD (17%). In 2 patients 
(8%) a phenotype reminiscent of Coats’ disease developed at the age of 56 and 61, 
respectively, consisting of an exudative serous retinal detachment with RPE atrophy and 
coarse hyperpigmentations (Figure 4.6A and B). Furthermore, two patients (44 and 57 
years) originating from two different branches of the pedigree, showed a retinal phenotype 
similar to end-stage retinitis pigmentosa, with attenuated arterioles, peripheral pigment 
changes resembling bone spicules, a waxy-pale optic disc, in addition to advanced 
chorioretinal atrophy in the posterior pole (Figure 4.6C and D). Both patients showed 
fundoscopic signs of CFCs in their childhood. These two patients had difficulties with night 
vision, with markedly abnormal dark adaptation and marked constriction of the peripheral 
visual field on Goldmann perimetry. Full-field ERG showed no scotopic response and a 
decreased photopic response corresponding to a rod-cone dystrophy dysfunction pattern. 
Both patients had a subnormal EOG with mildly reduced Arden ratios. Both patients shared 
the genetic DCMD locus, and their affected parents showed a typical DCMD phenotype 
without these retinitis pigmentosa-like features.
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Figure 4.6 Atypical cases of dominant cystoid macular dystrophy (DCMD). (A-B) Coats-like exudative 
abnormalities in a 62-year-old DCMD patient (visual acuity (VA): light perception; spherical equivalent 
(SE) +4.25 diopters (D)). (A) Composite color fundus photograph showing a serous retinal detachment 
with exudates superior to the upper vascular arcade and temporal pigment accumulations mimicking 
bone spicules. This patient experienced vision loss at the age of 30 years, with cystoid fluid collections 
(CFCs) in the macula. (B) Horizontal optical coherence tomography (OCT) scan through the scanning 
plane indicated by the black arrowhead in A, showing retinal atrophy and a mild epiretinal membrane. 
(C-D) Retinitis pigmentosa-like phenotype in a 44-year-old patient with stage 3 DCMD (VA 20/63; SE 
+7.00 D), who also experienced night blindness and constriction of the peripheral visual fields. (C) 
Composite color fundus photograph, showing peripheral bone-spicule-like pigment changes, a waxy-
pale optic disc, attenuated arterioles, and chorioretinal atrophy. Vision loss started at the age of 7 with 
fundoscopic foveal pigment changes and wrinkling of the internal limiting membrane. Because of loss 
of follow-up, no findings of CFCs are available, but in that period of time he experienced fluctuating 
vision loss. (D) OCT scan through the fovea (black arrowhead in C) showing retinal pigment epithelium 
atrophy in the macula with some structural sparing of the fovea.
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The different stages of DCMD correlated significantly with age (r=0.871; P < 0.001), 
VA (r=-0.562; P <0.001), EOG test results (r=-0.404; P <0.001) and ERG findings (r=-0.590; 
P <0.001) (Table 4.1). During progression of the disease, electrophysiological testing became 
more abnormal and constriction of the peripheral visual field developed in stage 2 and stage 
3 DCMD. Of the 16 patients with stage 2 DCMD, 1 patient (6%) showed no abnormalities, 
11 patients (69%) demonstrated small central absolute scotomata / sensitivity loss, and 4 
(25%) patients showed sensitivity loss of the central retina with mild constriction of the 
peripheral visual field (40-50° nasal and 60-80° temporal for the II4e isopter). All stage 
3 DCMD patients showed central absolute scotomata (15° for the V4e isopter) of which 
5 patients (63%) additionally showed a moderate constricted peripheral visual field in 
Goldmann perimetry (25-45° nasal and 45-65° temporal for the III4e isopter and 0-25° nasal 
and 30-35° temporal for the I4e isopter) and 2 (25%) presented with nyctalopia. These were 
the 2 patients with the retinitis pigmentosa-like phenotype (Figure 4.4C).
In all DCMD stages, dark adaptation testing could be normal as well as abnormal, but 
abnormal test results were most often present in DCMD stage 3 (6/8; 75%). In stage 1 and 
2 only 38% (3/8) and 33% (6/18), respectively, has an abnormal dark adaptation. From 
the 15 patients with abnormal dark adaptation, 8 underwent Goldmann perimetry, which 
revealed a constricted peripheral visual field in 3 patients (38%), who also had pigment 
lesions in their peripheral retina. Abnormalities of color vision testing were seen in all 
DCMD stages, ranging from anomaloscopic diminished red-sensitivity in stage 1 (35%), to 
an acquired blue-yellow defect in stage 2 (76%) and 3 (100%), with an additional red-green 
defect when fixation became eccentric in 10/13 stage 3 DCMD patients (77%).
Follow-up
Follow-up data were available for 71 patients, with a mean follow-up time of 17 years 
(range: 0.5-44 years). Fifteen patients (21%) progressed from stage 1 to stage 2 after a mean 
follow-up time of 17 years (range: 4-28 years) and 9 patients (13%) progressed from stage 
2 to stage 3 after a mean time of 23 years (range: 10-35 years) (Figure 4.7). Additionally, 
a progression from stage 1, via stage 2, to stage 3 was observed in 3 patients (4%) after a 
mean time of 32 years (range: 29-34 years). 
The degree of CFCs was observed to decrease progressively with advancing disease 
stages, while chorioretinal atrophy and pigmentary abnormalities concurrently became 
more pronounced. Visual acuity, EOG and full-field ERG data of patients who progressed 
from one stage of DCMD to the next stage are summarized in Table 4.2. 
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Figure 4.7 Long-term follow-up of dominant cystoid macular dystrophy (DCMD). (A-D) Follow-up 
images showing (A-B) progression during stage 2 DCMD and (C-D)progression to stage 3 DCMD. (A) 
Color fundus photograph of a 35-year-old patient with early stage 2 DCMD, (visual acuity (VA) 20/160; 
spherical equivalent (SE) +7.00 diopters (D)) showing pigmentary changes of the retinal pigment 
epithelium (RPE) and some small cystoid fluid collections (CFCs). At the age of 7 years, vision loss 
started and pigmentary changes and CFCs were seen. (B) Ten years later, a central atrophic lesion 
developed with absence of CFCs. (C-D) Follow-up color fundus photographs showing progression 
from stage 2 to stage 3 DCMD. (C) Color fundus photograph of a 38-year-old patient with stage 
2 DCMD (VA 20/100; SE +5.50 D), showing mild atrophic hypopigmentation and a central spot of 
hyperpigmentation. (D) Thirty-five years later, a progression to profound chorioretinal atrophy with 
marked hyperpigmentations and some arteriolar attenuation was seen. The VA at this stage was 
20/400.
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Table 4.2 Follow-up results of patients who progressed to another stage of dominant cystoid 
macular dystrophy
Stage 
progression
Stage VA EOG* Full-field ERG †
Mean Normal Mildly 
reduced
Severely 
reduced
Normal Subnormal Abnormal
1  2 1 20/25 6/8 2/8 0/8 2/2 0/2 0/2
2
20/63
2/8 5/8 1/8 2/2 0/2 0/2
2  3 2 0/9 6/9 3/9 2/5 2/5 1/5
3 20/300 0/9 3/9 6/9 0/5 0/5 5/5
Abbreviations: EOG = electro-oculography; ERG = electroretinography
* EOG Arden ratios were stratified as normal (≥1.8), mildly reduced (<1.8, but ≥1.5), or severely 
reduced (<1.5). 
† Full-field ERG was defined as normal in case of normal amplitudes of the B-wave (photopic: >78 mV, 
scotopic: >263 mV), subnormal in case of moderately reduced amplitudes (photopic: ≥69 µV and <78 
µV, scotopic: ≥195 µV and <263 µV) or as abnormal in case of severely reduced amplitudes (photopic: 
<69 µV, scotopic: <19).
Treatment
During the natural course of DCMD stage 1 and 2, the degree of CFCs varied largely over time 
in 26 patients (mean follow-up: 18 years; range 4-43 years) (Figure 4.4A-E), but the fluid 
collections could also be influenced by treatment (Figure 4.4F-J). In an attempt to reduce 
the CFCs, 16 patients with stage 1 or 2 DCMD used acetazolamide, a carbonic anhydrase 
inhibitor, generally for several years (mean 40 months; range 2-221 months). In 10 of these 
patients (63%), oral administration of acetazolamide for several years (mean 56 months; 
range 2-221 months) seemed to result in a reduction of CFCs on OCT, with an improvement 
of the VA (mean VA from 20/46 to 20/35). In 2 patients (13%), the treatment resulted in 
reduction of CFCs without VA improvement. The daily dose in which a significant reduction 
of CFCs was seen on OCT ranged from 125 mg twice daily to 250 mg four times daily. 
Octreotide-acetate, a somatostatin analogue assumed to promote the removal of 
intraretinal edema across the RPE,15 was used in 16 patients with stage 1 or 2 DCMD for 
several years (mean 68 months; range 6-151 months). In 12 patients (75%), octreotide-
acetate administered 20 mg intramuscular monthly for several years (mean 84 months; 
range 14-151 months) seemed effective in reducing CFCs and improving the VA with a 
mean increase in VA of 20/125, but in two patients (13%) side effects like nausea, diarrhea, 
fatigue and cholelithiasis were present, resulting in cessation of this treatment in 1 patient. 
Four patients (25%) treated with octreotide-acetate stopped the treatment because of the 
lack of effect on VA. In 3 of them, no effect on CFCs was detectable on OCT. 
During six years of follow-up, in three patients with stage 1 DCMD who were treated, 
the mean VA increased from 20/34 to 20/25, whereas in four patients with stage 1 DCMD 
who were not treated, the mean VA decreased from 20/29 to 20/35. In stage 2 DCMD 
patients, the mean VA decreased from 20/51 to 20/67 in 12 treated patients with a follow-
up of 17 years and in 12 untreated patients, the mean VA decreased from 20/54 to 20/87 
during 15 years of follow-up.
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Haplotype Analysis
Linkage analysis previously showed that DCMD is linked to the interval D7S493 – D7S526 
at 7p15-p21,6 but the disease-associated gene and mutation have not yet been identified. 
In 69 of the 97 clinically affected DCMD patients (71%), the haplotypes at the DCMD locus 
were analyzed, and all carried the disease-associated haplotype. The genetic DCMD locus 
seemed to be completely penetrant. Haplotype analysis in the 52 clinically unaffected family 
members revealed the absence of the DCMD haplotype in all. One DCMD patient with the 
genetic DCMD locus was also tested for the BEST1 gene, but he showed no mutations in 
this gene. 
DISCUSSION
Clinical characteristics and staging of dominant cystoid macular dystrophy
Dominant cystoid macular dystrophy is a unique retinal dystrophy, because the appearance 
of CFCs in the macula is the first and most prominent abnormality at the onset of the 
disease, resembling cystoid macular edema.16 The spectrum of severity of DCMD ranges 
from an absence of the foveal reflex with mild CFCs and some pigment changes in the 
macula early in the course of the disease, to profound chorioretinal atrophy in the posterior 
pole in the late stage of DCMD. In this study, we propose a clinical classification system 
for DCMD into three stages. This classification system is based on ophthalmoscopy and 
multimodal imaging, and correlates well with age, VA and results on EOG and full-field ERG 
(Table 4.1). We observed an evolution of DCMD through the proposed stages, supporting 
that DCMD is a progressive disease. 
The age at onset of visual symptoms in DCMD is generally in childhood, but seems 
to vary depending on the generation. The apparently earlier age at onset in more recent 
generations may be due to an increased awareness and earlier screening of younger family 
members as a result of their affected father or mother.
All patients show a gradual decrease in VA, and most progress to visual disability at a 
relatively early age. In advanced DCMD, the VA generally evolves to finger counting (20/800), 
or even worse when relatively rare complications such as serous retinal detachment or 
acute angle-closure glaucoma occur. Due to the short axial length of the eye, glaucoma 
can accompany the retinal abnormalities, and (high) hyperopia is present in most DCMD 
patients, similar to other retinal dystrophies such as the bestrophinopathies which are 
caused by mutations in the BEST1 gene.17, 18 
The finding that EOG abnormalities generally preceded photopic and scotopic dysfunction 
on full-field ERG indicates that impaired RPE function occurs earlier in the course of DCMD, 
whereas the panretinal photoreceptor function is affected later in the disease.1 Because 
half of the stage 1 DCMD patients with macular CFCs had normal EOG results, primary 
panretinal RPE dysfunction with dysfunctional ionic homeostasis, as observed in BEST1-
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related dystrophies such as Best vitelliform macular dystrophy and autosomal recessive 
bestrophinopathy,17 is presumably not present in DCMD. Presence of primary CFCs without 
reduced EOG might be explained by primary dysfunction of a cell population other than the 
RPE and photoreceptors, such as the Müller cells.
In addition to the large DCMD family described in the present study, two cases and 
one small family with features of DMCD have been described.7-9 The clinical findings of a 
Spanish patient with presumed DCMD are consistent with DCMD stage 2.9 In an American 
DCMD family from Greek ancestry,7 the EOG results in affected patients were normal, and 
none of the examined children of affected family members, 10 to 18 years of age, showed 
any abnormalities. This does not support an autosomal dominant mode of inheritance, and 
rather suggests a different disease than the typical DCMD phenotype observed in our large 
Dutch family.
Differential diagnosis
Several other retinal diseases with early-onset CFCs should be considered in the differential 
diagnosis of DCMD, such as X-linked juvenile retinoschisis, retinitis pigmentosa, phenotypes 
associated with mutations in the BEST1 gene, and uveitis. In the absence of a genetic 
association with the DCMD locus in a patient with presumed DCMD, one should review the 
clinical evidence for DCMD carefully, and consider the possibility of one of the following 
clinical entities associated with early-onset CFCs. 
X-linked juvenile retinoschisis, which is inherited in an X-linked pattern in contrast 
to DCMD, gives rise to vision loss in boys at a young age and progresses to atrophy and 
alterations of the RPE,19 like in DCMD. The ‘cystoid’ schisis cavities are mainly situated in 
the inner and outer nuclear layer,20 like the CFCs in DCMD, but the schisis cavities in X-linked 
juvenile retinoschisis often become confluent, with only small strands of tissue bordering 
these spaces on OCT, and without apparent fluorescein leakage into the schisis spaces on 
FA, in contrast to the CFCs in DCMD.21 Also, a typical radial pattern is visible in the fovea 
on FAF and red-free images in X-linked juvenile retinoschisis cases, which is not observed 
in DCMD. The full-field ERG in X-linked juvenile retinoschisis characteristically shows an 
‘electronegative’ aspect,19 in contrast to DCMD. 
Like stage 3 DCMD, retinitis pigmentosa can present with hyperpigmentation in the (mid)
peripheral fundus, and cystoid macular edema.22 However, compared to DCMD, patients 
with retinitis pigmentosa experience night blindness early in the course of the disease, and 
retinitis pigmentosa patients characteristically show early arteriolar attenuation and bone-
spicule pigmentary changes, with a rod-cone dysfunction on full-field ERG that outweighs 
EOG abnormalities. In contrast to bone-spicule hyperpigmentation in retinitis pigmentosa, 
the hyperpigmented abnormalities in DCMD are typically more coarse and mainly located 
in the posterior pole.
Phenotypes associated with BEST1 gene mutations – inherited either autosomal 
dominantly or recessively - can have somewhat similar retinal lesions and abnormalities, 
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like an abnormal EOG that outweighs full-field ERG abnormalities, hyperopia and CFCs in 
the macula.16-18 In contrast to DCMD, all patients with BEST1-related dystrophies have a 
severely abnormal EOG at onset, and BEST1-related fundus abnormalities usually include 
highly autofluorescent yellowish deposits in the macula.17
Posterior uveitis should also be considered, since DCMD can be accompanied by a 
variable degree of whitish punctate deposits (although these are not cells) in the vitreous 
body in stage 2 and 3 disease. Finally, the clinical characteristics of vascular causes of 
cystoid macular edema such as diabetic retinopathy, retinal venous occlusions, as well as 
age-related macular degeneration,23 allow an easy distinction from DCMD.
Genetic Background 
Dominant cystoid macular dystrophy is inherited autosomal dominantly, but the associated 
gene and mutation have not yet been identified.6 We show that the genetic defect in DCMD 
appears to be completely penetrant in the large family in this study. The KLHL7 gene, 
causing autosomal dominant retinitis pigmentosa,24 is located within the critical interval 
of the DCMD locus, which may explain why two DCMD patients in our study exhibited 
abnormalities and phenotypic characteristics of retinitis pigmentosa (Figure 4.6C and D). 
However, no coding variant in the coding region of the KLHL7 gene was detected in our 
DCMD family. This, however, does not exclude the presence of a deep intronic mutation 
or a mutation affecting a regulatory element of the KLHL7 gene. Alternatively, due to the 
distinct disease characteristics between the families described by Friedman et al and our 
DCMD family, it is plausible that another gene at the DCMD locus can be involved in the 
disease rather than KLHL7. Further analysis of all genes located within the DCMD locus at 
the genomic and at a transcriptional level using next-generation sequencing technologies 
may identify the causative mutation of DCMD in the near future. Identification of the 
associated gene can provide insight into the pathogenesis of the disease, and may improve 
our understanding on the development of hyperopia and cystoid fluid collections in other 
rare and common retinal diseases.
Pathophysiology and treatment
Cystoid fluid accumulation in the macula is the first clinically visible abnormality in DCMD. 
This indicates that the CFCs in DCMD are the direct result of the primary genetic defect and 
its immediate pathophysiological consequences. Interestingly, a histopathological study on 
2 donor eyes of a 78-year-old American patient with presumed DCMD has been published.25 
Large intraretinal cystoid spaces were observed in the macula, with mildly attenuated 
retinal vessels, atrophy and marked disorganization of the inner nuclear layer. The large 
cyst-like spaces within the inner nuclear layer were surrounded by Müller cell fibers and 
pigment-laden cells with remnants of photoreceptor segments, and degeneration of Müller 
cells was seen. Based on these findings, the authors suggested a primary pathologic process 
affecting Müller cells in DCMD.25 These histopathological findings correlate well with the 
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clinical findings in our DCMD cohort, which could support primary Müller cell dysfunction 
in DCMD.8 If this is the case, DCMD would be a rare example of retinal dystrophy that 
results from a genetic defect that primarily affects Müller cell function. The gene defect in 
DCMD might interfere with capillary permeability, resulting in a disturbance of the inner 
blood-retinal barrier and early CFCs.
It is also possible that CFCs in DCMD are the result of primary dysfunction of the RPE, 
as the EOG becomes abnormal early in the course of the disease. It is unlikely that the 
photoreceptors are primarily affected, at least on the panretinal level, as the full-field ERG 
remains normal for a long time. Cystoid macular edema in the outer neuroretinal layers, 
such as in the course of retinitis pigmentosa, is presumed to be caused by a dysfunction 
of the outer blood-retina barrier.26-28 In DCMD, CFCs located in the outer nuclear layer are 
possibly induced by dysfunction of the RPE layer, comparable to cystoid macular edema 
that occurs in retinitis pigmentosa.29
Cystoid macular edema in the inner neuroretinal layers, such as in pseudophakic macular 
edema and diabetic retinopathy, is predominantly caused by a failure of the inner blood-
retinal barrier.27, 30 The CFCs located in the inner nuclear layer in DCMD could also be caused 
by a dysfunctional macular inner blood-retinal-barrier, which depends on Müller cells, 
astrocytes, and pericytes.27 This could be supported by the fundoscopic and fluorescein 
angiographic finding of perifoveal capillary dilation early in the course of the disease. 
We suggest that the Müller cells, the RPE, or both, may be the primarily affected cells in 
DCMD, resulting in CFCs early in the course of the disease.
Previous studies in patients with retinal dystrophies showed that treatment with 
acetazolamide reduced intraretinal fluid collections,18, 22, 31-34 although the effect can 
be dose-dependent,18 but the exact mechanism is unclear. Boon et al. suggested that 
acetazolamide may interact with carbonic anhydrase subtypes XIV and II in the RPE and 
Müller cells, resulting in intracellular acidification with consequently Cl- transport in the 
RPE, with water following passively.18 Treatment with acetazolamide has previously been 
shown to be ineffective in treating CFCs in most DCMD patients at a daily dose of 250 mg,35 
but we now demonstrate that the effect can be dose dependent in DCMD, as treatment 
with higher doses can indeed be effective in DCMD patients. A possible rebound effect that 
has been postulated in half of the retinitis pigmentosa patients with cystoid macular edema 
treated with acetazolamide for 8 to 12 weeks,31 was present in only 2 of the 16 DCMD 
patients after 1.5 and 6 years of treatment with acetazolamide. Treatment seems be most 
effective in DCMD patients with stage 1 and has a less strong influence on the long term VA 
in stage 2 DCMD patients.
In conclusion, we describe the clinical spectrum, which can be subdivided into three clinical 
stages, in the largest DCMD cohort to date. CFCs are a hallmark feature in earlier disease, 
but during progression the CFCs diminish and chorioretinal atrophy develops. Haplotype 
analysis using microsatellite markers at the DCMD locus at 7p15.3 confirmed the diagnosis, 
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and the disease was fully penetrant in our DCMD cohort. Future studies will be directed 
towards determining the causative gene by next-generation sequencing at a genomic and 
transcriptional level. The elucidation of the causative gene and pathogenesis in DCMD will 
not only give important insight into this intriguing and peculiar retinal dystrophy, but the 
findings can also shed a light on the pathogenesis of hyperopia and cystoid macular edema 
in other retinal dystrophies, uveitis, diabetic macular edema or following ophthalmic 
surgery, and provide a new target for treatment.
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Butterfly-shaped pigment dystrophy is a macular disease, which in the advanced stage 
bears similarity to age-related macular degeneration. Here, we report the identification 
of heterozygous missense mutations in the α-catenin 1 (CTNNA1) gene in three families 
with butterfly-shaped pigment dystrophy. In addition, we identified a Ctnna1 missense 
mutation in a chemically-induced mouse mutant, tvrm5. Parallel clinical phenotypes were 
observed in the retinal pigment epithelium (RPE) of individuals with butterfly-shaped 
pigment dystrophy and in tvrm5 mice, including pigmentary abnormalities, focal thickening 
and elevated lesions, and decreased light-activated responses. Morphological studies in 
tvrm5 mice revealed increased cell shedding and large multinucleated RPE cells, suggesting 
defects in intercellular adhesion and cytokinesis. This study identifies CTNNA1 gene variants 
as a cause of macular dystrophy, suggests that α-catenin 1 is involved in maintaining RPE 
integrity, and suggests that other components that participate in intercellular adhesion 
may be implicated in macular disease. 
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INTRODUCTION
Butterfly-shaped pigment dystrophy (MIM 608970) belongs to a group of autosomal 
dominant pattern dystrophies of the retinal pigment epithelium (RPE), and was first 
described in a large Dutch family (Family A, Figure 5.1A) by Deutman et al. in 1970.1-3 The 
disease is characterized by bilateral accumulation of pigmented and/or yellowish/gray 
material at the level of the RPE in the macula, which can resemble the wings of a butterfly.3 
Affected individuals present from middle age with either normal or slightly diminished best-
corrected visual acuity (BCVA) and color vision, and the activity of the RPE measured by 
electrooculogram (EOG) recordings may be abnormal.4-6 Responses of the retina, recorded 
by full-field electroretinogram (ERG), and dark adaptation are generally normal.4,7,8 The 
disease is relatively benign, but it can progress to a form resembling age-related macular 
degeneration (AMD), with chorioretinal atrophy in the (para)foveal and peripapillary 
regions4,6,8 and to subretinal neovascularization,9 both resulting in severe vision loss. 
Mutations in the PRPH2 gene (also known as peripherin 2 or RDS, MIM 179605) have 
been identified in individuals with butterfly-shaped pigment dystrophy,1,4,7,10-15 but in the 
majority of individuals the genetic cause is unknown. Genetic heterogeneity for butterfly-
shaped pigment dystrophy has been demonstrated through the analysis of a large 
Dutch family with butterfly-shaped pigment dystrophy (Family A, Figure 5.1A), in which 
the involvement of the PRPH2 gene as well as several other retinal disease genes were 
excluded8. Subsequently, a genome-wide linkage scan identified a novel disease locus for 
butterfly-shaped pigment dystrophy in this family, located on chromosome 5q21.2-q33.2.16
Here we report the identification of mutations in the α-catenin 1 (CTNNA1) gene (MIM 
116805) in the large Dutch family (Family A, Figure 5.1A) and in additional PRPH2-negative 
cases with butterfly-shaped pigment dystrophy. In addition, we describe a Ctnna1 mutation 
in a chemically-induced mouse mutant, tvrm5, and characterize the pathologic events 
leading to RPE dysmorphology in this model. 
METHODS
Clinical Evaluations of Human Subjects
Fourteen affected and twelve unaffected individuals from three BSMD families were 
included in this study. Participants received the diagnosis of BSMD based on the aspect 
of the lesions on ophthalmoscopy sometimes combined with fluorescein angiography 
(FA). The medical histories, age at onset, (best-corrected) Snellen visual acuity (BCVA) 
and fundus appearance, including slit-lamp examination, fundus examination by indirect 
ophthalmoscopy and fundus photography were retrieved from medical records of all included 
subjects. Additionally, FA was available in 11 affected subjects, fundus autofluorescence 
and near-infra red images were obtained in 6 and spectral-domain optical coherence 
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tomography (OCT) in 4 affected participants. Eleven affected subjects underwent electro-
oculography (EOG) and electroretinography (ERG) and color vision testing were available 
in 6 and 7 affected subjects, respectively. ERG and EOG were recorded and interpreted as 
previously described.49 In 6 patients, EOG was performed according to the International 
Society for Clinical Electrophysiology of Vision (ISCEV) protocol. The study was approved by 
the local medical ethics committees (Commissie Mensgebonden Onderzoek regio Arnhem-
Nijmegen, Ethics Committee of Ghent University Hospital, and Ethical Committee of the 
Second University of Naples) and adhered to the tenets of the Declaration of Helsinki. All 
participants provided written informed consent prior to participation in the study.
Whole Exome Sequencing and Mutation Analysis in Human Subjects
To identify the genetic defect in a large Dutch family with nine individuals affected by 
butterfly-shaped pigment dystrophy (family A; Figure 5.1A), the DNA of two affected 
individuals (A-III:7 and A-III:11) was analyzed using whole exome sequencing. The exomes 
were enriched using Agilent’s SureSelect Human All Exon v.2 Kit (50Mb), which targets the 
exonic sequences of approximately 21.000 genes, according to the manufacturer’s protocol 
(Agilent, Santa Clara, CA, USA). Sequencing was performed on a 5500xl SOLiD sequencing 
platform (Life Technologies, Carlsbad, CA, USA). BioScope software v.1.3 (Life Technologies, 
Carlsbad, CA, USA) was used to map color space reads along the hg19 reference genome 
assembly. The high-stringency calling DiBayes algorithm was used for single-nucleotide 
variant calling, and small insertions and deletions were detected using the small Indel Tool. 
All coding exons and intron-exon boundaries of the CTNNA1 gene were screened for 
mutations in 93 unrelated probands with butterfly-shaped pigment dystrophy (N=19) or 
other pattern dystrophies (N=74) by Sanger sequencing. Primers for PCR amplification and 
sequencing were designed with Primer3 software (Table 5.1). Missense variants detected 
in the CTNNA1 gene were analyzed in ethnically matched control individuals by restriction 
enzyme analysis (TaqI for c.953T>C; p.[Leu318Ser] and BccI for c.1293T>G; p.[Ile431Met]), 
allele-specific PCR (for c.919G>A; p.[Glu307Lys]), or Sanger sequencing (for c.160C>T; 
p.[Arg54Cys]). 
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Figure 5.1 CTNNA1 mutations in three families with butterfly-shaped pigment dystrophy. (A) Two 
affected individuals (A-III:7 and A-III:11) of family A were analyzed by whole exome sequencing and 
the c.953T>C; p.(Leu318Ser) variant in the CTNNA1 gene segregated in all family members. Two 
additional variants in the CTNNA1 gene were identified in family B and C with complete segregation 
in both families. (B) The heterozygous mutation c.953T>C; p.[Leu318Ser] (M1) was found in the large 
Dutch family A, and mutations c.1293T>G; p.[Ile431Met] (M2) and c.919G>A; p.[Glu307Lys] (M3) 
were found heterozygously in Dutch family B and Belgian family C, respectively.
Chapter 5
240
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
Table 5.1 Primer sequences for amplification of coding exons and splice junctions of CTNNA1
CTNNA1 exon Forward primer sequence Reverse primer sequence Product size (bp)
Exon 2 CCTGATGCAAAAGTCCCAAA CCTTGCTCTTATGGTTGTTACCC 277
Exon 3 CATTAAGAAAGCTGAATTATTTTGGA AAGGCCTGCCTCTCTTTACC 433
Exon 4 TGAGTTCATTCTTGCTGAGTTTG GAACTAAGGAAGGCCAGTAGCA 279
Exon 5 GCGCAAACTCGAGAGCTAAG TGGAACTATATTGGCGAAGG 368
Exon 6 CTTTTCAGCATTTACCAGCAA TGAGCTATCATCAGAAGCCTTG 453
Exon 7 CAGTAGGCCATCTTCTGTGG CGGACAGCATTACACTCTGC 334
Exon 8 TCAGTGTTGACATGAGCACAA GCACTTTCTTGTGAAAATCCATC 298
Exon 9 TGAGGGGTCCTCATGTAAGTG TGTTAAGCGAGCCCTTACAAAT 392
Exon 10 CAGAATGGTCAGAGGTAGGG CCCAAGACTTCCATCTAAAATCC 300
Exon 11 GCATGTGGTGTGATGTCTCC CATAGCAGTGTTTGCCCATT 335
Exon 12 TTCTTGGGGGTGATAACAGG CTCCTCCTTCCTCACCACAG 486
Exon 13 CCCTTCACACAGGTAGAAGCA AGAATGACGCATTGCTCAAG 358
Exon 14 AACACTGCACATTAAAATCCAGAA TGGAAACAAGAAAGGGGACA 300
Exon 15-16 CTTCAGGCGAAATGAAACCT GCCCATGAAACTTACCCTGA 688
Exon 17 GAGGAAGCATGTGAGTGCCA CCATCTCCCAGGCTCAAGTA 595
Exon 18 GTCAGGCCGGTGCTTCTTAC CTGGTTCAGTCTGCCCATTT 456
Mouse Maintenance and Mutagenesis 
All procedures used in animal experiments for this study were approved by the Institutional 
Animal Care and Use Committees of the institutions involved and were in accordance with 
the ‘Guide for the Care and Use of Experimental Animals’ established by the National 
Institutes of Health (1996, Revised 2011) and the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Mice 
were bred and maintained on a 12 hour light-dark cycle in the Research Animal Facility 
vivarium of The Jackson Laboratory (JAX). Pasteurized JL Mouse and Rat Auto 4F/No Hysil 
5K54 diet (fat content, 4%, PMI Nutrition International, Brentwood, MO) and HCl-acidified 
water (pH 2.8-3.2) were provided ad libitum. 
The tvrm5 mutant (The Jackson Laboratory Stock# 021610) was identified among G3 
mice from an ethylnitrosourea mutagenesis screen of C57BL/6J (B6J; JAX stock number 
000664) mice generated by the Center for New Mouse Models of Heart, Lung, Blood and 
Sleep Disorders at JAX.50 Phenotypic screening of these mice by indirect ophthalmoscopy 
at ~21 weeks of age was performed by the Translational Vision Research Models (TVRM) 
program.51 Once heritability was established, the tvrm5 strain was backcrossed to B6J 
for seven generations and thereafter maintained in a homozygous state by intercrossing. 
B6J mice were also used as wild-type controls and in segregating crosses to generate 
heterozygous animals from the homozygous inbred mutant stock. 
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tvrm5 Mapping and Sequence Analysis
To identify the causative locus, a mutant tvrm5 male was outcrossed with a DBA/2J 
(+/+) female, the resulting F1 progeny were intercrossed, and 31 F2 generation mice 
were analyzed for linkage using a pool scan with genome-wide simple sequence length 
polymorphic (SSLP) markers. The map location was confirmed by testing individual F2 
mice that made up the pool and additional SSLP markers were used to refine the map 
position. For whole exome sequencing, genomic DNA (1 µg) was fragmented to a peak 
size of 300 bp by sonicating for 30 s power on, 30 s power off on low power for a total of 
10 min using a Diagenode Bioruptor UCD-200TM-EX (Denville, NJ, USA). The pre-capture 
paired end library was constructed using the Illumina (Illumina, San Diego, CA, USA) TruSeq 
DNA Sample Preparation Kit (part number FC-121-100) with no size selection step and 
18 cycles of PCR. The pre-capture library was hybridized to the Roche NimbleGen Mouse 
Exome (Reference #9999042611) capture probe set (Roche NimbleGen, Madison, WI, USA) 
according to the manufacturer’s instructions. The sequencing library was quantified by 
QPCR, pooled with two similar libraries, and sequenced on a single lane of an Illumina HiSeq 
2000 (Illumina, San Diego, CA, USA) using a 2x100 bases (paired end) sequencing protocol. 
Genotypes were confirmed by sequencing the PCR product obtained with the primers 
Ctnna1F (5′-TTAGAGCTCTCGAAGCCTGTG) and Ctnna1R (5′-GAAAGAAGGAAGGGAAAGCAA) 
amplified as follows: 97°C, 3 min; 45 cycles of 95°C, 10 s and 50°C, 30 s; 72°C, 30 s; 72°C, 3 
min.
Live Imaging and Histology of Mouse Eyes
Fundus images of live mice were obtained with a Micron III Retinal Imaging System (Phoenix 
Research Laboratories, Pleasanton, CA) and an R2200 ultrahigh resolution spectral domain 
optical coherence tomography (OCT) system (Bioptigen, Raleigh, NC). Image acquisition and 
processing were performed as described previously.52 For conventional histology, animals 
were first asphyxiated with carbon dioxide. Eyes were enucleated and treated with a 3:1:4 
mixture of methanol:acetic acid:phosphate-buffered saline with subsequent paraffin 
embedding and staining with hematoxylin and eosin as described.53 Brightfield images 
were acquired using a DMLB light microscope (Leica Microsystems, Buffalo Grove, IL). For 
flatmounts, enucleated eyes were placed in 4% w/v paraformaldehyde in 0.75x phosphate-
buffered saline, dissected to recover the retina and RPE/choroid/sclera complex, and stained 
with DAPI and rhodoamine phalloidin as described,52 except that the RPE was examined 
instead of the retina. Confocal image stacks were obtained with a 63x objective on an SP5 
confocal microscope (Leica). Conventional fluorescence images were obtained with a 10x 
objective on an Axio Observer Z.1 (Carl Zeiss Microscopy, Peabody, MA). Confocal images 
were processed in Fiji54 by dividing the blue by the green channel after denoising to reduce 
the contribution of autofluorescence to the DAPI signal, and images were oriented with 
the Interactive Stack Rotation plugin. A subset of the image stacks was maximally projected 
to visualize the F-actin circumferential boundary with minimal overlap from apical F-actin. 
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Conventional fluorescence images were oriented with the Interactive Stack Rotation plugin, 
and contrast and brightness were adjusted in Fiji.
Mouse Visual Electroretinography
Mice were studied using ERG stimulation and recording protocols designed to evaluate outer 
retinal or RPE function. Each experimental session was conducted following overnight dark 
adaptation. Mice were anesthetized with ketamine (80 mg/kg) and xylazine (16 mg/kg), 
and placed on a temperature-regulated heating pad throughout the testing sessions. Pupils 
were dilated with eye drops (2.5% phenylephrine HCl, 1% cyclopentolate, 1% tropicamide). 
The corneal surface was anesthetized with 1% proparacaine HCl.
The functional response of the outer retina was examined using a conventional strobe-
flash ERG protocol.7 ERGs were recorded using a stainless-steel wire active electrode 
referenced to a needle electrode placed in the cheek. A second needle electrode placed 
in the tail served as ground lead. Responses were differentially amplified (0.3–1.500 Hz), 
averaged, and stored using a UTAS E-3000 signal averaging system (LKC Technologies, 
Gaithersburg, MD). White light strobe flashes were initially presented in darkness within 
a Ganzfeld bowl. Stimuli were presented in increasing order, from -3.6 log cd s/m2 up to 
2.1 log cd s/m2. Cone ERGs were isolated by superimposing stimuli (-0.8 to 1.9 log cd s/
m2) upon a steady adapting field (20 cd/m2). The amplitude of the a-wave was measured 
8 ms after flash onset from the prestimulus baseline. The amplitude of the b-wave was 
measured from the a-wave trough to the peak of the b-wave or, if no a-wave was present, 
from the prestimulus baseline.
ERG components generated by the RPE were examined using a dc-ERG protocol.55 
Responses were obtained from the corneal surface of the left eye using a capillary tube 
with filament (BF100-50-10; Sutter Instrument, Novato, CA) that was filled with Hank’s 
buffered salt solution to make contact with an Ag/Ag Cl wire electrode. A similar electrode 
placed in contact with the right eye served as the reference. Responses were differentially 
amplified (dc-100 Hz), digitized at 20 Hz, and stored using LabScribe Data Recording 
Software (iWorx; Dover, NH). White light stimuli were derived from an optical channel 
using a Leica microscope illuminator as the light source and delivered to the test eye with 
a 1-cm-diameter fiber-optic bundle. The stimulus luminance was 2.4 log cd/m2. Stimulus 
timing and duration was controlled at 7 min by a Uniblitz shutter system (Rochester, NY). 
The amplitude of the c-wave was measured from the prestimulus baseline to the peak of 
the c-wave. The amplitude of the fast oscillation (FO) was measured from the c-wave peak 
to the trough of the FO. The amplitude of the light peak (LP) was measured from the FO 
trough to the asymptotic value. The off-response amplitude was measured from the LP 
value just prior to stimulus light offset to the peak of the initial component.
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Statistical Analysis
Response functions obtained for a- and b-wave amplitudes were compared across genotypes 
using a two-way repeated measures ANOVA. The amplitudes of dc-ERG components 
obtained under a standard stimulus condition were compared using Student’s t-test.
Co-immunoprecipitations
Co-immunoprecipitation analyses were performed to test the interaction of wild-type and 
mutant α-catenin 1 (CTNNA1) with vinculin (VCL [MIM 193065]). Expression constructs 
to produce 3xHA-CTNNA1 (wild-type and variants c.160C>T; p.[Arg54Cys], c.919G>A; 
p.[Glu307Lys], c.953T>C; p.[Leu318Ser], c.1293T>G; p.[Ile431Met], and c.1307T>C; 
p.[Leu436Pro]) and 3xFLAG-VCL proteins were co-transfected in human embryonic kidney 
293T (HEK293T) cells. As a negative control, production of the functionally unrelated p63 
protein (MIM 603273) was used. As positive controls, the previously described interactions 
between nephrocystin-4 (MIM 607215) and RPGRIP1 (MIM 605446) were used in this 
assay.56 Following transfection, cells were cultured for 24 hr and subsequently lysed on ice in 
lysis buffer (50 mM Tris-HCL [pH 7.5], 150 mM NaCl, and 0.5% Triton X-100) supplemented 
with complete protease inhibitor cocktail (Roche). Lysates were incubated with anti-FLAG 
M2 agarose from mouse (Sigma-Aldrich) for 2 hr at 4°C. After incubation, beads with bound 
protein complexes were washed in lysis buffer and subsequently taken up in 4x NuPAGE 
Sample Buffer and heated for 10 min at 70°C. Beads were precipitated by centrifugation, 
and supernatant was run on a NuPAGE Novex 4%–12% Bis-Tris SDS-PAGE gel. The interaction 
between 3xHA-CTNNA1 and 3xFLAG-VCL was assessed by immunoblotting, followed by 
staining with either polyclonal rabbit anti-HA (1:1.000; Sigma-Aldrich) or monoclonal mouse 
anti-FLAG (1:1.000; Sigma-Aldrich) as a primary antibody, and goat anti-rabbit IRDye800 
(1:20.000; Li-Cor) or goat anti-mouse Alexa Fluor 680 (1:20.000; Molecular Probes) as a 
secondary antibody. Fluorescence was analyzed on a Li-Cor Odyssey 2.1 infrared scanner. 
RESULTS
Identification of CTNNA1 mutations in families with butterfly-shaped pigment dystrophy
Whole exome sequencing in two affected individuals of family A (Figure 5.1A) uncovered 
38.153 variants for individual A-III:7 and 40.212 variants for individual A-III:11, of which 
23.783 variants were shared by both individuals. Shared variants located within the linkage 
interval on 5q21.2-q33.2 (between markers D5S433 and D5S487),16 were filtered for 
heterozygous (present on ≥20% and ≤80% variant reads), non-synonymous variants, with a 
frequency of less than 0.5% in the Exome Variant Server (EVS) database, and a PhyloP score 
>2.7. Only one potential causative variant was identified, residing in the CTNNA1 gene 
(c.953T>C; p.[Leu318Ser]; PhyloP score 5.1). Sanger sequencing confirmed the presence 
of a heterozygous c.953T>C; p.(Leu318Ser) allele in the CTNNA1 gene [MIM 116805] in 
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affected relatives but absent in all unaffected family members. The variant was predicted 
disease-causing by SIFT, affects a residue that is completely conserved among vertebrate 
species (Figure 5.2), and was not found in 162 ethnically matched controls nor in the EVS 
database. 
   Arg54Cys
   |
Homo sapiens alpha-catenin 1 31 PLVTQVTTLVNTNSKGPSNKKRGRSKKAHVLAASVEQATE
Macaca mulatta alpha-catenin 1 31 PLVTQVTTLVNTNSKGPSNKKRGRSKKAHVLAASVEQATE
Mus musculus alpha-catenin 1 31 PLVTQVTTLVNTNSKGPSNKKRGRSKKAHVLAASVEQATE
Rattus norvegicus alpha-catenin 1 31 PLVTQVTTLVNTNSKGPSNKKRGRSKKAHVLAASVEQATE
Bos taurus alpha-catenin 1 31 PLVTQVTTLVNTNSKGPSNKKRGRSKKAHVLAASVEQATE
Gallus gallus alpha-catenin 1 31 PLVTQVTTLVNTSNKGPSNKKRGRSKKAHVLAASVEQATE
Danio rerio alpha-catenin 1 31 PLVTQVTTLVNSSNKGPSNKKKGRSKKAHVLAASVDEATQ
               
                                                   
   Glu307Lys Leu318Ser
   | |
Homo sapiens alpha-catenin 1 300 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Macaca mulatta alpha-catenin 1 300 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Mus musculus alpha-catenin 1 300 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Rattus norvegicus alpha-catenin 1 302 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Bos taurus alpha-catenin 1 300 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Gallus gallus alpha-catenin 1 299 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNA
Danio rerio alpha-catenin 1 300 RFRPSLEERLESIISGAALMADSSCTRDDRRERIVAECNS
      Ile431Met  Leu436Pro
   | |
Homo sapiens alpha-catenin 1 420 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Macaca mulatta alpha-catenin 1 420 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Mus musculus alpha-catenin 1 420 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Rattus norvegicus alpha-catenin 1 422 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Bos taurus alpha-catenin 1 420 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Gallus gallus alpha-catenin 1 419 AQVFREHANKLIEVANLACSISNNEEGVKLVRMSASQLEAL
Danio rerio alpha-catenin 1 420 AQVFREHANKLIEVANLACSISNNEEGVKLVRMAASQLETL
Figure 5.2 Protein sequence alignment of α-catenin 1 orthologs. The amino acids affected by 
the mutations identified in three families with butterfly-shaped pigment dystrophy (p.[Glu307Lys], 
p.[Leu318Ser], p.[Ile431Met]) and in the tvrm5 mouse (p.[Leu436Pro]) are completely conserved 
among vertebrates. Accession numbers: Homo sapiens α-catenin 1 NP_001894, Macaca mulatta 
α-catenin 1 NP_001244297, Mus musculus α-catenin 1 NP_033948, Rattus norvegicus α-catenin 1 
NP_001007146, Bos taurus α-catenin 1 NP_001030443, Gallus gallus α-catenin 1 XP_414513, Danio 
rerio α-catenin 1 NP_571531.
Sequencing of all 17 coding exons of the CTNNA1 gene in 93 unrelated probands 
with butterfly-shaped pigment dystrophy and other pattern dystrophies identified three 
additional rare missense variants in the CTNNA1 gene (Table 5.2). 
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Heterozygous variants c.1293T>G; p.(Ile431Met) and c.919G>A; p.(Glu307Lys) were 
identified in two probands of Dutch and Belgian ancestry, respectively (Figure 5.1B), in 
whom PRPH2 mutations had been excluded. Analysis of both variants in members of Family 
B and C, respectively, confirmed segregation with the disease (Figure 5.1A). Both variants 
were predicted disease-causing by Polyphen and SIFT, affect residues that are completely 
conserved among vertebrate species (Figure 5.2), and were not identified in 162 ethnically 
matched controls nor in the EVS database. A third missense variant, c.160C>T; p.(Arg54Cys), 
was identified in an Italian proband who presented fundoscopically with a small area of RPE 
atrophy, superior to the fovea in the right eye, without classical phenotypical features as 
seen in pattern dystrophies. The variant was predicted disease-causing by Polyphen and 
SIFT, affects a residue that is completely conserved among vertebrate species (Figure 5.2), 
was not identified in 200 ethnically matched unrelated control individuals nor in the EVS 
database, but was present in the unaffected 64-year old father of this individual. Therefore, 
the pathogenic nature of this variant remains unclear. 
Clinical features of butterfly-shaped pigment dystrophy caused by CTNNA1 mutations
The clinical features of the affected individuals of the three families with butterfly-shaped 
pigment dystrophy are described in Table 5.3. A remarkable homogeneous intrafamilial 
phenotype was observed in affected individuals of the large Dutch pedigree (family A), 
but considerable phenotypic heterogeneity was noted in families B and C. Among the 
three families, the age at first presentation was highly variable, even among members of 
the same family, ranging from 15 to 55 years. In most cases, the BCVA was relatively well 
preserved, as only three of 13 affected individuals had a BCVA below 20/40. The BCVA 
values seemed to correlate with the amount and location of RPE atrophy. Follow-up BCVA 
data was available in four affected individuals of the second generation of family A, with only 
individual A-II:8 demonstrating significant progressive visual loss. The EOG was abnormal in 
nine of 11 affected individuals, and Arden ratios on EOG varied from normal values (ISCEV 
≥ 2.0 or non-ISCEV ≥ 1.8)17 to 1.0 (no light rise on EOG). Full-field ERG results were normal 
in all six examined affected individuals, and in two of seven examined affected individuals 
color vision testing identified a red-green defect. 
Fundoscopy showed typical butterfly-shaped hyperpigmentation in the center of the 
macula, surrounded by hypopigmentation in all affected individuals of family A (Figure 
5.3A). On fluorescein angiography, the central pigmented lesions were hypofluorescent 
radially branching ‘butterfly-shaped’ structures with hyperfluorescence of the surrounding 
hypopigmented retina (Figure 5.3B). Additionally, two affected relatives showed spicular 
retinal hyperpigmentation in the peripheral retina, and in four affected relatives chorioretinal 
atrophy was present in the macula. The clinical presentation of both affected individuals 
of family B was comparable, although the macular lesion was less butterfly-shaped than 
in family A. Individual B-II:1 showed a less pronounced butterfly-shaped pigmented 
lesion, with atrophy of the RPE and photoreceptors (Figure 5.3C and D), while only a mild 
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phenotype of ‘dot and halo’ lesions was present in individual B-I:2. These ‘dot and halo’ 
lesions may progress to a more classic butterfly-shaped pigment dystrophy phenotype18. 
Optical coherence tomography (OCT) imaging showed hyperreflective lesions at the level of 
the RPE with atrophy of the RPE and photoreceptors at the fovea (Figure 5.3E). The proband 
of family C (C-II:1) showed a pattern dystrophy phenotype with a pattern resembling a 
starfish, with accumulation of material in the foveal area at the level of the RPE in both eyes 
(Figure 5.3 I). Autofluorescence imaging showed that the deposits were predominantly 
hyperautofluorescent (Figure 5.3G). The mother of the proband (individual C-I:2) showed a 
milder phenotype with irregular hyperpigmentation radiating from the fovea. At age seven, 
the daughter of the proband (individual C-III:1) had an entirely normal fundus in both eyes, 
despite being heterozygous for the c.919G>A; p.(Glu307Lys) variant. 
Identification of a Ctnna1 mutant mouse model
An indirect ophthalmoscopy screen of mice from a B6J mutagenesis program identified a 
mutant, tvrm5, which showed widespread mottling of the fundus and occasional bright 
spots, often with dark centers (ring spots). Linkage analysis of a tvrm5 × DBA/2J intercross 
based on the ring spot phenotype revealed a recessive locus associated with the disease 
phenotype on chromosome 18 that was narrowed to ~14.5 Mbp by fine mapping (distal 
to D18Mit22 and proximal to D18Mit236). Examination of whole exome sequences in this 
region identified coding variants in Ctnna1 (c.1307T>C; p.[Leu436Pro]; PhyloP score 2.6) 
and Pcdhb14 (c.1259C>T; p.[Thr420Ile]; PhyloP score 0.3). The higher PhyloP score, the 
predicted pathogenicity by SIFT, and the much higher expression of Ctnna1 compared to 
Pcdhb14 in the retina and RPE (biogps.org) strongly supports that the Ctnna1 mutation is the 
causative allele. By Sanger sequencing, the Ctnna1 allele was confirmed to be homozygous 
in 17 affected progeny of the mapping cross, heterozygous in two unaffected progeny 
and absent from eight unaffected progeny as well as B6J and DBA/2J mice, indicating co-
segregation of the mutant allele with ring spot phenotype. Based on these considerations 
and the similarity of the human CTNNA1 disease phenotype to that of tvrm5 mutants (see 
below), the mutant allele will be referred to herein as Ctnna1tvrm5.
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Figure 5.3 Retinal images of three families with butterfly-shaped pigment dystrophy. (A-B) Retinal 
imaging of the right eye of individual A-III:11 at age 36. (A) Fundus photography showing a peculiar 
butterfly-shaped pigmented lesion in the center of the macula. (B) Fluorescein angiography (FA) 
showing hypofluorescence of the hyperpigmentation surrounded by some hyperfluorescence. (C-E) 
Retinal imaging of the left eye of individual B-II:1 at age 62. (C) Fundus photographs showing mild 
pigmentary changes in the macula. (D) On near-infrared reflectance images the retinal changes are 
more pronounced. (E) Spectral-domain optical coherence tomography (SD-OCT) (scan in the plane 
indicated by black arrow in C) shows that the abnormalities on near-infrared reflectance imaging in 
D are hyperreflective and located at or just anterior to the retinal pigment epithelium (RPE), and also 
shows some atrophy of the RPE and outer retina. (F-I) Retinal imaging of the right eye of individual 
C-II:1 at age 33 (F, G and I) and age 23 (H). (F) Fundus photographs showing pattern dystrophy with a 
starfish-aspect with thickened fovea and six branches with hyperpigmentation. Relatively pronounced 
yellowish macular pigment deposition can be seen. (G) Fundus autofluorescence imaging showing 
hyperautofluorescence of lesions. (H) FA shows blockage of background fluorescence by pigmented 
lesions. (I) SD-OCT of the central foveal lesion of the right eye (scan in the plane indicated by black 
arrowhead in A), showing a dome-shaped sub-RPE lesion in the fovea.
RPE lesions and photoreceptor loss in Ctnna1tvrm5 mutants
To assess the clinical manifestation of the disease, mouse eyes were examined noninvasively. 
Fundus imaging of homozygous Ctnna1tvrm5 mice (Figure 5.4A) revealed lesions in the central 
fundus biased toward the posterior pole, which were correlated with the spots (Figure 5.4C) 
and ring spots (Figure 5.4D and E) phenotype. Fine pigment mottling was also detected 
throughout the fundus (Figure 5.4A). Single en face slices generated from processed OCT 
image volumes of the same eyes revealed hyperreflective objects at the same locations 
as observed by fundus imaging (Figure 5.4B). OCT B-scans of spots (Figure 5.4F) showed 
localized thickening of hyperreflectivity corresponding to the RPE and a slight distortion 
of the photoreceptor inner/outer segment junction and external limiting membrane 
toward the vitreous. B-scans of ring spots showed localized thickening surrounding an 
elevated hyporeflective core (Figure 5.4G and H). Notably, the B-scan profiles of lesions 
in homozygous Ctnna1tvrm5 mice and individuals with butterfly-shaped pigment dystrophy 
were similar, both for small and large lesions (compare Figures 5.3E and 5.4F and 5.3 I and 
5.4H, respectively). 
OCT analysis also revealed a slight but significant decrease in outer nuclear layer (ONL) 
thickness of 9% (p < 0.001) in young homozygous Ctnna1tvrm5 compared to B6J mice (1 
month, 51.2±1.2 µm [n=7] vs. 56.0±0.7 µm [n=3], respectively; 3 months, 50.9±0.7 µm 
[n=3] vs. 55.8±1.5 µm [n=5], respectively). With age, ONL thickness was decreased by 16% 
(p < 0.004) in homozygous Ctnna1tvrm5 compared to B6J mice (12-14 months, 44.1±1.0 µm 
[n=3] vs. 53.0±1.5 µm [n=5], respectively). In heterozygotes, lesions were not evident by 
either fundus imaging or OCT, and ONL thickness was not significantly affected at 1, 3 or 
12-14 months of age. Taken together, these findings indicate that pathologic changes occur 
at the apical surface of the RPE or within the RPE itself and include the outer retina, where 
progressive photoreceptor loss is observed in homozygous Ctnna1tvrm5 mice. 
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Figure 5.4 Live retinal imaging of homozygous Ctnna1tvrm5 mice. (A) Fundus imaging at one year of 
age revealed bright lesions in the central fundus near the posterior pole and mottling throughout the 
fundus. (B) Averaged projection of the OCT volume from the inner nuclear layer to the photoreceptor 
inner/outer segment junction is shown en face, to guide comparison with the fundus image in A. The 
lesions identified in A are superimposed as single en face slices. (C-E) Detail of lesions shown from left 
to right in A, respectively, obtained from a less saturated image. (F-G) OCT B-scans corresponding to 
lesions shown from left to right in B, respectively. Spot lesions (F), show a slight focal thickening of 
RPE hyperreflectivity and distortion of the overlying retinal layers. Ring lesions (G and H) include an 
elevated hyperreflective region surrounding a central hyporeflective area above the RPE.
Decreased light-activated RPE response in Ctnna1tvrm5 mutant mice
To test whether the morphological RPE defects were accompanied by a decrease in RPE 
function, we examined Ctnna1 mutant mice by dc-ERG electrophysiology. In comparison 
to wild-type (B6J) mice, dc-ERG responses were reduced in amplitude at one year of age 
in both heterozygous and homozygous Ctnna1tvrm5 mice (Figure 5.5A). When the main 
components of the response were quantified, significant differences from B6J were noted 
for the c-wave, fast oscillation (FO) and off-response in both heterozygous and homozygous 
Ctnna1tvrm5 mice (Figure 5.5B); the amplitude reduction of the light peak component, which 
tends to be variable in amplitude in mice, was not significant. Differences were not noted 
in responses between heterozygous and homozygous Ctnna1tvrm5 mice. 
As the dc-ERG signal is generated in response to rod photoreceptor activity19, it was 
essential to determine whether the reduced dc-ERGs of Ctnna1 mutant mice resulted from 
a decrease in RPE function alone or were accompanied by a decline in rod photoreceptor 
function. Therefore, we also recorded strobe flash ERGs from B6J and Ctnna1tvrm5 mutant 
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mice. While the overall waveform did not differ across genotypes, the amplitudes of both 
the dark-adapted a- and b-wave were significantly reduced in homozygous Ctnna1tvrm5 
as compared to B6J or heterozygous Ctnna1tvrm5 mice (Figure 5.5C). Thus, the reduction 
in the dc-ERG responses in homozygous Ctnna1tvrm5 mice may reflect dysfunction of 
photoreceptors, RPE cells, or both. By contrast, dark-adapted responses did not differ in 
heterozygous Ctnna1tvrm5 and B6J mice (Figure 5.5C), indicating that the reduction in dc-ERG 
response in heterozygous mice occurs without a loss of photoreceptor function. The cone 
ERG response was significantly reduced in homozygous Ctnna1tvrm5 mice compared with 
B6J or heterozygous Ctnna1tvrm5 mice, which also did not differ (Figure 5.5D). Together with 
the live imaging results, the ERG observations support a pathogenic mechanism in which 
heterozygous Ctnna1tvrm5 mice develop RPE dysfunction without significant photoreceptor 
damage, while homozygous animals develop a more severe RPE functional deficit causing 
rod and cone photoreceptor cell loss. 
Pigmented cells on the RPE apical surface and eosinophilic inclusions in Ctnna1tvrm5 mice
To assess cellular changes that might provide clues to the underlying cause of RPE lesions 
and functional defects in Ctnna1tvrm5 mice, we examined fixed retinal tissues by histology. 
At one month of age, retinal layers in homozygous Ctnna1tvrm5 mice (Figure 5.6B) were 
grossly normal compared to those in B6J mice (Figure 5.6A), apart from slight ONL thinning. 
However, distortion of the outer retina was occasionally noted in areas where one of several 
unusual features was found in the underlying RPE. First, pigmented cells were present on 
the RPE apical surface in focal lesions appearing as a slightly thickened RPE layer contiguous 
with the epithelium (Figure 5.6C) or as an extensive double layer (Figure 5.6D). Single 
pigmented cells were also observed (Figure 5.6E), which may be shed RPE cells. However, 
the observation of nuclei with no evidence of surrounding pigment (Figure 5.6F) suggested 
the presence of additional cell types in the subretinal space. Second, eosinophilic inclusions 
were found frequently within the RPE cell layer (Figure 5.6G), often with an internal laminar 
appearance. Serial sections revealed nuclei on the edges of these inclusions and sparse 
melanin pigment enclosed within a well-defined boundary, compatible with an intracellular 
location. Finally, pigmented cells on the RPE apical surface and eosinophilic inclusions were 
both present in larger lesions (Figure 5.6H-K), suggesting a common pathogenic basis of 
these features. In agreement with live imaging results, these features were observed at 
one month and at 12-14 months in homozygous Ctnna1tvrm5 mice but were not detected in 
heterozygous and B6J animals.
These findings provide a histological correlate of the live imaging results. The pigmented 
cells accumulating on the apical surface of the RPE (Figure 5.6C and D) corresponded to 
the bright spots observed by fundus imaging and en face OCT (Figure 5.4A and B), and 
to the localized thickening of the hyperreflective RPE layer in OCT B-scans (Figure 5.4F-
H). Accumulation of eosinophilic material in the epithelial layer (Figure 5.6G) may also 
contribute to localized thickening observed by OCT. Lesions containing large eosinophilic 
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inclusions flanked by double layers of pigmented cells corresponded to the ring spots 
observed by live imaging (Figure 5.6H-K). 
Figure 5.5 ERG recordings of Ctnna1tvrm5 mice. (A) Waveforms indicate average dc-ERG waveforms 
obtained from wild-type B6J (+/+, n=11), heterozygous (tvrm5/+, n=5), and homozygous Ctnna1tvrm 
(tvrm5/tvrm5, n=9) mice. (B) Average (± SEM) amplitude of the major dc-ERG components. In 
comparison to B6J, the amplitudes of the c-wave, fast oscillation (FO) and off response components 
were significantly reduced in Ctnna1 mutant mice (*: P < 0.015; **: P < 0.001). The reductions of 
the light peak (LP) component were not significant. There was no significant difference in dc-ERG 
amplitude between heterozygous and homozygous Ctnna1tvrm5 mice. (C) Response functions for the 
amplitude of the a- and b-wave components of the dark-adapted strobe flash ERG. Data points indicate 
average (± SEM) for B6J, heterozygous and homozygous Ctnna1tvrm5 mice (n=3, 10 and 6, respectively). 
Responses were significantly reduced (P<0.01) in homozygous as compared to B6J or heterozygous 
mice, which did not differ. (D) Response function for the amplitude of the cone ERG. Responses were 
significantly reduced (P<0.01) in homozygous Ctnna1tvrm5 as compared to B6J or heterozygous mice, 
which did not differ.
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Figure 5.6 Light micrographs of hematoxylin and eosin stained paraffin-embedded ocular sections 
from Ctnna1tvrm5 mice at one month of age. (A) B6J retina. (B) Homozygous Ctnna1tvrm5 retina showing 
normal layered organization with occasional outer retinal distortion in an area of abnormal RPE. 
(C-K) Detail of RPE lesions in eyes of homozygous Ctnna1tvrm5 mice. (C) Slight RPE thickening. (D) A 
double layer of pigmented cells, possibly RPE. (E) A single pigmented, nucleated cell on the RPE apical 
surface. (F) A nucleus without surrounding pigment (arrowhead) on the RPE apical surface and a 
small eosinophilc inclusion (asterisk). (G) An eosinophilic inclusion bounded by melanin pigment. (H-
L). Sections 3, 5, 8 and 13 from a series of 14 sections of a large RPE lesion containing both pigmented 
cells on the RPE surface and an eosinophilic inclusion. Nuclei (asterisks) in I may be in the same cell 
as the eosinophilic inclusion. Scale bars in panels B, G and K are 100, 20 and 20 µm, respectively, and 
apply to each row of images. ONL, outer nuclear layer; RPE, retinal pigment epithelium. 
RPE dysmorphology and multinucleate cells
As an additional test for RPE structural defects, we stained RPE/choroid/sclera flatmounts 
at one month of age to detect nuclei and the F-actin cytoskeleton at RPE cell boundaries. 
Flatmounts from B6J mice revealed mono- and binucleate polygonal RPE cells with vertices 
shared by three cells (Figure 5.7A). By contrast, homozygous Ctnna1tvrm5 mice exhibited 
unusual RPE morphology comprising four or more cells surrounding an F-actin circle of 
variable size (Figure 5.7B-D) or a shared vertex (Figure 5.7E). Orthogonal views of B6J 
image stacks indicated that RPE nuclei are normally located below F-actin staining at the 
RPE apical surface (Figure 5.7F, left), which is presumably due to staining of F-actin bundles 
in the microvilli, and below the circumferential F-actin band that defines the polygonal cell 
boundary (Figure 5.7F, right). In homozygous Ctnna1tvrm5 mice, nuclei were occasionally 
observed directly above the circular F-actin motif (Figure 5.7G), consistent with apical 
shedding of an RPE cell. However, in most of these structures, nuclei were not apparent or 
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were positioned basally to the circular F-actin motif, possibly indicating that basal shedding 
also occurs. 
RPE dysmorphology was also evident at 12-14 months of age. Compared to normal 
polygonal cells in B6J mice (Figure 5.7H), the RPE cells in heterozygous (Figure 5.7 I) 
and homozygous Ctnna1tvrm5 mice (Figure 5.7J) were highly variable in size and included 
extremely large, irregularly-shaped multinucleate cells. In addition to the absence of apical 
F-actin boundaries in the interior of these abnormal RPE cells, the disordered clustering 
of nuclei suggested a lack of intercellular barriers. Bright F-actin structures, including 
tangles and intense staining at the boundaries of rounded cells, were more pronounced in 
homozygous than in heterozygous Ctnna1tvrm5 mice. In summary, a primary consequence of 
the Ctnna1tvrm5 mutation appears to be significant dysmorphology in the form of RPE cell 
shedding and the accumulation of large multinucleate RPE cells. 
Figure 5.7 RPE cell dysmorphology in RPE/choroid/sclera flatmounts of Ctnna1tvrm5 mice stained 
with rhodamine phalloidin (red) and DAPI (blue) to reveal F-actin and nuclei, respectively. (A) Merged 
projections of a confocal image stack show normal mono- and binucleate polygonal cells in B6J mice 
at one month of age. (B-D) Circular F-actin structures or (E) vertices shared by four or more cells were 
frequent in homozygous Ctnna1tvrm5 mice. (F) Orthogonal displays at two z-positions of cells in panel A 
show that RPE nuclei in B6J mice lie below F-actin on the apical surface (left) and in the circumferential 
band (right). (G) Orthogonal display of cells from panel C showing a flattened nucleus between apical 
F-actin and the circular F-actin structure in homozygous Ctnna1tvrm5 mice. (H) RPE cells B6J mice at 
12-14 months of age remained mostly mono- and binucleate. (I) Heterozygous Ctnna1tvrm5 mice at 
12-14 months of age showed large multinucleate RPE cells. (J) Homozygous Ctnna1tvrm5 mice exhibited 
multinucleate cells as well bright F-actin tangles and rounded cells with bright F-actin boundaries. 
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Scale bars in panels E and J are 25 and 50 µm, respectively, and apply to the corresponding rows of 
images. 
Modeling and functionality of variants in α-catenin 1
CTNNA1 encodes α-catenin 1 (also known as αE-catenin or CTNNA1), which stabilizes 
intercellular adherens junctions as a force-sensing adaptor between cell surface cadherins 
and the actin cytoskeleton.20,21 α-Catenin 1 responds to increased intercellular tension by 
unfurling binding sites for actin-associated proteins, such as vinculin, afadin, α-actinin, 
and formin.20,21 Given the importance of adherens junctions for RPE integrity,22 we 
explored possible structural and functional consequences of the α-catenin 1 variants. 
The CTNNA1 variants detected in the three families with butterfly-shaped pigment 
dystrophy (p.[Glu307Lys], p.[Leu318Ser], and p.[Ile431Met]) and the mouse Ctnna1tvrm5 
variant (p.[Leu436Pro]) are predicted to alter residues in α-catenin 1 that are completely 
conserved among vertebrate species (Figure 5.2). As shown in an x-ray crystallographic 
structural model of the human protein (Figure 5.8), four of the five variants affect amino 
acid residues (p.Glu307, p.Leu318, p.Ile431, p.Leu436) that are clustered in the middle of 
protein. The variants map to the proposed force-sensing module (domains D3-D4, amino 
acid residues 260-630) and to protein binding domains within this module that may be 
sensitive to tension (D3a, residues 260-400; D3b, residues 400-507).21 The four variants 
map in or near the region that has been reported to bind vinculin.21,23-25 The fifth variant, 
which is of uncertain pathogenic significance, affects Arg54 within the N-terminal domain 
that binds β-catenin, a direct binding partner of cadherin. To test for an effect of the variants 
on vinculin binding, the wild-type and mutant α-catenin 1 proteins were heterologously 
co-expressed with vinculin. Although co-immunoprecipitations confirmed interaction of 
α-catenin 1 with vinculin, the mutations did not affect the interaction of these proteins 
(Figure 5.9). 
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Figure 5.8 Structural model of human α-catenin 1 showing the location of amino acid residues 
altered by CTNNA1 mutations identified in three families with butterfly-shaped pigment dystrophy 
and in Ctnna1tvrm5 mice. The model (Protein DataBank entry 4IGG) shows residues 82-635 and 666-
861 of polypeptide chain A. The α-helices are depicted as rockets and colored according to domain 
classification (D1, N-terminal domain; D3a, D3b and D4, middle domains also known as MI, MII and 
MIII, respectively; D5, C-terminal domain). Affected residues are shown in space-filling representation 
(yellow, human variants; white, mouse variant). The sequences of human and mouse α-catenin 1 are 
identical within the affected domains shown.
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Figure 5.9 Co-immunoprecipitation studies of α-catenin 1 (CTNNA1) and vinculin (VCL). Wild-type 
3xHA-CTNNA1 efficiently co-immunoprecipitated with 3xFLAG-VCL (panel 4, lane 1), and introduction 
of the CTNNA1 variants c.160C>T; p.(Arg54Cys) (lane 2), c.919G>A; p.(Glu307Lys) (lane 3), c.953T>C; 
p.(Leu318Ser) (lane 4), c.1293T>G; p.(Ile431Met) (lane 5), and c.1307T>C; p.(Leu436Pro) (lane 6) did 
not significantly affect the binding. Specificity was confirmed by inclusion of the unrelated p63, which 
failed to co-immunoprecipitate with wild-type vinculin (lane 7). As positive control, RPGRIP1 efficiently 
co-immunoprecipitated with nephrocystin-4 (NPHP4; lane 8). Immunoblots of the input are shown in 
panels 1 and 2, and immunoblots of the FLAG immunoprecipitates are shown in panels 3 and 4. Size 
markers are depicted in kDa.
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DISCUSSION
This work for the first time implicates a member of the catenin family in posterior eye 
disease, namely, mutations in the CTNNA1 gene as a genetic cause of butterfly-shaped 
pigment dystrophy. Previously, mutations in peripherin 2 have been associated with this 
condition, a protein that is thought to function in outer segment disc biogenesis of retinal 
photoreceptor cells.1 The finding that the disease is also caused by variants in α-catenin 1, 
a central component of a complex that links cell surface cadherins to the actin cytoskeleton, 
broadens our perspective on the cellular and molecular basis of this disease. Intriguingly, a 
juvenile form of macular dystrophy (MIM 114021) that results in atrophy and pigmentary 
changes has been linked to variants in CDH3, which encodes P-cadherin.26 Thus, cellular 
components that participate in cadherin-based intercellular adhesion may be implicated in 
macular dystrophies.
Affected individuals of the families carrying CTNNA1 mutations show a remarkable 
interfamilial and intrafamilial heterogenous phenotype, which has also been observed in 
other families with butterfly-shaped pigment dystrophy due to mutations in PRPH2.4,27 
In advanced cases, the phenotype can progress to chorioretinal atrophy or subretinal 
neovascularization.4,6,8,9 At this stage the disease can be indistinguishable from advanced 
age-related macular degeneration (AMD), a common cause of visual impairment in the 
elderly, characterized by yellow deposits called drusen,28 which may progress to geographic 
atrophy or choroidal neovascularization.29 Genetic testing of the CTNNA1 and PRPH2 genes 
can thus aid in establishing the differential diagnosis between advanced cases of butterfly-
shaped pigment dystrophy and AMD.29 
Our studies revealed parallel clinical phenotypes in individuals with butterfly-shaped 
pigment dystrophy carrying a variant allele of CTNNA1 and in homozygous Ctnna1tvrm5 
mice, including pigmentary abnormalities, focal RPE thickening and elevated lesions, and 
RPE dysfunction in response to light. These observations imply that similar pathogenic 
mechanisms underlie CTNNA1/Ctnna1-associated disease in both species, and suggest that 
Ctnna1tvrm5 mice accurately model the human disease. Importantly, the dysmorphology 
of RPE cells observed in Ctnna1tvrm5 mice raises the possibility that RPE defects are a 
precipitating event in the disease. Although the phenotype is stronger in homozygous 
Ctnna1trmv5 mice, we also observed defects in heterozygous Ctnna1trmv5 mice such as a 
decrease in RPE function and large multinucleated RPE cells. This indicates that in mice the 
Ctnna1 variant also has an effect in heterozygous state, albeight less detrimental than in the 
homozygous state, suggesting a gene-dosage effect. Although Ctnna1 is widely expressed, 
it is likely that the variants affect an RPE-specific function of α-catenin 1, as the human 
disease affects only the eye, and the mouse Ctnna1tvrm5 mutation is less disruptive than a 
Ctnna1 gene-trap allele, which results in embryonic lethality,30 or a conditional knockout 
allele targeted to retinal progenitor cells, which causes dramatic retinal developmental 
defects.31 Thus, our results point to a causative role of RPE defects in butterfly-shaped 
pigment dystrophy due to CTNNA1 variants. 
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Shed RPE cells in the subretinal space may contribute to the focal thickening of the RPE 
and melanin pigment abnormalities in patients with butterfly-shaped pigment dystrophy. 
Consistent with shedding, we observed pigmented cells on the RPE apical surface and 
aberrant F-actin structures in Ctnna1tvrm5 mice that were similar to shedding structures in 
chick embryonic RPE32 and in mouse models of RPE injury.33,34 The fate of shed RPE cells is 
unknown. Some may survive to accumulate and/or proliferate locally at lesions, creating 
a double layer of pigmented cells as observed in our study. Double RPE layers have been 
documented in atrophic lesions of geographic atrophy35 and in mouse models that target 
damage to the RPE.33,36 Alternatively, shed RPE cells may die and be phagocytosed by 
intact RPE or immune cells. Subretinal macrophages containing melanin pigment granules, 
presumably derived from the RPE, have been observed in mouse models of retinal 
degeneration.37,38 Based on these findings, we propose that RPE shedding is an initial event 
leading to changes in melanin pigment distribution in CTNNA1-associated butterfly-shaped 
pigment dystrophy. 
The large eosinophilic inclusions observed in the RPE of homozygous Ctnna1tvrm5 mice 
bear similarities to hard drusen – small (<63 µm diameter) spherical or dome-shaped 
eosinophilic masses that are located between RPE cells and Bruch’s membrane and are 
associated with AMD when abundant.28,39-41 The eosinophilic inclusions possess internal 
substructure, as is often observed in hard drusen,42 and their laminar appearance is 
reminiscent of the ‘onion-skin’ feature of drusen associated with Doyne honeycomb retinal 
dystrophy/Malattia leventinese.43 The inclusions are contiguous with the RPE and appear to 
be intracellular, although the cell type in which they are localized is unknown. Based on the 
similar OCT appearance of elevated lesions in affected patients and mice, we suggest that 
the deep retinal lesions in butterfly-shaped pigment dystrophy derive from aberrant cells in 
the RPE that accumulate an excess of eosinophilic material. 
The presence of abnormally large multinucleate RPE cells in Ctnna1tvrm5 mutant mice 
may indicate a defect in RPE cytokinesis. This feature was more apparent in older mice, 
indicating that these changes accumulate with age in the RPE cell population, which is 
considered largely postmitotic. RPE hyperproliferation and a cytokinesis defect due to 
the Ctnna1tvrm5 mutation may yield this phenotypic feature through repeated rounds of 
nuclear division without cell division. Alternatively, altered RPE cell adhesion due to the 
Ctnna1tvrm5 mutation may lead to syncytia, which are multinucleate cells formed by cell 
fusion. Large multinucleate cells observed upon conditional deletion of Ranbp2 in the RPE 
were interpreted previously as syncytia.44
The clustering of the pathogenic human and mouse variants within the α-catenin 1 
structure suggests that the variants have a shared effect on the activity of this multifunctional 
protein. The variants may disrupt the stability of adherens junctions, which are found in RPE 
cells and are likely critical for maintaining the integrity of the epithelium.22 As our studies 
do not indicate a decreased affinity of α-catenin 1 variants for vinculin, the mutations may 
disrupt the binding of other actin-associated proteins or alter the conformational response 
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to mechanical stress. More recent studies have revealed that α-catenin 1 participates in 
multiple signal transduction pathways independent of its role in cell adhesion, such as the 
NF-ΚB, Ras-MAPK, Hedgehog and Hippo signaling pathways. 45,47 Subsequently, the variants 
may perturb a function of α-catenin 1 in various cellular processes regulated by these 
pathways, such as cytokinesis, cell differentiation or growth.45-47
In conclusion, this study identified mutations in the human CTNNA1 and mouse Ctnna1 
genes as a cause of macular dystrophy and RPE dysmorphology with accompanying 
photoreceptor loss. Our findings have clinical implications, since genetic testing of the 
CTNNA1 gene can aid in establishing the differential diagnosis between butterfly-shaped 
pigment dystrophy and AMD. Additionally, this gene may be used as a target for the 
development of gene therapy in individuals with butterfly-shaped pigment dystrophy due to 
CTNNA1 mutations.48 Finally, future studies may focus on identifying other components of 
the RPE cell adhesion complexes that contribute to macular disease, and on understanding 
the cellular and molecular mechanisms by which α-catenin 1 dysfunction affects RPE 
turnover, proliferation, and the pathogenesis of pattern dystrophy.
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“Doctor, my father and three of my sisters became blind from macular degeneration; what 
is my risk of getting the same disease?” Ophthalmologists are confronted frequently with 
this type of question, which can be answered with confidence in the case of some retinal 
dystrophies with known genetic causes. On the other hand, this question is notoriously 
difficult to answer in the case of complex retinal diseases such as age-related macular 
degeneration (AMD), despite the fact that risk assessment is particularly important to—
and desired by—patients with affected relatives. Little is known regarding the risk of AMD 
among individuals with a positive family history of AMD, and little is known regarding 
the differences in risk factors between familial and sporadic AMD. This thesis addresses 
both the clinical and genetic differences between familial AMD and sporadic AMD, and it 
explores the risk assessment of AMD in subjects with a positive family history of AMD. To 
facilitate the development of personalized medicine for the macular disorders described 
in this thesis, preventive and therapeutic decision-making should be tailored to the 
clinical and genetic characteristics of both the individual patient and the patient’s family 
history. This chapter elaborates on the primary findings of this thesis, placing them in a 
broader perspective and discussing their clinical relevance, with particular emphasis on 
the importance of establishing a strong collaboration between the ophthalmologist and 
geneticist for providing appropriate medical care and pursuing scientific research regarding 
familial macular diseases.
6.1 Primary findings and clinical implications 
6.1.1 Differential diagnosis in familial macular diseases
Given the phenotypic heterogeneity of AMD, several other macular disorders have 
characteristics similar to AMD and can therefore be confused with the diagnosis AMD 
(Chapter 2). This overlap in clinical presentation may suggest related underlying molecular 
mechanisms and can therefore aid in the understanding of the pathogenesis of AMD. On 
the other hand, because macular dystrophies and AMD differ in several important aspects, 
including age at onset, visual prognosis, and inheritance pattern, the ability to reliably 
distinguish between these entities is extremely important. Monogenic macular dystrophies 
are caused by the inheritance of rare, highly penetrant genetic variants (often referred to as 
mutations); these macular dystrophies generally present at an earlier age than multifactorial 
diseases such as AMD. On the other hand, because AMD is a multifactorial disease, its 
onset is associated with non-genetic (i.e., environmental) factors and a combination of 
several common genetic variants. However, some AMD patients carry rare, highly penetrant 
genetic variants, and these patients differ clinically from AMD patients who do not carry 
such rare genetic variants (see Chapter 3.1), as they have a significantly earlier age at onset 
(Figure 6.1).1, 2
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Figure 6.1 Contribution of non-genetic (i.e., environmental) and genetic factors in sporadic and 
familial age-related macular degeneration (AMD), cuticular drusen, and inherited macular 
dystrophies. Age-related macular degeneration (AMD) is a multifactorial disease caused by both non-
genetic and genetic factors. In patients with a positive family history for AMD (familial AMD) and 
patients with cuticular drusen (CD), a subtype of AMD, genetic factors play a more important role 
than in sporadic AMD patients. In contrast to AMD, dominant cystoid macular dystrophy (DCMD) 
and butterfly-shaped pigment dystrophy (BSPD) are monogenic macular dystrophies with autosomal 
dominant inheritance. AMD patients with a positive family history have a significantly earlier onset of 
first symptoms than sporadic patients. The presence of a rare variant in the CFI, C9, or C3 gene results 
in a lower age at onset in AMD patients, and a rare variant in the CFH gene results in an earlier onset 
in patients with CD. This is consistent with the general finding of an inverse correlation between the 
degree to which genetics contributes to a disease and its age at onset. Therefore, monogenic diseases 
such as BSPD and DCMD are early-onset diseases, whereas multifactorial AMD is a late-onset disease.
6.1.2 Phenotype and genotype
AMD is a highly prevalent multifactorial degenerative disease of the macula that arises 
from a complex interaction between genetic susceptibility variants, environmental factors, 
and age-associated changes in the retina, retinal pigment epithelium (RPE), and choroid.3-6 
Unlike inherited macular dystrophies—in which a highly penetrant mutation is the primary 
cause of the disease—several genetic variants are associated to a greater or lesser extent 
with the development of AMD (Figure 6.1). The extent to which genetic factors play a role 
in the development of AMD is generally correlated with the phenotype and the individual’s 
family history of AMD (Figure 6.1 and 6.2). Studies have shown that related family members 
can present with strikingly similar phenotypes.7, 8 In addition, we found a significantly higher 
prevalence of geographic atrophy (GA) in patients with familial AMD than in patients with 
sporadic AMD (Chapter 3.1). This finding suggests that genetics may play a larger role in 
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the development of GA than in the development of choroidal neovascularization (CNV). 
This notion is supported by the higher prevalence of non-exudative AMD compared to 
neovascular AMD in twins studied by Gottfredsdottir et al.7 On the other hand, neovascular 
AMD can also have high concordance in twins.9 
Patients with familial AMD also present more frequently with cuticular drusen (Chapter 
3.1), a subtype of AMD that often runs in families and has a relatively early age at onset. 
The cuticular drusen phenotype is more strongly associated with the CFH Y402H variant 
than AMD without cuticular drusen, whereas smoking is more strongly associated with the 
AMD phenotype without cuticular drusen.10 This is also the case for several environmental 
risk factors, which have a lower association with familial AMD than with sporadic AMD 
(Figure 6.2). 
Figure 6.2 Schematic summary of the primary findings in this thesis with respect to familial AMD, 
showing the complex interplay between positive family history and rare genetic variants with risk 
factors and phenotypic characteristics. AMD is caused by a combination of both genetic and non-
genetic factors. A positive family history for AMD results in a lower risk effect of several environmental 
risk factors and the ARMS2 SNP. Patients carrying a rare variant in a complement gene (CFH, CFI, C9, 
or C3) frequently have a positive family history; however, thus far a rare genetic variant has been 
identified in only a minority of families with AMD. Patients with a positive family history and patients 
who carry a rare genetic variant are more likely to have geographic atrophy and cuticular drusen, an 
earlier age at first symptoms, and they may have higher levels of complement activation (i.e., a higher 
C3d/C3 ratio). The red arrows indicate an increased effect, and the green arrows indicate a decreased 
effect. BMI = body mass index; AMD = age-related macular degeneration; SNPs = single nucleotide 
polymorphisms
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In contrast, the relatively common ARMS2 SNP A69S, which confers a higher risk of 
developing CNV than GA,11-13 is associated more strongly with sporadic AMD than familial 
AMD (Chapter 3.3). In addition to the previously identified rare variants in the CFH, CFI, 
C9, and C3 complement genes,14-17 we also identified several novel, rare variants in the 
CFH gene (Chapter 3.5), and we demonstrated that rare variants are more common 
among individuals with a positive family history than among patients with sporadic AMD 
(Figure 6.2). Although several rare genetic variants that confer a high risk of AMD have 
been identified in familial AMD patients, most of these rare variants did not completely 
segregate within the families (Chapter 3.4). Together, these findings indicate that even in 
densely affected families, AMD is not strictly monogenic, but is also a multifactorial disease, 
with genetic factors playing a strong—but not exclusive—role. 
The estimated heritability of AMD ranges from 45% (for early-stage disease) up to 70% 
(for advanced-stage disease).18 Many AMD-associated SNPs have been identified, and 
together these SNPs can account for up to 65% of AMD heritability.12, 19 Furthermore, several 
rare genetic variants have been identified in AMD.14, 15, 20 Compared to common genetic 
variants, rare variants are more likely to play a causal role and may have a larger functional 
impact. Consequently, these rare genetic variants may offer more insight into disease 
pathophysiology and may provide more suitable targets for new therapies.21 Additional 
genetics research in AMD patients and families will likely reveal additional rare variants, 
thus explaining some of the currently ‘missing’ heritability. Gene-environment interactions 
and other genetic factors—for example, copy number variation, mitochondrial sequence 
variations, and epigenetics—may also play a role in the development of AMD;22 however, 
little is currently known regarding these putative additional genetic factors. Epigenetics 
refers to heritable modifications in gene activity due to a change in genomic structure 
and function without a change in the DNA sequence itself. Epigenetic mechanisms that 
regulate gene expression include DNA methylation, histone modifications, and microRNAs 
(small non-coding RNAs).22, 23 These mechanisms regulate gene transcription in a variety 
of ways, for example by affecting DNA accessibility, recruiting DNA-binding proteins, and 
post-transcriptional downregulation of gene expression.23 Thus, epigenetic mechanisms 
may be a mechanistic link between environmental risk factors and the development of 
AMD,24 and they may explain how interactions between genetics and the environment give 
rise to particular phenotypes.22 Although epigenetics may explain some of the remaining 
heritability, the extent to which these epigenetic effects contribute to AMD is currently 
unknown. 
6.1.3 AMD risk prediction
The ability to accurately predict the risk of developing AMD is important in genetic 
counseling, particularly for individuals with affected family members. In addition, prediction 
models can help identify the high-risk patients who will benefit most from newly emerging 
preventive and therapeutic strategies. Furthermore, predictive tests can identify patients 
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who do not carry the known genetic risk factors and may therefore benefit from additional 
genetic testing in order to identify the underlying genetic cause(s).
Several commercial tests that assess the risk of developing advanced AMD are (or have 
been) available on the market. These tests are based on several common genetic risk factors 
(i.e., SNPs) and in some cases are used in combination with demographic data. However, 
these commercial prediction tests have only limited value and are not yet suitable for 
clinical applications in the general population,25 as it is currently not possible to prevent the 
development of early or intermediate AMD. Nutritional supplements of the Age-Related 
Eye Disease Study (AREDS) formulation only prevent the progression to advanced AMD in 
AMD patients with extensive intermediate or large drusen, or in patients with advanced 
AMD in one eye.26 Therefore, clinicians are confounded with respect to giving advice to 
individuals who have a high risk of developing advanced AMD but do not meet these 
clinical criteria.25 Population-based risk prediction for AMD may become more justifiable if 
a preventive therapy becomes available, particularly if this therapy is suitable for all high-
risk individuals. Additionally, population-based risk prediction will be more suitable for 
clinical use with the introduction of a preventive intervention that goes beyond good health 
practices (like quitting smoking, eating a balanced diet, exercising regularly, and taking 
nutritional supplements) and includes risk and cost elements that limit this intervention to 
individuals with increased risk.
In general, the relatives of patients with familial AMD tend to ask the most questions 
regarding their risk of developing AMD, as they are directly confronted with the disease and 
their family members’ visual impairment. Although a positive family history is a significant 
risk factor for developing AMD, most research-based and commercial prediction models 
do not take family history into account; rather, they are based only on demographics, 
environmental factors, and common SNPs. Thus, patients who will develop AMD due to 
other factors (e.g., rare genetic variants, which play an important role in the development 
of AMD in (part of the) cases of familial AMD) will be missed by these models (Chapter 3.4). 
Incorporating family history into these AMD risk prediction tests will therefore improve 
their accuracy. 
Previous studies have shown that including an extended set of genetic variants can 
improve a model’s predictive ability.27 Optimal prediction models currently have an area 
under the curve of 0.80-0.90, which is highly predictive but far from perfect.27, 28 Adding rare 
genetic variants in addition to demographic, environmental, and common genetic factors 
may further refine personalized risk prediction.25, 28 However, testing for rare genetic variants 
in prediction models may be problematic, as the occurrence of these variants may be limited 
to specific geographic regions and/or populations, or may even be specific to one family, 
making it difficult to determine their effect size for developing AMD. The prevalence of four 
rare variants in complement genes was considerably lower in the general AMD population 
compared to densely affected families with AMD (Chapter 3.4). Therefore, although rare 
variants may not account for a large percentage of AMD risk in the overall population, they 
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can have a strong effect on the risk of developing AMD in certain individuals and in AMD 
families, for whom the ability to predict AMD risk is highly desirable.21 
The number of siblings and/or parents with AMD can also provide important information 
regarding one’s risk of developing AMD. For example, belonging to a large, densely affected 
family markedly increases an individual’s risk of AMD (Chapter 3.2). When a subject has 
three or more first-degree relatives with AMD, we found that adding SNP analyses to a 
model that already includes the subject’s extended family history and several non-genetic 
factors does not increase the model’s predictive value. This finding suggests that the risk 
effect of common SNPs may be smaller in familial AMD than in sporadic AMD, as suggested 
by the inverse interaction between family history and the major ARMS2 allele (Chapter 
3.3), and/or may indicate that the risk conferred by common variants is already included 
in the risk of a positive family history. Therefore, analyzing common AMD-associated risk 
SNPs may not be necessary in order to predict AMD risk in members of families with many 
affected relatives. 
6.2 Future perspectives
6.2.1 Preventive and therapeutic options for AMD
6.2.1.1 Nutritional supplements
Nutritional supplements of the AREDS formulation (containing vitamin C, vitamin E, zinc, 
copper, lutein, and zeaxanthin) have been shown to reduce the risk of progressing to 
advanced AMD in high-risk patients by approximately 25%.26 These high-risk patients had 
AREDS category 3 (intermediate AMD) or category 4 (unilateral advanced AMD) in at least 
one eye. The preventive effect of such nutritional supplements may depend on the patient’s 
genotype,29, 30 although this is somewhat controversial.31 Studies suggest that strong genetic 
predisposition to AMD conferred by the presence of two risk alleles in the CFH gene limits 
the benefits available from (supplements containing) zinc.29, 30 On the other hand, Chew 
et al.31, 32 failed to confirm this interaction between genotype and the preventive effect of 
nutritional supplements in a replication and residual cohort, demonstrating that AREDS 
supplements reduced the rate of AMD progression in all genotype groups.
The Rotterdam Study found that high dietary intake of zinc and nutrients with 
antioxidant properties reduces the risk of early AMD selectively in patients with high genetic 
risk based on the presence of two CFH risk alleles and at least one ARMS2 risk allele.33 If 
future research can replicate these results, they may have clinical implications in terms of 
providing personalized medicine based on genotype-specific prevention. Because patients 
with familial AMD and unaffected family members have a higher frequency of the CFH 
Y402H and ARMS2 A69S risk alleles than sporadic individuals (Chapter 3.3), these results 
suggest that consuming high amounts of zinc and nutrients with antioxidant properties 
can reduce the risk of developing AMD, particularly in individuals with a positive family 
history. Further research is needed in order to determine the beneficial effects of taking 
General discussion
275
6
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R40
R41
antioxidants and zinc in familial subjects with a high genetic risk with respect to the ability 
to reduce their risk of developing early AMD and/or progressing to advanced AMD. 
Recent studies indicate that nutritional supplements may affect the complement 
system, which plays a central role in the pathogenesis of AMD; for example, taking lutein 
supplements decreases levels of the complement activation products C5a and C3d in the 
serum.34 In addition, zinc supplements decrease both C5a levels and the C3d/C3 ratio in 
AMD patients with elevated complement activation.35 Rare variants in complement genes 
are more common among patients with familial AMD compared to sporadic AMD, (Chapter 
3.4), and complement activation seems to play a more important role in the development 
of familial AMD (Chapter 3.3). Therefore, nutritional supplements may have a larger 
preventive effect in familial AMD than in sporadic AMD, making familial subjects particularly 
valuable for testing the effects of supplements. However, it will be challenging to prove 
such effects at a statistically significant level, since a large cohort size would be required.
Because AREDS nutritional supplements have been shown to reduce the risk of 
progressing to advanced AMD, and because subjects with a positive family history of 
advanced AMD have a ten-fold higher risk of developing advanced AMD than sporadic 
subjects,36 individuals with familial AMD should be advised to take these nutritional 
supplements.
6.2.1.2 Complement modulation
The complement system plays an important role in the pathogenesis of AMD and is therefore 
a promising target for preventive and/or therapeutic interventions. The major CFH Y402H 
SNP is strongly associated with atrophic AMD,12 and rare variants in complement genes were 
most often present in AMD patients with GA (Chapter 3.4), suggesting a strong association 
between the complement system and the development of GA. Currently, no therapy is 
available for treating or preventing GA, and therefore the development of treatments for 
GA is of great importance.
The complement system is a complex cascade that is tightly controlled by specific 
regulatory proteins and affects a wide range of target pathways (Figure 6.3). The complement 
system can be modulated by targeting these regulatory components.37-43 Several strategies 
for modulating complement activation in patients with GA are currently being evaluated in 
both clinical and pre-clinical trials.44, 45 Preliminary studies have been rather disappointing;37, 
46 however, a phase II trial evaluating the effect of an antibody that blocks complement 
factor D (a regulator of the alternative complement pathway) has shown promising results 
in terms of inhibiting systemic complement activity and reducing the progression of GA.45, 47 
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Figure 6.3 The complement system is a tightly regulated cascade that plays an important role in the 
pathogenesis of AMD. Several complement components have been identified in drusen, the hallmark 
of AMD. Moreover, the C3d/C3 ratio, a measure of complement activation, is elevated in AMD 
patients. In addition, many AMD-associated SNPs and rare genetic variants are located in genes that 
encode complement components. In this thesis, we focused on the C3d/C3 ratio (circled in green) and 
the presence of rare variants in the complement factor H (CFH), complement factor I (CFI), component 
9 (C9), and component 3 (C3) genes (red boxes).
In addition to searching for new therapeutic options, researchers must determine in which 
patients—and at which disease stage—newly developed therapeutic options will provide 
the greatest benefit, thereby facilitating the implementation of personalized medicine.44 
The relatively high frequency of rare variants in complement genes among familial AMD 
patients—coupled with our finding that increased complement activation is more strongly 
associated with familial AMD than sporadic AMD—suggests that familial individuals may 
benefit most from complement-modulating therapies. Because many years of chronic 
local complement activation likely underlies the formation of drusen (and their associated 
complications in AMD), complement inhibitors are probably most effective after prolonged 
administration and before the disease has developed to an advanced stage. Individuals 
in families with AMD generally present early in the course of the disease due to their 
increased risk and their increased awareness of disease-associated visual symptoms. 
Therefore, in addition to reducing environmental risk factors (for example, by quitting 
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smoking, increasing physical activity, and eating a balanced diet, all of which will benefit 
all individuals, regardless of their family history), inhibiting the complement system in 
individuals with a family history of AMD may be more effective when started before the 
onset of irreversible visual loss. 
Because the complement system is an essential component of the innate immune 
system, chronic treatment with complement inhibitors may increase one’s susceptibility 
to infections. Therefore, in order to justify pharmaceutical modulation of the complement 
system in patients with early AMD, the likelihood of progressing to advanced AMD needs to 
be predicted with high accuracy, thus balancing the benefits against any possible adverse 
effects. This emphasizes the high importance of developing models that accurately predict 
progression to advanced AMD.
6.2.2 Genetics and therapeutic options for dominant cystoid macular dystrophy
We proposed a classification system for DCMD in which the disease can be classified into 
three stages, which correlated with age and visual acuity. Currently available treatment 
options for patients with DCMD are limited to carbonic anhydrase inhibitors, such as 
acetazolamide, and octreotide acetate, which reduce cystoid fluid collections, and the 
treatment of DCMD-associated complications such as angle-closure glaucoma (Chapter 4). 
Although the causative genetic mutation and the identity of the gene at the DCMD locus 
have not yet been identified, genetic testing of polymorphic markers at the DCMD locus 
can be used to confirm the diagnosis and allows for genetic counseling of family members 
who may be currently asymptomatic, as we observed that the disease haplotype at the 
DCMD locus has complete penetrance. Moreover, although the disease can potentially 
be prevented by taking steps to avoid passing the affected allele to the offspring, this 
approach has complicated ethical considerations. Nevertheless, identifying the causative 
gene can provide important clues regarding the pathogenesis of DCMD and may improve 
our understanding of the pathophysiological pathways underlying other diseases with 
cystoid macular edema, including retinal dystrophies, uveitis, diabetic macular edema, and 
after ophthalmic surgery. Identifying the affected gene and the downstream pathway may 
ultimately lead to the development of new treatment strategies that address the primary 
molecular defect underlying DCMD.
6.2.3 Genetics and therapeutic options in butterfly-shaped pigment dystrophy
Butterfly-shaped pigment dystrophy (BSPD) is inherited in an autosomal dominant fashion, 
and only in a fraction of patients a mutation in the PRPH2 gene is identified.48 Genetic 
counseling is only possible for relatives of patients who have an identified genetic cause. 
Therefore, our identification of mutations in the CTNNA1 gene (Chapter 5) in BSPD patients 
who do not carry a mutation in the PRPH2 gene is an important finding. However, only three 
of our 19 BSPD patients carry a mutation in the CTNNA1 gene, thus explaining only a small 
fraction of these patients. Further research is needed in order to identify the genetic cause 
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of BSPD in patients who do not carry a mutation in either the PRPH2 gene or the CTNNA1 
gene. Nevertheless, identifying the disease mechanism underlying CTNNA1 mutations may 
provide important insight into the pathogenesis of BSPD and other RPE dystrophies and 
may ultimately lead to the development of new treatment strategies.
6.2.4 Gene-based therapy
Significant progress has been made towards understanding the genetic pathogenesis 
of retinal diseases, and ocular gene therapy research has improved the safety and 
specificity of vector-based ocular gene transfer methods, providing a major step forward 
in the development of gene replacement therapy.49 The ultimate goal of gene replacement 
therapy is to replace the mutated gene with a fully functional gene, leading to normal levels 
of functional protein. In diseases caused by a loss-of-function mutation, which are common 
for autosomal recessive and X-linked disorders, introducing a normal copy of the missing or 
defective gene can provide cells with normal functioning proteins. The safety and putative 
efficacy of gene therapy strategies have been demonstrated in autosomal recessive Leber 
congenital amaurosis and X-linked choroideremia.50-52 However, in the case of mutations 
that cause a gain-of-function or dominant-negative effect (for example, in most autosomal 
dominant diseases, perhaps including the DCMD and BSPD phenotypes described in this 
thesis), the mutant allele must be silenced in order to restore function.53 
Our identification of mutations in the CTNNA1 gene in a subset of patients with BSPD 
(Chapter 5) together with the future identification of the causative gene in DCMD will likely 
provide gene-based therapeutic targets for treating these autosomal dominant macular 
dystrophies. Interestingly, a role for gene therapy has even been suggested for multifactorial 
AMD, as virus-encoded RNA-interference effector molecules can silence endogenous VEGF 
gene expression, thereby inhibiting neovascularization.54, 55 In advanced disease stages in 
which significant, irreversible retinal structural damage has already occurred (for example, 
in stage 3 DCMD and fovea-involving GA), replacing photoreceptors and/or RPE cells using 
stem cell therapy, an approach currently being tested at the experimental phase, may 
provide a promising therapeutic option in the future.49, 56, 57 Other artificial vision-restoring 
strategies such as electronic retinal implants are also being developed and may become 
available after future improvements for use in patients with severe visual impairment due 
to inherited macular diseases.58
6.2.5 The importance of close collaboration between ophthalmology and genetics
Unraveling the genetic causes of retinal diseases and the emerging availability of advanced 
genetic sequencing techniques can help ophthalmologists to establish the correct clinical 
diagnosis. Therefore, a close collaboration between ophthalmologists and geneticists is 
essential for establishing procedures for diagnosing inherited eye diseases. In addition, 
genetic testing will likely be incorporated into personalized medicine in the future, as the 
onset of AMD, the progression of AMD to advanced stages, and the patient’s treatment 
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response may depend on the patient’s unique genotype with respect to several AMD risk-
associated genes.13, 59-68 
Optimal personalized healthcare requires a complete overview of the patient’s 
environmental, clinical, and genetic profile during diagnosis, during the course of the 
disease, and when evaluating therapeutic procedures. Therefore, combining the expertise 
of ophthalmologists with the power of genetics is essential in both patient care and 
scientific research. 
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SUMMARY
Degenerative diseases affecting the macula constitute a major cause of incurable vision 
loss and exhibit considerable clinical and genetic heterogeneity, ranging from early-onset 
monogenic diseases such as dominant cystoid macular dystrophy (DCMD) and butterfly-
shaped pigment dystrophy (BSPD) to multifactorial late-onset age-related macular 
degeneration (AMD). 
In the Western world, AMD is the most common cause of irreversible vision loss among 
the elderly. AMD is caused by a combination of demographic, environmental, and genetic 
risk factors. Despite its multifactorial etiology, AMD can run in families, although little is 
known regarding the clinical and genetic differences between familial AMD and sporadic 
AMD. The aim of this thesis is to increase our understanding of the clinical features of AMD 
and the contribution of environmental and genetic risk factors to the risk of developing 
AMD in patients with a family history of AMD. This information may provide individuals 
with more accurate information regarding their unique risk for developing AMD, particularly 
among relatives of patients with familial AMD, for whom this issue is highly relevant. 
Chapter 1 provides a general introduction to the anatomy and function of the retina, the 
techniques commonly used to evaluate these features, and a brief background regarding 
the field of molecular genetics. We also describe the clinical and genetic features of AMD, 
DCMD, and BSPD.
Given its heterogeneous presentation, distinguishing AMD from other macular diseases 
that mimic the features of AMD can be challenging to clinicians. Importantly, this clinical 
overlap can potentially lead to misdiagnosis. In Chapter 2, we discuss the characteristics 
of AMD and the macular dystrophies that can mimic AMD, and we present an overview of 
overlapping and distinguishing clinical features. This information can help clinicians choose 
the most appropriate clinical and/or genetic tests in order to correctly diagnose patients. 
Furthermore, it can provide patients with more accurate prognostic information.
Approximately one-third of all patients with AMD have at least one first-degree relative 
with AMD; in such cases, the patient is diagnosed with familial AMD. In Chapter 3, we 
investigate the importance of having a positive family history of AMD with respect to both 
the clinical and genetic aspects. 
Chapter 3.1 reports that the initial onset of symptoms in patients with familial AMD 
occurs an average of three years earlier than in patients with sporadic AMD. Although ageing 
and smoking are associated with both familial and sporadic AMD, low physical activity and 
daily consumption of red meat are significantly associated with only the sporadic form of 
AMD. Clinically, both geographic atrophy and cuticular drusen are nearly twice as prevalent 
among patients with familial AMD compared to patients with sporadic AMD; however, no 
difference was observed in early, intermediate, and neovascular AMD. 
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Chapter 3.2 discusses the important role that a positive family history of AMD plays in 
an individual’s risk of developing AMD. Particularly in large, densely affected AMD families 
the positive family history can have a high impact on the risk of developing AMD. Therefore, 
we created a model for predicting AMD that includes family history, demographics, and 
environmental risk factors. This model was found to be valid for predicting both familial 
AMD and sporadic AMD. Extending the model by incorporating AMD-associated common 
genetic variants (also known as risk-associated single-nucleotide polymorphisms, or risk 
SNPs) increased the model’s predictive value for sporadic AMD. In contrast, including 
common SNPs in the risk prediction model had no effect on the predictive value in 
individuals from AMD families with three or more affected relatives. 
In Chapter 3.3, we tested two major AMD-associated SNPs (in the CFH and ARMS2 
genes), and the results indicate that the major risk SNP in ARMS2 interacts with positive 
family history and does not play a role in the development of AMD in patients with familial 
AMD. In contrast, the levels of complement activation are slightly higher in patients with 
familial AMD (particularly in subjects with a densely affected family) than in patients with 
sporadic AMD.
Chapter 3.4 discusses our finding that 6.4% of patients with AMD carry a rare, highly 
penetrant gene variant in the CFI, C9, or C3 gene. The presence of one of these rare variants 
is associated with a high familial occurrence, as more than half of all patients who carry 
such a rare variant report a positive family history for AMD, which is significantly more 
often than among affected non-carriers. However, these rare variants do not segregate fully 
with AMD in the affected families. Clinically, the initial onset of symptoms in carriers of 
these rare variants occurs an average of six years earlier than in non-carriers. In addition, 
these genetic rare variants are more prevalent among patients with advanced AMD and 
geographic atrophy than in patients with neovascular AMD. 
In Chapter 3.5, we report that a rare variant in the CFH gene is present in 8.8% of 
patients with the cuticular drusen phenotype of AMD. The age at onset for carriers of this 
rare CFH variant is nine years earlier than among non-carriers.
DCMD is a rare form of macular dystrophy characterized by early-onset cystoid fluid 
collections, hyperopia, and chorioretinal atrophy. In Chapter 4, we present a clinical 
classification of the DCMD phenotype into three stages based on 97 affected individuals in 
one large family in the Netherlands. We also discuss therapeutic options and the efficacy of 
these therapies in reducing cystoid fluid collections in stage 1 and stage 2 patients.
BSPD is another rare macular dystrophy with autosomal dominant inheritance. BSPD 
has been identified in a large Dutch family. Until recently, BSPD was associated exclusively 
with mutations in the PRPH2 gene; however mutations in the PRPH2 gene—and several 
other genes commonly associated with retinal disease—were excluded in this family. 
Chapter 5 presents the identification of a rare variant in the CTNNA1 gene in this family; 
this variant segregates fully with the disease. In addition, variants in this gene have been 
detected in two other families with BSPD. These variants have also been identified in a 
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mutant mouse model. The fundi of these mice exhibits yellowish flecks in the center of 
the retina, and morphological studies revealed that the structure of the retinal pigment 
epithelium is highly disrupted. The identification of this gene as the cause of the disease 
aids genetic counseling in families with BSPD.
Chapter 6 provides a general discussion of the main findings in this thesis and their 
clinical implications. The importance of a positive family history of AMD is described with 
respect to clinical features, the ability to predict the risk of developing AMD, and the effect 
of environmental and genetic risk factors. In addition, we describe the clinical implications 
of a positive family history with respect to nutritional supplements and modulation of the 
complement system. We also discuss how the identification of new genes associated with 
macular diseases can improve genetic counseling, facilitate studies of disease pathogenesis, 
and create opportunities for developing and testing novel therapies. Finally, we discuss 
the importance of personalized healthcare and the benefits of establishing a close working 
relationship between clinical ophthalmologists and geneticists in providing medical care. 
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SAMENVATTING
Degeneratieve ziekten die de macula aantasten vormen een belangrijke oorzaak 
van onherstelbaar visusverlies. Ze vertonen een aanzienlijke klinische en genetische 
heterogeniteit, variërend van monogene ziektebeelden die op jonge leeftijd ontstaan, 
zoals dominante cystoïde macula dystrofie (DCMD) en ‘butterfly-shaped’ pigment dystrofie 
(BSPD), tot leeftijdsgebonden maculadegeneratie (LMD) welke multifactorieel is en op late 
leeftijd ontstaat. LMD is de meest voorkomende oorzaak van onherstelbaar visusverlies in de 
oudere populatie in de Westerse wereld en wordt veroorzaakt door zowel demografische- 
en omgevingsfactoren als genetische factoren. LMD komt soms voor in families, maar er 
is weinig bekend over klinische en genetische verschillen tussen familiaire en sporadische 
LMD patiënten. Het doel van dit proefschrift is om inzicht te krijgen in klinische kenmerken 
en omgevings- en genetische factoren die een rol spelen bij het ontstaan van LMD bij 
patiënten met een positieve familiegeschiedenis voor LMD. Dit kan in de toekomst mogelijk 
leiden tot een betere voorspelling van het risico op LMD, in het bijzonder voor familieleden 
van LMD patiënten, voor wie deze vraag het meest dringend is.
Hoofdstuk 1 dient als een algemene introductie van de anatomie en functie van de retina 
en de technieken die worden gebruikt om deze zaken te analyseren, evenals een inleiding 
over genetica. Daarnaast beschrijft het de klinische en genetische aspecten van LMD, 
DCMD en BSPD.
Door de variabele presentatie van LMD kan het lastig zijn om LMD van diverse maculaire 
aandoeningen te onderscheiden die op LMD kunnen lijken. Deze klinische overlap kan 
leiden tot een verkeerde diagnose. In Hoofdstuk 2 bespreken we de kenmerken van LMD en 
de maculadystrofieën die op LMD kunnen lijken en wordt een overzicht gepresenteerd van 
overlappende en onderscheidende klinische kenmerken. Dit helpt oogartsen om de juiste 
klinische en genetische diagnostische testen te gebruiken om tot de correcte diagnose te 
komen en om de patiënt van de juiste prognostische informatie te voorzien.
Ongeveer een derde van de LMD patiënten heeft tenminste één (genetisch gezien) 
eerstegraads familielid met LMD, wat wij definiëren als familiaire LMD. In Hoofdstuk 3 
onderzoeken we het belang van een positieve familiegeschiedenis voor LMD en analyseren 
we klinische en genetische factoren in familiaire en sporadische patiënten. 
Hoofdstuk 3.1 toont dat de eerste visusklachten bij familiaire LMD patiënten drie 
jaar eerder ontstaan dan bij sporadische patiënten. Hoewel een hogere leeftijd en 
roken zowel met familiaire als met sporadische LMD zijn geassocieerd, zijn verminderde 
lichaamsbeweging en dagelijkse consumptie van rood vlees alleen met sporadische LMD 
geassocieerd. Klinische kenmerken zoals geografische atrofie en cuticulaire drusen komen 
bijna tweemaal zo vaak voor in familiaire patiënten als in sporadische patiënten, maar er 
werd geen verschil gevonden voor vroege, intermediaire en neovasculaire LMD.
Hoofdstuk 3.2 onderzoekt de invloed van een positieve familiegeschiedenis op het 
risico om LMD te ontwikkelen. Vooral in grote families waarin veel familieleden zijn 
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aangedaan is een positieve familiegeschiedenis sterk geassocieerd met een verhoogd risico 
om LMD te ontwikkelen. Op basis hiervan hebben wij een voorspellend model voor het 
ontwikkelen van LMD ontworpen, waarin naast demografische- en omgevingsfactoren ook 
de familiegeschiedenis is meegenomen. Het model was toepasbaar op zowel familiaire als 
sporadische individuen en uitbreiding van het model met LMD geassocieerde genetische 
varianten (SNPs) gaf een betere voorspellende waarde bij sporadische patiënten, maar niet 
bij personen die drie of meer aangedane familieleden hebben. 
In Hoofdstuk 3.3 zijn de twee belangrijkste LMD-geassocieerde SNPs in CFH en 
ARMS2 getest. De genetische variant in ARMS2 vertoont een interactie met een positieve 
familiegeschiedenis en speelt daarbij geen rol in de ontwikkeling van LMD bij familiaire 
patiënten. Daarentegen lijkt een verhoogde activiteit van het complementsysteem een 
belangrijkere rol te spelen bij familiaire patiënten dan bij sporadische patiënten, met name 
bij familiaire patiënten met veel aangedane familieleden. 
Hoofdstuk 3.4 toont de aanwezigheid van drie LMD-geassocieerde zeldzame genetische 
varianten in het CFI-, C9- of C3-gen in 6,4% van de patiënten met LMD. Deze drie zeldzame 
genetische varianten komen vaker voor in familiaire LMD patiënten en meer dan de helft 
van de patiënten die een zeldzame genetische variant dragen hebben een positieve familie-
anamnese voor LMD. Dit is beduidend meer dan bij patiënten die deze drie zeldzame 
varianten niet dragen. Deze zeldzame genetische varianten segregeren echter niet volledig 
met de ziekte in deze families. Bij patiënten die een zeldzame genetische variant dragen 
starten de visusklachten zes jaar eerder dan bij patiënten zonder een zeldzame genetische 
variant. Patiënten met geografische atrofie dragen vaker een zeldzame genetische variant 
dan patiënten met neovasculaire LMD. 
In Hoofdstuk 3.5 presenteren we zeldzame varianten in het CFH-gen in 8,8% van de LMD 
patiënten met het cuticulaire drusen subtype. Bij patiënten met een zeldzame genetische 
variant in het CFH-gen ontstaan de eerste visusklachten negen jaar eerder dan bij patiënten 
zonder een zeldzame variant.
DCMD is een zeldzame maculadystrofie, gekenmerkt door cystoïde vochtophopingen 
op jonge leeftijd, hypermetropie en chorioretinale atrofie. In Hoofdstuk 4 presenteren we 
een klinische classificatie van het DCMD fenotype in 3 stadia op basis van de bevindingen 
bij 97 personen uit één grote Nederlandse familie met DCMD. Verder gaan we in op de 
therapeutische opties en de effectiviteit om de cystoïde vochtophopingen te verminderen 
in patiënten met stadium 1 en 2 DCMD. 
BSPD is ook een zeldzame maculadystrofie, die onder andere voorkomt in een grote 
Nederlandse familie met een autosomaal dominant overervingspatroon. Tot dusver 
zijn alleen mutaties in het PRPH2-gen geassocieerd met BSPD. Mutaties in dit gen en in 
diverse andere genen zijn echter uitgesloten in deze Nederlandse BSPD familie. Hoofdstuk 
5 beschrijft de identificatie van een zeldzame variant in het CTNNA1-gen, die segregeert 
met de ziekte in deze familie. Daarnaast hebben we varianten in dit gen gevonden in twee 
andere families met BSPD en in een gemuteerd muismodel. Deze muizen vertonen gele 
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vlekken in de centrale retina en morfologische studies tonen een verstoorde structuur van 
het retinaal pigment epitheel. De identificatie van dit gen als nieuwe genetische oorzaak 
van deze ziekte kan genetische counseling bij families met BSPD verbeteren. 
Hoofdstuk 6 is een algemene discussie van de belangrijkste bevindingen in dit proefschrift 
en de klinische implicaties daarvan. Het belang van een positieve familiegeschiedenis voor 
LMD wordt beschreven voor de klinische kenmerken, risico-predictie en voor het effect 
van omgevingsfactoren en genetische factoren. Vervolgens worden de klinische implicaties 
voor het gebruik van voedingsupplementen en modulatie van het complementsysteem 
besproken ten aanzien van een positieve familiegeschiedenis voor LMD. De identificatie 
van nieuwe genen in aandoeningen van de macula kan genetische counseling en de 
opheldering van de pathogenese faciliteren en mogelijkheden bieden voor nieuwe 
therapieën. Tenslotte wordt besproken dat gepersonaliseerde gezondheidszorg de kwaliteit 
van zorg zal verbeteren, waarbij een goede samenwerking tussen oogartsen en genetici 
essentieel is. 
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Een promotieonderzoek kost veel energie en vergt doorzettingsvermogen, maar het 
geeft ook voldoening. Daarom zou ik mijn promotietraject willen vergelijken met mijn 
ontwikkeling in het hardlopen. Tijdens het promotieonderzoek heb ik in het oogheelkunde 
team van het RadboudUMC aan diverse hardloopwedstrijden deelgenomen, waaronder de 
Zevenheuvelenloop (15km). De eerste 5 kilometer ging snel voorbij, wat overeenkomt met 
mijn 1e promotiejaar, waarin ik alle AMD families heb verzameld. De tweede 5 kilometer 
gaat over de zware Zevenheuvelenweg en karakteriseert mijn 2e promotiejaar, waarin de 
exome sequencing van de verzamelde familieleden wat vertraging opliep, maar waarin ik 
veel heb geleerd in Oxford en mijn eerste artikel werd geaccepteerd. De laatste 5 kilometer 
gaat vals plat naar beneden, waardoor je kunt versnellen, overeenkomstig met mijn laatste 
promotiejaar. Het blijft dan echter wel goed opletten dat je niet struikelt, want er zitten 
hobbels in de weg en het wordt steeds drukker op het parcours. Daar staan ook steeds 
meer mensen aan de kant van de weg om aan te moedigen, wat het mogelijk maakt om dan 
nog de eindsprint in te zetten.
Gedurende het gehele traject van trainen, voorbereidingen en hardloopwedstrijden werd 
ik bijgestaan door heel veel mensen. Zo ook gedurende mijn promotietraject. Het is dan ook 
een onmogelijke taak om iedereen persoonlijk te bedanken die op welke manier dan ook bij 
mijn promotieonderzoek betrokken is geweest. Daarom wil ik hierbij iedereen bedanken! 
Echter, in het bijzonder wil ik de volgende mensen bedanken:
Beste Prof. dr. Hoyng, beste Carel, door jouw klinische ervaring wist je altijd het klinisch 
belang van het onderzoek voorop te stellen, iets wat bij wetenschappelijk onderzoek soms 
wordt vergeten. Je bent een man met humor die overal juist de mogelijkheden in ziet. 
Jij hebt me geholpen bij het verzamelen van familiaire AMD patiënten en de middelen 
geboden die nodig waren voor het onderzoek. Daarnaast heb jij mij ook de vrijheid gegeven 
om mezelf te ontwikkelen en de kans gegeven om me te bewijzen als onderzoeker. Ik wil je 
bedanken voor je vertrouwen in mij en mijn onderzoek.
Beste Prof. dr. Den Hollander, beste Anneke, jij keek mijn manuscripten altijd met 
grote precisie na. Je weet dingen zo te formuleren dat ik vaak bij het doornemen van 
jouw revisies dacht ‘ja, dat is precies wat ik bedoelde’, maar daar kwam ik dan zelf niet op. 
Jouw vermogen om onderzoeksplannen te schrijven en daarmee subsidies te werven en 
het vormen van de brug tussen genetica en de oogheelkunde is van groot belang geweest 
bij mijn onderzoeken. Tijdens mijn onderzoek ben jij tot professor benoemd, waardoor ik 
ineens twee promotoren had. Bedankt dat jouw deur altijd voor mij open stond en dat je 
altijd op de hoogte was van mijn projecten. Je was de constante factor in de begeleiding 
van mijn promotietraject.
Beste dr. Boon, beste Camiel, jouw grote kennis op het gebied van erfelijke retinale 
aandoeningen en jouw enthousiasme maken jou tot een uitstekende co-promotor. Dit, 
samen met je prettige klinische begeleiding en altijd positieve instelling waren voor mij 
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telkens weer een grote inspiratiebron. Ook toen je Nijmegen verliet bleef je me op afstand 
begeleiden of kwam ik naar je toe, zoals in Oxford. Dat was een leerzame en onvergetelijke 
periode voor mij, waarin ik de kunst van het schrijven (in zekere mate) van jou heb mogen 
leren. Bedankt voor je bijna 24-uur non-stop begeleiding, want zelfs ’s avonds en in de 
weekenden hadden we regelmatig skype-meetings en een mail werd vrijwel altijd diezelfde 
dag (of nacht) nog door jou beantwoord. Dank voor je enthousiasme en steun waar ik altijd 
op kon rekenen.
Beste Prof. dr. Keunen, tijdens klinische besprekingen en het schrijven van mijn review 
heb ik uw motiverende begeleiding, enorme kennis en expertise mogen ervaren. Hartelijk 
dank daarvoor. 
Beste Prof. dr. Klaver, beste Caroline, de combinatie van genetica, epidemiologie en het 
klinisch beeld maakte mijn onderzoek complex, maar deze combinatie is aan jou helemaal 
toevertrouwd. Bedankt voor jouw ideeën, begeleiding en inspiratie op de momenten dat ik 
zelf niet meer wist hoe ik verder moest gaan.
Beste Prof. Daha, dank dat u met uw expertise op het gebied van het complement 
systeem mij wilde bijstaan in de complement analyses binnen de diverse onderzoeken naar 
maculadegeneratie.
Dear Prof. dr Holz, dr. Monica Fleckenstein and dr. Steffen Schmitz-Valckenberg: I’m 
really thankful for our nice collaboration in writing the impressive review for the journal 
Progress in Retinal and Eye Research. 
I am also grateful to my German colleagues in the EUGENDA database for our close 
collaboration.
Dear Patsy Nishina, Mark Krebs and the analysts of the Jackson Laboratory: thank you 
for our collaboration which has strengthened our findings in humans and mice, leading to 
a great result. I am also grateful to the Belgian and Italian groups of Prof. dr. Bart Leroy and 
dr. Sandro Banfi, respectively, for providing us with clinical data of patients with pattern 
dystrophy. 
Kornelia Neveling, Stef Letteboer en Ronald Roepman, ik wil jullie bedanken voor 
jullie bijdrage in het functionele onderzoek naar patroon dystrofie. Dat toont maar weer 
dat onderzoek doen niet iets is wat je alleen doet, maar een samenwerking van allerlei 
expertises vereist. 
Bij wetenschappelijk onderzoek vind je meestal niet in één keer het antwoord op de 
vraag, maar dit gaat vaak stapsgewijs. Beste dr. Van Lith-Verhoeven, beste Janneke, jouw 
onderzoek naar ‘butterfly-shaped’ pigment dystrofie en dominante cystoïde macula 
dystrofie vormde een goede basis voor mijn vervolg onderzoek. Dank hiervoor.
Vervolgens een speciale plek voor mijn collega-promovendi. Myrte, Ramon, John, 
Dženita, Yara, Freekje, Nathalie, Stanley, Michel, Eveline, Constantin, Mahesh, Maartje, 
Shazia en Mark, bedankt voor jullie betrokkenheid en samenwerking, maar ook voor de 
gezelligheid samen. Met de klinische collega’s hoop ik in de kliniek weer fijn samen te 
mogen werken als arts-assistent.
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Frederieke, Bjorn, Tamara, en Eiko, hoewel ik niet altijd begreep waarom sommige 
genetische processen zoveel tijd in beslag namen en ik soms ongeduldig werd van jullie 
uiterst gedetailleerde verslaglegging van werkelijk alles wat jullie deden, is jullie genetische 
ondersteuning en begeleiding voor mij van groot belang geweest. En Frederieke, ik kan het 
nog steeds niet bevatten dat jij mij hebt kunnen overtuigen het onzichtbare te pipetteren en 
dat we daarmee uiteindelijk een nieuwe genetisch oorzaak voor ‘Butterfly-shaped pigment 
dystrofie’ hebben geïdentificeerd.
Bert, Tiny, en Saskia, hoewel jullie werk zich vooral achter de schermen plaatsvindt, gaf 
het me altijd een goed gevoel de bloedmonsters bij jullie af te kunnen leveren, want bij 
jullie was het in goede handen voor de verwerking ervan. 
Beste Arjen, jouw bio-informatische ondersteuning was onmisbaar om met de enorme 
hoeveelheid exome sequencing data van aangedane families te kunnen werken. Bedankt. 
Beste drs. Groenewoud, beste Hans. Jouw statistische kennis en inzicht hebben mij 
geholpen mijn enorme data bestanden te analyseren en te komen tot de resultaten van dit 
proefschrift. Tussen alle analyses door waren jouw boeiende verhalen over vlinders en de 
natuur telkens weer een gezellige en leerzame afleiding. Dank voor alles.
Het hele optometristenteam, en in het bijzonder Liesbeth en Jack, wil ik bedanken 
voor de goede ondersteuning bij de onderzoeken van mijn patiënten. Altijd kon ik bij jullie 
terecht voor het maken van extra afbeeldingen en het uitvoeren van extra testen, zelfs al 
was daar eigenlijk geen tijd voor.
Dames van het trialcentrum, bedankt voor jullie ondersteuning bij het verzamelen van 
mijn onderzoekspatiënten, in het bijzonder Anne voor al het belwerk voor de AMD dagen, 
maar ook voor jullie gezelligheid.
Collega’s van de verpleegpost, de administratie en het stafsecretariaat oogheelkunde 
bedankt voor de gezelligheid en jullie ondersteuning bij het maken van alle afspraken met 
de patiënten en met mijn begeleiders.
De studenten Sanne, Eveline en Leonie wie ik tijdens mijn promotieonderzoek heb 
mogen begeleiden: naast een leerzame periode voor jullie, was het voor mij ook leerzaam 
om jullie te begeleiden.
Arts-assistenten oogheelkunde, bedankt voor jullie gezelligheid en prettige 
samenwerking van afgelopen jaar, waarin ik mijn opleiding tot oogarts ben gestart en mijn 
proefschrift heb afgerond. Wat fijn om jullie als collega’s te hebben. 
Hardloopgroep B van Running-Elst, bedankt voor de ontspanning en hardlooptechniek. 
Uiteraard ben ik alle patiënten die hebben deelgenomen aan het onderzoek uiterst 
dankbaar, want zonder hun medewerking was mijn onderzoek onmogelijk. Hun blijk van 
waardering dat je onderzoek doet naar hetgeen wat voor hen van groot belang is, geeft 
mij energie om door te zetten. Het klinisch belang van wetenschappelijk onderzoek mag 
namelijk nooit uit het oog worden verloren en is uiteindelijk hetgeen waar je het allemaal 
voor doet!
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Al mijn vriendinnen, in het bijzonder Marieke, Ilse, Nicole en Manon, dank voor jullie 
belangstelling, steun en afleiding ondanks jullie eigen drukke agenda’s. We hebben het altijd 
erg gezellig, maar het is ook fijn om te weten dat we er altijd voor elkaar zijn. Vriendschap is 
een waardevol goed; het verdubbelt de vreugde en deelt de frustraties. 
Gary, José, Iris, Tim en Rogier, ik wil jullie bedanken voor alle gezelligheid en jullie 
oprechte interesse in mij als jullie ‘Nicolovic’ van het gezin. Het is mooi te zien dat Iris naast 
het piano spelen ook mijn passie voor de geneeskunde deelt. 
Mijn paranimfen Ilse en Myrte, wat fijn dat jullie op deze belangrijke dag naast mij 
willen staan, zoals jullie mij ook tijdens mijn promotieonderzoek altijd hebben bijgestaan. 
Met vragen of problemen kunnen we bij elkaar terecht en bieden we een luisterend oor. 
We hebben de hoogtepunten van het onderzoek samen gevierd en samen heel veel plezier 
gehad. Bedankt.
Als laatste, mijn lieve familie, welke voor mij heel belangrijk is. In het bijzonder mijn 
ouders, die mij hebben geleerd door te zetten en er alles uit te halen wat erin zit, want 
dat is waar ‘een echte Saksens’ voor staat en waar ik trots op ben. Jullie steunen me in 
mijn keuzes en alles wat ik doe, zo ook tijdens mijn promotieonderzoek. Jullie staan altijd 
voor jullie kinderen klaar, hebben samen veel bereikt en zijn een groot voorbeeld voor 
mij. Daarnaast wil ik ook Ramon, Erik, Tanja en mijn schoonfamilie bedanken voor alle 
gezelligheid, steun en interesse in alles wat ik doe. En Tanja, ik kan oprecht zeggen: jij ben 
de allerliefste zus die ik me kan wensen. 
Lieve Roderik, met jouw liefdevolle ondersteuning en vermogen om mij op de juiste 
momenten af te remmen, heb ik dit proefschrift kunnen volbrengen, mijzelf verder kunnen 
ontwikkelen en ben ik trots dat jij mijn man bent.
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